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Chemicals in the environment are of growing concern as this presence is increasing alongside human 
population and use. There is increasing evidence that these contaminants of emerging concern (CECs) 
could drastically impact the environment, despite regulation and legislation in many countries across 
the world to monitor and limit them. 
Current literature concludes there is a need for analytical methods sensitive enough to quantify 
chemicals from a wide range of classes, e.g. pharmaceuticals, industrial chemicals and pesticides, in 
various environmental matrices. However, current studies are limited by a small range of chemicals, 
low method sensitivity and being focussed on aqueous matrices only.  
This work captures the development and validation of a highly sensitive ultra-performance liquid 
chromatography coupled with tandem mass spectrometry method for the analysis of five 
environmentally relevant matrices. This method has method quantification limits of 0.004 ng L-1 
(bisphenol A in surface water) to 3,118 ng L-1 (creatinine in wastewater influent) and method accuracy 
and precision of 107.0% and 13.4% for 142 compounds covering 33 different classes. This method was 
then applied to 5 wastewater treatment works (WwTWs) within the same river catchment in South-
West England, providing a detailed high-resolution picture of the levels of chemical contamination and 
the contribution from the local population.  
Within this catchment it was found that raw wastewater entering the WwTWs contained 169.3 kg d-1 of 
CECs, the majority of which was found in the liquid phase, with only 1.4 kg d-1 found adsorbed to 
suspended particulate matter. The population normalised load was very consistent across the catchment 
with 154 ± 12 mg d-1 inhabitant-1. Although the WwTWs removed most of the CECs from the liquid 
phase, there was variation between the WwTWs, with WwTW A only discharging 0.19 kg d-1 and 7.3 
kg d-1 at WwTW E. However, this did correlate highly with the contributing population. Whether the 
CECs were completely degraded, adsorbed to the solid phase or transformed is unknown, future work 
should consider the use of untargeted analysis and further sampling of the solid matrices during 
treatment processes to determine the final fate. Analysis of the solid phases showed a preference for 
antifungals and antidepressants to adsorb to the matrix. Analysis of the surface water showed many 
CECs were ubiquitous through the catchment with daily loads ranging from 0.005 g d-1 (ketamine) to 
1890.3 g d-1 (metformin). 
This data was then combined with existing ecotoxicity data to provide an environment risk assessment 
(ERA) of these CECs in this catchment. Overall, it was found that there was minimal risk from 
individual CECs, however similarly acting chemicals in the same group may pose a much higher risk. 
It also showed increasing levels of CECs and environmental risk as the river flowed through higher 
populated urban areas.  
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A novel ecotoxicity test using the protozoa, Tetrahymena Thermophila, was also developed. This test 
allows smaller quantities of contaminants to be tested but is also highly sensitive and has showed critical 
evidence of stereospecific ecotoxicity.  
Further work should include the use of HR (high-resolution)-MS, analysis of metabolites and 







1.1 The presence of contaminants of emerging concern in the environment  
Many chemicals have been detected in the environment around the world; in surface water (Camacho-
Muñoz and Kasprzyk-Hordern, 2017; Gogoi et al., 2018; Kümmerer, 2009a; Miller et al., 2017; 
Noguera-oviedo and Aga, 2016; Rosi-Marshall et al., 2015; Sousa et al., 2018; Wilkinson et al., 2017), 
groundwater (Lapworth et al., 2012; Stuart et al., 2011),  marine water, (B. M. Gustavsson et al., 2017; 
Minguez et al., 2016), sediments (Díaz-Cruz et al., 2019; Gorga et al., 2015; Kaiser et al., 2012; Kim 
and Carlson, 2007) and soils (Grossberger et al., 2014; Simpson and McKelvie, 2009; Šudoma et al., 
2019; Zhang et al., 2015). They are usually present in the concentration range of ng L-1 to µg L-1 in the 
aqueous environment or ng g-1 to µg g-1 in the terrestrial environment. These contaminants cover a wide 
range of chemical classes including human and veterinary pharmaceuticals, additives, personal care 
products, industrial chemicals and pesticides. The entry of these contaminants into the environment is 
either via point sources, e.g. wastewater treatment works (WwTW) discharges, or diffuse sources, e.g. 
agricultural application of pesticides. Depending on the physicochemical properties of the chemicals, 
they may move throughout the environment in-between matrices.  
When considering chemicals in the environment, it is important to appreciate the scale and breadth of 
potential sources. Currently, the European Inventory of Existing Commercial Chemical Substances 
(EINECs) and the new system, REACH (Restriction, Evaluation, Authorisation and restriction of 
CHemicals), record a vast number of chemicals (~100,000), very few of which are currently monitored 
in the environment (ECHA EU, 2009; Loos et al., 2009). The result is a large range of potential CECs, 
which are further increased in number by the metabolites and transformation products that they may 
produce. The levels of these CECs in the environment may persist or degrade by a variety of means, 
including abiotic and biotic processes e.g. photolysis, hydrolysis of microbial metabolism (Andrés-
Costa et al., 2017; Vasquez et al., 2014). Priority substances have been identified of high risk to the 
environment and their use should be minimised. This classification was based upon their widespread 
presence, persistence, mobility, risk to human health and the environment (Official Journal of the 
European Union, 2004). A further 11 substances and groups have been prioritised for inclusion in the 
priority substances list, dependent on further data collection i.e. the Watch List and Water Framework 
Directive (WFD) ((Carvalho et al., 2015; European Commission, 2015, 2013, 2008, 2006, 2000). These 
regulatory directives have been initiated to improve and protect environmental water quality, as well as 
promoting international collaboration. This is essential in Europe, where waterways are not limited by 
national boundaries.  
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Overall for many of the chemicals in use, their actual levels, distribution and effects are widely 
unknown, despite their potential for negative biological effects and hence are being acknowledged as 
‘chemicals/contaminants of emerging concern’ (CECs). 
1.2 Monitoring CECs in the environment 
The quantification of many of these CECs in the environment is often split between two methods: gas-
chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS). 
The selection of the method depends on the physicochemical parameters of the CECs. Usually more 
volatile and/or non-polar CECs are analysed by GC-MS whilst more polar, less volatile compounds are 
analysed by LC-MS (García-Córcoles et al., 2019; Richardson and Kimura, 2017; Sousa et al., 2018). 
In particular, UPLC-MS/MS (ultra-performance liquid chromatography coupled with tandem mass 
spectrometry) has enabled the widest range of CECs to be analysed at the lowest ranges, suitable for 
the trace levels found in surface and ground water in the environment, with high accuracy. Furthermore, 
the use of the soft ionisation method, electrospray ionisation (ESI), coupled with tandem mass 
spectrometry allows robust compound quantification and confirmation which is particularly important 
in complex matrices such as wastewater. These methods are now widely used in the monitoring of CECs 
internationally (Sousa et al., 2018). 
Despite this, there is a lot of variation between methods used across different studies, often because of 
the different equipment in use, the CECs of interest to the study and the matrices to be analysed. This 
can lead to difficultly in comparing results between studies, due to the use of different methods of 
sampling, extraction and analysis leading to different levels of accuracy and sensitivity. It requires 
higher levels of reporting of methods and method validation to begin to draw suitable comparisons (Ort 
et al., 2010; Ort and Gujer, 2006; Sousa et al., 2018). 
Environmental monitoring studies have been limited in scope because they often focus on a specific 
category of CECs, based on its entry into the environment, e.g. pharmaceuticals from households or 
hospitals (Emmanuel et al., 2005; Paíga et al., 2019), veterinary medicines or pesticides from 
aquaculture or agriculture (Ccanccapa et al., 2016; M. Gustavsson et al., 2017; Masiá et al., 2015), 
industrial chemicals or personal care products ingredients from household, trade or production effluents 
(Hussain et al., 2018; Petre et al., 2014). Many studies focus on specific classes often based upon similar 
uses or their mode of action, such as antibiotics (Baquero et al., 2008; Gros et al., 2013), antidepressants 
(Ribeiro et al., 2014), anticancer drugs (Negreira et al., 2013), illicit drugs (Pal et al., 2013), pesticides 
(Ccanccapa et al., 2016; M. Gustavsson et al., 2017; Masiá et al., 2015) and endocrine disrupters (Chang 
et al., 2009). CECs of high interest or high risk have also been a focus of study, e.g. priority substances 
and persistent organic pollutants (Estevez et al., 2016; Reemtsma et al., 2016). There is also the risk of 
the ‘Matthew Effect’, where further monitoring is biased towards CECs which have already been 
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detected over those which have not yet been considered (Daughton, 2014), something which the 
NORMAN Network aims to prevent, amongst other objectives (Network of reference laboratories, 
research centres and related organisations for the monitoring of emerging environmental substances, 
(Dulio et al., 2018)).   
Much of current literature and research has focused primarily on aqueous matrices, as these are both 
simpler to analyse and between aqueous and solids matrices, have the potential for greater transport 
through the environment. Organisms have higher levels of contact with aqueous matrices and are 
therefore more likely to be at more risk of adverse effects. Additionally, solid matrices are often not 
considered due to complex matrix effects and time-consuming sample preparation (Petrie et al., 2014).  
Studies focusing on aqueous matrices have considered a variety of different aspects (Gogoi et al., 2018; 
Luo et al., 2014). Influent is often a focus for wastewater based epidemiology, to not only understand 
human behaviour through their licit and illicit drug use (Castrignanò et al., 2016; Mastroianni et al., 
2017) but also in the context of public health monitoring (Choi et al., 2018; Rice and Kasprzyk-Hordern, 
2019). This is due to the ease of which a sample, representative of the entire population, can be collected. 
Previously data on drug use or tracking epidemics or pandemics were done through surveys, individual 
urine sample collections or a rise in cases at hospitals or GP surgeries. However, by analysing the 
wastewater of a population for chemicals, metabolites and biomarkers of interest this data can 
potentially be provided much more accurately and with minimal bias. This method of gathering data on 
the health of a population would be much closer to real-time and additionally would provide information 
on spatial and temporal trends. 
Considering both influent wastewater (untreated) and effluent wastewater (treated) can provide 
evidence to understand effective treatment technologies for the removal of CECs (Wang and Wang, 
2016), factors which effect removal (Kumar et al., 2019; Tsui et al., 2014) and minimising entry of 
potential high risk chemicals into the environment (Gros et al., 2007; Kasprzyk-Hordern et al., 2009; 
Martín et al., 2012). Furthermore, monitoring effluent allows quantification of chemicals entering the 
environment prior to dilution, allowing the calculation of predicted environmental concentrations. This 
can be useful in cases where the environmental concentrations are too low to be monitored but may still 
pose a risk. 
A better understanding of the risk posed by wastewater effluent to the environment can come from 
comparing the environmental concentrations upstream and downstream of the wastewater effluent 
discharge point (Acuña et al., 2015). This can quantify the environmental burden of the wastewater 
treatment plant and local population, and provide a more accurate environmental risk assessment of the 




Groundwater is also often analysed. This is water that has been ‘filtered’ by the surrounding soil etc. 
and can further understanding of the mobility of some compounds, particularly those which are not 
adsorbed onto soil, and may pose the most risk to drinking water abstraction sources (Lapworth et al., 
2012; Postigo and Barceló, 2015; Stuart et al., 2012). 
Drinking water itself is also monitored as some CECs have been found in drinking water sources and 
may not be adequately removed during drinking water treatment (Metcalfe et al., 2014). Furthermore, 
transformation products of these compounds are of particular interest, as these compounds may persist 
through later stages of the water treatment process and are a potential risk to humans (Huang et al., 
2020; Postigo and Richardson, 2014). 
1.3 The biological effects of CECs 
The presence of CECs in the environment can cause significant adverse effects to the ecological 
balance. Consider the food web, which consists of a wide range of different organisms, spanning several 
trophic levels. Viewed as a pyramid, the lower trophic levels such as algae and microorganisms are 
many in number and support the higher trophic levels. Drastic changes to one layer of the food web 
may cause other layers to grow out of control or collapse, particularly if keystone species are affected 
(Clements et al., 2012; Clements and Rohr, 2009; Grove et al., 2009; Rohr et al., 2006). This is a delicate 
balance and often human interference with the environment has caused drastic effects, e.g. overfishing 
or deforestation. Although trace level chemical pollution may not result in more subtle outcomes than 
these examples, it can still have a serious impact on the long-term future of organism populations e.g. 
feminisation of fish (steroidal estrogens and xenoestrogens) (Jobling et al., 2009, 1998; Kidd et al., 
2007), drastic reduction in the population of vultures in Pakistan (diclofenac) (Oaks et al., 2004), 
behavioural changes in fish (sertraline) (Hedgespeth et al., 2013), amphipods and starlings (fluoxetine) 
(Bean et al., 2014; Kohler et al., 2018) and increasing levels of antibiotic, antifungal, pesticide and 
herbicide resistance(Hawkins et al., 2019; Kümmerer, 2009b, 2004; Peterson et al., 2018; Schütte et al., 
2017). The results from these investigations have led to a more proactive approach to environmental 
risk assessment, particularly with the growing understanding of the potential impact of sublethal and 
chronic effects to the environment, rather than just acute toxic effects and the potential for 
bioaccumulation and bioconcentration (Katagi, 2010; Zenker et al., 2014). 
1.4 Understanding complexity and quantifying the (potential) effects of CECs in the 
environment 
Understanding and quantifying the effects of CECs in the environment is a complex process as different 
concentrations and exposure characteristics of CECs can produce varying effects in organisms covering 
several trophic levels. Furthermore, the presence of other substances, other sources of stress or different 





To investigate this complex situation, studies often simplify the study to within a lab setting by focusing 
on one condition at a time, i.e. a single compound and varying concentration, exposure time, organism 
etc. Many toxicity studies have previously only focused on acute effects (end points) i.e. immobility 
and death, from high concentrations over short periods (Santos et al., 2010). However, it is becoming 
increasingly understood that the effects of an organism’s longer term exposure to lower concentrations 
is far more relevant to the environment. Therefore, there is now an increasing focus on chronic 
ecotoxicity studies, which are carried out with lower concentrations over a longer period, i.e. several 
days to weeks, to understand the effects of exposure over several generational cycles of the organism 
(long-term effects) (European Medicines Agency, 2018; Santos et al., 2010). The end point may still 
include mortality or immobility, but more often focus on fecundity, size, and behaviour. These tests 
usually cover several concentrations to form a dose-response curve, from which the EC50 is determined 
(effect concentration at which 50% of the population is affected, similar to LC50 – lethal concentration 
at 50% of the population has died) (Backhaus and Faust, 2012; European Medicines Agency, 2018; 
Laws, 2013). The EC10 (concentration at which 10% of the population is affected), the LOEC (lowest 
observed effect concentrations) and the NOEC (no-observed effect concentration) can also be calculated 
from these curves. 
There are limitations to the ecotoxicity data currently available: 
- EC50 and LC50 data are still far more widely available than EC10 or LOECs for the majority 
of compounds across a variety of organisms. Therefore, studies which investigate more 
novel chemicals need to carry out ecotoxicity tests to fill the gaps in the data or use 
predictive models such as ‘Quantitative structure activity relationship’ (QSAR). 
 
- Different end points can result in different effect concentrations (EC10, EC50), as they will 
be dependent upon the mode of action of the chemical. Furthermore, not all end points have 
been investigated for all compounds in all organisms. 
 
- A large proportion of the currently available ecotoxicity data is primarily available for 
aquatic organisms and there is limited information available for the terrestrial compartment. 
 
- Focus on individual chemicals - The ecotoxicity values are based on an individual 
chemical. The exposure data from the numerous studies of CECs in the environment 
suggests that organisms are rarely exposed to a single chemical. Therefore, these 
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laboratory-based toxicity tests do not provide an accurate representation of the 
environmental effect since it does not consider the potential synergistic or antagonistic 
effects of other CECs, or even the simplest effect of concentration addition of similarly 
acting compounds.  A single compound itself can become a mixture in the environment, as 
it may be metabolised by organisms or transformed by the processes of hydrolysis or 
photolysis. 
1.5 Environmental Risk Assessment 
Despite environmental monitoring showing that CECs are ubiquitous in the environment, the potential 
effects remain difficult to quantify, identify or predict. Currently the risk of individual chemicals to the 
environment is assessed at the regulative level e.g. European Medical Agency (EMEA), or REACH 
(European Commission, 2006; European Medicines Agency (EMEA), 2006; European Medicines 
Agency, 2018). These environmental risk assessments (ERAs) consider the main active ingredient in 
each formulation and potential additives of metabolites that are >10% of the main active ingredient. 
From this they calculate the potential usage of these products and predict the environmental 
concentrations (PECs, predicted environmental concentrations). There are many limitations to this 
approach whilst predicting exposure levels (PECs); primarily the number of assumptions that must be 
made regarding, usage, human metabolism (in the case of pharmaceuticals), WwTW treatment 
efficiency, dilution to the environment, to name a few. These PECs are then compared with predicted 
no-effect concentrations (PNECs) to provide a risk quotient (RQ). An RQ greater than 1 shows that 
there may be a risk to the environment and more work is required to increase the accuracy of the 
prediction.  
In the assessment of environmental risk, the EC50 or LC50 is used as an acute ecotoxicity parameter and 
lower levels such as the EC10, LOEC or NOEC are typically used as chronic ecotoxicity parameters 
(European Medicines Agency, 2018). For ERAs, traditionally EC50s were used in the calculation of 
predicted-no-effect-concentrations (PNEC) along with an assessment factor (AF) (Backhaus 2012, 
2014). However, there is a growing use of EC10 in these calculations as it requires a lower AF since it 
is more representative of the environment. Therefore, recent guidelines advise the use of chronic 
ecotoxicity data, with a preference for the use of EC10 as these are more likely to be statistically 
determined, rather than the LOEC and NOEC, which are often not statistically determined (European 
Medicines Agency, 2018). Also, since different organisms can have varying responses to specific 
chemicals, it is standard to compare the ecotoxicity results to three organisms from different trophic 
levels within an environmental compartment e.g. freshwater aquatic systems, marine aquatic systems, 
sediments, and soils (European Medicines Agency, 2018), to ensure the more sensitive trophic levels 
are considered and provide a more complete picture to the total environment. However, there is limited 
chronic toxicity data available for all but the freshwater aquatic systems. 
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The ecotoxic concentrations which are obtained from these studies are converted to a PNEC based on 
the lowest EC50 or EC10 or LOEC if available and divided by an assessment factor (AF). AF are included 
in the ERA as a deliberate safety margin to account for limitations in the estimations of risk such as the 
use of lab-raised organisms in ecotoxicity and the lack of inter- and intra-species variation in sensitivity, 
which will limit how representative the tests are to the environment and real-life situations. This may 
also provide more time to mitigate the risk to the environment by preventing the use of or implementing 
treatment technologies in the case of the PEC reaching the PNEC, resulting in a RQ >1, which would 
show the potential risk to the environmental is high (European Medicines Agency, 2018). 
As previously stated, the environment contains a complex mixture of CECs and therefore the potential 
effect of the mixture should be considered as well as the individual components, though this is not 
carried out at a regulative and legislative level. There are two models which can be used in considering 
the effects of mixtures. The first, concentration addition (CA), assumes that all components contribute 
proportionally, based on their individual PEC/PNEC, to the overall effect on a single target system. The 
second model, independent action, (IA) assumes that all components contribute to the overall effect, 
but via different modes of action. Although IA describes a situation that more clearly resembles a 
mixture in the environment, it does not consider potential synergistic or antagonistic actions of the 
mixtures’ constituents and therefore in practice, the ERA of the mixture often falls between IA and CA. 
For this reason, CA is often applied in ERA as it provides a slightly more cautious risk assessment 
(Backhaus and Faust, 2012; European Medicines Agency, 2018). 
A further limitation of ERAs is the lack of consideration of stereochemistry. It is well known in the 
pharmaceutical industry that differences in stereochemistry in pharmaceuticals have different levels of 
potency in humans, e.g. S-(-)-ibuprofen is 100 times more potent than R-(+)-ibuprofen (Buser et al., 
1999), and may lead to different biological effects e.g. R-(+)-thalidomide acts as a sedative and S-(-)-
thalidomide is teratogenic (Höglund et al., 1998; Wnendt et al., 1996). Enantiomers are even known to 
have the potential to cause antagonistic effects towards their antipode e.g. R-(-)-citalopram inhibits S-
(+)-citalopram (Sánchez et al., 2004),  (Evans and Kasprzyk-Hordern, 2014). Yet despite these factors, 
the effects of varying enantiomeric fractions (EFs) on non-target organisms is only known for a few 
compounds (Petrie et al., 2014).  
 
Aims and Objectives 
Overall, this work will implement novel analytical and bioanalytical methods to investigate the fate and 
effects of CECs in the environment. Chemical and biological methods need to be combined to provide 
evidence on both exposure and effects of CECs in the environment. This is with the aim to provide 
higher levels of accuracy with regards to the use of PECs in ERAs by not only replacing them with 
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measured environmental concentrations (MECs) but also with consideration of spatial and temporal 
variations to provide a more robust ERA.  
Both solid and liquid matrices will be sampled and analysed to provide a more holistic understanding 
of the levels of exposure to CECs that are experienced by organisms in different environmental 
compartments. To achieve this, CECs will need to be prioritised for development of a targeted multi-
residue method using UPLC-MS/MS, for the quantification of CECs in both solid and liquid 
environmental matrices at trace level. Furthermore, the impact of WwTWs on the presence of CECs 
will be considered and evaluated, based on spatial and temporal trends of the CECs entering the 
WwTWs and being discharged into the environment via effluent and digested solids. 
Effect driven approaches will then be considered, using current ERA techniques to assess the 
environmental risk of the CECs, both individually and as a mixture, for both the aquatic and terrestrial 
environments. For the aquatic environment, this will be investigated at a local and catchment level, to 
determine the impact of WwTW effluent to the environment.  Furthermore, this work will consider gaps 
and limitations of current ERA approaches and develop new tools and recommendations for 
improvements to ERAs. 
 
Objectives: 
1) The first objective will be to develop and validate a new multi-residue UPLC-MS/MS method 
which contains a wider range of CECs than previously published, for both solid and liquid 
matrices (Chapter 2).  
2) The next objective will be to apply the newly validated method in a catchment-based study to 
several key matrices, wastewater influent (both solid and liquid phases), treated effluent, 
digested solids and the receiving surface waters to which the effluent is discharged. This will 
further understanding on the removal of CECs within WwTWs and entry into the environment. 
This will also determine levels of exposure experienced by aquatic and terrestrial organisms 
(Chapter 3). 
3) The measured environmental concentrations will be used to assess the environmental risk of 
these levels of exposure within the catchment to aquatic and terrestrial organisms, for both 
individual CECs and the overall mixture (Chapter 4). This will provide a more robust and ERA 
for a wide range of CECs within this catchment. 
4) Several limitations have been identified in literature regarding ecotoxicity tests and therefore 
this area will be explored more in-depth with the aim to develop novel approaches and further 
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Abstract
This paper presents a new multi-residue method for the quantification of more than 142 anthropogenic compounds of emerging
concern (CECs) in various environmental matrices. These CECs are from a wide range of major classes including pharmaceu-
ticals, household, industrial and agricultural. This method utilises ultra-performance liquid chromatography coupled with tandem
mass spectrometry (UPLC-MS/MS) for analysis of fivematrices (three liquid and two solid) fromwastewater treatment processes
and the surrounding environment. Relative recoveries were predominantly between 80 and 120%; however, due to the com-
plexity of the matrices used in this work, not all compounds were recovered in all matrices, from 138/142 analytes in surface
water to 96/142 analytes in digested solids. Method quantification limits (MQLs) ranged from 0.004 ng L−1 (bisoprolol in surface
water) to 3118 ng L−1 (creatinine in wastewater treatment work (WwTW) influent). The overall method accuracy was 107.0%,
and precision was 13.4%. To test its performance, the method was applied to the range of environmental matrices at WwTWs in
South West England. Overall, this method was found to be suitable for application in catchment-based exposure-driven studies,
as, of the total number of analytes quantifiable in each matrix, 61% on average was found to be above their corresponding MQL.
The results confirm the need for analysing both the liquid and solid compartments within aWwTW to prevent under-reporting of
concentrations.
Keywords Chemicals of emerging concern . Analysis . Environment .Mass spectrometry
Introduction
The use of anthropogenic, household, industrial or agricultural
chemicals such as pharmaceuticals, pesticides, plasticisers,
UV filters, industrial chemicals and microplastics is ubiqui-
tous, and they have been recognised as a source of environ-
mental contamination. These compounds have been quanti-
fied at levels ranging from ng L−1 to μg L−1, and their impact
on the environment is not well known. These compounds are
often designed to be biologically active and can be persistent
in the environment, where they have the potential to
bioaccumulate within the tissues of organisms [1–4]. For these
reasons, among many others, they are known as compounds
of emerging concern (CECs) [5–7].
CECs are primarily introduced to the environment via point
sources such as wastewater treatment works (WwTWs), indus-
trial discharge points and landfill leachates [8–11]. Diffuse
sources, such as direct application to land in agriculture, have
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been identified as a source of select sub-classes of CECs, such as
pesticides and veterinary pharmaceuticals. Additionally, the ap-
plication of digested sludge, fromWwTW processes, directly to
the land in modern farming practices is a potential source of
other classes of CECs [12]. Bisphenol A (BPA) for instance,
has been found at high levels within this matrix [13, 14].
CECs have been detected across the world in a multitude of
environmental matrices [6, 15, 16]. This is due to their wide-
spread use and to partitioning that can occur from the aqueous
phases into suspended solids and sediments, where it can af-
fect terrestrial organisms and fauna.Whilst their presence does
not necessarily mean harm, the ecotoxicological effects of
many of the CECs have been quantified in laboratory-based
studies for a variety of different organisms across trophic
levels and toxic effects have been demonstrated [17–19].
These laboratory-based ecotoxicological studies broadly fo-
cus on a single compound versus a single organism, but the
environment is a ‘cocktail’ of CECs and different microorgan-
isms. Ermler et al. [20] addressed this lack of knowledge for
anti-androgens and found that concentration addition is a good
model for predicting the effect of mixtures for up to six com-
pounds. Leading on from this work, Orton et al. [21] tested
multi-component mixtures of up to 30 compounds with vary-
ing mixture ratios. At the point where one mixture caused a
10% inhibition of the cancer cell assay, the concentrations of
the components were a factor of 5.8 lower than the concentra-
tion that would be needed for them to individually cause this
effect [21]. This highlights the need for current analytical
methods to have method quantification limits (MQLs) lower
than the no-observed effect concentrations (NOECs) of indi-
vidual CECs, to enable accurate measurements of very low
concentrations, for a better understanding of the risk they pose
to the environment in combination.
Work is being done to further understand the fate, behav-
iour and effect of CECs within our environment. However, the
sheer number of them and their everchanging usage makes
this a challenge. The European Inventory of Existing
Commercial Chemical Substances (EINECS) contains over
100,000 substances [22], with further substances being regis-
tered across all EEA countries, through Registration,
Evaluation, Authorisation and Restriction of Chemicals
(REACH). Currently, there are 94,705 registrations containing
22,257 substances, or 22,096 unique substances that are in use
[23]. This number is increasing every year, as new substances
are developed and registered, and this pattern can be found
across all classes of CECs.
The exponential growth of populations across the world, due
to increased life expectancy and decreased infant mortality, is
increasing the usage of pharmaceuticals. This puts further pres-
sure on agriculture to produce food faster and cheaper, often via
the use of pesticides, herbicides and other anthropogenic com-
pounds. With the number of CECs in use, and more being
developed each year, it is not feasible to determine the exposure
and effects of all these compounds in a single catchment,
let alone across a country or continent. To further complicate
matters, many CECs degrade through different processes such
as hydrolysis, photolysis and metabolism. These form transfor-
mation products and metabolites, which are often more harmful
than the parent compounds [24].
Brack et al. [25] conducted a review of the EU Water
Framework Directive (WFD) and concluded that there are spe-
cific challenges both at European scale and at a local scale.
Regulation and national monitoring schemes such as the WFD
and the UK Chemical Investigations Programme (CIP) are suit-
able for furthering the understanding of this problem on a wider
scale. Through identification and assessment of the most wide-
spread CECs, high-risk compounds can be identified and man-
aged through harmonised methods across diverse areas.
However, they are often limited by the sampling method, i.e. a
few samples collected at many locations, using only grab sam-
ples, which are not very representative [26]. Sampling at a local
scale is crucial to determine catchment-specific substances and
mixtures that might be a specific problem in the local environ-
ment. This can allow more targeted management of risks and
hazards at local catchment level. There is a further need for
analytical methods which can detect CECs down to, or below,
the predicted no-effect concentration (PNEC), as this will allow
a more adequate risk assessment [27].
To gain a better understanding of the fate of CECs within
an environmental catchment, analysis of the influent and ef-
fluent of contributing WwTWs is required, including analysis
of solid particulate matter (SPM) and digested solids, as well
as corresponding surface water. Overall, in the literature, there
is still a lack of multi-residue methods for quantification of
CECs in solid matrices. Even fewer publications consider both
the liquid and solid phases in the WwTWor the environment.
Many studies focus specifically on pharmaceuticals, personal
care products, industrial chemicals, veterinary pharmaceuti-
cals or pesticides. However, a catchment potentially contains
compounds from a variety, if not all, classes of CECs, though
it is rare that they are all the focus of analysis in a single
campaign. One study by Gustavsson et al. [28] covers many
different classes of CEC, leading to the analysis of 172 com-
pounds; however, this was only achieved through multiple
sample preparation methods. For a comprehensive under-
standing of the exposure and environmental risk of chemical
mixtures, multi-residue quantitative methods covering a large
variety of CECs are required.
The aim of this work is to develop and validate a new multi-
residue method (< 190 compounds including internal standards)
for a wide range of CECs prioritised for risk assessment at a
catchment scale, and accounting for the highly urbanised and
agricultural areas of one catchment. The classes of CECs covered
by this method include the following: UV filters, parabens,
plasticisers, steroid estrogens, antibacterials/antibiotics, antifun-
gals, hypertension drugs, non-steroidal anti-inflammatory drugs
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(NSAIDs), lipid regulators, antihyperlipidaemics, antihyperten-
sives, antihistamines, drugs for erectile dysfunction, drugs for
diabetes, cough suppressants, beta blockers, H2 receptor ago-
nists, X-ray contrast media, drug precursors, anticancer drugs,
anaesthetics, antidepressants, anti-epileptics, calcium channel
blockers, hypnotics, antipsychotics, drugs for dementia, human
indicators, analgesics, stimulants, opioids, drugs used in veteri-
nary medicine, pesticides, fungicides and herbicides and metab-
olites. The selection of analyte groups was based not only on
prioritisation including existing and proposed legislation,
European and national watch lists (UKWIR CIP, EU Watch
List) [29–32] and the literature [33, 34] but also on exploring
usage statistics (NHS prescriptions [35]), entry into the environ-
ment (metabolism, excretion from DrugBank [36]), persistence,
bioaccumulation, transport throughout the environment and tox-
icity of organisms [mammals, aquatic and benthic (log Kow, log
Koc, logDow, water solubility, vapour pressure, Henry’s law con-
stant, bioconcentration factor, EPI Suite, ACD/Labs [37, 38])].
Materials and methods
This paper provides an expanded and broader scope method
based on the method published by Petrie et al. [39]. Electronic
Supplementary Material (ESM) Table S1 contains data on the
suppliers of the compounds as well as their physiochemical
properties.
The analytes were primarily purchased in solid form, be-
fore being accurately weighed and dissolved in HPLC grade
methanol (MeOH) (Sigma-Aldrich), or other suitable sol-
vents, at a concentration of 1.0 mg mL−1. These stock solu-
tions were stored in silanised glass vials in the dark at − 20 °C,
unless otherwise stated. Multi-analyte mixtures were prepared
from these stock solutions. The CECs, their corresponding
internal standards, data acquisition method andMS/MS detec-
t ion parameters can be found in ESM Table S2.
Chromatograms of all analytes can be found in ESM Fig. S1.
The internal standards 1S,2R-(+) ephedrine-d3, amphet-
amine-d5, benzoylecgonine-d8, cocaethylene-d8, cocaine-d3,
codeine-d6, cotinine-d3, 2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrroloidine-d3 (EDDP-d3), estradiol (2,4,16,16-d4),
estrone (2,4,16,16-d4), heroin-d9, ketamine-d4, 3,4-
methylenedioxyamphetamine-d5 (MDA-d5), 3,4-
methylenedioxymethamphetamine (MDMA-d5), mephedrone-
d3, methadone-d9, methamphetamine-d5, methylparaben-13C,
morphine-d3, norketamine-d4, quetiapine-d8 and tempazepam-
d5 were purchased from LGC Standards (Middlesex, UK).
Amitrpityline-d3, amoxicillin-d4, capecitabine-d11, ciprofloxa-
cin-d8, citalopram-d6, diazepam-d5, erythromycin-13C,d3, flu-
oxetine-d5, gabapentin-d4, imidacloprid-d4, metazachlor-d6,
metoprolol-d7, mirtazapine-d3, norsertraline-d4, nortriptyline-
d3, ofloxacin-d3, oxazepam-d5, sildenafil-d8 and verapamil-d7
were purchased from Toronto Research Chemicals (TRC)
(Toronto, Canada). Acetaminophen-d4, atenolol-d5, bisphenol
A-d16, carbamazepine-13C6, ibuprofen-d3, ketoprofen-d3,
metformin (dimethyl-d6), methiocarb-d3, naproxen-d3, pro-
pranolol-d7, sertraline-d3 and tamoxifen-13C2,15N were pur-
chased from Sigma-Aldrich (Gillingham, UK), and
bezafibrate-d6 was purchased from QMX Laboratories
(Thaxted, UK). These were purchased as solutions at a concen-
tration of 0.1 mg mL−1 or 1.0 mg mL−1 in methanol or other
appropriate solvents. If no solutionswere available, 1.0mg pow-
der was purchased, and the entire contents of the vial were
dissolved in methanol. The MS/MS detection parameters for
the internal standards can be found in ESM Table S3.
All glassware in this paper was silanised to prevent the
analytes and internal standards from absorbing to the surface.
This was done by coating the internal surfaces of the glass-
ware with 5% dimethylchlorosilane (DMDCS) in toluene
(Sigma-Aldrich), rinsing with toluene (Sigma-Aldrich) twice,
then rinsing again with MeOH three times, and leaving to dry
between each coating or rinse.
Methods for sample collection
Sampling was carried out in a river catchment in South
West England. Sampling involved collection of samples
from all major WwTWs and receiving environmental wa-
ters. Twenty-four-hour composites using a 3700 ISCO
sampler (RS Hydro) were collected for both influent and
effluent wastewaters in each case. Grab samples were
utilised in surface water samples. SPM was collected from
influent samples.
SPM per litre was calculated by filtering 30 mL through a
pre-dried and pre-weighed GF/F glass microfibre filter. This
was then re-dried at 105 °C for 8 h, left to cool and re-weighed
to quantify SPM in grams per litre. Data are shown in ESM
Table S4. Digested sludge was collected on three consecutive
days, both directly after digestion and prior to disposal. Data
are shown in ESM Table S5.
All samples were kept on ice during sampling (ice was
placed within the composite sampler to maintain a cool tem-
perature of 0–4 °C and promote stability) or placed in a cool
box and kept on ice until the samples were transported to the
lab. Once at the lab, samples for liquid analysis were trans-
ferred to 125-mL PPE bottles (Fisherbrand) and frozen (−
20 °C) for further preparation and analysis at a later date.
For the influent samples, the remainder of the sample was
filtered to collect the SPM, which was then frozen (− 20 °C).
Most compounds do not adsorb to the PPE bottles, with very
few exceptions (ESM Table S6).
Methods for extraction and analysis
The methods used for sample preparation of both liquid
and solid matrices, as well as their analysis, can be found
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in Fig. 1; this is also discussed in more detail below.
Development of an extraction method for liquid matrices
with hydrophilic-lipophilic-balanced solid-phase extrac-
tion (HLB SPE) was developed based on the method pub-
lished by Kasprzyk-Hordern et al. [40]. The microwave-
assisted extraction (MAE) for solid matrices was devel-
oped based on the method published by Petrie et al. [39].
Extraction for liquid matrices
The samples were filtered with a GF/F glass fibre filter
(0.7 μm) (Whatman, Sigma-Aldrich) and adjusted to
pH 7.5–8.5. 50 mL of influent or effluent (100 mL surface
water) was accurately measured and spiked with 50 μL of
1 μg mL−1 (50 ng) internal standard mixture in MeOH.
The 60-mg HLB SPE cartridges (OASIS, Waters, UK)
were conditioned and equilibrated with 2 mL of MeOH,
followed by 2 mL of deionised water (H2O) at a rate of <
1 mL min−1 (under gravity). The deionised H2O was ob-
tained from a Milli-Q system (18.2 MΩ). The sample was
loaded at 5 mL min−1 before the cartridges were dried
under vacuum. Analytes were eluted using 4 mL MeOH
at 1 mL min−1 (under gravity). Once eluted, the extracts
were evaporated to dryness at 40 °C, with a steady flow
of nitrogen using a TurboVap LV concentration worksta-
tion. Finally, the samples were reconstituted in 500 μL of
80:20 H2O:MeOH, mixed thoroughly to ensure completed
dissolution and transferred to LC vials (polypropylene)
(Waters, UK).
Extraction for solid matrices
The solid samples, digested sludge and SPM were initially fro-
zen and freeze-dried (ScanVac, CoolSafe freeze dryer, Lynge,
Denmark). The freeze-dried samples were homogenised, and
0.25–0.5 g was weighed out and spiked with 50 μL of
1 μg mL−1 (50 ng) internal standard mixture in MeOH. This
was left for 30 min to 1 h, for the methanol to evaporate off.
The samples were then transferred to MAE perfluoroalkoxy
(PFA) tubes with 25–30 mL of 50:50 acidified H2O
(pH 2):MeOH. The MAE tubes were placed in 800 W MARS
6 microwave (CEM, UK). The temperature was ramped to
110 °C, over 10 min, then held at this temperature for 30 min,
before allowing the samples to cool. SPE was then carried out
using 60-mg mixed-mode cationic exchange (MCX) cartridges
(Oasis, Water, UK). These were conditioned and equilibrated
using 2 mL MeOH and 2 mL acidified H2O (pH 2) at <
1 mL min−1 under gravity. The samples were then loaded at
5 mL min−1 and dried under vacuum. Once dried, the acid
analytes were eluted first with 2 mL of 0.6% formic acid
(HCOOH) (Sigma-Aldrich) in MeOH. The basic analytes were
eluted secondwith 3mL of 7% ammoniumhydroxide (NH4OH)
Fig. 1 Flow chart from sample
preparation to analysis, for
analysis of liquid and solid
samples by ESI− and ESI+
methods
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in MeOH (Sigma-Aldrich). These extracts were evaporated to
dryness at 40 °C, with a steady flow of nitrogen using a
TurboVap. The residue was reconstituted in 500 μL of 80:20
H2O:MeOH, mixed thoroughly to ensure completed dissolution
and transferred to LC vials.
Analysis of samples
The analytes were separated by UPLC performed on theWaters
ACQUITY UPLC™ system (Waters, UK). The column used
was a reversed-phase C18 column (Waters, UK), 150 mm×
1.0 mm, with a particle size of 1.7 μm. The samples were
analysed with Xevo Triple Quadrupole (TQD) Mass
Spectrometer (Waters, UK), equipped with an electrospray
ionisation (ESI) source in positive and negative modes. To op-
timise ionisation, two different sets of parameters were used for
the ESI-positive and ESI-negative modes. The parameters for
these can be seen in Fig. 1. The systems were controlled using
MassLynx (Waters, UK). Argon (99.998%) gas, supplied by a
BOC cylinder, was used as a collision gas. The nebulising gas
was nitrogen, provided by a high-purity nitrogen generator
(Waters, Manchester, UK). Two mobile phases were used in
the gradient mode ESI+: mobile phase A contained 80:20
H2O:MeOH with 5 mM ammonium acetate (NH4OAc) and
3 mM acetic acid (CH3COOH) (pH 4.7), and mobile phase B
contained 100% MeOH. Starting conditions were 100% A,
decreasing to 10% A over 20 min, maintained at this level for
6 min, before increasing back to 100%A over 0.5 min and held
for 7.5min to return the column to equilibrium; in ESI−: mobile
phase A contained 80:20 H2O:MeOH with 1 mM ammonium
fluoride (NH4F) and mobile phase B, which was 5:95
H2O:MeOH containing 1 mM NH4F. The gradient began at
100% A for 0.5 min and reduced to 40% A over 2 min, before
being further reduced to 0% A over the next 5.5 min. It was
held at 0% A for 6 min before increasing back up to 100% A
over 0.1 min. This was maintained for 8.4 min to re-equilibrate
the column. The HPLC grade MeOH, NH4OAc (Fluka) and
CH3COOH were obtained from Sigma-Aldrich (Gillingham,
UK). The NH4F (Fluka) was obtained from Fisher Scientific
(Loughborough, UK) and deionised water (18.2 MΩ) obtained
from a Milli-Q system. The temperature of the built-in sample
manager was 4.0 °C with an injection volume of 20 μL. The
mobile phases were run at a rate of 0.04mLmin−1, as a gradient
of a high ratio of aqueous (80%) to 100% MeOH in both pos-
itive and negative ionisation modes. The exact gradients and
composition of the mobile phases can be also seen in Fig. 1.
Data processing was carried out using TargetLynx software,
which is an extension to MassLynx (version 4.1, Waters).
Instrument performance
To quantify the analytes, an internal standard approach with an
18-point calibration curve was used. For the majority of the
compounds, the analysed range covers 6 orders of magnitude,
from ng L−1 to mg L−1. Each point was repeated every 24 h over
3 days. These calibration samples were prepared in a ratio of
80:20 H2O:MeOH unbuffered solutions. The signal-to-noise ra-
tios of these samples were used to determine the concentration
of the instrument detection limit (IDL) and instrument quantifi-
cation limit (IQL), where S/N ≥ 3 or S/N ≥ 10, respectively.
Determination coefficients (r2) were calculated for the full linear
range (IDL to ≤ 1000 μg L−1). Inter- and intra-day precision and
accuracy were calculated from repeated injections, at regular
intervals (n = 3) of three concentrations (10 μg L−1,
100 μg L−1, 500 μg L−1) in 80:20 H2O:MeOH, across 24 h
(intra-day) and across 72 h (inter-day).
Method performance
As SPE was used as a preconcentration and clean-up step, the
recovery of each analyte must be assessed. Absolute and rel-
ative recoveries for SPE of liquid matrices were calculated
from matrices spiked in duplicate (n = 2) at three concentra-
tions for A-ESI+ (100 ng L−1, 1000 ng L−1 and 5000 ng L−1
for effluent and influent, and 50 ng L−1, 500 ng L−1 and
2500 ng L−1 for surface water). For B-ESI+ and C-ESI−, the
matrices were spiked at two concentrations (100 ng L−1 and
1000 ng L−1 for effluent and influent, and 50 ng L−1 and
500 ng L−1 for surface water). For influent suspended partic-
ulate matter (SPM) and digested sludge (DS), the absolute and
relative recoveries take into account MAE and SPE. The sam-
ples were spiked at 50 ng g−1 and 100 ng g−1.
Method detection limits (MDLs) and MQLs were calculat-
ed using Eq. 1
MDL ¼ IDL 100
Rec Cf ð1Þ
where IDL is the instrumental detection limit, which is
calculated as discussed in the section “Method performance”;
100 is the conversion factor for recovery of a specific matrix
(Rec); and Cf is the concentration factor for the specific liquid
matrix, e.g. 200 for surface waters or 100 for effluent of efflu-
ent. For solid matrices, Cf is replaced with a conversion factor
of 2, which converts the volume into grams, based on the
0.25 g of solid matrix being extracted into a 0.5-mL vial for
analysis. MQL is calculated with the same equation but by
replacing IDL with IQL.
Furthermore, the accuracy and precision of the overall
method, including SPE, are also required. These were calcu-
lated from samples of 3 matrices taken from 5 different
WwTWs in the South West UK. These samples were spiked
at 100 ng L−1 and 1000 ng L−1 for influent and effluent sam-
ples and at 50 ng L−1 and 500 ng L−1 for surface water for A-
ESI+ and at 100 ng L−1 for all matrices for B-ESI+ and C-ESI
−. The accuracy of the method was determined from the
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percentage deviation from the known concentration of analyte
added to the sample. Precision was calculated as the relative
standard deviation (RSD) of the replicates.
It has been found that complex matrices such as in-
fluent can affect the detection of analytes, especially
when these samples have undergone SPE with HLB
cartridges, as these cartridges extract a huge range of
compounds. Therefore, matrix suppression was deter-
mined for the liquid matrices, which were extracted by
employing a method using this approach. Samples for
calculating matrix suppression were prepared by spiking
samples with 50 μL of 1 μg mL−1 of internal standards,
after the elution step of SPE, and prior to evaporation
and reconstitution. Once analysed, matrix suppression
for each analyte was calculated using the following
equation:
Matrix suppression ¼ 1− PA in SS−PA in US
PA in MP QC
 
ð2Þ
where PA is the peak area of the analyte in spiked sample
(SS), unspiked sample (US) and mobile phase quality control
(MP QC) sample.
All matrices used were collected via grab sampling and
homogenised, and all analyses were carried out on this single
sample to ensure consistent results. Due to the use of these
environmental matrices and the potential presence of analytes
within the matrices prior to spiking, the ‘blank’ or unspiked
(with analytes) portion of the sample was spiked with internal
standards and analysed to confirm the concentration of analytes,
prior to spiking, for recoveries and matrix effect analysis.
Quality control
Quality control samples were analysed before and after each
batch at three concentrations (10 μg L−1, 100 μg L−1,
500 μg L−1) along with procedural blanks, to ensure the meth-
od and instrumental performance and to monitor for contam-
ination of the equipment.
All samples were spiked with the internal standards listed
in ESM Table S3, for accurate quantification, and to account
for loss from the point of spiking until analysis and to limit
matrix effects.
Results and discussion
This paper provides an expanded and broader scope method
based on a method published by Petrie et al. [39], enabling the
analysis of household and agricultural chemicals whilst
utilising one sample preparation protocol and comprehensive
UPLC-MS/MS methodology.
UPLC-MS/MS method
All analytes were analysed using MRM and ESI− and ESI+
modes and conditions previously selected by Petrie et al. [39].
Following EU guidelines, twoMRM transitions were used for
most of the 195 compounds (142 analytes and 53 ISTDs).
This is except for cefalexin, ketoprofen, diclofenac, ibuprofen,
1,7-dimethylxanthine and norfluoxetine, which are to be con-
sidered as semi-quantitative. For ESI−, the parent ion [M−H]−
was selected, and for ESI+ mode, [M−H]+ was selected. The
most abundant daughter ion was used for quantification and
the second most for confirmation. ESM Table S2 includes the
MRMs for all analytes, the acquisition method was used to
analyse them and the assigned internal standard. The MRMs
for the internal standards can be found in ESM Table S3.
The reversed-phase BEH C18 column provided good sep-
aration and sensitivity for all compounds. These conditions
achieved good separation and peak shape for most analytes.
Further information can be found in Fig. 1. A more acidic
mobile phase was also trialled in the ESI+ method, and al-
though the peak shape and separation for the acidic com-
pounds, particularly the fluoroquinolones, were improved
slightly, they only benefitted a small number of compounds
and had a detrimental effect against many others. Satisfactory
separation of analytes was achieved within a < 40-min reten-
tion time.
Quality control criteria as recommended by the EU direc-
tive [41] utilised quality control samples, standard tolerances
of ion ratio, chromatographic retention time, relative retention
time and signal-to-noise ratio.
Instrument performance
The instrument performance was assessed by considering lin-
ear response, inter- and intra-day precision and accuracy and,
finally, instrumental detection and quantification limits. This
data can be found in Table 1.
For the linear response, a linear range covering several
orders of magnitude with the r2 value of ≥ 0.997 was ideal.
However, for a few analytes (triclosan, benzoylecgonine and
mirtazapine), this could only be achieved through splitting the
linear range into two overlapping ranges, each with the r2
value ≥ 0.997. This allowed adequate quantification across
the entire range. Of the 142 compounds, 120 have r2 values
≥ 0.997. Twenty-one of the remaining compounds have r2
values ≥ 0.992. Although this is not ideal, it is still adequate
for accurate quantification, as the other parameters indicate.
Chlorpyrifos has the lowest r2 value, likely due to the lack of
an analogous internal standard; however, it passes further in-
strumental performance criteria.
The intra-day instrumental performance is high across
many compounds. Out of the 142 analytes, the majority of
which are very precise, with a deviation of ≤ 5%. The

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Multi-residue ultra-performance liquid chromatography coupled with tandem mass spectrometry method for...
precision of 20 compounds was between 5 and 10%, and only
one compoundwas > 10% (chlorpyrifos (11.8%), likely due to
poor r2). However, all deviations are inside the recommended
maximum of 20%. For 119/142 compounds, the accuracy lay
within the ideal range of 90–110%. Of the remaining com-
pounds, only triclosan has an inaccuracy of > 20%.
Regarding the inter-day instrumental performance, the pre-
cision is high across many analytes with 115 analytes with a
deviation of ≤ 5%. Of the 27 analytes with > 5% deviation,
only 8 were > 10%. The inter-day accuracy of these com-
pounds was also high, with only 20 compounds that deviated
from the QC by > 10%, 4 of which were only slightly greater
than 20%. Data for both intra- and inter-day precision and
accuracy can be found ESM Table S7.
IDLs ranged from 0.4 ng L−1 (bisoprolol) to 4783 ng L−1
(cefalexin), and IQLs ranged from 1.2 ng L−1 (bisoprolol) to
15,940 ng L−1 (cefalexin). Whilst many of these IQL concen-
trations are very low, the samples may still need to be concen-
trated (utilising SPE), as the concentrations of most com-
pounds in environmental matrices are likely to be even lower.
Method performance
Sample extractionwas carried out using SPE following themeth-
od shown in Fig. 1 (sections “Extraction for liquid matrices” and
“Extraction for solid matrices”) and has shown good extraction
performance formanyCECs. TheOasis HLB sorbent is essential
to multi-residue methods, as it has the ability to retain a large
range of polar analytes at neutral pH and is therefore widely used
in analysis of environmental matrices. However, two drawbacks
have been found in the use of this sorbent. Firstly, HLB might
result in low recovery of very polar compounds such as metfor-
min and creatinine. This is easily remedied, as metformin and
creatinine along with acetaminophen, nicotine, caffeine and 1,7-
dimethylxanthine are present in the environment as such high
levels that direct injection are utilised instead. The second draw-
back of HLB is its lack of selectivity. Whilst enabling the extrac-
tion of a large variety of polar analytes, in complex matrices,
much of the matrix can be extracted along with the chosen
analytes, causing significant signal interference. It is therefore
important to assess matrix suppression. Previously, it was found
that the use of HLB with digested solids provided poor results.
This not only necessitated the use of an alternative sorbent,
MCX, but also splitting the eluents into acidic and basic fractions
(see Fig. 1) [39].
Figure 2 shows relative recoveries for all matrices: surface
water, effluent, influent, SPM and digested solids. These very
different matrices exhibit similar ranges of relative recovery.
Most of the compounds had recoveries between 80 and 120%.
Due to the complexity of environmental matrices, not all com-
pounds were recovered adequately across all matrices; therefore,
the number of compounds accurately quantifiable in each matrix
varies from 138 analytes in surface water to 96 analytes in
digested solids. The data for relative and absolute recoveries for
all matrices can be found in ESM Tables S8 and S9 and Fig. S2.
Matrix suppression was analysed for liquid matrices (see
Fig. 3 and ESM Table S10). Proximity to zero shows limited
matrix effects. Most analytes experienced matrix suppression,
shown in Fig. 3 as a positive percentage. For all matrices, at least
108 analytes were below 70% suppression. However, a few
compounds, primarily from ESI−, experienced significant (>
20%) signal enhancement. Some compounds experienced signal
enhancement in some matrices and suppression in others
(naproxen, erythromycin, EE2, bicalutamide, candesartan
cilexetil, gemfibrozil, chlorpyrifos). This considerable variation
is to be expected for a multi-residue method with this variety of
analytes. It especially highlights the importance of using relevant
analogous internal standards, as well as thoroughly exploring the
different matrices relevant to this work.
The method accuracy of the method was 107.0%, and the
precision was 13.4%. MQLs for liquid matrices range from
0.004 ng L−1 for bisoprolol, in surface water, to 3118 ng L−1
for creatinine, in influent (Table 2). For the remaining analytes,
there is not enough environmental data on their presence in the
UK to comment on whether the MDLs and MQLs are low
enough to measure these levels in the catchment of interest.
Therefore, this method was applied to five different matrices at
a WwTW in the South West UK, which were influent, effluent,
surface water, SPM and digested solids, to underline the
utilisation of this method to relevant environmental matrices.
Overall, this method provides a clear benefit when used in a
catchment-based study, compared to more complex approaches
with multiple sample preparation and analytical methods for
different classes of CECs from the same matrices. The main
advantage of the multi-residue method presented in this paper
is the applicability of this method to liquid and solid matrices. In
particular, SPM,which is an often forgotten but critical aspect of
wastewater, as it contains many more hydrophobic compounds
at significant concentrations within this matrix [28, 42, 43].
Application to environmental matrices
The data is presented as average concentrations with variation
across a week (Table 3 and ESMTables S11–S15). As expected,
the liquid influent fraction shows the highest variation in con-
centrations both across theweek and between different CECs. Of
the 138 analytes of this method, 70% were quantified in influent
at this site. Creatinine had the highest average concentration of
any analyte in this study (1.3 ± 0.3 mg L−1) and is often used a
human indicator due to its correlation to population [44, 45].
Other human indicators were present at high levels throughout
the week. The other CECs were present at a range of concentra-
tions. Methiocarb, for example, is present intermittently across
the week with an average concentration of 3.7 ± 0.6 ng L−1,
which is very close to its MQL of 0.86 ng L−1. However, acet-
aminophen reaches concentrations several magnitudes higher
Proctor K. et al.
than methiocarb, at 393.6 ± 100.0 μg L−1. This is slightly higher
than those published in a review by Verlicchi et al. [11] which
had an absolute highest concentration of 246 μg L−1. It is inter-
esting to see the presence of the (pesticide) methiocarb in
Digested solids SPM Influent Effluent Surface water

















































































































































Fig. 2 Relative recoveries for all matrices. Error bars show the range of standard deviation
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Fig. 3 Matrix suppression for all liquid matrices. Error bars show the range of standard deviation
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Table 2 Method performance data for ECs of interest in the mobile phase (ordered by class)










MDL MQL MDL MQL MDL MQL MDL MQL MDL MQL
UV filter Benzophenone-1 0.07 0.35 0.14 0.71 0.23 1.15 0.004 0.02 0.14 0.70
Benzophenone-2 0.16 0.79 0.34 1.68 0.36 1.82 0.004 0.02 0.09 0.44
Benzophenone-3 0.15 0.77 0.19 0.97 0.37 1.87 – – – –
Benzophenone-4 2.09 6.90 5.78 19.1 7.83 25.8 0.21 0.70 4.01 13.2
Parabens Methylparaben 0.08 0.40 0.19 0.94 0.28 1.41 0.003 0.02 0.06 0.31
Ethylparaben 0.24 0.79 0.46 1.52 0.49 1.61 0.01 0.05 0.17 0.57
Propylparaben 0.25 0.83 0.47 1.54 0.63 2.08 0.01 0.03 0.22 0.72
Butylparaben 0.08 0.38 0.14 0.71 0.24 1.21 0.002 0.01 0.10 0.52
Plasticizer Bisphenol A 0.26 0.86 0.56 1.84 0.85 2.79 0.03 0.09 0.27 0.88
Steroid estrogens E1 0.78 3.92 0.15 7.69 1.96 9.78 0.04 0.21 1.68 8.38
E2 0.90 4.48 1.41 7.03 1.84 9.22 0.04 0.21 1.48 7.41
EE2 0.98 4.91 1.46 7.32 1.83 9.15 – – – –
Antibiotics and
antibacterials
Sulfasalazine 4.31 14.2 9.66 31.9 12.6 41.4 – – – –
Clarithromycin 0.18 0.90 0.28 1.40 0.34 1.69 – – – –
Azithromycin 0.08 0.26 0.21 0.68 0.14 0.45 0.03 0.10 0.01 0.04
Trimethoprim 0.26 0.85 0.51 1.67 0.73 2.41 0.01 0.03 0.07 0.22
Sulfamethoxazole 0.19 0.63 0.47 1.56 0.72 2.38 0.02 0.08 0.12 0.41
Triclosan 2.93 9.68 4.55 15.0 4.93 16.3 – – – –
Amoxicillin – – 0.26 0.86 – – – –
Metronidazole 0.29 0.98 0.68 2.27 0.57 1.90 0.03 0.09 0.03 0.10
Sulfadiazine 0.05 0.18 0.18 0.59 0.18 0.62 0.003 0.01 0.003 0.01
Cefalexin 35.6 118.7 10.2 33.9 18.9 63.1 – – – –
Ofloxacin 0.35 1.17 0.72 2.40 0.58 1.93 – – – –
Ciprofloxacin 1.85 6.17 5.10 17.0 3.48 11.6 – – – –
Tetracycline 0.15 0.50 0.30 1.01 0.18 0.59 – – – –
Danofloxacin 1.58 5.28 4.45 14.85 3.62 12.08 – – 2.84 9.45
Oxytetracycline 6.04 20.1 10.1 33.6 8.26 27.5 – – – –
Chloramphenicol 3.18 10.6 6.52 21.7 4.21 14.0 0.21 0.69 0.15 0.48
Penicillin G 0.89 2.98 – – – – – – – –
Penicillin V 0.56 1.86 0.92 3.06 2.40 8.00 0.84 2.80 – –
Erythromycin 1.15 3.83 2.35 7.85 2.22 7.41 – – – –
Prulifloxacin – – 51.3 171.0 35.3 117.6 – – – –
Norfloxacin 0.01 0.04 0.02 0.06 0.02 0.07 – – – –
Antifungal Griseofulvin 0.32 1.06 0.52 1.74 0.59 1.98 0.05 0.16 0.06 0.21
Ketoconazole 0.06 0.21 0.03 0.10 0.04 0.12 0.02 0.07 0.00 0.01
Hypertension Valsartan 2.81 9.26 6.40 21.1 7.24 23.9 – – – –
Irbesartan 0.89 4.47 1.88 9.38 2.50 12.5 – – – –
Lisinopril 2.17 21.7 4.25 42.5 3.25 32.5 0.04 0.43 0.25 2.47
NSAIDs Ketoprofen 0.74 3.72 1.60 8.00 2.38 11.9 0.06 0.28 0.47 2.35
Ibuprofen 0.06 0.31 0.08 0.42 0.19 0.93 0.005 0.02 0.07 0.36
Naproxen 0.61 3.07 1.17 5.85 6.29 31.5 0.05 0.25 0.60 3.02
Diclofenac 0.22 0.73 0.44 1.44 0.67 2.22 0.02 0.06 0.75 2.46
Acetaminophen 1.20 6.02 2.39 12.0 138.0* 1017* 0.04 0.21 2.74 13.7
Lipid regulator Bezafibrate 0.22 0.66 0.38 1.25 0.64 2.11 0.02 0.05 0.18 0.60
Atorvastatin 0.14 0.70 0.17 0.84 0.17 0.85 – – – –
Antihyperlipidemic Gemfibrozil 0.30 1.00 0.63 2.11 1.12 3.75 – – 0.20 0.67
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Table 2 (continued)










MDL MQL MDL MQL MDL MQL MDL MQL MDL MQL
Antihyperintensive Candesartan Cilexetil 6.89 23.0 – – – – – – – –
Antihistamine Fexofenadine 0.21 0.69 0.40 1.32 0.56 1.85 – – – –
Cetirizine 0.26 0.87 0.32 1.06 0.52 1.72 – – – –
GUD/ED Sildenafil 0.01 0.03 0.02 0.05 0.01 0.05 0.001 0.003 0.001 0.003
Diabetes Metformin 156.0* 515.0* 163.0* 460.0* 457.0* 1509* – – – –
Gliclazide 0.15 0.77 0.16 0.82 0.22 1.09 – – – –
Sitagliptin 0.03 0.09 0.08 0.27 0.06 0.22 0.004 0.01 0.003 0.01
Cough suppressant Pholcodine 2.25 7.42 8.02 26.5 25.3 83.3 0.28 0.92 1.52 5.00
Beta blocker Atenolol 0.20 0.66 0.56 1.84 0.71 2.35 0.01 0.05 0.10 0.33
Metoprolol 0.07 0.35 0.19 0.96 0.28 1.40 0.01 0.03 0.03 0.14
Propranolol 0.29 0.96 0.73 2.41 0.68 2.25 0.01 0.04 0.13 0.42
Bisoprolol 0.001 0.004 0.004 0.01 0.003 0.01 0.0001 0.0005 0.0001 0.0005
H2 receptor agonist Ranitidine 7.96 39.8 22.3 111.4 14.8 73.8 0.44 2.19 4.81 24.1
Cimetidine 1.60 7.98 3.12 15.6 5.06 25.3 – – – –
X-ray contrast
media
Iopromide 5.97 29.9 14.1 70.6 24.5 123.0 – – – –
Various Buprenorphine 0.06 0.20 0.11 0.36 0.18 0.61 0.02 0.07 0.01 0.05
Drug precursor Ephedrine/pseudoephedrine 0.60 1.97 1.62 5.36 1.32 4.36 0.02 0.07 0.11 0.35
Norephedrine 0.18 8.82 0.35 17.3 0.37 18.6 0.01 0.39 0.04 1.85
Anticancer Azathioprine 0.17 0.55 0.36 1.20 0.41 1.36 – – – –
Methotrexate 6.13 20.2 9.04 29.8 7.11 23.5 0.16 0.53 1.64 5.42
Ifosfamide 0.08 0.40 0.24 1.22 0.31 1.53 – – – –
Tamoxifen 14.5 72.6 0.76 3.82 0.70 3.50 0.004 0.01 2.23 11.14
Imatinib 0.88 2.93 1.13 3.76 1.78 5.95 0.10 0.35 0.06 0.21
Capecitabine 0.01 0.02 0.01 0.03 0.01 0.03 0.002 0.01 0.001 0.003
Bicalutamide 0.22 0.72 0.31 1.02 0.32 1.07 0.02 0.06 0.01 0.03
Anaesthetic and
metabolite
Ketamine 0.07 0.37 0.19 0.93 0.24 1.20 0.005 0.02 0.03 0.17
Norketamine 0.23 0.76 0.56 1.86 0.72 2.37 0.02 0.05 0.10 0.33
Venlafaxine 0.07 0.37 0.24 1.20 0.37 1.83 0.01 0.03 0.08 0.38
Desmethylvenlafaxine 0.24 0.80 0.66 2.18 0.85 2.79 0.01 0.05 0.09 0.29
Fluoxetine 1.14 5.71 1.42 7.08 0.50 2.52 0.005 0.02 0.11 0.53
Norfluoxetine 1.64 8.21 1.27 6.35 0.42 2.12 0.004 0.02 0.14 0.68
Sertraline 1.61 8.07 1.21 6.05 0.74 3.72 0.002 0.01 0.17 0.86
Mirtazapine 0.09 0.44 0.25 1.25 0.39 1.94 0.01 0.03 0.05 0.27
Citalopram 0.61 6.08 1.41 14.1 1.24 12.4 0.02 0.24 0.16 1.64
Desmethylcitalopram 0.14 0.69 0.36 1.82 0.31 1.54 0.01 0.03 0.05 0.24
Paroxetine 0.18 0.59 0.21 0.69 0.13 0.45 0.01 0.02 0.005 0.02
Duloxetine 0.04 0.13 0.05 0.18 0.04 0.12 0.003 0.01 0.002 0.01
Amitriptyline 0.16 0.55 0.33 1.09 0.30 1.02 0.02 0.07 0.01 0.03
Nortriptyline 0.33 1.11 0.63 2.11 0.61 2.03 0.03 0.10 0.02 0.06
Norsertraline – – – – 1.07 3.58 0.09 0.28 – –
Anti-epileptic Carbamazepine 0.08 0.38 0.19 0.93 0.27 1.37 0.01 0.03 0.10 0.48
Carbamazepine-10,11-epoxide 0.16 0.53 0.55 1.82 0.53 1.76 – – – –
10,11-Dihydro-10-
hydroxycarbamazepine
0.34 3.37 0.84 8.41 0.99 9.94 0.02 0.25 0.43 4.35
Calcium channel
blocker
Diltiazem 0.11 1.11 0.32 3.23 0.27 2.68 – – – –
Verapamil 0.01 0.02 0.01 0.04 0.01 0.03 0.001 0.002 0.0004 0.001
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MDL MQL MDL MQL MDL MQL MDL MQL MDL MQL
Hypnotic Temazepam 0.08 0.38 0.14 0.69 0.18 0.92 0.01 0.04 0.16 0.82
Oxazepam 0.11 0.36 0.22 0.72 0.20 0.66 – – 0.01 0.03
Diazepam 0.02 0.06 0.04 0.13 0.04 0.12 0.002 0.01 0.002 0.01
Antipsychotic Quetiapine 0.10 0.48 0.21 1.07 0.26 1.32 0.004 0.02 0.05 0.26
Risperidone 0.01 0.02 0.02 0.06 0.02 0.06 0.001 0.004 0.002 0.01
Dementia Donepezil 0.55 1.83 1.54 5.12 1.48 4.93 0.09 0.30 0.09 0.29
Memantine 0.04 0.14 0.11 0.36 0.12 0.39 0.02 0.07 0.01 0.04
Human indicators Creatinine 511* 1686* 771* 2544* 945* 3118* – – – –
Nicotine 3.34 11.0 5.44 18.0 508* 2296* 0.16 – 0.66 2.19
Caffeine 0.37 1.83 1.11 5.57 121* 581* – – – –
Cotinine 0.07 0.35 0.21 1.06 0.27 1.34 0.005 0.02 0.24 1.22
1,7-Dimethylxanthine 3.19 10.5 11.4 37.6 560* 2165* – – – –
Analgesics and
metabolites
Morphine 2.65 8.75 6.34 20.9 8.85 29.2 0.11 0.37 1.92 6.33
Dihydromorphine 0.11 0.55 0.32 1.59 0.05 2.51 0.01 0.04 0.09 0.45
Normorphine 3.54 11.7 7.84 25.9 9.99 33.0 0.12 0.39 1.74 5.75
Methadone 0.11 0.54 0.21 1.04 0.20 1.01 0.01 0.03 0.03 0.17
EDDP 0.21 1.05 0.29 1.47 0.23 1.13 0.01 0.03 0.04 0.20
Codeine 0.74 3.71 1.46 7.31 2.56 12.8 0.04 0.21 0.33 1.66
Norcodeine 2.88 9.52 8.32 27.4 8.53 28.2 0.19 0.64 1.26 4.17
Dihydrocodeine 0.23 0.75 0.55 1.83 0.88 2.89 0.02 0.05 0.11 0.36
Tramadol 0.08 8.20 0.21 21.3 0.30 30.0 0.01 0.62 0.03 3.26
N-Desmethyltramadol 0.12 5.92 0.30 15.0 0.56 27.9 0.01 0.30 0.04 2.02
O-Desmethyltramadol 0.09 8.53 0.28 27.8 0.31 31.4 – – – –
Stimulants and metabolites Amphetamine 0.68 2.23 1.11 3.65 1.23 4.07 0.01 0.05 0.09 0.29
Methamphetamine 0.32 1.05 0.71 2.35 0.95 3.13 0.01 0.04 0.09 0.30
MDMA 0.10 0.50 0.27 1.35 0.34 1.70 0.01 0.03 0.04 0.18
MDA 0.53 1.74 1.00 3.30 0.99 3.26 – – – –
Cocaine 0.07 0.35 0.22 1.11 0.46 2.31 0.01 0.03 0.03 0.15
Benzoylecgonine 0.07 0.34 0.18 0.91 0.21 1.07 0.005 0.02 0.03 0.14
Anhydroecgonine
methyl ester
0.93 4.67 1.99 9.96 2.95 14.8 – – – –
Cocaethylene 0.07 0.35 0.21 1.04 1.31 6.54 0.01 0.03 0.03 0.17
Mephedrone 0.22 1.09 0.44 2.19 0.55 2.75 0.01 0.04 0.06 0.31
MDPV 0.04 0.22 0.12 0.59 0.48 2.41 0.01 0.03 0.04 0.20
Opioid and
metabolite
Heroin 0.92 4.62 3.44 17.2 4.18 20.9 0.05 0.25 0.56 2.79




Thiamethoxam 0.13 0.42 0.44 1.46 0.53 1.76 0.01 0.03 0.01 0.02
Imidacloprid 0.04 0.15 0.10 0.33 0.10 0.33 0.01 0.02 – –
Clothianidin 0.06 0.19 0.14 0.47 0.15 0.50 0.004 0.01 – –
Metazachlor 0.02 0.06 0.04 0.14 0.04 0.13 0.002 0.01 0.002 0.01
Terbuthylazine 0.03 0.11 0.07 0.22 0.07 0.23 0.01 0.02 0.01 0.02
Methiocarb 0.13 0.43 0.27 0.91 0.26 0.86 0.01 0.04 0.01 0.04
Dichlofluanid – – – – 25.2 83.8 – – – –
Flufenacet 0.01 0.04 0.02 0.07 0.02 0.07 0.002 0.01 0.002 0.01
Oxadiazon 0.15 0.49 0.26 0.85 0.30 0.98 0.08 0.26 0.05 0.16
Chlorpyrifos 12.9 42.9 8.54 28.5 – – – – 0.33 1.09
Triallate 0.11 0.37 0.20 0.68 0.09 0.31 – – – –
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influent, as this is generally used for plant protection, particularly
against slugs. It is thought to be an unlikely compound to make
its way into influent and thought to enter surfacewaters via direct
application to the environment. Its presence in the sewage treat-
ment works, although in a low concentration, is notable as it may
indicate incorrect disposal, although a higher concentration
would be expected from this. It was recently banned for use as
a molluscicide in 2014, the grace period of which ended the
month before these samples were collected; however, it could
still be used as an insect repellent and seed treatment [46]. Other
pesticides found in influent at this site include imidacloprid and
flufenacet, which are more widely used for vegetable and fruit
crops and may be due to rinsing of food prior to consumption.
However, this needs further detailed investigation.
Of further interest is the presence of veterinary pharmaceuti-
cals in wastewater, and the presence of these can be justified by
considering the number of household pets and the possible dis-
posal route of pet waste down the lavatory. However, it is inter-
esting to note that sulfapyridine (1339.5 ± 330.3 ng L−1) and
ceftiofur (451.8 ± 129.2 ng L−1) are usually reserved for the use
with individual pigs and cows. These levels suggest potential
herd applications, incorrect disposal or unknown contribution
of livestock wastewater to this WwTW. Further investigation is
needed to determine the source and persistence of these levels.
For the solid portion of influent (SPM), 64% of the 98
analytes quantifiable with this method were found. Only a
small fraction of the total concentration can be found in the
SPM, as most CECs, particularly pharmaceuticals, prefer to
partition to the aqueous phase. For example, only a fraction of
the total concentration (6.4%) of bisphenol A (3.64 log Kow)
appears in SPM. However, in this case, the concentrations are
so high in influent that this results in bisphenol A contributing
a large portion of the total measurable concentration of CECs.
Concentrations range from an average concentration of
0.1 ng L−1 to 1383 ng L−1 in SPM (converted to ng L−1 for
simple comparison to influent concentrations). Ketoconazole
prefers to partition to the solid phase with 31% higher average
concentration present in SPM. This is not surprising when
considering its logKow of 4.45. The antidepressants fluoxetine
(4.65 log Kow) and amitriptyline (4.95 log Kow) partition
partially with SPM concentrations at 82% and 73% to that in
influent. The results for fluoxetine are in line with the results
published by Baker and Kasprzyk-Hordern [47]. However,
sorption of amitriptyline is far higher in this study. This to
be expected, as influent is highly variable, and many factors
can affect sorption to solids. Therefore, it is important to ana-
lyse both the liquid and solid compartments of this matrix.
There are fewer CECs in effluent than in influent. Of the
137 analytes quantifiable in effluent, 62% were found at the
WwTW. Generally, these results show lower concentrations
after treatment. However, imatinib, O-desmethyltramadol,
carbamazepine and its epoxide metabolite and venlafaxine
and its metabolite increase in effluent. For metabolites, this
may be due to degradation/metabolism of the parent com-
pound during treatment. For the parent compounds, this may
be due to the undetected presence of conjugatedmetabolites in
influent transforming back to the parent compound. This phe-
nomenon requires more detailed investigation. Comparison of
the influent and effluent concentrations can provide data on
treatment efficiencies. Trickling filters are employed at the
WwTW for the treatment of influent. The results show poor
removal of imidacloprid, tramadol, N-desmethyltramadol,
bicalutamide, ranitidine, cetirizine and fexofenadine.
Acetaminophen, on the other hand, shows high removal of
99%, similar to what is often seen in the literature for conven-
tional activated sludge treatment [11, 48]. Caffeine, its metab-
olite 1,7-dimethylxanthine and metformin are highly removed
but still at high concentrations of 2.9 ± 0.4 μg L−1, 8.4 ±
1.1 μg L−1 and 14.1 ± 0.9 μg L−1, respectively.
In the surface waters downstream of the WwTW, 51% of the
138 analytes that can be quantified are in this matrix. Of partic-
ular noteworthiness is the antidiabetic metformin, which is found
at levels > 3000 ngL−1.Metformin has very high usage, and after
administration, 100% of the dose is excreted unchanged [49].
Caldwell et al. [50] calculated the PNEC of metformin to be
1 mg L−1, based on critical evaluation of previously published
work. This suggests that despite the high environmental levels,
metformin is currently of low risk to this catchment. Within the
literature, many compounds can be found to have different
PNECs due to a lack of consistency in (a) assessment factors
Table 2 (continued)










MDL MQL MDL MQL MDL MQL MDL MQL MDL MQL
Veterinary
pharmaceuticals
Tylosin 1.28 6.39 2.23 11.1 3.27 16.3 – – – –
Sulfapyridine 0.04 0.14 0.11 0.37 0.10 0.33 – – – –
Sarafloxacin 0.83 2.78 2.66 8.86 2.01 6.72 – – – –
Ceftiofur 2.17 7.23 1.32 4.41 1.02 3.39 – – – –
Diazinon 0.03 0.11 0.07 0.23 0.06 0.21 0.00 0.01 0.003 0.01
*Calculated for direct injection
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used, (b) limited sources or databases used in studying
ecotoxicity data and (c) varying criteria in accepting ecotoxicity
study results. This has highlighted the need to harmonise these
methods to ensure PNECs are calculated consistently, to provide
comparable comparisons between studies and to be clearer of the
risks CECs pose to the environment.
Regarding digested solids, the concentrations are in ng g−1
of solid material, which cannot be directly compared to the
concentrations of the other matrices, as it is a combination of
sludge from various parts of the wastewater treatment process.
However, it is an important consideration as a source of CECs
in the environment, due to subsequent direct application to the
land in agricultural practices. Of the 96 analytes that can be
quantified with this method, 55% were found at this site.
Antidepressants are high in concentration, with average con-
centrations of five of the analytes between 126.3 and
782.9 ng g−1. Of the more industrial CECs, methylparaben
and bisphenol A are present in solids at high levels. In particu-
lar, bisphenol A has been quantified at levels exceeding
4000 ng g−1 at this site. Gemfibrozil, an antihyperlipidaemic,
although not found in other matrices at this site, was quantified
in digested solids at a concentration of 849.6 ± 183.8 ng g−1.
This suggests accumulation of gemfibrozil in other sections of
the WwTW that were not analysed. Due to the low MQL, the
lack of incoming concentration during the sampling period sug-
gests occasional loads high in gemfibrozil before the study.
Conclusions
This work presents a validated multi-residue method for the
analysis of 195 compounds in five matrices (3 liquid and 2
solid). These CECs cover a variety classes, both veterinary
and human pharmaceuticals, industrial chemical, personal
care products and pesticides. Application of the method to
environmental matrices has shown that the method is appro-
priate for assessing treatment efficiency, partitioning to solids,
and environmental concentrations. Discussion of the results
has identified several key areas regarding environmental risk
assessment, e.g. PNECs that need to be addressed; however,
that is outside the scope of this paper. The achieved MDL and
MQL concentrations appear low enough to be used to assess
the environmental risk of these CECs. The results show a need
for analysing both the liquid and solid phases within a
WwTW; however, it also indicates a need to monitor all out-
going treated waste materials, e.g. effluent and digested
sludge. This was due to the appearance of gemfibrozil, which
was not present at quantifiable levels in any other matrix at
this site. Overall, this method is suitable to be used in
catchment-based exposure-driven studies to further increase
knowledge of the contribution of CECs by WwTWs to the
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Abstract 
This study provided a holistic understanding of the sources, fate and behaviour of 142 compounds of 
emerging concern (CECs) throughout a river catchment impacted by 5 major urban areas. Of the 
incoming 169.3 kg d-1 of CECs entering the WwTWs, 167.9 kg d-1 was present in the liquid phase of 
influent and 1.4 kg d-1 was present in the solid phase (solid particulate matter, SPM). Analysis of SPM 
was important to determine accurate loads of incoming antidepressants and antifungal compounds, 
which are primarily found in the solid phase. Furthermore, these classes and the plasticiser, bisphenol 
A (BPA) were the highest contributors to CEC load in digested solids. Population normalised loads 
showed little variation across the catchment at 154 ± 12 mg d-1 inhabitant-1 indicating that population 
size is the main driver of CECs in the studied catchment. Across the catchment 154.6 kg d-1 were 
removed from the liquid phase during treatment processes. CECs discharged into surface waters from 
individual WwTWs contributed between 0.19 kg d-1 at WwTW A to 7.3 kg d-1 at WwTW E, which 
correlated strongly with the respective contributing populations. Spatial and temporal variations of 
individual CECs and their respective classes were found in WwTW influent (both solid (influentSPM) 
and liquid phases (influentAQ)) throughout the catchment, showing that different urban areas impact the 
catchment in different ways, with key variables being lifestyle, use of over-the-counter pharmaceuticals 
and industrial activity. Understanding of both spatial and temporal variation of CECs at the catchment 
level helped to identify possible instances of direct disposal, as in the case of carbamazepine. Analysis 
of surface waters throughout the catchment showed increasing mass loads of CECs from upstream of 
WwTW A to downstream at WwTW D, showing clear individual contributions from WwTWs. Many 
CECs were ubiquitous throughout the river water in the catchment. Daily loads ranged from 0.005 g d-
1 (ketamine, WwTW A) up to 1890.3 g d-1 (metformin, WwTW C) for the 84/138 CECs that were 
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detected downstream of the WwTWs. For metformin this represents the equivalent of ~1,890 tablets 
(1,000 mg per tablet) dissolved in the river water downstream of WwTW C. 
Key words: micropollutants, catchment, pharmaceuticals, pesticides, endocrine disruptors, river, 
wastewater, solids 
1. Introduction 
Anthropogenic substances, such as pharmaceuticals, pesticides, plasticizers, UV filters, industrial 
chemicals etc., have been widely recognised to be entering the environment from a variety of sources. 
Many of these substances, particularly pharmaceuticals and personal care products ingredients, enter 
primarily via point sources such as wastewater treatment works (WwTWs), or for other classes such as 
veterinary pharmaceuticals and pesticides, as diffuse sources such as agriculture.  
There are many studies that detail the presence of a range of compounds in a variety of matrices, 
however the majority of this existing work has been focused on one or two classes at a time, or a small 
number of compounds of emerging concern (CECs), primarily in aqueous matrices (Boogaerts et al., 
2019; Loos et al., 2009; Mole and Brooks, 2019; Musolff et al., 2009; Petrie et al., 2014a). There is a 
broad range of existing data (Geissen et al., 2015; Petrie et al., 2014a; Sousa et al., 2018) due to the 
large number of potential substances, matrices, methods, and multiple lines of investigation that can be 
pursued. Much of this data cannot be compared directly due to the different methods utilised, as they 
have different quantification parameters. Even the sampling process can have a huge effect on how the 
results are interpreted, methodological details are often lacking (Ort, C., Lawrence, M. G., 
Rieckermann, J., and Joss, 2010; Ort et al., 2010). 
Work investigating solid matrices such as solid particulate matter (SPM), activated and digested sludge, 
sediments and soils is less common, due to the difficulty of analysing such complicated matrices. 
Analysis of solid matrices alongside liquid matrices is critical for a better understanding of the fate and 
impact of many compounds (Langdon et al., 2012; Petrie et al., 2014a). Some CECs, such as 
antidepressants, are excreted in or adsorb to SPM before they reach the WwTWs, as well as being 
released during treatment (Baker and Kasprzyk-Hordern, 2011). The solids produced during WwTW 
processes, are treated to remove excess water and dangerous pathogens by a variety of processes. This 
digested sludge, usually termed ‘biosolids’ is often applied directly to soil as it is rich in nutrients 
suitable for crops (Kinney et al., 2006; Langdon et al., 2012), but these biosolids have been widely 




Despite the limitations of studies discussed above, they clearly show that a single wastewater or 
environmental sample can or has the potential to contain many different CECs from different classes. 
Furthermore, many studies have shown the products of metabolism, degradation and transformation of 
many of these CECs are/have the potential to also be present. Overall this leads to a very complex issue 
in understanding true exposure levels in the environment and the potential risk they may pose.  
Identification of mixtures of co-occurring, high risk CECs, or priority mixtures, is one of the challenges 
in water quality monitoring (Altenburger et al., 2015). To gain further understanding of these mixtures, 
their consistency/fluxes within the environment will allow a better understanding of the environmental 
risk posed by these CECs. Understanding the fluxes of these mixtures will allow the potential changes 
in risks to be anticipated, potentially leading to optimised treatment and mitigation of risk to the 
environment. Currently, further work is required to investigate the composition of the mixture in 
samples from a range of matrices. This will not only require analysis of the mixtures present, but it will 
provide insight into spatial and temporal trends, between matrices and across a catchment. 
The aim of the paper is to investigate the changes in micropollutant load throughout a river catchment 
system in the South-West of the UK, to gain further information on their sources, fate and behaviour. 
This was achieved by undertaking a comprehensive investigation of 142 CECs, previously prioritised 
and analytical method validated (Proctor et al., 2019), at five strategic WwTWs representing >75% of 
the catchment population. At each WwTW, influent (both liquid and solid phases) and effluent 
wastewater, digested solids, and upstream and downstream river water were monitored for 7 
consecutive days. Five aspects were considered: 1) spatial and temporal variations in the influent, 2) 
partitioning between aqueous (influentAQ) and solid phases (influentSPM) in the influent, 3) percentage 
removal of CECs from the liquid phase, 4) mixture profiles of CECs in all matrices, and 5) spatial trends 
in river water composition throughout the catchment. This provides a high resolution and more holistic 
view of the distribution of these CECs throughout the catchment.
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Benzophenone-1 4 4 4 3 3 Anaesthetic and 
metabolite 
Ketamine 2 2 2 2 2 
Benzophenone-2      Norketamine      
Benzophenone-3      
Anti-depressants 
Venlafaxine 12 12 13 13 12 
Benzophenone-4      Desvenlafaxine      
Parabens 
Methylparaben 4 4 4 4 4 Fluoxetine      
Ethylparaben      Norfluoxetine      
Propylparaben      Sertraline      
Butylparaben      Mirtazapine      
Plasticizer Bisphenol-A 1 1 1 1 1 Citalopram      
Steroid Estrogens 
E1 3 3 3 2 2 Desmethylcitalopram      
E2      Paroxetine      
EE2      Duloxetine      
Antibiotics and 
Antibacterial 
Sulfasalazine 19 20 19 7 7 Amitriptyline      
Clarithromycin      Nortriptyline      
Azithromycin      Norsertraline      
Trimethoprim      
Anti-epileptic 
Carbamazepine 3 3 3 2 2 
Sulfamethoxazole      Carbamazepine10,11-epoxide      
Triclosan 
     
10,11-Dihydro-10-
hydroxycarbamazepine 
     
Amoxicillin      Calcium-channel 
blocker 
Diltiazem 2 2 2 1 1 
Metronidazole      Verapamil 
     
Sulfadiazine      
Hypnotic 
Temazepam 3 3 3 2 2 
Cefalexin       Oxazepam 
     
Ofloxacin      Diazepam 
     
Ciprofloxacin      Anti-psychotic 
Quetiapine 2 2 2 2 2 
Tetracycline      Risperidone 
     
Danofloxacin      Dementia 
Donepezil 2 2 2 2 2 
Oxytetracycline      Memantine 
     
Chloramphenicol      Creatinine Creatinine 5 5 5 2 2 
Penicillin G      
Lifestyle 
Chemicals 
Nicotine      
Penicillin V      Caffeine 
     
Erythromycin      Cotinine 
     
Prulifloxacin      1,7 dimethylxantine 
     
Norfloxacin      
Analgaesics and 
Metabolites 
Morphine 11 11 11 10 10 
Antifungal 
Griseofulvin 2 2 2 2 2 Dihydromorphine      
Ketoconazole      Normorphine      
Hypertension 
Valsartan 3 3 3 1 1 Methadone      
Irbesartan      EDDP      
Lisinopril      Codeine      
NSAIDs 
Ketoprofen 5 5 5 5 5 Norcodeine      
Ibuprofen      Dihydrocodeine      
Naproxen      Tramadol      
Diclofenac      N-desmethyltramadol      
Acetaminophen      O-desmethyltramadol      
Lipid regulator 
Bezafibrate 2 2 2 1 1 
Stimulants and 
metabolites 
Amphetamine 10 10 10 8 8 
Atorvostatin      Methamphetamine      
Anti-hyperlipidemic Gemfibrozil 1 1 1 0 1 MDMA      
Anti-hyperintensive Candesartan Cilexetil 1 0 0 0 0 MDA      
Antihistamine 
Fexofenadine 2 2 2 0 0 Cocaine      
Cetirizine      Benzoylecgonine      
GUD/ED Sildenafil 1 1 1 1 1 Anhydroecgonine methylester      
Antidiabetics 
Metformin 3 3 3 1 1 Cocaethylene      
Gliclazide      Mephedrone      
Sitagliptin      MDPV      
Cough suppressant Pholcodine 1 1 1 1 1 Opioid and 
metabolite 
Heroin 2 2 2 1 1 
Beta-blocker 
Atenolol 4 4 4 4 4 6-acetylmorphine      




Thiamethoxam 10 10 10 8 7 
Propranolol      Imidacloprid      
Bisoprolol      Clothiniadin      
H2 receptor agonist 
Ranitidine 2 2 2 1 1 Metazachlor      
Cimetidine      Terbuthylazine      
X-ray contrast media Iopromide 1 1 1 1 1 Methiocarb      
Various Buprenorphine 1 1 1 1 1 Dichlofluanid      
Drug precursor 
Ephedrine/pseudoephedrine 2 2 2 2 2 Flufenacet      
Norephedrine      Oxadiazon      
Anti-cancer 
Azathioprine 7 7 7 5 5 Chlorpyrifos      
Methotrexate      Triallate      
Ifosfamide      
Veterinary 
Pharma 
Tylosin 5 5 5 1 1 
Tamoxifen      Sulfapyridine      
Imatinib      Sarafloxacin      
Capecitabine      Ceftiofur 
     
Bicalutamide      Diazinon           
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2. Materials and methods 
2.1. Materials 
All materials used in the investigation are detailed in the Supporting information (SI), Section S1. The 
analytical standards were of the highest purity possible and purchased from Sigma Aldrich, LGC 
standards or Toronto Research Chemicals (TRC). The solvents used were of HPLC grade. All glassware 
was silonised to prevent losses of analytes to the untreated glassware. The classes covered by this study 
are shown in Table 1. Due to the wide range of CECs and complex matrices, not all CECs could be 
validated for every matrix. Table 1 shows the CECs which are present in each class (green box) and 
which are validated for each matrix (Proctor et al., 2019). 
2.2. Sampling methods and location 
Samples were collected at each of the five WwTWs (A-E) for 7 consecutive days between June and 
October 2015. The five WwTWs utilise a range of treatment technology and different sized populations 
(Table 2). Sampling was carried out using volume proportional sampling for influent wastewater, time-
proportional for effluent and grab sampling for river water upstream and downstream of the effluent 
discharge point (sample point distance from discharge point is in Table 2). Digested sludge was 
collected, via grab sampling, on three consecutive days from WwTW B and WwTW E. Further detail 
and discussion on the methods and location used can be found in the SI: Section S1, 2.1 and 2.2. 
2.3. Sample preparation and analysis 
Liquid samples were spiked with internal standards and analytes extracted by solid phase extraction 
(SPE) using OASIS HLB cartridges before analysis with ultra-performance liquid chromatography 
coupled with tandem mass spectrometry (UPLC-MS/MS) (Waters). The solid samples were frozen, 
freeze-dried, homogenised, weighed and spiked with internal standard before undergoing microwave 
assisted extraction (MAE) followed by SPE with OASIS MCX cartridges. Further detail and discussion 
on the methods used can be found in the SI, Section S1, 2.3. 
2.4. Quality control  
To ensure the quality of generated data, spiked quality control samples were analysed for both liquid 
and solid matrices. All samples were spiked with internal standards to compensate for matrix 
suppression effects, as well as any losses of analyte during sample preparation. All sample analysis was 
performed in duplicate. 
A further element of quality control was considered with regards to river water sampling. To ensure 
downstream river waters were completely mixed with effluent, mass balances were estimated for 
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Table 2 Site information of studied STWs and corresponding river locations   
 




























Up Down  
A <0.5-4 AS 19 46.2 n/a 
Carbonaceou
s & nitrifying 
37,000 0.4 % 
8,242 ± 
3,085 
0.5 n/ad n/ad 
B <0.5-4 TF n/a 24.5 Stone 
Carbonaceou
s & nitrifying 
67,870 30.0 % 
11,202 ± 
3,202 
0.5 0.5 102 










2 2 111 






s & nitrifying 
17,638 0.1 % 
2,924 ± 
199 
1 1 97 
E <1-24 
90 % SBR 













n/ae n/a n/a 
Key: WwTW, wastewater treatment process; SWRT, sewer residence time; SRT, solids retention time; HRT, hydraulic retention 
time; p, ‘pulses’ or toilet flushes, AS, activated sludge; TF, trickling filter; SBR, sequencing batch reactor 
a Under typical summer flows 
bAll WwTWs utilised primary sedimentation dosed with ferric sulfate for phosphorus removal and all processes used 
conventional sedimentation following secondary treatment except SBRs which decanted following settling in-situ 
cMass balances were calculated according to: 𝑀𝑎𝑠𝑠 𝑏𝑎𝑙𝑎𝑛𝑐𝑒 (%) =
𝐷𝑜𝑤𝑛𝑠𝑡𝑟𝑒𝑎𝑚
𝑈𝑝𝑠𝑡𝑟𝑒𝑎𝑚+ 𝐸𝑓𝑓𝑙𝑢𝑒𝑛𝑡
× 100 where Downstream is the load of 
carbamazepine in river water downstream of the effluent discharge point (g d-1), Upstream is the load of carbamazepine in river 
water upstream of the effluent discharge point (g d-1) and Effluent is the load of carbamazepine in effluent (g d-1) 
d Mass balance at site E was > 400 % demonstrating complete mixing of effluent and river water was not achieved at the 
sampling point due to restricted access to river.  Therefore mass loads in river water downstream of the discharge point was 
calculated by adding effluent loads with river water loads upstream of the discharge point.  This assumes complete mixing 
without any micropollutants losses.  Micropollutant concentrations in downstream river water were then estimated using river 
flow data.    
e Effluent discharged into estuary 
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carbamazepine (e.g. Equation 1). Carbamazepine was selected due to its resistance to biological 
degradation and photodegradation, which is expected to be negligible over the short distances between 
sampling points (Heberer, 2002). Further discussion of this can be found in the SI, Section S1, 2.2.1 
and Section S2 and results can be found in Table 2. 
3. Results and discussion 
The discussion of results in this paper is primarily in loads, i.e. g d-1, as it allows direct comparison 
between different matrices and sites. Number of CECs per class (c) and number of samples with 
measurable concentration in each matrix (n) are discussed for some CECs within the text and can be 
found for all classes in Table 1. General chemical information and physicochemical parameters of the 
CECs of interest is gathered in Table S8. Further information is available in the SI. 
3.1. Solid-liquid phase distribution of CECs within communal discharges  
Overall, 112 of the 138 CECs quantifiable in influentAQ were detected at least once during the study 
entering the five WwTWs. 74 of the 96 micropollutants were quantified in influentSPM. 39 of which 
were found in all influentAQ and influentSPM samples with classes ranging from antidepressants, 
analgesics and their metabolites to illicit stimulants e.g. cocaine and industrial chemicals such as 
parabens, the plasticiser BPA and the UV filter, benzophenone-1.   
The chemical content of each phase of influent is distinctly different (Figure 1 and 2). With lifestyle 
chemicals, such as caffeine, nicotine and their metabolites, NSAIDs (and acetaminophen) and 
antidiabetics, predominantly found in the aqueous phase (99.4 %, 99.8 % and 96.2 % of the total load 
of each chemical present in the aqueous phase, on average across the catchment) and making up the 
majority of the incoming wastewater. Whilst influentSPM, is primarily made up of the plasticiser, BPA 
(69.6 %), antidepressants (12.9 %) and antifungals (4.1 %). The latter two of which in particular show 
high levels of sorption to the solid phase over the aqueous, 36.3 % (including metabolites) and 55.4 % 
respectively.  
Much of the differences between the influentAQ and influentSPM, is of course likely due to the 
physicochemical characteristics of these compounds such as their log Kow, and water solubility. For 
example, the NSAIDs: ibuprofen, naproxen and acetaminophen have log Kow values of 3.79, 3.10 and 
0.29 respectively and water solubility of 41.1, 145, and 30400 mg L-1 and all are primarily found in 
influentAQ (0.3%, 0.3% and 0.01% of the total load of each compound). These levels of partitioning are 
far lower than previously reported by Samaras et al. (Samaras et al., 2013), however similar phase 
distribution was shown by Petrie et al. for crude wastewater (Petrie et al., 2014b). This may be due to 
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UV Filter (1) Parabens (2) Plasticizer (3)
Steroids (4) Antibiotic (5) Antifungal (6)
Hypertension (7) NSAIDs (8) Lipid regulator (9)
Anti-hyperlipidemic (10) Anti-hyperintensive (11) Antihistamine (12)
GUD/ED (13) Anti-diabetics (14) Cough suppressant (15)
Beta-blocker (16) H2 receptor agonist (17) X-ray contrast media (18)
Various (19) Drug precursor (20) Anti-cancer (21)
Anaesthetic and metabolite (22) Antidepressants (23) Anti-epileptic (24)
Calcium-channel blocker (25) Hypnotic (26) Anti-psychotic (27)
Dementia (28) Lifestyle Chemicals (29) Analgaesics and Metabolites (30)



























































































































































































Figure 1 Weekly percentage of total loads in influentAQ of the entire catchment as a pie chart of classes, 
with chart showing spatial and temporal trends. Note: creatinine is not included.0.0% shows negligible to 
no contribution to the total. Numbers in brackets indicate numbers assigned for identification in small 
figures and table 
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(e.g. pH). Despite these low levels of partitioning, ibuprofen, naproxen and acetaminophen are in the 
top 20 CEC contributors (16, 12, 11 respectively) to total influentSPM load in this study with daily loads 
of 8.6, 10.1, 11.8 g d-1 (or 6.0 – 9.1 mg d-1 1000 inh-1 (ibuprofen), 5.7 – 12.8 mg d-1 1000 inh-1 (naproxen) 
and 4.6 – 13.2 mg d-1 1000 inh-1 (acetaminophen) if considering population normalised loads). Within 
influentSPM these three painkillers show similar loads, however with the influentAQ phase, 
acetaminophen has a much higher normalised load; 44.8 – 77.0 g d-1 1000 inh-1 (18.0 % daily variation 
across the catchment). Whilst, loads for naproxen and ibuprofen were much lower with 3.1 ± 0.6 g d-1 
1,000 inh-1 and 2.7 ± 0.7 g d-1 1,000 inh-1 respectively. These pharmaceuticals are commonly found in 
the influentAQ of many WwTWs across the globe, due to their high usage and availability without a 
prescription (Sousa et al., 2018). This is despite low excretion rates due to the extensive metabolism of 
these NSAIDs (Luo et al., 2014). These results are similar to those found by Mendoza et al., where 
ibuprofen, naproxen and acetaminophen were found to be the most abundant pharmaceuticals of the 
study (Mendoza et al., 2015; Paíga et al., 2019). Diclofenac and ketoprofen, which are not so readily 
available over the counter in the UK, present much lower loads (131.2 ± 37.9 mg d-1 1,000 inh-1 (n = 
35) and 8.7 ± 17.5 mg d -1 1,000 inh-1, (n = 7) respectively) in influentAQ and less frequently in the case 
of ketoprofen, which only appears at WwTW E. Despite their worldwide use and abundance, their 
presence in influentSPM is often overlooked. 
As previously mentioned, antidepressants and antifungals are two classes for which a high proportion 
of the total incoming load can be found within influentSPM (36.3% and 55.4 % respectively). 
Antidepressants (no. of analytes = 13) contribute 12.9 % to the total influentSPM load and antifungals 
(no. of analytes = 2) contribute 4.1 % (Figure 2). All antidepressants and metabolites in this study, apart 
from paroxetine (3.95 log Kow, 35.3 mg L-1 water solubility) and duloxetine (4.68 log Kow, 13.0 mg L-
1) can be found in influentSPM. With log Kow of the parent compound ranging from 3.28 (venlafaxine) to 
5.29 (sertraline), the percentage of the total load of each compound found in influentSPM is between 2.9 
% (venlafaxine) to 67.0 % (sertraline). These results are not unusual and similar data has been obtained 
from wastewater samples collected in a week long study in the Czech Republic (CR) and over a yearlong 
study in the UK by Baker et al., (Baker et al., 2012; Baker and Kasprzyk-Hordern, 2013). The presence 
of antifungals, on the other hand, is primarily due to ketoconazole (log Kow 4.45). This CEC is primarily 
found in the influentSPM, with 55.8 % of the load in this phase. This result is comparable to a study by 
Peng et al. (Peng et al., 2012), who also found ketoconazole primarily in influentSPM. In that study, other 
azoles were also analysed, such as fluconazole, clotrimazole, miconazole, and econazole, all of which 
were found in influentSPM only and not influentAQ, showing that this may be a key matrix to investigate 
for this class and a wider range of antifungals should be considered in future.  
Overall lifestyle chemicals, have the highest contribution to this catchment with 38.6% of the load, 
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Steroids (4) Antibiotic (5) Antifungal (6)
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Beta-blocker (16) H2 receptor agonist (17) X-ray contrast media (18)
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Figure 2 Weekly percentage of total loads in influentSPM of the entire catchment as a pie chart of classes, 
with chart showing spatial and temporal trends. Note: creatinine is not included. 0.0% shows negligible to 
no contribution to the total. Numbers in brackets indicate numbers assigned for identification in small 
figures and table 
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seven days of sampling at each of the five sites (n = 35), shows caffeine has one of the lowest daily load 
variations (23.1 %) of most compounds in this study. The other lifestyle chemicals show more variation; 
1,7-dimethylxanthine (26.5 %), nicotine (42.5 %) and its metabolite cotinine (26.2 %) and creatinine 
(52.1 %). This can provide some insight into the patterns of people’s lifestyle habits across a catchment.  
As an example, wastewater-based epidemiology was applied to caffeine and its metabolite 1,7-
dimethylxanthine (methodological details can be found in the SI, Section S3, 1.2.1) to understand usage 
patterns across the catchment. Overall it was found the loads present suggest an intake of 26 – 57 mg 
of caffeine per person per day, which is in line with a cup of coffee of a few cups of black tea per day 
(de Mejia and Ramirez-Mares, 2014; Wishart et al., 2018).    
The loads calculated in influentSPM represent a large proportion of antidepressants and antifungals but 
also for other individual compounds; the anti-cancer drug imatinib (39.9 % partitioning to influentSPM) 
and the anti-psychotic risperidone (87.7 % partitioning to influentSPM). For some CECs, such as 
verapamil, thiamethoxam, oxadiazon, methiocarb and donepezil, influentSPM represents all of the total 
load for these compounds and is therefore the primary route of entry of these CECs to the environment, 
which may have gone undetected in studies which focus only on the influentAQ. SPM matrix is therefore 
key to understanding the fate of these classes and CECs. 
Various factors are considered important in the consideration of partitioning between liquid and solid 
phases, these include, water solubility, log Kow, partition coefficient (Kd), log Dow, as well as a 
compounds polarity and structure. In theory, the likelihood of a compound to sorb to the solid phase 
increases with log Kow (Hyland et al., 2012). In this study, when considering the classes individually, 
there is some correlation between these factors, however, considering the full range of CECs the 
simplistic model of ‘the higher the log Kow, the more partitioning to solids’ cannot be easily applied. 
Further work is needed to understand this behaviour. 
3.2. Spatial and temporal CEC trends in WwTWs 
3.2.1. Overall spatial and temporal trends of CEC loads  
The spatial and temporal trends (Figure 1 and 2) of the overall load, in both influentAQ and influentSPM,  
shows that similar chemical speciation between these two matrices is observed across all WwTWs 
within this catchment, with the loads in influentAQ  being primarily driven by  population size (Table 
S3 and Figure 1). The five WwTWs ranged in size from 18,274 to 867,244 population equivalents. The 
incoming flow ratio of residential population to commercial/trade also varied from site to site, which is 
displayed as a percentage of the total population equivalents in Table 2. However, influentSPM, (Table 
S4 and Figure 2) shows there is far more temporal and spatial variation than appears in the influentAQ.  
3.2.1.1. Industrial chemicals 
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Figure 1 shows a correlation can be seen between higher industrial contributions to wastewater seen at 
WwTW B (30.0%) and E (23.9%),the total weekly load of BPA, UV filters and parabens and 
particularly the weekly influentSPM load e.g. 92.8 g week-1 (B) to 6522 g week-1 (E) (BPA), 2.9 g week-
1 (B) to 10.3 g week-1 (E) (UV filters), and 14.8 g week-1 (B) to 218.5 g week-1 (E) (parabens) compared 
with 7.5 g week-1 (D) to 23.6 g week-1 (C), 0.1 g week-1 (D) to 0.6 g week-1 (C), 1.2 g week-1 (D) to 5.0 
g week-1 (C) respectively at the other WwTWs. This can also be seen in the population normalised loads 
(Figure 1 and 2), although the correlation is far clearer in the influentSPM, than the influentAQ. BPA, in 
particular, contributes 45.4 % (WwTW B) to 72.8 % (WwTW E) to the total load of influentSPM 
throughout the campaign. This equates to total population equivalent normalised loads of 29.5 – 694.3 
mg d-1 1,000 inh-1 and 40.6 – 2827 mg d-1 1,000 inh-1 for WwTWs B and E, respectively. When 
comparing these results to the 7.0 %, 10.8 % and 16.8 % (partitioning to influentSPM) or 6.7 mg d-1 1,000 
inh-1 (minimum at C) to 307.2 mg d-1 1,000 inh-1 (maximum at D), it is a considerable portion. 
Furthermore, clear temporal trends can also be seen for BPA in both phases (Figure S3), showing 
increasing levels throughout the working week, reducing to lower levels over the weekend. The 
presence of BPA in domestic wastewater has previously been linked to leaching from plastics, such as 
pipes or drinking bottles which would account for the low level loads commonly seen (Flint et al., 2012; 
Petrie et al., 2019; Rubin, 2011). The increase levels from industrial waste may be linked to the 
production of epoxy resins, polycarbonate plastics and thermoprinting paper, however it has not been 
linked to a specific trade within this catchment at this time. The presence and trends of this compound 
in this catchment is described in more detail by Petrie et al. and Lopardo et al. (Lopardo et al., 2019; 
Petrie et al., 2019). 
The personal care product ingredient methylparaben, also shows specific industrial spatial and temporal 
trends. It is present at a constant level across the week at WwTWs A, C and D, with normalised loads 
in influentAQ ranging from 564.6 – 976.1 mg d-1 1,000 inh-1. It is often found in personal care products 
such as shampoos and shower gels. Therefore, for this CEC, a consistent level across the week is 
expected. However, at WwTWs with higher industrial input e.g. WwTW B and E, the trends seen in 
influentAQ show significant increase of methylparaben on certain days of the week, which may be as a 
result of relevant industrial processes, such as toiletry manufacture, which is known to be present in the 
area. These trends can be seen in both influentAQ and influentSPM (FigureS3), as levels increase from 
across the working week and decrease over the weekend (up to 16,242 mg d-1 1000 inh-1 on Thursday 
to 681.0 mg d-1 1,000 inh-1 on Sunday in influentAQ and up to 48.2 mg d-1 1,000 inh-1 on Thursday to 
8.5 mg d-1 1,000 inh-1 on Sunday in influentSPM at WwTW B, whereas for WwTW E the trends are 
strongest in the influentSPM with trends increasing up to 41.9 mg d-1 1,000 inh-1 on Friday to 15.5 mg d-
1 1,000 inh-1 on Sunday). The influence of industrial activity on the highly variable loads of these 
chemicals, may have a significant environmental impact, if they are not effectively removed.  
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3.2.1.2. Illicit drugs 
Spatial trends were also observed for some illicit stimulants, demonstrating variation in the usage 
behaviour throughout the catchment area. It was postulated that those areas with the greater population 
size and night life (WwTWs C and E) would see the greater loads of illicit stimulants (e.g. MDMA, 
cocaine, amphetamine and mephedrone) due to recreational usage. Cocaine, amphetamine and MDMA 
followed this trend. For example, at WwTWs C and E, total MDMA loads (sum of both influentAQ and 
influentSPM) were found up to 120.8 and 157.1 mg d-1 1,000 inh-1 respectively (Tables S3 and S4). At 
the remaining sites, maximum loads were found in the range 33.3 – 79.9 mg d-1 1,000 inh-1. Previous 
studies have found cocaine, amphetamine and MDMA use to be greater in large urban populations than 
in smaller more rural locations (Lai et al., 2016; Nefau et al., 2013). In contrast, mephedrone loads were 
highest at WwTW D which treats wastewater from the smallest population size (18,274 inhabitants). 
Total influent loads ranged between 13.1 and 38.9 mg d-1 1,000 inh-1 in comparison to loads of 3.8 to 
8.5 mg d-1 1,000 inh-1 at WwTW C and 7.2 to 20.5 mg d-1 1,000 inh-1 at WwTW E (Table S3 and S4). 
Mephedrone was not detected in wastewater at WwTWs A and B.   
The weekly trends for stimulants are also very pronounced (Figure S2). There was an increasing 
weekend load of not only MDMA and cocaine but also their metabolites: MDA (MDMA), 
benzoylecgonine (cocaine) and cocaethylene (combination of cocaine and alcohol), but not 
anhydroecgonine methylester (metabolite from smoking crack cocaine). This shows increased usage of 
both MDMA and cocaine throughout the catchment during the weekend, though this is less pronounced 
in areas that are less populated, more rural and with less night life. These trends have previously been 
seen on numerous occasions across the world (US, (Gushgari et al., 2018), Czech Republic (Baker et 
al., 2012), England and Europe (Castrignanò et al., 2018b), China (Zhang et al., 2019). The trends, 
shown in Figure S3, can also been seen in influentSPM for both cocaine, benzoylecgonine and MDMA, 
despite there being proportionately less load present in influentSPM, 1.4 %, 0.1 %, and 0.9 % respectively. 
Interestingly, a spike in load is observed on one day for influentSPM, rather than over the entire weekend 
for influentAQ.  
3.2.1.3. Pharmaceuticals linked to hospital effluent 
Total population normalised loads of the analgesic morphine were greater at WwTWs C and E. With 
ranges between 377.5 to 607.6 mg d-1 1,000 inh-1 at WwTW C and 372.2 to 443.1 mg d-1 1,000 inh-1 at 
WwTW E, compared to the other sites which ranged between 184.5 mg d-1 1,000 inh-1 at WwTW A to 
284.9 mg d-1 1,000 inh-1, also at WwTW A (the ranges of the remaining two WwTWs are quite similar 
and fall within this range (Tables S3 and S4). Higher morphine loads at WwTWs C and E can be 
attributed to hospitals within their catchment areas, similar to a study conducted in Portugal, which 
found that 51 % of the total analgesic load in municipal wastewater was from hospitals (Santos et al., 
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2013). However, within this catchment a more detailed investigation is required to confirm the 
contribution of hospital wastewater. Furthermore, the anti-cancer drug ifosfamide was only detected in 
wastewater at WwTWs C and E (Table S3 and Table S4). Although ifosfamide is not directly linked to 
hospital wastewater, as it can be excreted from the homes of patients receiving chemotherapy, it was 
not detected at WwTWs which did not receive hospital wastewater. 
3.2.1.4. Lifestyle chemicals and pharmaceuticals 
Many CECs, such as lifestyle chemicals and some NSAIDs, which are freely available without 
prescription and used widely, show little variation between sites across the catchment e.g. caffeine, with 
average loads of 23,826 ± 5,498 mg d-1 1,000 inh-1, showing 23.1% daily variation across the catchment, 
acetaminophen, with 58,374 ± 10,494 mg d-1 1,000 inh-1 and 18.0%, and ibuprofen with 3,092 ± 629 
mg d-1 1,000 inh-1 and 20.4%. 
This trend continues with many pharmaceuticals which are prescribed widely for chronic conditions 
e.g. the anti-diabetic, metformin, (daily variation across the catchment = 21.5 %, with average total 
influent load of 20,260 ± 4,357 mg d -1 1,000 inh-1), analgesic for moderate pain, tramadol, (17.4 %, 
241.3 ± 42.1 mg d-1 1,000 inh-1), and the antidepressants, citalopram (14.5 %, 108.0 ± 15.6 mg d-1 1,000 
inh-1) and amitriptyline (20.5 %, 53.9 ± 11.1 mg d -1 1,000 inh-1). Interestingly, compounds in the same 
class, which appear at much lower loads, show more spatial variation and minimal temporal variation 
e.g. the anti-diabetic, sitagliptin (35.7 %, 70.2 ± 25.0 mg d-1 1,000 inh-1), and the antidepressant, 
fluoxetine (41.0 %, 20.7 ± 8.5 mg d-1 1,000 inh-1). This may be a sign of variation in prescribing 
behaviour of healthcare professionals (Rowlingson et al., 2013), spatial variation in the prevalence of 
relevant conditions, or it may be due to differences in the stability of the pharmaceutical within the 
sewer and the difference in sewer residence time to the site. This has been found to be an issue with 
illicit drug monitoring and other pharmaceuticals have shown the potential to degrade within sewers 
(Gao et al., 2017; Jelic et al., 2015; McCall et al., 2016). Further investigation is required to provide a 
more detailed assessment. 
Antibiotics and antibacterial compounds (c = 19), only contribute a small proportion, 1.1 %, to the total 
influentAQ load, and influentSPM load, 1.0% (c =7). Several of these CECs, such as sulfasalazine, 
clarithromycin, azithromycin, trimethoprim, sulfamethoxazole and triclosan were found in all 
influentAQ samples at all WwTWs (with the exception of azithromycin, which was missing from one 
sample at WwTW A), but showed highly variable population normalised loads (Table S3). Within 
influentSPM, only trimethoprim was found in all samples, ranging from 1.4 mg d-1 1,000 inh-1 at WwTW 
B to 13.7 mg d-1 1,000 inh-1 at WwTW C. Few other antibiotics were found in SPM, only sulfadiazine 
was found with some regularity and only at WwTW B (100% of samples at population normalised loads 
between 0.9 to 2.2 mg d-1 1,000 inh-1). Unfortunately, this method was unable to quantify 
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fluoroquinolones in this matrix, a class of antibiotics known for their ability to partition to the solid 
phase (Castrignanò et al., 2018a; Martín et al., 2015; Petrie et al., 2014b), therefore the antibiotic load 
of this matrix is likely to be underestimated for these compounds. Despite this it is clear that these 
compounds are widely used (from influentAQ results) and two, azithromycin and clarithromycin, have 
been placed on the WFD Watch List as substances of potential environmental concern (Carvalho et al., 
2015).  
Ciprofloxacin and erythromycin are also present on this list and yet within this catchment they are 
detected less frequently within the influentAQ (n = 7 and 21), though their loads, when found, are 
significant (ciprofloxacin 15.8 ± 10.6 g d-1 at WwTW A only, and erythromycin is found at levels 
between 9.0 ± 1.9 g d-1 at WwTW D to 189.6 ± 13.6 g d-1 at WwTW E). Other antibiotics, such as 
metronidazole, sulfadiazine, cefalexin, ofloxacin, tetracycline, danofloxacin, and chloramphenicol are 
found sporadically in the influentAQ throughout the catchment, often at lower loads than the other 
antibiotics. Their sporadic presence may be due to limited use. Further consideration of prescription 
levels will provide a clearer understanding, but this is outside the scope of this paper. 
Trends of the population normalised loads for antibiotic and antibacterial compounds show some 
variation between WwTWs and between individual compounds. For example, WwTW B shows the 
highest population normalised loads for sulfasalazine (93.1 ± 28.5 mg d-1 1,000 inh-1 compared to 45.0 
± 15.1 mg d-1 1,000 inh-1 at WwTW A which has the lowest), azithromycin (135.7 ± 70.4 mg d-1 1,000 
inh-1 compared to 21.9 ± 15.5 mg d-1 1,000 inh-1 at the lowest at WwTW A), and triclosan (405.5 ± 
181.1 mg d-1 1,000 inh-1 compared to 154.1 ± 10.2 mg d-1 1,000 inh-1 at the lowest at WwTW C). 
However, WwTW B also has the lowest levels for other antibiotics such as clarithromycin (209.8 ± 
49.4 mg d-1 1,000 inh-1 compared to 369 ± 86.6 mg d-1 1,000 inh-1 at WwTW D), trimethoprim (99.0 ± 
7.8 mg d-1 1,000 inh-1 compared to 247.1 ± 21.5 mg d-1 1,000 inh-1 at WwTW C), and the second lowest 
for sulfamethoxazole levels at 18.8 ± 6.7 mg d-1 1,000 inh-1, which is less than 20 % of the highest levels 
(100.5 ± 6.6 mg d-1 1,000 inh-1 WwTW E). This variation may be due to differences in the prescription 
practices, which could be influenced by variable uptake of prescription advice from the Government as 
part of the UK Five Year Antimicrobial Resistance Strategy  (Department of Health & and Department 
for Environment Food and Rural Affairs United Kingdom, 2013). 
Some CECs, particularly pharmaceuticals, that are regularly and widely used by the population, show 
no temporal trends throughout the week. This is to be expected, as those pharmaceuticals that are 
sporadically but widely used, such as NSAIDs and painkillers e.g. acetaminophen and ibuprofen (Figure 
S2), will show only small variations in load. Other pharmaceuticals, such as antibiotics, are used in 
treating specific conditions and often require courses of several days, but may be prescribed less often, 
so are used less widely. Antibiotics, such as sulfamethoxazole and trimethoprim which are often 
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prescribed together (as co-trimoxazole) as a long administration course (14 - 21 days), show a steady 
trend across the week. Other antibiotics, with typically shorter courses, such as azithromycin, 
clarithromycin, metronidazole and ciprofloxacin, show more variation across the week. To see trends 
of these compounds, longer term studies are required to cover time periods encompassing seasons or 
even years, such as those performed in CR, Greece, Spain, and New Zealand (Golovko et al., 2014; 
Kumar et al., 2019; Mastroianni et al., 2017; Papageorgiou et al., 2016). This would be particularly 
useful for antibiotics as it will indicate whether reducing prescription reduces the influent load and any 
seasonal trends may indicate incorrect prescribing practices (from prescriptions of antibiotics for flu 
during winter months for which it is not effective) (Coutu et al., 2013; Golovko et al., 2014). 
3.2.1.5. Veterinary pharma and pesticides 
Surprisingly, the veterinary antibiotic, sulfapyridine, is present at population normalised loads, for total 
influent, ranging from 205.4 ± 23.8 mg d-1 inh-1 to 299.8 ± 25.8 mg d-1 inh-1 and shows little daily 
variation (17.8 %) across the sampling campaign. It has been found previously at low level in influentAQ 
and its presence has been linked to human use (Ebele et al., 2017; Golovko et al., 2014; Paíga et al., 
2016; Wilkinson et al., 2017) as well as veterinary use (Sarmah et al., 2006). However, this antibiotic 
is no longer prescribed or advised for use by humans in the UK, as it is of critical importance for use 
with food producing animals, but it is also produced during the human metabolism of sulfasalazine 
(European Medicines Agency, 2019; Kasprzyk-Hordern et al., 2008; Peppercorn, 1984; Wishart et al., 
2018). In this study, it is thought this metabolism of sulfasalazine may be the main source contributing 
to sulfapyridine’s consistent presence across the catchment. This can also be seen in the similarity of 
their temporal and spatial trends. It is thought that if the main contributing factor was due to usage on 
livestock, its presence would not be consistent across the catchment, as large variances between rural 
areas (WwTW B) and highly urban areas (WwTW E) would be expected. Furthermore, the similarity 
in temporal and spatial trends with sulfasalazine would be very unlikely. Sarafloxacin and diazinon 
were the only other veterinary pharmaceuticals found, with sarafloxacin only found at in one influentAQ 
sample at WwTW D at 5.7 mg d-1 1000 inh-1 and diazinon found across the catchment in 80% of the 
influentAQ samples and 22.9% of the influentSPM samples at total influent loads ranging from 0.6 mg d-
11000 inh-1 (WwTW C) to 85.5 mg d-1 1000 inh-1 (WwTW E). Interestingly, diazinon is primarily found 
in influent from the larger WwTWs serving the two major cities. This is it perhaps an indication of a 
larger numbers of pets relative to inhabitants in these areas compared to more rural areas, or a higher 
prevalence in the use of deworming medication for which it is primarily used. Overall, veterinary 
pharmaceuticals and pesticides represent a small proportion, < 0.5% of the total influent chemical load, 




3.2.1.6. Anticipated and accidental micropollutant fluxes 
Considering the temporal and spatial distribution of CECs across the catchment allows a better 
understanding over the micropollutant mixtures and fluxes of load that are experienced by the WwTWs, 
allowing for pattern to emerge regarding human behaviour, degradation and seasonal changes in larger 
studies. This will allow the loads and fluxes to be anticipated allowing optimisation of treatment 
technologies for better removal of these contaminants. However, studying the trends in this work 
anomalies can be detected. 
Figure 2 shows a significantly higher proportion of the total load of influentSPM is due to antifungals, 
specifically ketoconazole, as griseofulvin was not found at this site. Ketoconazole was found in all 
influentSPM samples at all sites, showing its frequent and widespread use. At WwTW C however, the 
normalised loads were on average 79.2 ± 35.7 mg d-1 1,000 inh-1 compared to the 27.5 to 50.2 mg d-1 
1,000 inh-1 at the other sites. The high standard deviation seen at WwTW C compared to the other sites 
may be more indicative of incorrect usage, incidental release or direct disposal rather than difference in 
prescription.  
A similar situation is seen at WwTW A, as anti-epileptics represent a far higher proportion of influentSPM 
(25.4 %, Figure 2). This is entirely due to the presence of the parent compound as the metabolite 10,11-
dihydro-10-hydroxycarbamazepine was not detected in influentSPM and the other metabolite, 
carbamazepine-10,11-epoxide could not be analysed in influentSPM. The normalised loads of 
carbamazepine at WwTWs B-E were in the range of <MQL (1 sample at WwTW D) to 5.3 ± 8.0 mg d-
1 1,000 inh-1, whilst at WwTW A they were 119.3 ± 287.4 mg d-1 1,000 inh-1. This standard deviation 
indicates a very skewed distribution of carbamazepine load at WwTW A, which is not consistent for a 
pharmaceutical used solely to treat chronic conditions. This is likely a further example of incorrect 
usage or direct disposal of unused carbamazepine. To gain further understanding of this distribution, 
the temporal trends were considered. 
For ketoconazole, with a normalised load of 79.2 ± 35.7 mg d-1 1,000 inh-1 at WwTW C, it shows high 
daily variation through the week (45.0%) with high loads seen on Monday-Wednesday and lower 
throughout the rest of the week. A similar trend is also seen at WwTW B with the highest loads on 
Tuesday and Wednesday and a daily variation of 44.1 %, the other sites have daily variation of 21.5 – 
29.7 %. From further research, this is likely due to the primary mode of administration of this 
pharmaceutical in the form of a medicated shampoo (based on prescription data from this catchment), 
which is applied one to two times a week for the prevention or treatment of seborrheic dermatitis and 
dandruff (20 mg g-1) and is available both over the counter and with a prescription (National Health 
Service Business Services Authority, 2019; Wishart et al., 2018).  
71 
 
Carbamazepine shows a significant increase in influentSPM load on Sunday at WwTW A, which is not 
seen in the metabolites. In influentAQ, the carbamazepine load increases by >300 %, from the average 
load of 4.3 g d-1 to 12.7 g d -1. Carbamazepine has previously shown no measurable degradation under 
typical sewer conditions (O’Brien et al., 2017), therefore the levels seen are likely unchanged from 
entering the sewer. Within the catchment of this WwTW, this pharmaceutical is mainly administered in 
tablet form as 100, 200, or 400 mg (National Health Service Business Services Authority, 2019; Wishart 
et al., 2018). Therefore, this peak represents disposal of between 21 × 400 mg tablets or 84 × 100 mg 
tablets. In influentSPM, the same trend can be seen, however it occurs to a greater magnitude (from the 
mean of the rest of the week: 0.2 g d-1 to 30.2 g d-1 on Sunday). When influentSPM is combined with 
influent to calculate a total load, the increase is from 4.5 g d-1 to 42.9 g d-1, which suggests disposal 
between 96 × 400 mg tablets or 384 × 100 mg tablets. The percentage partitioning for this day was 
drastically altered from the 3.6 % average for the remainder of the week to the high value to 70 % on 
the day. This is perhaps indicative of the disposal of a highly concentrated solid load.   
Fluoxetine disposal has been previously observed within this catchment, which was attributed to ~915 
pills, as described by Petrie et al. (Petrie et al., 2016), adding to evidence which suggests direct disposal 
of pharmaceuticals is more common than previously thought. Within that study Petrie et al. proposed a 
framework to differentiate between normal, daily usage of these CECs and direct disposal of them in 
influent. It is likely that the use of 24-hour composites with a short period between subsample collection 
allowed these events to be captured. Currently, the effects of these unexpected spikes of CECs are 
unknown. The biological treatments at WwTWs will largely adapt to the everyday fluxes of CEC load, 
however, the sudden increase in CECs such as carbamazepine, ketoconazole or fluoxetine could 
potentially cause changes in the microbiology that reduce treatment efficiency.  Furthermore, these 
events will likely lead to an increase in load and concentration leaving the works, which may cause a 
similar phenomenon with the environmental flora and fauna, as it is exposed to an acute impact of CEC 
load. 
3.2.2. CEC removal from the liquid phase during WwTW treatment 
The catchment-scale study enabled the performance of five WwTWs for the removal of micropollutants 
to be assessed under similar weather conditions (Table S9). Percentage removal (% removal) was 
calculated as described in Section S2, SI. To summarise, it is the percentage reduction in load of a CEC 
between liquid phases of influent (influentAQ) and effluent. The process types monitored include two 
activated sludge treatments, conventional activated sludge (CAS) (WwTWs A and E), and sequencing 
batch reactors (SBRs) (WwTW E). Trickling (rotating biological) filters (TF) configured with different 
bed media were used at the remaining WwTWs (WwTW B, C and D). CAS is generally considered to 
achieve greater micropollutant removals than TFs from collated full-scale data (Baker and Kasprzyk-
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Hordern, 2013; Kasprzyk-Hordern et al., 2009). This is considered to be as a result of longer hydraulic 
retention times (HRT) associated with CAS, enabling greater contact time for biodegradation. HRTs 
for this catchment can be found in Table 2. However, this study found this is not the case for all classes 
of CECs. Figure S1 shows average percentage removals ± relative standard deviation per site and 
overall removal in bar charts, the data for which can be found in Table S7. Figure 3 shows the removal 
data of selected classes of CECs across all WwTWs in the form of box plots. 
The removal of lifestyle chemicals and creatinine were high, with creatinine removed at 99.6 ± 0.9 %, 
caffeine at 97.8 ± 1.8 %, nicotine at 96.6 ± 3.1 %, 1,7-dimethylxanthine at 95.6 ± 3.6 % and cotinine at 
93.2 ± 5.7 %. The CAS and SBR WwTWs (WwTWs A, E) show better removals for caffeine and 
nicotine and significantly better removals for their metabolites. This is in line with removals seen at 
other sites in the UK with TFs and CAS in a study by Baker et al (Baker and Kasprzyk-Hordern, 2013). 
This trend can be seen in the NSAIDs, where this pattern continues with acetaminophen (only slight 
improvement at WwTWs A, E due to such high removal 99.4 ± 0.7 %), ibuprofen (94.4 ± 5.3 %), and 
naproxen (83.0 ± 12.9 %). In contrast, diclofenac shows the best removal at sites with TFs (WwTWs 
B-D, removal range 29.0 – 64.5 %), and worst at WwTW E (-3.0 ± 10.7 %). Ketoprofen showed 11.4 
± 9.9 % removal at WwTW E but was not detected at the other sites and therefore removal cannot be 
determined. The trend seen for the other NSAIDs is consistent with those found by Martín et al. and 
Kasprzyk-Hordern et al., (Kasprzyk-Hordern et al., 2009; Martín et al., 2012). 
The plasticiser, BPA (93.0 ± 3.6 %), and other industrial and personal care product ingredients, 
generally show high removal across the catchment with little variation between sites, such as the UV 
filters (benzophenone-1 with 96.6 ± 3.1 %, benzophenone-2 with 99.6 ± 0.8 %, benzophenone-3 with 
91.7 ± 2.0 %, not benzophenone-4 with 32.6 ± 32.3 % removal however), and all parabens 
(methylparaben with 99.5 ± 0.3 %, ethylparaben with 99.8 ± 0.4 %, propylparaben with 99.2 ± 0.7 % 
and butylparaben with 100.0 ± 0.0 % removal). This is consistent with removals obtained for these 
CECs at sites with TFs and CAS treatment in Wales (Kasprzyk-Hordern et al., 2009). 
Several antidepressants show low-medium level removal with little variation between TF WwTWs B-
D, i.e. citalopram (average removals are between 17.3 to 20.5 %), amitriptyline (50.9 to 57.6 %) and 
sertraline (53.1 to 58.2 %), but show the medium to high levels of removal at CAS WwTW A (51.5 ± 
19.4 %, 87.6 ± 10.2 %, and 54.4 ± 24.1 % for citalopram, amitriptyline and sertraline respectively). 
Kasprzyk-Hordern et al., found similar levels of removal for amitriptyline at both TFs and CAS sites 
(Kasprzyk-Hordern et al., 2009). Mirtazapine shows similar levels of removal for WwTWs A-C (22.0 
± 6.3 %) and had the highest levels of removal at WwTW D (39.8 ± 11.4 %). Venlafaxine saw negative 
removals at WwTWs A-C (-28.8 ± 14.5 %) and, similarly to mirtazapine, showed the highest levels of 
removal at WwTW D, 28.4 ± 23.6 %. Fluoxetine also shows negative removal at WwTW A-B (-53.8
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to -27.4 %), WwTW C showed high highest levels of removal 32.7 ± 8.9 %, no overall removal at 
WwTW D. Both venlafaxine and fluoxetine have previously shown greater removal levels at both TF 
and CAS sites (Baker and Kasprzyk-Hordern, 2013; Verlicchi et al., 2012). WwTW E showed the worst 
removals for all antidepressants, ranging from -81.3 % for fluoxetine to 35.7 % for sertraline (except 
venlafaxine, which showed negligible removal at this site), this may be due to the short hydraulic 
residence time (HRT = 10.9 h) in the main treatment stream (90 % sequencing batch rectors) at this site. 
The antidepressant metabolites were either completely removed (norfluoxetine, norsertraline), similar 
to results found by Baker et al., and Comber et al., (Baker and Kasprzyk-Hordern, 2013; Comber et al., 
2019), were removed similarly to the parent drug (desmethylcitalopram), or increased in load between 
influentAQ and effluent, likely due to degradation of the parent drug into the metabolite (nortriptyline, 
desmethylvenlafaxine), similar to what was found by Baker et al. and Paiga et al., (concentration based 
calculation of removal, rather than load) (Baker and Kasprzyk-Hordern, 2013; Paíga et al., 2019).  
Carbamazepine and its metabolites, carbamazepine-10,11-epoxide and 10,11-dihydro-10-
hydroxycarbamazepine, show increased levels between influentAQ and effluent at the CAS WwTW A. 
10,11-dihydro-10-hydroxycarbamazepine forms O-glucuronides during human metabolism, which can 
be cleaved by β-glucuronidase, from faecal bacteria, leading to this increase (Ta et al., 1999). 
Carbamazepine and carbamazepine-10,11-epoxide, on the other hand, form N-glucuronides during 
human metabolism, which have shown they cannot be degraded by this enzyme but still show increased 
loads in effluent (Bahlmann et al., 2014). 
The lack of degradation for tramadol in this study contrasts with the results found by Baker et al., for 
both TFs and CAS, however, it is comparable to removal levels found by Kasprzyk-Hordern et al., and 
Archer et al., (Archer et al., 2017; Baker and Kasprzyk-Hordern, 2013; Kasprzyk-Hordern et al., 2009). 
The O-desmethyltramadol metabolite can be further metabolised to form O-glucuronides (Wishart et 
al., 2018), which as previously discussed, are cleaved during biological treatment.  
The high removal of the lifestyle chemicals, NSAIDs, parabens and plasticisers has led to a very 
different profile for treated wastewater compared to raw wastewater. This is observed in analgesics and 
metabolites, which represent a quarter of the total load after treatment. Anti-diabetics also show an 
increased proportion of the total load, due to relatively low removal at the WwTWs. Overall, antibiotics 
are poorly removed, < 50 %, although WwTWs A and E have higher levels of removal for sulfasalazine 
(73.7 ± 9.2 % WwTW A and 71.8 ± 3.2 % at WwTW E) and clarithromycin (83.0 ± 9.8 % WwTW A 
and 64.3 ± 7.3 % WwTW E). WwTW E removed 74.2 ± 7.3 % and 68.7 ± 6.1 % of azithromycin and 
sulfamethoxazole respectively, but A has very poor removal for these compounds. WwTWs using 
biological activated sludge have previously shown reasonable removal for these compounds, similar to 
what was seen at WwTW E in this study (Golovko et al., 2014). Furthermore, it shows that long term 
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seasonal changes may have further effects on removal that are not seen in this study, but which should 
be taken into account for the wider picture.  
In summary, although, previously CAS was considered a better micropollutant removal process than 
TFs, this considered a smaller range of compounds (Baker and Kasprzyk-Hordern, 2013; Kasprzyk-
Hordern et al., 2009). The larger range of compounds considered in this study shows this is not so clear 
cut and there is great variation between classes, as well as CECs within the classes. In the next section 
overall mass balance is taken into consideration and may provide a clearer result. 
3.2.3. CEC mass balance in studied WwTWs 
The estimated total mass of 119 of the 138 CECs in this work entering (quantifiable in total influent) 
the WwTW of this catchment is 1,185 kg per week (wk-1) (or 1,847 kg wk-1 with creatinine). InfluentSPM 
contributes only 0.8 % (9.6 kg wk-1) of the total load, but as seen in Figures 1 and 2, it has a very 
different chemical profile. This results in total mass loads of 135 to 167 g d-1 1,000 inh-1 in influent, 
these are far higher than the 2.1 g d-1 1,000 inh-1 mass loads calculated from the work by Castiglioni et 
al., in Italy (based on the sum of the influentAQ loads of five main classes, 5,049 g d-1, divided by the 
estimated population (2,400,000) of the contributing WwTWs)(Castiglioni et al., 2018). Though both 
studies cover a large range of pharmaceuticals, industrial chemicals and personal care products 
ingredients, Castiglioni’s study only has 82 CECs, compared to 138 in this study, though both contain 
many similar high usage CECs. Furthermore, there are likely to be large differences in prescriptions 
and industrial contribution between Italy and the UK.  
1,082 kg (1,696 kg, including creatinine) is removed from the influentAQ over the course of the study, 
leaving 72 kg (73 kg including creatinine) in effluent and entering the environment. 51 kg of this is 
from WwTW E which discharges directly into the estuary, which could not be sampled as part of this 
study. For the remaining WwTWs the highest contributor, by mass, was WwTW C with 11.6 kg 
discharged and leads to clear increases in daily river loads both downstream at WwTW C and upstream 
at WwTW D. The mass discharged by each WwTW generally increases by population equivalents 
contributing to the WwTWs i.e. WwTW B < WwTW C < WwTW E, however WwTW D, despite 
having around half the population of WwTW A, shows much higher mass discharge. Normalising the 
daily load discharge by each WwTW shows the highest population normalised loads are at WwTW D. 
WwTW A ( 5 g d-1 1,000 inh-1) < WwTW E ( 9 g d-1 1,000 inh-1) < WwTW B (12 g d-1 1,000 inh-1) < 
WwTW C (15 g d-1 1,000 inh-1) < WwTW D (16 g d-1 1,000 inh-1 (21 g d-1 1,000 inh-1 with creatinine)). 
Despite this, WwTW D removed the highest mass load per person, 151 g d-1 1,000 inh-1, which is close 
to WwTW E’s removal at 146 g d-1 1,000 inh-1. Based on this TF and SBR show similar removal per 
person, however, as a proportion of the incoming load WwTW E removed 94.5 %, whereas WwTW D 
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Figure 4 Weekly percentage of total loads in river water of the entire catchment as a pie chart of classes, 
with chart showing spatial and temporal trends. Note: creatinine is not included. 0.0% shows negligible to 
no contribution to the total. Numbers in brackets indicate numbers assigned for identification in small 
figures and table 
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SBR, (WwTWs B and C removed 78.1 % and 88.7 % respectively) whereas WwTW A appears to be 
the worst with 69.8 % total CEC mass removed. Although, WwTW A showed the lowest contribution 
with only 0.2 kg over the course of the study difference between upstream and downstream or 0.7 g d-1 
1,000 inh-1. The small discharge into a large river at WwTW D, shows only a small difference between 
upstream and downstream of 0.4 kg over the course of the study or 3 g d-1 1,000 inh-1 in the river. 
WwTW B and C had the highest increase in mass between upstream and downstream at 6.5 kg and 10.2 
kg, or 14 and 13 g d-1 1,000 inh-1, respectively. Overall, the river upstream of WwTW A contained total 
mass loads of 1.8 kg, or 287 g d-1, which increased to 25.2 kg, or 3.6 kg d-1 downstream of WwTW D 
(distance between A and D, is approximately 60 km). Throughout the catchment, 10.4 kg d-1 was 
discharged into the environment from the studied WwTWs. 
3.3. Impact of effluent discharge to receiving river water 
The river upstream of the WwTW A had 50/138 CECs above MQL ranging from 0.02 g d-1 (cocaine) 
to 47.8 g d-1 (caffeine), which is due to other smaller WwTWs present upstream, leaching from landfills 
sites, and possible infiltration from septic tanks, which are often used in more rural areas in the UK. 
Other classes such as plasticisers, veterinary pharmaceuticals, pesticides, fungicides and herbicides may 
possibly be present as well, due to surface runoff. Samples from the river downstream of the sites show 
higher loads overall, but also a different distribution of classes, with anti-diabetics, namely metformin, 
present at a larger proportion (from first being undetectable upstream of WwTW A, to representing 
1,309.6 ± 135.5 g d-1 downstream of WwTW D). Daily loads ranged from 0.005 g d-1 (ketamine, WwTW 
A) to 1,890.3 g d-1 (metformin, WwTW C, equivalent to ~1,890 tablets (DrugBank, 2015)) for the 
84/138 CECs that were detected downstream of the WwTWs. This trend of increasing load down the 
river is both expected, although perhaps not to this degree, and concerning.  
Figure 4 (and Figure S5-6) show spatial trends of daily cumulative load and shows a steady increase 
down the river. Similar trends have been seen in Italy with samples which were collected in the River 
Lambro basin either side of Milan (Castiglioni et al., 2018). WwTW C is clearly the highest contributor 
to river load, which is not surprising as it has the highest population out of WwTWs A-D. The key 
classes of importance in river water are anti-diabetics, human indicators, NSAIDs, antihistamines, 
antibiotics, UV filters and analgesics and metabolites which contribute large portions to the total load 
with the river. This is interesting to compare with the distribution of classes within effluent, as 
analgesics and metabolites appear to contribute far more highly to effluent (21.0 %), however 
downstream from the discharge point they contribute far less, only 7.3 %. This indicates that once in 
the environment, they are far less persistent in the aqueous phase than other classes. A similar trend can 
also be seen for anti-depressants. Whether these compounds are truly degraded or have partitioned to 
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Figure 5 Weekly percentage of total loads in effluent of the entire catchment as a pie chart of classes, with 
chart showing spatial and temporal trends. Note: creatinine is not included. 0.0% shows negligible to no 




spatio-temporal study in the Llobregat showed that psychiatric drugs, among many other 
pharmaceuticals, were at levels ranging from 4.41 - 18.02 ng g-1 in sediment between the two sampling 
campaigns and locations. This may be indicative of portioning to solid phases within the river of this 
catchment. Sertraline in particular showed high concentration levels in Llobregat with 12.08 ng g-1 in 
one sampling campaign (Osorio et al., 2016). Furthermore, antibiotics, such as tetracyclines, will pose 
further concern as they have been shown to preferentially partition to sediment over surface waters 
(Kim and Carlson, 2007). 
Anti-diabetics, metformin specifically, despite high level of removal (78.7 %), still represent a large 
proportion of effluent load (15.0 kg of 72.6 kg of the estimated total of the campaign, 20.7 % (Figure 
5)). It shows that this removal level is insufficient in preventing anti-diabetics from entering the 
environment, as an increasing trend is observed through the catchment, as seen in Figure 6. A similar 
situation is seen for the lifestyle chemicals, which represents 38.6 % of the influentAQ load and despite 
their high removal rates they are at quantifiable levels in the environment and show an increasing trend 
through the catchment (Figure 6). This is less so for NSAIDs, which are similarly prevalent in 
influentAQ, at 36.8 % of influentAQ load on average, but show less of an increase through the catchment. 
Diclofenac shows clear decreases in loads between sites, whether this is degradation or partitioning to 
solids, is yet to be determined. However, it has been previously found to partition to river sediments 
downstream of discharge points, along with other NSAIDs, therefore this fate seems likely within this 
catchment (Duan et al., 2013).  
Benzophenone-3, methylparaben and propylparaben are shown to increase between downstream at 
WwTW B and upstream at WwTW C. For many other CECs, there is a slight increase suggesting the 
presence of another source of these compounds in the catchment. The increase of these compounds, 
associated with personal care products, could be due to much smaller WwTWs contributing to 
tributaries in the area, however, a similar increase in other CECs would also be expected e.g. 
carbamazepine, which is not seen. These CECs are usually found in greywater, i.e. from showers and 
washing. It is currently allowed, although not advised, for greywater from boats to be disposed of 
directly into the river. It is a practice that may be common in areas outside of marinas where disposal 
points are few and storage of wastewater onboard is limited and reserved for sewage (Canal and River 
Trust, 2017). Therefore, the presence of a large number of moorings in this area may contribute to this 
increase in personal care product ingredients. However, further investigation is required as both 
locations were not sampled as the same time and the use of grab sampling adds a level of uncertainty. 
The river trends of flufenacet and oxadiazon show some small contributions from WwTWs, however 
the increase between downstream at one site and upstream at the next (particularly between WwTW B 
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Figure 6 Spatial trends down river for selected compounds. Note: Error bars indicate weekly 
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Figure 6 cont. Spatial trends down river for selected compounds. Note: Error bars indicate 
weekly variation of the sampling site 
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determine the source. Entry of pesticides into environmental surface waters has previously been 
attributed to diffuse sources such as agricultural application, particularly in proximity to surface waters 
and further surface runoff during wet weather (Lefrancq et al., 2017; Stuart et al., 2012). Due to the 
planning of the sampling campaign, rainfall and surface water runoff were at a minimum though this 
still seems likely to be a source, especially considering the level of agriculture and proximity of farming 
fields adjacent to the river throughout most of the catchment. 
3.4. Presence of micropollutants in digested sludge for land application 
An alternative route of entry for anthropogenic micropollutants into the environment is the application 
of digested sludge (biosolids) onto agricultural land. This area is often overlooked due to the additional 
analytical requirements to extract micropollutants from solid matrices and the lack of good analytical 
approaches available (Petrie et al., 2014b). Within the catchment, two WwTW sites had facilities for 
anaerobic digestion of sludge. WwTWs B and E both receive tankered and piped sludge (primary and 
secondary) from WwTWs within the catchment in addition to the sludge produced on site.  
Digested sludge collected from WwTWs B and E was found to contain 65/96 different CECs (Table 
S5). This included NSAIDs (1.8 % of the total CEC concentration in digested solids (Figure 7)), 
antidepressants (10.6 %) and analgesics (1.9 %) which were ubiquitous in all samples studied. 
Ibuprofen, naproxen and diclofenac were all found in digested sludge, with ibuprofen at the highest 
concentrations for the class with 200 ± 42 ng g-1 dry weight (dw) at WwTW B. Although these 
concentrations are comparable to those previously reported (Guerra et al., 2014; Martín et al., 2012; 
Radjenović et al., 2009; Sabourin et al., 2012). Of the 12 antidepressants and metabolites studied and 
quantifiable in sludge, all were detected, including paroxetine and duloxetine which were found in no 
other samples throughout the catchment. This is attributed to their tendency to sorb to organic matter in 
wastewater and during treatment, as well as their recalcitrance in biologically mediated processes. 
Amitriptyline, sertraline and citalopram were present at concentrations > 400 ng g-1. Morphine was the 
analgesic found at the highest levels with a mean concentration of 413 ± 43 ng g-1 at WwTW E. For 
such compounds, there is limited published data on their occurrence.  
Other CECs found at notable concentrations (>100 ng g-1) were methylparaben, BPA, chloramphenicol, 
ketoconazole, gemfibrozil, propranolol, carbamazepine and nicotine. Of these micropollutants, BPA 
was found at the highest levels with mean concentrations of 4,366 ± 260 ng g-1 (WwTW B) and 37,025 
± 4,229 ng g-1 (WwTW E) (Table S5). These concentrations are greater than has been observed in 
previous studies, which have found BPA at concentrations of ~1,000 ng g-1 (Langdon et al., 2014; 
Samaras et al., 2013) to 14,400 ng g-1 (carbon normalised concentrations) (Kinney et al., 2006). The 


















































total 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 
WwTW 
B 0.1 3.3 39.4 0.4 2.4 8.4 0.0 3.3 0.1 7.7 0.0 0.0 0.2 0.2 0.0 1.8 0.0 0.0 0.1 0.0 1.6 0.0 24.4 1.1 0.5 0.0 0.2 0.0 2.4 1.9 0.1 0.0 0.4 0.1 
WwTW 
E 0.1 0.3 85.4 0.1 0.5 1.6 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.6 0.0 7.1 0.2 0.0 0.0 0.1 0.0 0.4 1.9 0.1 0.0 0.0 0.1 
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Figure 7 Percentage of total concentration in digested solids of the entire catchment as a pie chart of classes, 
with individual pie charts for each site. Note: creatinine is not included. 0.0% shows negligible to no 





from industrial activities. In this study, BPA contributed 76.1 % to the total concentration in digested 
solids.  
As described by Carballa et al., and Hyland et al., several factors including physicochemical properties 
of both digested solid and the CECs, as well as the pH, temperature and water content may influence 
sorption of CECs to the digested solids (Carballa et al., 2008; Hyland et al., 2012). Crucially, the CECs 
present in digested solids, which have affinity with the aqueous phase, e.g. ibuprofen and naproxen, 
may not stay partitioned to the solids upon application of digested solids to the environment. These may 
enter landfill leachates or surface runoff from agricultural applications and may enter the aqueous 
environment via this route. Other CECs such as BPA show some recalcitrance in amended soils, 
possibly due to strong sorption and lack of bioavailability, leading to a lack of degradation as found in 
a fraction of BPA by Zhang et al., (Zhang et al., 2015). 
4. Conclusions 
This paper aimed to investigate the changes in micropollutants load throughout a river catchment system 
in the South-West of the UK, to gain further information on their sources, fate and behaviour. This was 
achieved by undertaking a comprehensive investigation of an extended list of 142 CECs at five strategic 
WwTWs representing >75 % of the wastewater from the catchment population. The main conclusions 
are as follows: 
1. Lifestyle, availability of pharmaceuticals without prescription and industry have the biggest 
effects on the content of influent. Population size and the extent of urbanisation are key drivers 
of high variability across the catchment, and increased levels of CECs in the environment down 
the catchment. This is confirmed by normalisation of CEC loads for population results, which 
results in a more even distribution (154 ± 12 mg d-1 inh-1). 
2. The analysis of both aqueous and solid influent phases is key to determine true levels of CECs 
entering the works. Furthermore, each phase has a distinct chemical composition and some 
CECs may be found primarily in one phase or the other. Without analysis of both, a holistic 
understanding of pollutant fluxes is not possible. 
3. Investigating temporal trends can highlight potential instances of incorrect use, incidental 
release or direct disposal. Although this is evident in both phases, it is particularly clear in the 
solid phase in this study, e.g. carbamazepine and ketoconazole. Furthermore, the current impact 
of these sudden, acute, events is currently unknown but may have noticeable effects on 
wastewater treatment processes or pose an environmental risk. 
4. Despite WwTWs not being designed for the removal of CECs, the majority of the studied CECs 
were removed from the works to the high extent (10.3 kg d-1 remaining in effluent compared to 
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167.9 kg d-1 in influent). This markedly decreased the potential environmental burden posed by 
the extent of urbanisation and size of the population within this catchment.  
5. Analysis of the river water upstream and downstream of the WwTW discharge point allowed 
the contribution of each WwTW to the environmental burden to be considered. It also highlights 
the potential for contribution to the environmental burden from other sources, which may 
include: septic tanks, sewer overflows, smaller WwTWs, surface runoff and greywater disposal. 
Furthermore, it showed that many CECs are ubiquitous throughout the catchment, with many 
increasing in load down the river due to the persistent addition of these compounds to the 
environment being higher than their degradation rate.  
6. Analysis of digested solids has shown high levels of a wide range of CECs present (65/96). 
These concentrations are significant and considering the potential use of this ‘treated’ matrix 
in amended agricultural soils, further consideration should be given to the potential ecological 
risk of this matrix, which is currently barely understood. Furthermore, the removal 
trends/treatment efficiency require further study. 
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Table S1 shows the instrumental and method performance data for the analytical method. 
Section S2 describes the data processing that was used in this work 
Section S3 add some additional information to the results in the main text for additional context or more 
indepth discussion 
Table S2 shows the dilution factor of effluent in the river water at the discharge point at each site. 
Table S3 provides the 7-day mean population normalised loads for influentAQ. 
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Table S4 provides the 7-day mean population normalised loads for influentSPM. 
Table S5 presents the frequency of detection of each analyte, the minimum and maximum loads, the 
mean, standard deviation and variance across the 7 days in each matrix. 
Table S6 shows the 7-day average percentage partitioning of CECs in influent for all sites. 
Figure S1 presents the 7-day average percentage removal from influentAQ during WwTW treatment for 
each site and overall. 
Table S7 shows the data of Figure S1, i.e. 7-day average percentage removal from influentAQ during 
WwTW treatment for each site and overall. 
Table S8 shows the general and chemical information of all CECs analysed. 
Figure S2 shows the temporal trends in influent for selected compounds. 
Figure S3 shows the temporal trends in both influentAQ and influentSPM for selected compounds. 
Figure S4 shows the spatial trends in river water through the catchment as cumulative load by class. 
Figure S5 shows the spatial trends in river water through the catchment as cumulative load by individual 
CEC. 
Table S9 shows the metadata of the sampling campaign, i.e. daily temperature, rainfall and pH of 
samples. 
Section S4 shows the references for the SI. 
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Abstract 
Chemicals of emerging concern (CECs) have been found throughout the environment and around the 
globe. Efforts need to be taken in understanding the risk they pose to the environment. The 
environmental risk of individual CECs is of little use when considering the complex mixture of CECs 
present in the environment. This paper considers the acute and chronic environmental risk to aquatic 
and terrestrial organisms based on measured environmental concentrations from a comprehensive 
catchment study. 
For the aquatic environment, the mixtures present a high acute risk, which varied across the catchment, 
with an overall trend of increasing risk down river, with a risk quotient (RQMEC:PNEC) of 32.1, at the 
furthest sampled point upriver, to 106.0 at the furthest point downriver. There was elevated chronic 
aquatic risk with RQMEC:PNEC of 99.4 upriver to 516 downriver at the same sampling locations. The ‘sum 
of toxic units’ approach showed the algal trophic level was most at risk from acute toxic effects, whereas 
the daphnid trophic level was most at risk from chronic toxic effects. This work found most of the risk, 
>90 %, was contributed by a small number of compounds; bisphenol A and diazinon. 
For the terrestrial environment, there was not enough publicly available ecotoxicity data for a full 
mixture based environmental risk assessment. Consideration of the data that was available, for the 21 
out of 65 quantified CECs, shows there is little risk from amended soils to earthworms based on the 
predicted environmental concentration of soil. However, the digested solids themselves show a high 
acute and chronic risk for several CECs. Therefore, there is potential for localised pockets of high 





Micropollutants have been shown to be prevalent, usually in the range of ng L-1 to µg L-1, in many 
different environmental compartments, including surface waters, marine water, sediment and soils, as 
well as entering the food chain via lower trophic levels and bioaccumulation to higher levels. This is a 
global problem [1, 2] and efforts are being made by the European Commission to prioritise which of 
the 1000’s of compounds (REACH, EINECs) are of highest risk to the aquatic environment and which 
pose an unknown or high level of risk and require more data [3–6]. Despite the focus on aquatic 
environments, other environments may also be at risk. 
 
The risk micropollutants pose to the environment is complex, as rarely are the concentrations of 
individual micropollutants high enough to cause acute toxic effects. The problem lies within their 
potential to cause long-term chronic effects, both individually and as a mixture. For this reason, they 
have begun to be referred to as chemicals of emerging concern (CECs) [1, 7, 8]. 
 
It is widely understood that the ecotoxicity of individual compounds is often less than the toxicity of 
the overall mixture [9] and better understanding can come from reviewing the components in a mixture 
[10–12]. Much of the current environmental risk assessment (ERA) work has been focused on small 
numbers of compounds or a single class, e.g. antihypertensives [7], quinolone antibiotics [10], 
pharmaceuticals [13, 14], UV filters [15], pesticides [16] etc. Although a recent study was published 
looked at 47 CECs [17].  
 
Currently ERAs typically follow the European Medical Agency guidelines for individual 
pharmaceuticals i.e. calculating predicted-no-effect-concentrations (PNEC) from effect concentration 
levels (EC50, EC10 etc) and relevant assessment factor (AF), and comparing with the predicted 
environmental concentration (PEC), for the relevant environmental compartment[18]. This method 
maybe useful for understanding the potential effects of a single compound, however the environment 
is far more complex than that and analysis of the environmental risk of mixtures is critical. However, 
the work by Backhaus and Karlsson, found the overall toxic effect of the 26 pharmaceuticals was 
primarily the contribution of a one or two compounds in most cases. This has been found with pesticides 
on several occasions by Verro et al. [19], who found no more than three pesticides caused >80% of the 
toxic effect, though this was based on PECs, and Gustavsson et al, [16]. found a similar situation over 
11 years across six sites. However, they found that monitoring of 44 pesticides was still essential to 
account for at least 95% of the risk over this time period. A further study was carried out on Swedish 
coastal waters, by Gustavsson et al. [20], found 62 of the 172 compounds analysed were detected, at 3 
of the 5 sites the majority of the risk to the environment was posed by triclosan, at the other two the 
majority of the risk was more evenly distributed between three or four compounds. Overall, this shows 
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there is a need to analyse a wide variety of CECs to fully determine the risk to the environment, as a 
small number of compounds may be responsible for the majority of the risk, but they may not be 
identified if the scope of analysis is too narrow. In these studies, the compounds responsible for the 
majority of the risk have been shown to fluctuate with spatial and temporal variation. 
 
This work aims to provide the most comprehensive catchment based ERA to date, using measured 
environmental concentration (MEC) data from seven consecutive days at each of the 8 sites along a 
river considering spatial and temporal variations. Furthermore, a theoretical risk assessment of the 
application of digested solids, from two WwTWs within the catchment, to agricultural soils for 
terrestrial organisms is also carried out. This work considers the risk of CECs individually, as a mixture 
by class and as a total mixture to both the aquatic and terrestrial environment. 
 
2. Materials and Methods 
2.1. Materials 
 
All materials used in the investigation are detailed in the Supplementary Information (Section S1) 
or in the paper by Proctor et al., [21] (Chapter 3). 
 
2.2. Targeted chemical of emerging concern (CECs) 
 
The 142 CECs cover 30 classes in this paper, including, industrial chemicals, personal care 
products, pharmaceuticals for veterinary and human therapy, pesticides, herbicides and fungicides. 
They were selected based upon a review of current and proposed EU and national regulation and 
legislation and literature [3, 5, 6, 22, 23], as well as information on usage i.e. prescription data for 
pharmaceuticals [24], expert knowledge on pesticide use and data from literature for veterinary 
pharma [25–27], metabolism data (Drugbank [28], toxicity to mammals, aquatic and benthic 
organisms and potential persistence, bioaccumulation, transport through the environment based on 
physiochemical parameters such as Log Kow, Log Dow,  water solubility, and bioconcentration factor 
(BCF), from EPI Suite and ACD/Labs [29, 30]. They were prioritised for their potential to reach 
the environment and cause a negative impact. The general chemical information and 
physicochemical parameters can be found in the Supplementary Information, Table S1.  
 
2.3. Studied catchment and sampling locations 
 
The area studied in this work is a river catchment in the South West of the UK, covering 
approximately 2,000 km2. The river is approximately 120 km in length and has an average 
discharge of 20 m3 s-1 and accepts discharges from several WwTWs covering a population of ~1.5 
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million. The catchment also contains private treatment facilities, such as septic tanks. River 
sampling points were chosen upstream and between 0.5 to 2 km downstream of the discharge 
points 4 of these WwTWs. These are labelled R1 to R8 throughout, R1, R3, R5, and R7 were 
upstream of WwTW A, B, C and D respectively and R2, R4, R6, R8 were downstream of the 
WwTWs respectively as shown in Figure 1(further site information can be found in Supplementary 
Information, Table S2). At the most upstream WwTW, A, sampling downstream was shown to 
have poor mixing in the river and higher than expected environmental concentrations). For this 
site, R2, PECs were calculated based upon river upstream concentrations, effluent concentrations 
and dilution as discussed in section 2.7. Dilution of the effluent in the river was between 12.6 ± 
1.4 for WwTW B and 153.3 ± 23.9 for WwTW C. Further effluent dilution information can be 
found in Supplementary Information, Table S3. As previously calculated, in a previous study these 
four WwTWs were found to contribute 3.0 kg d-1 to the river, with between 0.18 kg d-1 (WwTW 
A) to 1.7 kg d-1 (WwTW C). River samples for WwTW E, the final and largest WwTW, treating 
wastewater equivalent of ~850,000 people, could not be collected as the effluent is discharged to 
the estuary and samples could not be collected safely. Flow data for effluent discharge and river 
water can be found in the Supplementary Information, Table S4. 
 
 
Figure 1 Catchment map showing, city/town, WwTW and river sampling site locations. The 






2.4. Sample collection 
 
Samples of the liquid and solid phases of influent, effluent and river water upstream and 
downstream were collected on seven consecutive days at each WwTW. 24-hour volume 
proportional composites were collected for influent and 24-hour time proportional composite 
samples were collected for effluent. The composite samplers collected subsamples of 80 mL 
approximately every 15 minutes. The samplers were stored on ice within the sampler to maintain a 
low temperature and prevent degradation of the analytes. Surface water was sampled via grab 
sampling each day to provide accurate concentrations, without needing to consider degradation or 
dilution within composites. All samples were placed on ice whilst being transported to the lab. 
 
2.5. Sample preparation 
 
Samples were prepared following the method discussed by Proctor et al., [21, 31]. To summarise, 
all samples were filtered with GF/F glass fibre filter paper, before measuring 100 mL and spiked 
with 50 µL of 1 µg mL-1 of internal standard (IS) mix. The samples were then loaded onto 
equilibrated HLB (hydrophilic lipophilic balanced) solid-phase extraction cartridges, before being 
eluted with methanol (MeOH) and evaporated to dryness with a Turbo evaporator under nitrogen. 
The sample was then reconstituted with 500 µL of 80:20 H2O:MeOH, mixed thoroughly and 
transferred to LC (liquid-chromatography) vials for analysis. 
 
Once at the lab digested solids were frozen at -20˚C, before being freeze dried and homogenised. 
The resultant powder was carefully weighed to 0.25 g and spiked with 50 µL of 1.0 µg mL-1 internal 
standard mix. This was then combined with 25 mL of 50:50 deionised water:acidified MeOH 
(methanol) (pH 2) in a microwave assisted extraction (MAE) tube and shaken well. The tubes were 
placed in the 800 W MARS 6 microwave and held at 110 ˚C for 30 mins. Once cool, the samples 
were filtered and the filtrate was loaded onto conditioned and equilibrated MCX (mixed-cation 
exchange) solid-phase extraction (SPE) cartridges. The analytes were eluted in two fractions. The 
acidic analytes were eluted first with 2 mL of 0.6% formic acid in MeOH, then the basic fractions 
were eluted with 3 mL of 7% ammonium hydroxide in MeOH. Both fractions were then evaporated 
to dryness at 40 ˚C under nitrogen, before being reconstituted in 500 µL 80:20 deionised 
water:MeOH and mixed thoroughly. These were then transferred to LC vials for analysis. 
 
 Analysis was carried out as described by Proctor et al. [31] (Chapter 2), specifically using a Waters 
ACQUITY UPLCTM (ultra-performance liquid chromatography) system coupled to Xevo Triple 
Quadrupole Mass spectrometer. Separation of analyte was carried out with a reversed phase C18 
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column (150 mm x 1.0 mm, with a particle size of 1.7 µm) and the mobile phase and gradient was 
dependent upon whether electrospray ionisation (ESI) was in positive of negative modes.  
 
2.6. Analytical methodologies 
 
All samples were analysed with ultra-performance liquid chromatography coupled with tandem 
mass spectrometry (UPLC-MS/MS). The parameters for the methods used can be found in the 
method validation paper by Proctor et al [31] (Chapter 2).  Method detection and quantification 
limits (MDLs and MQLs), accuracy and precision can be found in Supplementary Information, 
Table S5. 
 
2.7. Quality Control 
 
Spiked quality control samples were analysed for each matrix at each site, at concentrations of 100 
and 1000 ng L-1. Matrix suppression effects and losses of analyte during sample preparation were 
counteracted by the use of IS. Identity of analytes was confirmed with the use of two transitions, 
retention time (± 20 %), and ion ratio (± 20 %) [32]. 
 
Thorough mixing of the effluent discharge and river water downstream is required to ensure 
accurate environmental concentrations are detected. For this reason, mass balances were compared 
for carbamazepine load downstream, and the sum of upstream and effluent (Equation 1), as 
previously described by Proctor et al [21] (Chapter 3). With thorough mixing, the difference is 
assumed to be negligible. As mentioned in Section 2.3., site R2 showed poor mixing, therefore 
predicted environmental concentrations based on the sum of effluent/dilution and river water 
upstream were used instead. Results for this can be found in the Supplementary Information, 
Section 2. 
 
𝑀𝑎𝑠𝑠 𝑏𝑎𝑙𝑎𝑛𝑐𝑒 (%) = (
𝐷𝑜𝑤𝑛𝑠𝑡𝑟𝑒𝑎𝑚 𝑟𝑖𝑣𝑒𝑟 𝑙𝑜𝑎𝑑 (𝑔 𝑑−1)
(𝑈𝑝𝑠𝑡𝑟𝑒𝑎𝑚 𝑟𝑖𝑣𝑒𝑟 𝑙𝑜𝑎𝑑 (𝑔 𝑑−1)+ 𝑒𝑓𝑓𝑙𝑢𝑒𝑛𝑡 𝑙𝑜𝑎𝑑(𝑔 𝑑−1))
) 𝑥100  (1) 
 
2.8. Environmental Risk Assessment 
2.8.1.  Aquatic Ecotoxicity data 
 
Modelled acute and chronic ecotoxicity data was collected for three trophic levels (algae, 
daphnid and fish) from ECOSAR for all 138 CECs quantifiable in surface water. This was 
supplemented with publicly available, experimentally derived acute and chronic ecotoxicity 
data, i.e. EC10, or NOEC or LOEC if well defined, for 34 and 36 CECs, respectively, from 
103 
 
selected classes; lifestyle chemicals, analgesics, anti-diabetics, anti-epileptics, NSAIDs, UV 
filters and antidepressants. This data was acquired from Web of Science search, following a 
method previously implemented by Johnson et al., [33], more information can be found in 
Supplementary Information, Section 3. Further searches were carried out from the ECHA – 
REACH and TOXNET HSDB databases. In instances where the source of the data, i.e. the 
paper, could not be identified the database is given as the reference. The collection of papers 
was vetted for organism class, species, model/lab/wild organism source, test protocol, duration, 
well known endpoints, EC10, EC25, EC50, NOEC, LOEC units and references. Attention was 
made to NOEC and LOEC values and these were not used if the dose-response curve was not 
adequately characterised. 
 
Both acute and chronic toxicity data was used for comparison as EC50 ecotoxicity data is more 
commonly used but chronic toxicity data is more relevant to the environment. Furthermore, this 
approach has recently been advised in the newly amended EMA environmental risk assessment 
[18]. 
 
2.8.2. Aquatic environmental data 
As previously discussed, the aquatic environmental data was be obtained from the daily grab 
sampling that were collected over seven consecutive days at each site. Analysis of these samples 
will provide variation or consistency of the MECs over a week and across the catchment. 
 
2.8.3. Soil Ecotoxicity data 
Due to the lack of available experimental chronic toxicity data available for the majority of 
these compounds (publicly available experimental chronic toxicity data for only 9 out of 96 
CECs quantifiable in digested solids were found), modelled chronic ecotoxicity data from 
ECOSAR were also used, however this could only be obtained for 23 CECs out of the remaining 
87 (total of 32 compounds with data out of 96).  
 
2.8.4. Soil Environmental data 
Furthermore, the environmental concentrations within the soil (PECSOIL) are predicted based on 
the concentrations present in the digested sludge (Csludge) and the equation (2) using default 
values from ‘Guideline on the environment risk assessment of medicinal products’ by the 
European Medical Agency [18]. Where Applsludge is the yearly sludge application rate to soils 
(0.5 kg m-2), Depth is the mixing depth (0.2 m), and Density is the bulk density of the wet soil 
(1,700 kg m-3). 
𝑃𝐸𝐶𝑆𝑂𝐼𝐿 =  
𝐶𝑠𝑙𝑢𝑑𝑔𝑒 (𝑛𝑔 𝑔−1) × 𝐴𝑝𝑝𝑙𝑆𝐿𝑈𝐷𝐺𝐸 (𝑘𝑔 𝑚
−2)
𝐷𝑒𝑝𝑡ℎ (𝑚)×𝐷𝑒𝑛𝑠𝑖𝑡𝑦(𝑘𝑔 𝑚−3)




2.9. Predicted No Effect Concentration (PNEC) calculation 
 
PNECs were calculated using equation 3, as in the method described by Backhaus et al, EMA 
and European Commission TGD [18, 34, 35]. 
 
𝑃𝑁𝐸𝐶 (𝑢𝑔 𝐿−1) =
𝑙𝑜𝑤𝑒𝑠𝑡 𝐸𝐶10 (𝑢𝑔 𝐿−1)
𝐴𝐹
       (3) 
 
Where the ‘lowest EC10’ is the lowest EC10 from the literature or modelled ecotoxicity data 
of the three trophic levels, and the AF is the assessment factor. This factor is applied to allow a 
more conservative environmental risk assessment, allowing more protection for the 
environment. Overall, with increasing confidence in the ecotoxicity data the AF should 
decrease. For acute ecotoxicity data i.e. LC50, an AF of 1000 is often used, due to the difference 
between acute toxic effects and the potential sublethal effects that may be seen at environmental 
concentrations. The advice based on Backhaus et al, EMA ERA and European Commission 
TGD, suggests an AF of 100 should be used for one chronic EC10 or NOEC for fish or daphnia, 
an AF of 50 for two data on two trophic levels, and an AF of 10 based on three trophic levels. 
For sensitive species distribution data, an AF of 5-1 should be used [18, 34, 35].  
 
2.10. Risk Quotients  
 
Risk quotients are a measure of environmental risk based on the ratio of PEC or MEC and PNEC. 
This paper uses the average MECs for each site, from a comprehensive dataset of MECs for 138 
CECs, at 8 sampling locations in a river catchment for ERA of the aquatic phase and PECSOIL data 
calculated from 96 CECs in digested solids from two WwTWs within the catchment, providing a 
higher degree of confidence. 
 
As suggested by Backhaus et al., there are two ways to calculate the RQ of the mixture considering 
concentration addition: 
 









𝑖=1   (4) 
 
𝑅𝑄𝑆𝑇𝑈 =  ∑ max(𝑆𝑇𝑈𝑎𝑙𝑔𝑎𝑒 , 𝑆𝑇𝑈𝑑𝑎𝑝ℎ𝑛𝑖𝑑 , 𝑆𝑇𝑈𝑓𝑖𝑠ℎ)
𝑛
𝑖=1


















𝑖=1 ) × 𝐴𝐹   (5) 
 
RQs have been interpreted in different ways from paper to paper, with Backhaus and EMA 
suggesting there is a risk or the environmental quality standard is exceeded if RQ >1 [18, 34].  Sousa 
et al., suggests that an RQ <0.1 is low risk, 0.1 – 1.0 is medium risk, >1 is high risk [1]. 
 
As this work uses MECs rather than PECs and considering the multitude of CECs present in 
mixtures within the environment, this work assumes RQ < 0.1 is low to no risk, 0.1- 1.0 is medium 
risk, and >1 is a risk.  
 
Furthermore, this work calculates the RQ for several different aspects: 
1. RQMEC:PNEC  - a measure of the risk of MEC to the environment 
2. RQMQL:PNEC – a measure of the risk of the lowest quantifiable concentration for 
compounds which were below MQL. Provides information on the potential risk on 
unquantifiable levels of these CECs. 
3. RQmixture – a measure of the risk of a mixture to the environment. This is discussed for 
classes throughout as well as the overall risk of the mixture as a whole 
4. RQSTU – another measure of the risk of a mixture to the environment as described by 
Backhaus et al, based on the Sum of Toxic units (STU) for each trophic level. 
 
3. Results and Discussion 
3.1. Occurrence in river water and aquatic environmental risk assessment 
 
These results are based upon the average concentrations from a week sampling at 8 sites, (total 
n = 56 per compound). Figure 2 shows the distribution of classes in the average samples from 
each river sampling site. Figure 3 shows the average daily cumulative total for each river 
sampling site as a distribution of classes and as a distribution of CECs. More detailed 
information, on the average concentration of each CEC, at each site can be found in 
Supplementary Information, Table S6. Acute and chronic ecotoxicity data for three trophic 
levels, AF and PNEC discussed in the text below can be found in Tables 1 and 2. Acute and 
chronic RQMEC:PNEC for the 8 sampled sites down the river are displayed as a heat maps and 
can be found in Tables 3 and 4. Followed by the acute and chronic RQmixture for each class of 













































































































































































metabolites (30) 31 34
R8 
Chart TitleUV Filter (1) Parabens (2) Plasticizer (3)
Steroids (4) Antibiotic (5) Antifungal (6)
Hypertension (7) NSAIDs (8) Lipid regulator (9)
Anti-hyperlipidemic (10) Anti-hyperintensive (11) Antihistamine (12)
GUD/ED (13) Anti-diabetics (14) Cough suppressant (15)
Beta-blocker (16) H2 receptor agonist (17) X-ray contrast media (18)
Various (19) Drug precursor (20) Anti-cancer (21)
Anaesthetic and metabolite (22) Antidepressants (23) Anti-epileptic (24)
Calcium-channel blocker (25) Hypnotic (26) Anti-psychotic (27)
Dementia (28) Lifestyle Chemicals (29) Analgaesics and Metabolites (30)
Stimulants and metabolites (31) Opiod and metabolite (32) Pesticides, fungicides and herbicides (33)
Veterinary Pharma (34)
Figure 2 Pie charts for the distribution of classes in river water samples at each site, based on 
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The paper by Proctor et al., identified the UV filters, NSAIDs and acetaminophen, 
antidiabetics, antidepressants, anti-epileptics, lifestyle chemicals, and analgesics to be of 
particular interest for further investigation into potential environmental effects within this 
catchment due to their high levels and these CECs represent the majority of the CECs in river 
water [21]. 
 
3.1.1.  UV filters 
 
Benzophenone-1 and benzophenone-2 concentrations were too low to detect in river water 
throughout the catchment ( MQL for benzophenone-1 = 0.35 ng L-1 and benzophenone-2 = 0.79 
ng L-1). Benzophenone-3 was found at concentrations ranging from 13.8 to 46.3 ng L-1, whereas 
benzophenone-4 was found at concentrations ranging from 184.6 to 1,321.5 ng L-1. The levels 
seen for benzophenone-3 are very similar to the predicted environmental concentration for the 
UK, 24 ng L-1, by Dhanirama et al [36]. Benzophenone-3 was found at similar concentrations 
to those previously found in the UK, from <MQL (15 ng L-1) to 44 ng L-1 , whereas the levels 
previously found for benzophenone-4 are much lower, from <MQL (3 ng L-1) to 371 ng L-1, 
though they were not detected as frequently [37]. 
 
With regards to their chronic ecotoxicity to aquatic organisms, benzophenone-2 is the most 
toxic with a PNEC of 0.4 µg L-1, the others are ranked as such: benzophenone-3 (18.0 µg L-1) 
> benzophenone-1 (32.7 µg L-1) > benzophenone-4 (97.9 µg L-1). Though the acute ecotoxicity 
data provides a lower PNEC, is it deemed to be less accurate due to the higher assessment factor 
applied. 
 
Chronic risk quotients for benzophenone-4 shows the highest RQMEC:PNEC with 0.007 (R8), 
which shows there is a very low risk to three trophic levels based on the standard approach. 
Considering the UV filters in this study as a mixture, the highest RQMEC:PNEC across the 
catchment is 0.007 (R7). The sum of toxic units shows the daphnid/crustacean trophic levels is 
most at risk from this group of CECs. This is a lower risk than what was given by Riva et al 
[17], however, this is likely due to using chronic ecotoxicity data and a lower assessment factor 
. Both studies show limited risk to the aquatic environment from these compounds. However, 
this is in contradiction to Wu et al. [15], who found RQs of 2.7 and 0.8 for benzophenone-4 and 
benzophenone-3 at similar concentrations (up to 131 ng L-1 and 30.0 ng L-1, respectively), likely 
due to an overestimation of hazard. 
 
Whilst this appears not to have any chronic freshwater effects, the potential bioaccumulation 




benzophenone-3 has been highlighted in two marine species, cod and prawn, by Langford et al 
[39], suggesting that testing the BAF in aquatic organisms is a key parameter for this class. This 
is especially important, considering the potential for hormonal and reproductive effects in fish 




Only methylparaben was found in all environmental samples throughout the catchment, though 
propylparaben was found in 36 of the 56 samples collected. They were found at concentrations 
between 3.6 to 112.6 ng L-1 and <MQL (0.83 ng L-1) to 9.0 ng L-1, respectively. The MQL for 
ethylparaben and butylparaben are 0.79 and 0.38 ng L-1, respectively. These MECs are similar 
to those found by Kasprzyk-Hordern et al (UK) and Gorga et al (Spain), with methylparaben at 
levels between ND (not detected) to 144 ng L-1 and ND to 142 ng L-1 and propylparaben at ND 
to 11 ng L-1 and ND to 26 ng L-1, though both were detected less frequently than in this study. 
The ethylparaben was also found in both studies with ND to 15 ng L-1 and ND to 49 ng L-1 [37, 
42]  
Of the parabens, butylparaben appears to be the most toxic with a PNEC of 0.006 mg L-1. The 
remaining parabens decrease in toxicity with their molecular weight, propylparaben (0.025 mg 
L-1) > ethylparaben (0.210 mg L-1) > methylparaben (2.03 mg L-1). A lower PNEC was 
determined by De García et al 0.0069 mg L-1, however  this was calculated from EC50 data and 
an AF of 1000, though three trophic levels were considered [43]. The PNEC calculated with 
acute toxicity data in this study showed a similar PNEC of 0.020 mg L-1, however the more 
accurate chronic PNEC is used for the RQ calculation. 
 
The chronic RQMEC:PNEC for methylparaben and propylparaben were far below 0.01 ( 2.07 x 10-
5 and 1.99  x 10-4). Furthermore, when considered as a class of similarly acting substances they 
show negligible risk (2.19 x 10-4). However, more recent studies have begun to show estrogenic 
effects such as increasing levels of vitellogen production at 0.015 mg L-1 of methylparaben 
when no other lethal or non-lethal effects were seen [44, 45]. The lack of defined EC10 or 
NOEC data in these studies mean they could not be used in this work. Furthermore, these are 
effects that may be seen by the other parabens, further work into these effects is required. 
 
3.1.3.  Plasticiser – Bisphenol A 
 
The plasticiser bisphenol A was found at 7 of the 8 sampling points. It was detected with 
increasing frequency (n = 42 across catchment) and concentration down the river, with 




than those quantified by Česen et al in Slovenian and Croatian water (44.3 – 2,670 ng L-1) or 
the highest level, 4,130 ng L-1 (Australia), reported in the review by Sousa et al [1, 46, 47]. 
However, these levels are similar to what has previously been found in the UK [37, 48, 49]. 
The chronic PNEC for bisphenol A is 0.28 ng L-1 this is derived from the experimental data 
from Oehlmann et al (EC10, 13.9 ng L-1, feminisation of snails) [50]. A previous study has 
calculated a PNEC of 1000 ng L-1, based on acute toxicity data in algae [51–53], however the 
endocrine disrupting activity was not taken into account. Furthermore, considering effects on 
higher trophic levels such as fish, a PNEC of 158 ng L-1 can still be calculated (based on EC50 
of 158 ug L-1 for the vitellogen induction of male fathead minnow and an AF of 1000 due to 
EC50 and one species). 
 
The chronic RQMEC:PNEC for BPA based on the lowest PNEC, 0.28 ng L-1, results in high risk 
for the daphnid trophic levels with RQMEC:PNEC of 206 at the highest point across the catchment. 
Sites from R2 to R8 show RQMEC:PNECs above 1, (ranging from 2.57 at R2 to 207 at R8). When 
considering the PNEC calculated from the EC50 from the above literature, with a PNEC of 158 
ng L-1, the RQ is below 1 (0.364) at its highest across the catchment. Though this shows medium 
level of risk at current levels, the persistence and increasing bisphenol A levels throughout the 
catchment suggest that this may become a problem further downstream. This is comparable to 
levels seen by Riva et al.,[17] who found BPA was also posed a high risk in rivers running 
through Milan with RQMEC:PNEC of 0.57 to 1.9.  
 
3.1.4. Steroid estrogens 
 
Steroid estrogens were not found in any of the environmental matrices. This is likely due to the 
MQLs for these compounds which were 3.92, 4.48, 4.91 ng L-1 for E1, E2 and EE2 respectively, 
which are relatively low compared to many other compounds.  However, the  PNEC for E1 and 
E2 are 0.64 and 0.10 ng L-1, which shows this method was not sensitive enough to determine 
environmental risk for these two estrogens. EE2 however, has a PNEC of 174 ng L-1, which 
when compared to its MQL shows low risk to the aquatic environment, with a minimum RQ 
value 0.03. The predicted environmental concentrations at R2 shows potential concentration of 
3.03 ng L-1 for E1, based on effluent concentration, along with E1s presence in effluent at the 
other sites shows that E1 is entering the environment and it is likely due to the lack of sensitivity 
of the method for these compounds and the low population in this catchment compared to other 
studies (which tend to focus on large cities) that they were unable to be quantified. These CECs 
are some of the most studied compounds, with environmental concentration determined across 
5 continents, reaching 93 ng L-1 (Huangpu River, China), 87 ng L-1 (Piracicaba River, Brazil), 




comparison with the same PNEC calculated in this study shows RQ values greater than 1, (146 
for E1, 870 for E2 and 10.5 for EE2). This was comparable to the levels found by Sousa et al 
[1]. E2 and EE2 are proposed as priority hazardous substances with recommended legislative 
targets for consent of 0.41 and 0.035 ng L-1 annual average EQS, respectively, (0.035 ng L-1 




Table 1 Acute aquatic ecotoxicity data for three trophic levels with references, assessment factor, notes and PNEC 









Ref AF Notes PNEC 
   mg L-1  mg L-1  mg L-1    ng L-1 
UV Filter Benzophenone-1 131-56-6 2.12 [58] 3.9 [59] 3.7 [58] 1000 Experimental 2700 
 Benzophenone-2 131-55-5 2.8 [60] 26.0 [60] 4.5 [60] 1000 Modelled 570.0 
 Benzophenone-3 131-57-7 0.67 [58] 1.09 [61] 3.89 [61] 1000 Experimental 162.3 
 Benzophenone-4 4065-45-6 25.9 [59] 25.9 [59] 25 [58] 1000 Experimental 135.1 
Parabens Methylparaben 99-76-3 35.25 [62] 11.2 [58] 59.5 [58] 1000 Experimental 2899 
 Ethylparaben 120-47-8 37 [58] 7.4 [63] 14 [63] 1000 Experimental 46.00 
 Propylparaben 94-13-3 16 [58] 2 [63] 4.9 [63] 1000 Experimental 0.53 
 Butylparaben 94-26-8 4 [63] 1.9 [63] 3.1 [63] 1000 Experimental 2678 
Plasticizer Bisphenol A 80-05-7 2.7 [64] 7.8 [65] 5.1 [66] 1000 Experimental 21820 
Steroid estrogens E1 53-16-7 0.57 [58] 1.5 [58] 1.186 [58] 1000 Experimental 56.68 
 E2 50-28-2 0.2 [60] 2.87 [65] 0.46 [66] 1000 Experimental 2.00 
 EE2 57-63-6 0.1 [60] 1.6 [60] 1.4 [60] 1000 Modelled 40400 
Antibiotics and 
Antibacterial 
Sulfasalazine 599-79-1 2.9 [60] 4.6 [60] 11.7 [60] 1000 Modelled 40386 
 Clarithromycin 81103-11-9 0.046 [67] 3.3 [60] 5.0 [60] 1000 Modelled 738293 
 Azithromycin 83905-01-5 0.00053 [67] 3.0 [60] 18.8 [60] 1000 Modelled 1786232 
 Trimethoprim 738-70-5 2.7 [60] 120.7 [68] 100 [68] 1000 Experimental 1240428 
 Sulfamethoxazole 723-46-6 21.8 [60] 177.3 [68] 562.5 [68] 1000 Experimental 3301 
 Triclosan 3380-34-5 0.1 [60] 0.191 [58] 0.42 [69] 1000 Experimental N/A 








 Sulfadiazine 68-35-9 40.4 [60] 221 [58] 906.5 [60] 1000 Modelled 140933 
 Cefalexin 15686-71-2 879.2 [60] 738.3 [60] 7455.8 [60] 1000 Modelled 143301 
 Ofloxacin 82419-36-1 2444.5 [60] 1786.2 [60] 19352.1 [60] 1000 Modelled 3452 
 Ciprofloxacin 85721-33-1 1621.6 [60] 1240.4 [60] 13131.4 [60] 1000 Modelled N/A 
 Tetracycline 60-54-8 3.3 [60] 5.3 [60] 78.5 [60] 1000 Modelled 187480 
 Danofloxacin 112398-08-0 - - - - - - - - 49791 
 Oxytetracycline 79-57-2 8.0 [60] 11.0 [60] 227.8 [60] 1000 Modelled 110.4 
 Chloramphenicol 56-75-7 0.4 [60] 72.1 [60] 38.8 [60] 1000 Modelled 47613 
 Penicillin G 61-33-6 140.9 [60] 1221.0 [60] 1226.7 [60] 1000 Modelled N/A 
 Penicillin V 87-08-1 143.3 [60] 1228.1 [60] 1237.8 [60] 1000 Modelled 5633494 
 Erythromycin 114-07-8 3.5 [60] 8.6 [60] 15.2 [60] 1000 Modelled N/A 
 Prulifloxacin 123447-62-1 - - - - - - - - 164452 
 Norfloxacin 70458-96-7 2567.5 [60] 187.48 [70] 20081.4 [60] 1000 Modelled 36600 
Antifungal Griseofluvin 126-07-8 102.0 [60] 138.8 [60] 49.8 [60] 1000 Modelled 330.0 
 Ketoconazole 65277-42-1 0.2 [60] 1.2 [60] 0.1 [60] 1000 Modelled 90.00 
Hypertension Valsartan 137862-53-4 100 [58] 47.6 [60] 62.8 [60] 1000 Modelled 11850 
 Irbesartan 138402-11-6 - - - - - - - - 4865 
 Lisinopril 76547-98-3 9140.4 [60] 5633.5 [60] 66517.8 [60] 1000 Modelled 15.04 
 Candesartan Cilexetil 145040-37-5 - - - - - - - - 4933 













Ref AF Notes PNEC 
   mg L-1  mg L-1  mg L-1    ng L-1 
 Ibuprofen 15687-27-1 342.2 [71] 36.6 [58] 173 [58] 1000 Experimental 3409268 
 Naproxen 22204-53-1 31.82 [72] 0.33 [72] 193.3 [60] 1000 Experimental 1399 
 Diclofenac 15307-86-5 71.9 [71] 22.704 [73] 0.09 [74] 1000 Experimental 14300 
 Acetaminophen 103-90-2 112.7 [58] 11.85 [58] 160 [68] 1000 Experimental 123.1 
Lipid regulator Bezafibrate 41859-67-0 4.9 [60] 12.2 [60] 17.6 [60] 1000 Modelled 20093 
 Atorvastatin 134523-00-5 0.3 [60] 0.3 [60] 0.0 [60] 1000 Modelled 2101 
 Gemfibrozil 25812-30-0 10.6 [60] 4.9 [60] 6.7 [60] 1000 Modelled 143000 
Antihistamine Fexofenadine 83799-24-0 25.3 [60] 36.9 [60] 281.9 [60] 1000 Modelled 7300 
 Cetirizine 83881-51-0 5127.6 [60] 3409.3 [60] 38741.0 [60] 1000 Modelled 5000 
GUD/ED Sildenafil 139755-83-2 1.4 [60] 5.6 [60] 8.8 [60] 1000 Modelled 8009 
Antidiabetics Metformin 657-24-9 320 [75] 14.3 [76] 1315.5 [76] 1000 Experimental 78001 
 Gliclazide 21187-98-4 0.1 [60] 150 [77] 0.9 [60] 1000 Modelled 5542 
 Sitagliptin 486460-32-6 20.1 [60] 21.9 [60] 196.8 [60] 1000 Modelled 187.1 
Cough suppressant Pholcodine 509-67-1 2.1 [60] 60.2 [60] 19.5 [60] 1000 Modelled 63.67 
Beta-blocker Atenolol 29122-68-7 143 [78] 755 [78] 1096.4 [60] 1000 Experimental 41100 
 Metoprolol 51384-51-1 7.3 [75] 100 [75] 81.6 [60] 1000 Experimental 41755 
 Propranolol 525-66-6 5.8 [75] 5 [79] 20.2 [60] 1000 Experimental 12294 
 Bisoprolol 66722-44-9 8.0 [60] 9.4 [60] 79.9 [60] 1000 Modelled 202800 
H2 receptor agonist Ranitidine 66357-35-5 95.3 [60] 78.0 [60] 797.9 [60] 1000 Modelled 25.75 
 Cimetidine 51481-61-9 5.5 [60] 271.3 [68] 100 [68] 1000 Experimental 6.41 
X-ray contrast 
media 
Iopromide 73334-07-3 - - 0.2 [60] - - 1000 Modelled 2290 
Various Buprenorphine 52485-79-7 0.1 [60] - - 0.5 [60] 1000 Modelled 897.2 
Drug precursor Ephedrine/pseudoephedrine 299-42-3 41.1 [58] 170.8 [80] 464 [58] 1000 Experimental 9538 
 Norephedrine 492-39-7   41.8 [60] 431.0 [60] 1000 Modelled 722.2 
Anti-cancer Azathioprine 446-86-6 12.3 [60] 328.6 [60] 1735.3 [60] 1000 Modelled N/A 
 Methotrexate 59-05-2 202.8 [60] 326.8 [60] 67598.5 [60] 1000 Modelled 34000 
 Ifosfamide 3778-73-2 161.2 [60] 0.0 [60] 13.0 [60] 1000 Modelled 9400 
 Tamoxifen 10540-29-1 0.0 [60] 0.0 [60] 0.1 [60] 1000 Modelled 27.00 
 Imatinib 152459-95-5 2.29 [81] - - 565.7 [60] 1000 Modelled N/A 
 Capecitabine 154361-50-9 0.9 [60] 485.8 [60] - - 1000 Modelled 43.00 
 Bicalutamide 90357-06-5 9.5 [60] 65.5 [60] 70.5 [60] 1000 Modelled N/A 
Anaesthetic and 
metabolite 
Ketamine 6740-88-1 0.7 [60] 1.1 [60] 8.3 [60] 1000 Modelled 1600 
 Norketamine 35211-10-0 - - - - - - - - N/A 
 Venlafaxine 93413-69-5 47.58 [62] 34 [58] - - 1000 Experimental 140.0 
 Desmethylvenlafaxine 93413-62-8 32.2 [58] 33 [58] 9.4 [58] 1000 Experimental 71.69 
 Fluoxetine 54910-89-3 0.027 [82] 0.234 [83] 0.705 [83] 1000 Experimental 43.30 
 Norfluoxetine 83891-03-6 - - - - - - - - 131.9 
 Sertraline 79617-96-2 0.043 [82] 0.066 [84] 0.38 [84] 1000 Experimental 40920 
 Mirtazapine 85650-52-8 - - - - - - - - 6250 
 Citalopram 59729-33-8 1.6 [82] 20 [82] 4.5 [60] 1000 Experimental N/A 
 Desmethylcitalopram 62498-67-3 - - - - - - - - N/A 
 Paroxetine 61869-08-7 0.14 [82] 6.24 [85] 3.3 [60] 1000 Experimental 8200 
 Duloxetine 116539-59-4 0.1 [60] 0.2 [60] 0.7 [60] 1000 Modelled 90.86 













Ref AF Notes PNEC 
   mg L-1  mg L-1  mg L-1    ng L-1 
 Nortriptyline 72-69-5 - - 0.1 [60] 0.8 [60] 1000 Modelled 41553 
 Norsertraline 87857-41-8 - - - - 40.9 [60] 1000 Modelled 3545 
Anti-epileptic Carbamazepine 298-46-4 36.6 [86] 76.3 [68] 6.25 [87] 1000 Experimental 1092 




29331-92-8 - - - - - - - - 68.04 
Calcium-channel 
blocker 
Diltiazem 42399-41-7 9.6 [88] 8.2 [68] 15 [68] 1000 Experimental 386.0 
 Verapamil 52-53-9 0.1 [60] 21 [89] 0.8 [60] 1000 Modelled 100000 
Hypnotic Temazepam 846-50-4 - - 61.1 [60] 64.2 [60] 1000 Modelled 350.0 
 Oxazepam 604-75-1 - - 41.6 [60] 44.9 [60] 1000 Modelled 97000 
 Diazepam 439-14-5 3.5 [60] 19.8 [60] 22.6 [60] 1000 Modelled 170.0 
Anti-psychotic Quetiapine 111974-69-7 1.1 [60] 1.7 [60] 12.7 [60] 1000 Modelled 13.23 
 Risperidone 106266-06-2 0.7 [60] 1.2 [60] 8.3 [60] 1000 Modelled 2892 
Dementia Donepezil 120014-06-4 0.1 [60] 0.2 [60] 1.0 [60] 1000 Modelled N/A 
 Memantine 19982-08-2 0.4 [60] 0.6 [60] 4.6 [60] 1000 Modelled 1331 
Lifestyle Chemicals 
and Creatinine 
Creatinine 60-27-5 100 [58] 1000 [58] 2807.0 [60] 1000 Experimental 1231 
 Nicotine 54-11-5 37 [58] 0.35 [90] 4.9 [60] 1000 Experimental 1409 
 Caffeine 58-08-2 100 [58] 177.49 [70] 97 [58] 1000 Experimental 172.4 
 Cotinine 486-56-6 64.5 [60] 0.17 [90] 972.8 [60] 1000 Modelled N/A 
 1,7-dimethylxanthine 611-59-6 0.0 [60] 201.8 [60] 640.5 [60] 1000 Modelled 819.1 
Opioid Analgaesics 
and Metabolites 
Heroin 561-27-3 6.6 [60] 11.2 [60] 2.9 [60] 1000 Modelled 954.4 
 6-acetylmorphine 2784-73-8 - - - - - - - - 13018 
 Morphine 57-27-2 1.3 [60] 1.3 [60] 12.8 [60] 1000 Modelled 959.3 
 Dihydromorphine 509-60-4 2.5 [60] 1.2 [60] 15.1 [60] 1000 Modelled N/A 
 Normorphine 466-97-7 1.5 [60] 1.4 [60] 14.0 [60] 1000 Modelled N/A 
 Methadone 76-99-3 0.2 [60] 0.3 [60] 2.2 [60] 1000 Modelled 2700 
 EDDP 30223-73-5 - - - - - - - - 570.0 
 Codeine 76-57-3 0.8 [60] 18.8 [60] 9.2 [60] 1000 Modelled 162.3 
 Norcodeine 467-15-2 1.0 [60] 24.1 [60] 10.1 [60] 1000 Modelled 135.1 
 Dihydrocodeine 125-28-0 13.0 [60] 14.0 [60] 124.9 [60] 1000 Modelled 2899 
 Tramadol 27203-92-5 1.0 [60] 170 [89] 10.2 [60] 1000 Modelled 46.00 




- - - - - - - - 2678 
Stimulants and 
metabolites 
Amphetamine 300-62-9 3.8 [60] - - 37.6 [60] 1000 Modelled 3803 
 Methamphetamine 537-46-2 2.0 [60] 2.5 [60] 20.5 [60] 1000 Modelled 1967 
 MDMA 42542-10-9 2.3 [60] 0.2 [60] 24.2 [60] 1000 Modelled 215.8 
 MDA 101-77-9 4.7 [60] 0.35 [58] 20.6 [58] 1000 Modelled 350.0 
 Cocaine 50-36-2 4.4 [60] 5.5 [60] 32.3 [60] 1000 Modelled 4350 
 Benzoylecgonine 519-09-5 12041.7 [60] 6805.2 [60] 33458.8 [60] 1000 Modelled 6805166 
 Anhydroecgoninemethylester 43021-26-7 - - - - 2.7 [60] 1000 Modelled 2675 













Ref AF Notes PNEC 
   mg L-1  mg L-1  mg L-1    ng L-1 
 Mephedrone 1189805-46-6 - - - - - - - - N/A 




Thiamethoxam 153719-23-4 81.8 [58] 0.014 [58] 100 [58] 1000 Experimental 14.00 
 Imidacloprid 138261-41-3 10 [58] 85 [58] 211 [58] 1000 Experimental 10000 
 Clothiniadin 210880-92-5 42.8 [60] 37.9 [60] 354.2 [60] 1000 Modelled 37941 
 Metazachlor 67129-08-2 0.0 [60] 10.8 [60] 5.2 [60] 1000 Modelled 21.89 
 Terbuthylazine 5915-41-3 0.1 [60] 8.8 [60] 9.0 [60] 1000 Modelled 63.58 
 Methiocarb 2032-65-7 1.4 [60] 0.0 [60] 2.8 [60] 1000 Modelled 3.09 
 Dichlofluanid 1085-98-9 36.9 [60] 37.6 [60] 62.0 [60] 1000 Modelled 36867 
 Flufenacet 142459-58-3 7.0 [60] 45.7 [60] 49.9 [60] 1000 Modelled 7000 
 Oxadiazon 19666-30-9 0.2 [60] 0.4 [60] 0.1 [60] 1000 Modelled 75.08 
 Chlorpyrifos 2921-88-2 0.3 [60] 0.0 [60] 0.1 [60] 1000 Modelled 0.33 
 Triallate 2303-17-5 0.1 [60] 0.3 [60] 0.3 [60] 1000 Modelled 126.3 
Veterinary 
Pharmaceuticals 
Tylosin 1401-69-0 0.21 [67] 6.2 [60] - - 1000 Modelled 210.0 
 Sulfapyridine 144-83-2 5.28 [58] - - 246.3 [60] 1000 Modelled 5280 
 Sarafloxacin 98105-99-8 329.8 [60] 322.8 [60] 3016.7 [60] 1000 Modelled 322803 
 Ceftiofur 80370-57-6 114.4 [60] 69.8 [60] 53.3 [60] 1000 Modelled 53271 




3.1.5. Antibiotics and antibacterials 
Of the 21 antibiotics and antibacterials in this method, 12 were found in the environment, 3 
were found in all environmental samples (sulfasalazine 10.4 – 61.9 ng L-1, clarithromycin 39.8 
– 178.8 ng L-1, and sulfamethoxazole 26.1 – 51.3 ng L-1). The highest concentration found was 
erythromycin at 2,148 ng L-1, though this value may be exaggerated due to correction for poor 
recovery (uncorrected values were 140.7 ng L-1 on average). The macrolide antibiotics 
azithromycin, clarithromycin and erythromycin are in the 17 CECs prioritised by Directive 
2015/495/EU. In this study, concentrations for azithromycin and erythromycin ranged from 
<MQL (0.26 ng L-1) to 21.9 ng L-1 and <MQL (3.83 ng L-1) to 2,410 ng L-1 respectively. In 
literature they have been found at concentrations up to 16,633 ng L-1, 2,403 ng L-1, 65.1 ng L-1 
(for azithromycin, clarithromycin and erythromycin) in El Albujón watercourse in Spain [92]. 
These were identified as the highest concentrations for azithromycin and clarithromycin in 
literature since 2012 in a review by Sousa et al [1]. Other antibiotics of note include 
sulfamethoxazole, identified as one of the most reported antibiotics, excluding Watch List 
antibiotics, by Sousa et al,  and reported up to 1,820 ng L-1 (Taiwan), [1, 54]. In this study it 
was found at concentrations up to 44.7 ng L-1, similar to levels seen in the El Albujón 
watercourse in Spain. 
 
PNECs ranged from 0.12 mg L-1 for norfloxacin to 10 ng L-1 for amoxicillin (based on chronic 
data for daphnid trophic level from ECHA database (1.0 µg L-1, AF of 100)). Of the PNEC 
detected in the environment in this study concentrations ranged from 62 ng L-1 for azithromycin 
to 50,640 ng L-1 for cefalexin.  PNECs were previously calculated for several antibiotics (n = 
28) by Verlicchi et al [93], ranging from 3.7 ng L-1 for amoxicillin to 938,000 ng L-1 for 
ciprofloxacin but this was based on acute effects (EC50). PNECs could not be calculated for 
danofloxacin or prulifloxacin as no ecotoxicity data could be found, nor could it be predicted 
using ECOSAR. The RQMEC:PNEC ranged from 0.002 for penicillin V to 2.875 for erythromycin. 
Several antibiotics were in the range of 0.204 – 0.549. Ranked for risk to the environment from 
least to most toxic, penicillin V (0.002) < sulfadiazine (0.004) < cefalexin (0.005) < 
metronidazole (0.021) < sulfamethoxazole (0.068) < ciprofloxacin (0.204) < sulfasalazine 
(0.267) < azithromycin (0.270) < chloramphenicol (0.355)  < clarithromycin (0.379) < 
trimethoprim (0.549) < erythromycin (2.875). Sulfamethoxazole has previously been classified 
as medium risk with RQ of 0.1-1 and erythromycin and ciprofloxacin were classed as high risk 
with RQ < 1 by Sousa et al [1].  
 
The RQmixture is above 1 at 6 out of 8 sampling sites, (0.51 at R1, 0.791 at R3, both upstream of 




at R1 to 2.12 at R8, with a spike of 3.99 at R4. Sum of toxic units shows the algal trophic layer 
are most at risk. 
One aspect this approach does not consider is the potential development of antibiotics resistance 
at the low levels found within the environment. This is a crucial consideration for future work 




Of the two antifungals in this study, only ketoconazole was found in the environment. It was 
found in 19 out of 56 samples taken, but it was found at least once at each site, at concentrations 
ranging from 3.1 to 93.8 ng L-1. Ketoconazole has been found in Swedish coastal waters <MQL 
(<0.1 ng L-1) at 0.22 ng L-1 [20]. Another study found ketoconazole at low level, between 200 
m upstream of an effluent discharge point and several sites downstream up to 3 km away, at 
concentrations ranging from 2.7-3.7 ng L-1 in the aqueous phase [14]. However, two other 
studies have not found this antifungal in environmental waters [94, 95].  
 
With regards to ecotoxicity, ketoconazole is the more toxic of the two antifungals, with chronic 
PNEC of 20.3 ng L-1, compared to 2,990 ng L-1 for griseofulvin. For the concentrations 
throughout the catchment, ketoconazole presents a high risk to the catchment, with RQMEC:PNEC  
values ranging from 3.51 at R1 to 2.0 at R8. Interestingly, this is the reverse distribution trend 
than for many compounds, which generally show low-to-high levels from R1 to R8. This 
suggests the main source of ketoconazole is not from the WwTWs of the catchment and is from 
a source higher upstream than the sampled area. Overall average RQ for this stretch of the 
catchment river is 3.5. 
 
Similarly, to antibiotics, low levels of antifungals in the environment can encourage the spread 
of antifungal resistance. These sublethal effects can have important implication for the future 
of medicine. 
 
3.1.7.  Hypertension 
 
Of the four pharmaceuticals for treating hypertension of this study, lisinopril and candesartan 
were not found in the environment (<MQL = 21.7 ng L-1 and 23.0 ng L-1 respectively), valsartan 
was found in 14 samples, at the lower end of the catchment (R6-R8) at  average concentrations 
per site from 55.0 to 64.0 ng L-1 (<MQL = 9.26 ng L-1). Concentrations at R2 were calculated 




134.4 ng L-1. Valsartan was found at similar concentration in the UK <MQL (<0.5) to 73 ng L-
1 [37], and concentrations up to 7,479 ng L-1 were found in El Albujón watercourse (Spain), in 
another one-week intensive study at the same watercourse, average concentrations depended 
on season and varied from 18.5 ± 12.2 ng L-1 in autumn (Mean ± SD) to 466.9 ± 347.6 ng L-1 
in summer [92]. Concentrations for irbesartan were found up to 305.5 ng L-1 in the El Albujón 
watercourse (Spain), seasonal trends shows 152.4 ± 150.6 ng L-1 in summer to 71.8 ± 65.5 ng 
L-1 in winter, undetectable during sampling campaigns in other seasons [92]. To this author’s 
knowledge lisinopril has not yet been quantified in the aqueous environment. 
 
The ecotoxicity of irbesartan is largely unknown with no data found in TOXNET or ECOTOX 
database, no modelled data available through ECOSAR or any literature found in searches of 
‘irbesartan’ AND ‘toxicity’ AND ‘algae’ OR ‘daphnia’ OR ‘crustacean’ OR ‘fish’. Valsartan 
is the more ecotoxic than lisinopril, with a PNEC of 0.14 mg L-1 compared to 0.33 mg L-1. The 
highest RQMEC:PNEC for the catchment for valsartan is very low, 4.4 x 10-4, showing negligible 
risk for this compound. Assuming irbesartan would exhibit similar ecotoxicity as seen by 
valsartan, the highest RQMEC:PNEC is 7.7 x 10-3. Overall, this suggests a low risk to the aquatic 
environment from these compounds. 
 
3.1.8.  NSAIDs and acetaminophen 
 
Of the 4 NSAIDs and acetaminophen, 4 are found in the environment. Only ketoprofen was not 
found. The rest were found in all samples collected. Ibuprofen, naproxen, diclofenac and 
acetaminophen were found at the concentration ranges 8.3 to 159.2 ng L-1, 85.2 to 462.4 ng L-
1, 11.0 to 98.9 ng L-1, and 13.2 to 488.3 ng L-1 respectively. Diclofenac in particular is part of 
the Watch List as a prospective priority hazardous substance with recommended average annual 
EQS of 100 ng L-1 [57]. Within this study diclofenac does not quite reach this level, but is 
within 20% of this limit. Compared to another study in the UK, this catchment appears to show 
a wider range of concentrations that previously seen for all compounds except acetaminophen, 
which range from 185 to 1534 ng L-1 in a 5 month monitoring program in 2009 [49]. The highest 
concentration for diclofenac in literature since 2012, was 7,761 ng L-1, based on the review by 
Sousa et al [1], was found in the Antarctic Peninsula [96]. The other NSAIDs, showed similar 
high level concentrations in the µg L-1 range, ketoprofen 9,220 ng L-1 and naproxen 59,300 ng 
L-1 these were found in South African surface water. Ibuprofen showed lower levels in this 
environment with 2,570 ng L-1. Levels for acetaminophen have reached 30,421 ng L-1 during a 





Ketoprofen and acetaminophen have been shown to be similarly toxic, with PNEC of 0.021 mg 
L-1 although, acetaminophen is based on chronic experimental data with an applied AF of 10, 
compared to ketoprofens modelled data and applied AF of 1000. Therefore, the ecotoxicity 
ranking is acetaminophen ≈ ketoprofen > naproxen (0.426 mg L-1) > diclofenac (0.464 mg L-1) 
> ibuprofen (1.0 mg L-1). The highest RQMEC:PNEC is for acetaminophen with 0.013, showing 
there is limited risk to the environment individually. Furthermore, the RQmixture shows only 
slightly more risk than acetaminophen itself. These five pharmaceuticals were also considered 
by Riva et al., and they shows a similar lack of risk in the surface water of Milan also [17]. 
 
3.1.9. Lipid Regulators 
 
Bezafibrate was the most frequently found lipid regulator in this study. With concentrations of 
29.4 to 131.4 ng L-1 across all 56 samples collected. Atorvastatin, however, was only found in 
42 samples (it was not found in any samples upstream of WwTW A (R1), with concentrations 
ranging from 9.1 to 57.5 ng L-1. Gemfibrozil was only found in 3 samples at concentrations 
ranging from 1.5 to 37.3 ng L-1. 
 
Bezafibrate and gemfibrozil are frequently monitored in the environment, despite not being 
present on a watch list, at concentrations up to approximately 950 and 850 ng L-1 respectively 
[1]. Atorvastatin and its metabolites para- and ortho-hydroxylatorvastatin have been identified 
as particularly hazardous to the environment and have been included in the second stage of the 
UKWIR CIP (CIP2) programme for further monitoring in the UK [98]. 
 
Of the three atorvastatin poses the greatest risk to the aquatic environment with RQMEC:PNEC  >1 
at six of the sites across the catchment (R2, R3, R4, R6, R7, R8). Furthermore, this does not 
take into account the risk from the metabolites of this compound which are likely to be present. 
The risk posed by bezafibrate is an order of magnitude lower than atorvastatin, but would be 
classed as medium risk at six of the sites (between RQMEC:PNEC is 0.1-1 for sites R3-R8, by the 





Table 2 Chronic aquatic ecotoxicity data for three trophic levels with references, assessment factor, notes and PNEC 












Ref AF Notes PNEC 
   mg L-1  mg L-1  mg L-1    ng L-1 
UV Filters Benzophenone-1 131-56-6 0.33 [58] 5.77 [58] 1.45 [58] 10 Experimental 32700 
 Benzophenone-2 131-55-5 0.42 [60] 9.27 [60] 2.21 [60] 1000 Modelled 421.8 
 Benzophenone-3 131-57-7 0.18 [58] 0.19 [99] 0.72 [58] 10 Experimental 18000 
 Benzophenone-4 4065-45-6 664.23 [60] 5.00 [58] 4.90 [58] 50 Experimental 97940 
Parabens Methylparaben 99-76-3 20.34 [62] 27.01 [62] 25.00 [100] 10 Experimental 2034000 
 Ethylparaben 120-47-8 2.10 [58] 2.30 [100] 17.00 [100] 10 Experimental 210000 
 Propylparaben 94-13-3 2.10 [58] 0.25 [58] 2.50 [100] 10 Experimental 25000 
 Butylparaben 94-26-8 0.80 [58] 0.31 [60] 1.00 [100] 50 Experimental 6146 
Plasticizer Bisphenol A 80-05-7 0.23 [60] 1.39E-05 [50] 7.77 [91] 50 Experimental 0.28 
Steroid estrogens E1 53-16-7 0.57 [58] 0.44 [60] 0.00 [101] 50 Experimental 0.64 
 E2 50-28-2 3.10 [58] 138.70 [58] 0.00 [58] 10 Experimental 0.10 
 EE2 57-63-6 0.47 [60] 0.25 [60] 0.17 [60] 1000 Modelled 174.1 
Antibiotics and 
Antibacterial 
Sulfasalazine 599-79-1 0.72 [60] 0.82 [60] 0.20 [60] 1000 Modelled 200.9 
 Clarithromycin 81103-11-9 0.00 [99] 5.00 [99] 68.00 [99] 10 Experimental 370.0 
 Azithromycin 83905-01-5 0.01 [99] 0.29 [60] 0.82 [60] 100 Experimental 62.00 
 Trimethoprim 738-70-5 0.77 [60] 0.08 [60] 3.59 [60] 1000 Modelled 80.74 
 Sulfamethoxazole 723-46-6 0.07 [99] 125.06 [60] 5.00 [60] 100 Experimental 660.0 
 Triclosan 3380-34-5 0.00 [99] 0.21 [62] 0.04 [99] 10 Experimental 54.00 
 Amoxicillin 26787-78-0 5.12 [60] 0.00 [58] 1.73 [60] 100 Experimental 10.00 
 Metronidazole 443-48-1 2.70 [60] 3.08 [60] 0.95 [60] 1000 Modelled 949.2 
 Sulfadiazine 68-35-9 28.99 [60] 452.78 [60] 21.84 [60] 1000 Modelled 21837 
 Cefalexin 15686-71-2 255.35 [60] 50.64 [60] 110.61 [60] 1000 Modelled 50640 
 Ofloxacin 82419-36-1 1.30 [99] 0.03 [99] 2456.84 [60] 50 Experimental 580.0 
 Ciprofloxacin 85721-33-1 455.22 [60] 81.27 [60] 1553.58 [60] 1000 Modelled 81270 
 Tetracycline 60-54-8 0.79 [60] 1.25 [60] 1.29 [60] 1000 Modelled 789.0 
 Danofloxacin 112398-08-0 - - - - - - - - N/A 
 Oxytetracycline 79-57-2 1.69 [60] 2.84 [60] 4.48 [60] 1000 Modelled 1688 
 Chloramphenicol 56-75-7 0.22 [60] 47.61 [60] 15.46 [60] 1000 Modelled 217.1 
 Penicillin G 61-33-6 84.12 [60] 191.19 [60] 14.99 [60] 1000 Modelled 14988 
 Penicillin V 87-08-1 86.33 [60] 193.80 [60] 15.26 [60] 1000 Modelled 15263 
 Erythromycin 114-07-8 2.20 [60] 0.75 [60] 1.98 [60] 1000 Modelled 747.2 
 Prulifloxacin 123447-62-1 - - - - - - - - N/A 
 Norfloxacin 70458-96-7 702.54 [60] 115.88 [60] 2647.20 [60] 1000 Modelled 115882 
Antifungal Griseofluvin 126-07-8 50.78 [60] 13.80 [60] 2.99 [60] 1000 Modelled 2990 
 Ketoconazole 65277-42-1 0.11 [60] 0.02 [60] 0.03 [60] 1000 Modelled 20.31 
Hypertension Valsartan 137862-53-4 100.00 [58] 18.40 [60] 14.46 [60] 100 Experimental 144635 
 Irbesartan 138402-11-6 - - - - - - - - N/A 
 Lisinopril 76547-98-3 1614.70 [60] 331.92 [60] 801.46 [60] 1000 Modelled 331920 
 Candesartan Cilexetil 145040-37-5 - - - - - - - - N/A 
NSAIDs Ketoprofen 22071-15-4 57.73 [60] 20.74 [60] 28.78 [60] 1000 Modelled 20737 
 Ibuprofen 15687-27-1 11.00 [99] 66.00 [71] 10.00 [58] 10 Experimental 1000000 
















Ref AF Notes PNEC 
   mg L-1  mg L-1  mg L-1    ng L-1 
 Diclofenac 15307-86-5 49.20 [71] 15.20 [71] 4.64 [91] 10 Experimental 464000 
 Acetaminophen 103-90-2 490.00 [99] 0.21 [99] 95.00 [58] 10 Experimental 21000 
Lipid regulator Bezafibrate 41859-67-0 8.40 [60] 4.62 [60] 0.62 [60] 1000 Modelled 618.4 
 Atorvastatin 134523-00-5 0.19 [60] 0.02 [60] 0.05 [60] 1000 Modelled 15.16 
 Gemfibrozil 25812-30-0 4.89 [60] 0.98 [60] 0.89 [60] 1000 Modelled 889.0 
Antihistamine Fexofenadine 83799-24-0 8.98 [60] 3.33 [60] 12.31 [60] 1000 Modelled 3326 
 Cetirizine 83881-51-0 1367.74 [60] 208.50 [60] 5688.08 [60] 1000 Modelled 208500 
GUD/ED Sildenafil 139755-83-2 0.68 [60] 0.28 [60] 0.21 [60] 1000 Modelled 207.1 
Antidiabetics Metformin 657-24-9 1040.59 [60] 4.40 [76] 8360.70 [60] 100 Experimental 44000 
 Gliclazide 21187-98-4 0.02 [60] 0.38 [60] 1.17 [60] 1000 Modelled 20.40 
 Sitagliptin 486460-32-6 5.16 [60] 1.68 [60] 0.73 [60] 1000 Modelled 728.4 
Cough suppressant Pholcodine 509-67-1 16.14 [60] 4.60 [60] 18.03 [60] 1000 Modelled 4597 
Beta-blocker Atenolol 29122-68-7 27.00 [99] 7.70 [99] 15.22 [60] 50 Experimental 154000 
 Metoprolol 51384-51-1 2.69 [60] 0.74 [60] 5.29 [60] 1000 Modelled 744.6 
 Propranolol 525-66-6 0.10 [99] 0.76 [99] 0.22 [99] 10 Experimental 10000 
 Bisoprolol 66722-44-9 2.62 [60] 0.75 [60] 4.93 [60] 1000 Modelled 754.2 
H2 receptor agonist Ranitidine 66357-35-5 27.42 [60] 5.28 [60] 85.04 [60] 1000 Modelled 5284 
 Cimetidine 51481-61-9 2.28 [60] 2.04 [60] 0.77 [60] 1000 Modelled 773.8 
X-ray contrast 
media 
Iopromide 73334-07-3 - - - - - - - - N/A 
Various Buprenorphine 52485-79-7 0.03 [60] 0.06 [60] 0.01 [60] 1000 Modelled 10.04 
Drug precursor Ephedrine/pseudoephedrine 299-42-3 3.44 [58] 1.69 [60] 21.61 [60] 100 Experimental 16850 
 Norephedrine 492-39-7 14.84 [60] 2.80 [60] 47.20 [60] 1000 Modelled 2804 
Anti-cancer Azathioprine 446-86-6 4.76 [60] 5.63 [60] 1.68 [60] 1000 Modelled 1682 
 Methotrexate 59-05-2 45.34 [60] 2.93 [60] 1420.87 [60] 1000 Modelled 2933 
 Ifosfamide 3778-73-2 29.62 [60] 295.75 [60] 0.02 [60] 1000 Modelled 16.80 
 Tamoxifen 10540-29-1 0.00 [60] 0.00 [60] 0.00 [60] 1000 Modelled 1.35 
 Imatinib 152459-95-5 0.79 [81] - - 56.86 [60] 100 Experimental 7900 
 Capecitabine 154361-50-9 - - 52.33 [60] - - 1000 Modelled 52334 
 Bicalutamide 90357-06-5 6.94 [60] 12.11 [60] 1.05 [60] 1000 Modelled 1049 
Anaesthetic and 
metabolite 
Ketamine 6740-88-1 0.26 [60] 0.11 [60] 0.33 [60] 1000 Modelled 105.7 
 Norketamine 35211-10-0 - - - - - - - - N/A 
 Venlafaxine 93413-69-5 10.00 [62] 68.00 [62] 0.28 [60] 10 Experimental 28398 
 Desmethylvenlafaxine 93413-62-8 0.10 [60] 8.20 [58] 2.10 [58] 50 Experimental 2098 
 Fluoxetine 54910-89-3 31.34 [102] 170.00 [103] 9.00 [103] 10 Experimental 900000 
 Norfluoxetine 83891-03-6 - - - - - - - - N/A 
 Sertraline 79617-96-2 4.57 [102] 0.03 [84] 0.10 [84] 10 Experimental 3200 
 Mirtazapine 85650-52-8 - - - - - - - - N/A 
 Citalopram 59729-33-8 0.14 [60] 0.07 [60] 0.14 [60] 1000 Modelled 65.23 
 Desmethylcitalopram 62498-67-3 - - - - - - - - N/A 
 Paroxetine 61869-08-7 0.10 [60] 0.05 [60] 0.10 [60] 1000 Modelled 50.48 
 Duloxetine 116539-59-4 0.03 [60] 0.02 [60] 0.02 [60] 1000 Modelled 17.91 
 Amitriptyline 50-48-6 0.02 [60] 0.01 [60] 0.01 [60] 1000 Modelled 11.86 
















Ref AF Notes PNEC 
   mg L-1  mg L-1  mg L-1    ng L-1 
 Norsertraline 87857-41-8 - - - - - - - - N/A 
Anti-epileptic Carbamazepine 298-46-4 0.60 [62] 0.03 [73] 1.03 [91] 10 Experimental 2500 




29331-92-8 - - - - - - - - N/A 
Calcium-channel 
blocker 
Diltiazem 42399-41-7 0.76 [60] 0.28 [60] 0.51 [60] 1000 Modelled 281.2 
 Verapamil 52-53-9 0.04 [60] 11.00 [89] 0.03 [60] 100 Experimental 274.4 
Hypnotic Temazepam 846-50-4 5.61 [60] 10.68 [60] 0.90 [60] 1000 Modelled 895.3 
 Oxazepam 604-75-1 4.51 [60] 7.75 [60] 0.67 [60] 1000 Modelled 674.8 
 Diazepam 439-14-5 3.08 [60] 4.24 [60] 0.40 [60] 1000 Modelled 401.6 
Anti-psychotic Quetiapine 111974-69-7 0.40 [60] 0.16 [60] 0.49 [60] 1000 Modelled 162.1 
 Risperidone 106266-06-2 0.26 [60] 0.11 [60] 0.28 [60] 1000 Modelled 114.2 
Dementia Donepezil 120014-06-4 0.03 [60] 0.02 [60] 0.02 [60] 1000 Modelled 18.09 
 Memantine 19982-08-2 0.14 [60] 0.06 [60] 0.17 [60] 1000 Modelled 60.76 
Lifestyle Chemicals 
and Creatinine 
Creatinine 60-27-5 59.07 [60] 13.15 [60] 32.42 [60] 1000 Modelled 13155 
 Nicotine 54-11-5 5.20 [58] 0.02 [58] 3.00 [58] 10 Experimental 2000 
 Caffeine 58-08-2 120.00 [99] 35.00 [99] 31.00 [99] 10 Experimental 3100000 
 Cotinine 486-56-6 19.76 [60] 109.33 [60] 6.13 [60] 1000 Modelled 6129 
 1,7-dimethylxanthine 611-59-6 0.00 [60] 5.55 [60] 1.49 [60] 1000 Modelled 3.67 
Opioid Analgaesics 
and Metabolites 
Heroin 561-27-3 1.40 [60] - - 0.06 [60] 1000 Modelled 63.85 
 6-acetylmorphine 2784-73-8 - - - - - - - - N/A 
 Morphine 57-27-2 0.48 [60] 0.28 [60] 0.17 [60] 1000 Modelled 165.1 
 Dihydromorphine 509-60-4 0.42 [60] 0.26 [60] 0.14 [60] 1000 Modelled 140.4 
 Normorphine 466-97-7 0.53 [60] 0.30 [60] 0.19 [60] 1000 Modelled 185.4 
 Methadone 76-99-3 0.07 [60] 0.04 [60] 0.06 [60] 1000 Modelled 36.09 
 EDDP 30223-73-5 - - - - - - - - N/A 
 Codeine 76-57-3 5.73 [60] 1.43 [60] 4.79 [60] 1000 Modelled 1425 
 Norcodeine 467-15-2 7.05 [60] 1.78 [60] 6.28 [60] 1000 Modelled 1781 
 Dihydrocodeine 125-28-0 4.14 [60] 1.09 [60] 8.71 [60] 1000 Modelled 1089 
 Tramadol 27203-92-5 0.35 [60] 52.00 [89] 0.45 [60] 100 Experimental 3466 




- - - - - - - - N/A 
Stimulants and 
metabolites 
Amphetamine 300-62-9 1.24 [60] 0.35 [60] 2.39 [60] 1000 Modelled 348.1 
 Methamphetamine 537-46-2 0.67 [60] 0.21 [60] 1.10 [60] 1000 Modelled 211.3 
 MDMA 42542-10-9 0.78 [60] 0.22 [60] 0.86 [60] 1000 Modelled 222.8 
 MDA 101-77-9 1.18 [60] 0.01 [58] 0.15 [60] 100 Experimental 50.00 
 Cocaine 50-36-2 1.46 [60] 0.46 [60] 2.34 [60] 1000 Modelled 459.1 
 Benzoylecgonine 519-09-5 3027.30 [60] 384.22 [60] 5050.13 [60] 1000 Modelled 384223 
 Anhydroecgoninemethylester 43021-26-7 - - 0.04 [60] - - 1000 Modelled 41.18 
















Ref AF Notes PNEC 
   mg L-1  mg L-1  mg L-1    ng L-1 
 Mephedrone 1189805-46-6 - - - - - - - - N/A 




Thiamethoxam 153719-23-4 3.56 [60] 5.74 [60] 20.00 [58] 100 Experimental 35576 
 Imidacloprid 138261-41-3 10.00 [58] 1.80 [58] 50.00 [58] 10 Experimental 180000 
 Clothiniadin 210880-92-5 3.48 [60] 2.67 [60] 35.07 [60] 1000 Modelled 2674 
 Metazachlor 67129-08-2 0.00 [60] 0.19 [60] 0.13 [60] 1000 Modelled 4.93 
 Terbuthylazine 5915-41-3 0.32 [60] 0.47 [60] 0.67 [60] 1000 Modelled 318.0 
 Methiocarb 2032-65-7 0.31 [60] 0.01 [60] 0.20 [60] 1000 Modelled 6.15 
 Dichlofluanid 1085-98-9 11.19 [60] 4.41 [60] 6.55 [60] 1000 Modelled 4413 
 Flufenacet 142459-58-3 5.32 [60] 8.76 [60] 0.78 [60] 1000 Modelled 775.2 
 Oxadiazon 19666-30-9 0.04 [60] 0.03 [60] 0.04 [60] 1000 Modelled 26.51 
 Chlorpyrifos 2921-88-2 0.25 [60] 0.00 [60] 0.00 [60] 1000 Modelled 0.05 
 Triallate 2303-17-5 0.22 [60] 0.02 [60] 0.02 [60] 1000 Modelled 18.37 
Veterinary 
Pharmaceuticals 
Tylosin 1401-69-0 0.06 [67] - - - - 100 Experimental 640.0 
 Sulfapyridine 144-83-2 10.43 [60] 0.07 [60] 4.54 [60] 1000 Modelled 65.75 
 Sarafloxacin 98105-99-8 101.28 [60] 23.87 [60] 244.10 [60] 1000 Modelled 23875 
 Ceftiofur 80370-57-6 63.74 [60] 0.82 [60] 1.11 [60] 1000 Modelled 821.1 




3.1.10 Further Class Observations 
3.1.10.1 Antihistamines 
 
Both fexofenadine and cetirizine were found in all environmental samples at concentrations 
from 89.0 to 574.9 ng L-1 and 44.3 to 585.5 ng L-1 respectively. Fexofenadine is far more toxic 
than cetirizine, leading to a PNEC two orders of magnitude lower than cetirizine, 3 µg L-1 to 
208 µg L-1. Overall, these compounds pose low risk to the environment, however the apparent 
persistence and increasing levels of these CECs through the catchment show an increasing risk 
to the environment with an RQMEC:PNEC up to 0.136, fexofenadine is of medium risk to the 
aquatic environment towards lower end of the catchment. Cetirizine contribute <2% to the 




 Sildenafil was found in 39 out of the 56 samples collected. Concentrations ranged from 0.1 to 
3.5 ng L-1. PNEC was calculated as 207 ng L-1, showing this compound poses no immediate 




All three antidiabetics of this study were found throughout the environment. Metformin was 
found in 49 samples at concentrations ranging from 100.7 to 5,189.5 ng L-1. Gliclazide was the 
most ubiquitous and found in all samples, but at the lowest range of concentrations, from 6.4 
to 60.1 ng L-1. Sitagliptin was found in 55 samples and at concentrations ranging from 58.3 to 
229.1 ng L-1. Despite being present at the highest concentrations metformin poses the least 
threat to the environment with a PNEC of 44 µg L-1 providing an RQMEC:PNEC of 0.093 at the 
highest point of the catchment. Sitagliptin poses a medium risk to the aquatic environment with 
RQMEC:PNEC of 0.275. However, gliclazide, with the lowest concentrations of the three is of high 
risk to the environment with RQMEC:PNEC >1 at out of 8 sites across the catchment and up to 
2.321 at R4. The RQmixture was 2.598 at the highest (R4). The STU showed that the algal trophic 
layer were most at risk though the RQSTU was below 0.01. 
 
3.1.10.4 Cough Suppressant 
 
 The cough suppressant pholcodine was not found in the environment, with a PNEC of 4,596 
ng L-1 and MQL of 7.42 ng L-1, this compound appears to be of low to no risk to the aquatic 







 Of the beta blockers in the study atenolol and propranolol were found most frequently and in 
all environmental samples. Metoprolol and bisoprolol were only found in at site R2, which were 
predicted from calculation based on effluent concentrations, measured upstream concentrations 
and flow. (<MQL 0.35, 0.004 ng L-1, respectively). Atenolol and propranolol are the least toxic 
with PNECs of 154 µg L-1 to 10 µg L-1. No RQMEC:PNEC  for these compounds are above > 0.002 
and therefore show little risk either individually or together. 
 
3.1.10.6 H2 Receptor agonist 
 
 Ranitidine was only found in 49 out of 56 environmental samples at concentrations ranging 
from 52.3 to 246.3 ng L-1, with a chronic PNEC of 5,283 ng L-1, this shows RQMEC:PNEC of 0.03 
at the highest point in the catchment showing low risk to the aquatic environment. Cimetidine 
was not found in any samples (<MQL 7.98 ng L-1). At the level of MQL this compounds poses 
no risk with RQmixture of >0.01. Overall this class poses little risk to the environment. 
 
3.1.10.7 X-ray contrast media 
 
Iopromide was not found in the environment above MQL (29.9 ng L-1). The PNEC for this 
compound is 187 ng L-1 (based on EC50) which means that iopromide may pose a low risk to 




Buprenorphine was found in 19 samples out of 56 and was found at all sites except for R5, at 
concentration ranges from 0.7 to 11.9 ng L-1. The compound has a PNEC of 10.0 ng L-1 showing 
that this compound is at high aquatic risk at the environmental concentrations. The highest 
concentrations were found at R1 upstream of the studied WwTWs. This may be due to a high 
proportion of the small population using it upstream of this point and less dilution within the 
environment due to low river flows. Buprenorphine is commonly used for treatment of opioid 
addiction but can also be used for pain relief in patients who do not find relief with, or cannot 
use non-opioid analgesics (DrugBank [28]). 
 





Ephedrine was found in all environmental samples, but its metabolite was not. The parent 
compound was found at concentrations of 5.8 to 77.2 ng L-1. This range is far below the PNEC, 
resulting in a RQMEC:PNEC of 0.002. Norephedrine has a MQL of 8.82 ng L-1, for this level the 
PNEC of 2,804 ng L-1 results in a RQMEC:PNEC of 0.003. Overall, this class shows little risk to 
the environment. 
 
3.1.10.10 Anticancer pharmaceuticals 
 
Of the 7 anticancer pharmaceuticals, two were found in the environment. Imatinib was found 
in 12 out of 56 samples, at all sites apart from R6, at concentrations ranging from 6.9 to 144.3 
ng L-1. Bicalutamide was found in 55 out of 56 samples, at concentrations of 50.9 to 75.1 ng L-
1. Capecitabine was only found at low predicted concentrations at site R2 at 0.05 ng L-1. PNEC 
could not be calculated for imatinib or capecitabine. The PNEC for bicalutamide was 1.0 µg L-
1, resulting in an RQMEC:PNEC of 0.07.  The most toxic anticancer agent, tamoxifen has a MQL 
of 72.6 ng L-1 this is far higher than the PNEC of 1.35 ng L-1, resulting in and RQMEC:PNEC  of 
53, therefore may pose a high risk to the aquatic environment at unquantifiable levels. The 
second compound with the second most toxic PNEC (16.80 ng L-1) of this class, ifosfamide 
shows much lower risk of 0.02, due to it low MQL of 0.40 ng L-1. 
 
3.1.10.11 Anaesthetic and metabolite 
 
Ketamine was found in all samples from R2 to R8, at concentrations of 50.9 to 75.1 ng L-1. But 
the metabolite was not found. This is only slightly lower than the PNEC of 106 ng L-1, resulting 





Of the 13 antidepressants and metabolites, two, venlafaxine and desmethylvenlafaxine were 
found in all samples throughout the catchment, mirtazapine was found in 49 samples, 
citaloprams metabolite, desmethylcitalopram, was found in 41 samples, amitriptyline in 35 and 
nortriptyline in 18. Citalopram and sertraline were found in 7 samples, only at R2. The highest 
concentration was seen for desmethylvenlafaxine, ranging from 45.6 to 258.1 ng L-1, whilst the 
parent is present at 27.0 to 102.5 ng L-1. The RQMEC:PNEC for these compounds shows minimal 
risk for venlafaxine  (RQ = 0.003), whereas desmethylvenlafaxine shows a higher risk to 
aquatic organisms with an RQMEC:PNEC of 0.109. Citalopram and nortriptyline show higher levels 




concentrations of 2.2 to 15.5 ng L-1), shows the highest environment risk with RQMEC:PNEC of 
0.908, close to the high risk level of  1. Overall, the mixture of antidepressants at the 
concentrations seen in the environment shows high risk to the environment with a RQmixture of 





Carbamazepine and its metabolites were found in nearly all samples (10,11-dihydro-10-
hydroxycarbamazepine was present in 55). Carbamazepine was present at concentrations of 
60.3 to 185.1 ng L-1, whereas carbamazepine-10,11-epoxide and 10,11-dihydro-10-
hydroxycarbamazepine were present at concentrations of 11.1 to 36.3 ng L-1 and 1.3 to 30.8 ng 
L-1. PNECs for the metabolites could not be calculated as ecotoxicity information from either 
literature or modelled data was not available. RQMEC:PNEC was calculated as 0.06 for 
carbamazepine showing low risk to the environment. 
 
3.1.10.14 Calcium Channel blockers 
 
Verapamil was not found in the environment (MQL 0.02 ng L-1). For diltiazem, measurable 
concentrations were only detected downstream of the WwTW with concentrations ranging from 
1.88 to 10.41 ng L-1. Verapamil and diltiazem show similar PNECs with 274 ng L-1 and 281 ng 
L-1 respectively. The RQMQL:PNEC for verapamil shows little aquatic environmental risk. 
Diltiazem shows higher levels of risk but still very low RQMEC:PNEC with 0.03. Overall, at these 




All hypnotics studies were found in the aquatic environment, temazepam and diazepam were 
found in 35 samples. Diazepam was found throughout the catchment at concentrations of 1.0 
to 33.5 ng L-1 whereas temazepam was primarily found in the lower levels of the catchment at 
R5 to R8 at concentrations of 3.5 to 24.2 ng L-1. Oxazepam was the most frequently found 
hypnotic (n = 42), but at the lowest oxazepam 0.01 to 4.8 ng L-1. PNECs ranged from 402 ng 
L-1 (diazepam) to 895 ng L-1 (temazepam). All three individually posed little aquatic 
environmental risk with RQMEC:PNEC of <0.03. The RQmixture for the class reached 0.04 at R6, 






Table 3 Heat map for the acute environmental risk (RQMEC:PNEC) of each CEC to aquatic 
organisms at each river sampling site (R1 further point upstream, to R8 furthest point 
downstream). Gradient is from low risk (green) to high risk (red). 
Class Analyte R1 R2 R3 R4 R5 R6 R7 R8 
UV Filters 
Benzophenone-1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Benzophenone-2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Benzophenone-3 0.033 0.047 0.032 0.028 0.044 0.055 0.033 0.024 
Benzophenone-4 0.008 0.014 0.010 0.024 0.009 0.015 0.025 0.026 
Parabens 
Methylparaben 0.001 0.001 0.001 0.001 0.004 0.001 0.001 0.001 
Ethylparaben 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Propylparaben 0.000 0.000 0.000 0.002 0.002 0.002 0.000 0.000 
Butylparaben 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Plasticizer Bisphenol A 0.000 0.003 0.011 0.014 0.009 0.015 0.018 0.021 
Steroid estrogens 
E1 0.000 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
E2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
EE2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Antibiotics and 
Antibacterial 
Sulfasalazine 0.007 0.008 0.013 0.018 0.007 0.011 0.007 0.008 
Clarithromycin 1.223 1.546 1.036 2.217 1.678 3.052 2.688 2.404 
Azithromycin 0.000 31.576 6.833 8.399 0.000 0.000 0.000 10.087 
Trimethoprim 0.000 0.011 0.006 0.010 0.007 0.017 0.014 0.012 
Sulfamethoxazole 0.001 0.002 0.001 0.002 0.001 0.002 0.002 0.002 
Triclosan 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Amoxicillin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Metronidazole 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Sulfadiazine 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cefalexin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ofloxacin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ciprofloxacin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Tetracycline 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Danofloxacin N/A N/A N/A N/A N/A N/A N/A N/A 
Oxytetracycline 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Chloramphenicol 0.000 0.111 0.000 0.000 0.000 0.000 0.000 0.192 
Penicillin G 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Penicillin V 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Erythromycin 0.000 0.040 0.000 0.622 0.103 0.086 0.132 0.162 
Prulifloxacin N/A N/A N/A N/A N/A N/A N/A N/A 
Norfloxacin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Antifungal 
Griseofulvin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ketoconazole 0.647 0.488 0.436 0.421 0.492 0.598 0.548 0.370 
Hypertension 
Valsartan 0.000 0.000 0.000 0.000 0.000 0.001 0.001 0.001 
Irbesartan N/A N/A N/A N/A N/A N/A N/A N/A 
Lisinopril 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Candesartan Cilexetil N/A N/A N/A N/A N/A N/A N/A N/A 
NSAIDs 
Ketoprofen 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 




Class Analyte R1 R2 R3 R4 R5 R6 R7 R8 
Naproxen 0.278 0.317 0.455 0.712 0.418 1.072 0.841 0.893 
Diclofenac 0.422 0.764 0.706 0.980 0.236 0.437 0.383 0.408 
Acetaminophen 0.006 0.000 0.004 0.016 0.017 0.022 0.022 0.022 
Lipid regulator 
Bezafibrate 0.007 0.011 0.014 0.021 0.014 0.022 0.019 0.020 
Atorvastatin 0.000 1.063 2.128 2.954 0.000 2.780 1.678 2.136 
Gemfibrozil 0.000 0.000 0.000 0.000 0.000 0.006 0.000 0.000 
Antihistamine 
Fexofenadine 0.005 0.008 0.006 0.008 0.004 0.008 0.014 0.018 
Cetirizine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
GUD/ED Sildenafil 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.000 
Antidiabetics 
Metformin 0.000 0.014 0.204 0.252 0.166 0.246 0.285 0.276 
Gliclazide 0.178 0.238 0.262 0.385 0.065 0.106 0.238 0.266 
Sitagliptin 0.007 0.010 0.005 0.007 0.003 0.003 0.007 0.006 
Cough 
suppressant 
Pholcodine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Beta-blocker 
Atenolol 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Metoprolol 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Propranolol 0.002 0.005 0.002 0.004 0.001 0.003 0.004 0.004 
Bisoprolol 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
H2 receptor 
agonist 
Ranitidine 0.001 0.002 0.001 0.002 0.000 0.002 0.002 0.002 
Cimetidine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
X-ray contrast 
media 
Iopromide 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Various Buprenorphine 0.158 0.091 0.055 0.099 0.000 0.080 0.084 0.057 
Drug precursor 
Ephedrine/pseudoephedrine 0.000 0.000 0.000 0.001 0.000 0.000 0.001 0.001 
Norephedrine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Anticancer 
Azathioprine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Methotrexate 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ifosfamide 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Tamoxifen 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Imatinib 0.063 0.003 0.014 0.017 0.014 0.000 0.024 0.018 
Capecitabine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Bicalutamide 0.006 0.007 0.005 0.006 0.007 0.006 0.008 0.007 
Anaesthetic and 
metabolite 
Ketamine 0.000 0.002 0.008 0.016 0.010 0.015 0.022 0.023 
Norketamine N/A N/A N/A N/A N/A N/A N/A N/A 
Venlafaxine 0.001 0.002 0.002 0.003 0.001 0.001 0.002 0.003 
Desmethylvenlafaxine 0.011 0.019 0.018 0.024 0.005 0.010 0.014 0.015 
Fluoxetine 0.000 0.237 0.000 0.045 0.000 0.000 0.000 0.000 
Norfluoxetine N/A N/A N/A N/A N/A N/A N/A N/A 
Sertraline 0.000 0.046 0.000 0.000 0.000 0.000 0.000 0.000 
Mirtazapine N/A N/A N/A N/A N/A N/A N/A N/A 
Citalopram 0.000 0.016 0.000 0.000 0.000 0.000 0.000 0.000 
Desmethylcitalopram N/A N/A N/A N/A N/A N/A N/A N/A 
Paroxetine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Duloxetine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 




Class Analyte R1 R2 R3 R4 R5 R6 R7 R8 
Nortriptyline 0.000 0.027 0.026 0.059 0.016 0.008 0.060 0.061 
Norsertraline 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Antiepileptic 
Carbamazepine 0.013 0.023 0.020 0.026 0.011 0.015 0.022 0.022 
Carbamazepine 10,11-
epoxide 
N/A N/A N/A N/A N/A N/A N/A N/A 
10,11-Dihydro -10-
hydroxycarbamazepine 
N/A N/A N/A N/A N/A N/A N/A N/A 
Calcium-channel 
blocker 
Diltiazem 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.000 
Verapamil 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Hypnotic 
Temazepam 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Oxazepam 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Diazepam 0.002 0.003 0.002 0.002 0.002 0.002 0.002 0.002 
Antipsychotic 
Quetiapine 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 
Risperidone 0.003 0.002 0.002 0.002 0.000 0.000 0.002 0.003 
Dementia 
Donepezil 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 




Creatinine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Nicotine 0.202 0.206 0.065 0.103 0.051 0.064 0.130 0.121 
Caffeine 0.003 0.002 0.003 0.004 0.003 0.005 0.006 0.006 
Cotinine 0.127 0.000 0.165 0.222 0.164 0.272 0.289 0.293 
1,7-dimethylxanthine 21.400 0.000 54.105 69.814 50.737 53.331 66.804 78.455 
Opioid Analgesics 
and Metabolites 
Heroin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
6-acetylmorphine N/A N/A N/A N/A N/A N/A N/A N/A 
Morphine 0.000 0.019 0.000 0.000 0.000 0.017 0.021 0.021 
Dihydromorphine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Normorphine 0.000 0.010 0.000 0.000 0.000 0.000 0.000 0.000 
Methadone 0.007 0.014 0.000 0.018 0.000 0.020 0.023 0.024 
EDDP N/A N/A N/A N/A N/A N/A N/A N/A 
Codeine 0.025 0.045 0.061 0.105 0.052 0.110 0.102 0.110 
Norcodeine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Dihydrocodeine 0.000 0.001 0.001 0.002 0.002 0.003 0.002 0.002 
Tramadol 0.143 0.258 0.244 0.335 0.105 0.178 0.239 0.249 
N-desmethyltramadol N/A N/A N/A N/A N/A N/A N/A N/A 
O-desmethyltramadol N/A N/A N/A N/A N/A N/A N/A N/A 
Stimulants and 
metabolites 
Amphetamine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Methamphetamine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
MDMA 0.014 0.032 0.006 0.020 0.016 0.059 0.074 0.075 
MDA 0.033 0.038 0.026 0.028 0.000 0.000 0.000 0.000 
Cocaine 0.000 0.000 0.000 0.001 0.000 0.001 0.001 0.001 
Benzoylecgonine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Anhydroecgonine 
methylester 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cocaethylene N/A N/A N/A N/A N/A N/A N/A N/A 
Mephedrone N/A N/A N/A N/A N/A N/A N/A N/A 








Thiamethoxam 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Imidacloprid 0.000 0.001 0.002 0.005 0.000 0.000 0.000 0.000 
Clothiniadin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Metazachlor 0.000 0.000 0.474 0.204 0.000 0.000 0.000 0.000 
Terbuthylazine 0.000 0.000 0.000 0.000 0.107 0.000 0.000 0.000 
Methiocarb 0.000 0.000 0.475 0.000 0.000 2.548 0.543 2.173 
Dichlofluanid 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Flufenacet 0.004 0.004 0.003 0.003 0.004 0.004 0.004 0.004 
Oxadiazon 0.255 0.153 0.191 0.224 0.291 0.303 0.330 0.480 
Chlorpyrifos 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Triallate 0.285 0.000 0.000 0.000 0.000 0.000 0.000 0.423 
Veterinary 
Pharmaceuticals 
Tylosin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Sulfapyridine 0.025 0.039 0.018 0.024 0.011 0.014 0.013 0.016 
Sarafloxacin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ceftiofur 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 







Quetiapine was only found at R6 in all samples, whereas risperidone was found in 16 samples 
across 7 of the sites. Concentrations were low and ranged from 0.51 to 0.9 ng L-1 for quetiapine 
and 0.01 to 3.96 ng L-1 for risperidone, these low levels cause minimal risk with RQMEC:PNEC of 
0.004 and 0.02 respectively.  
 
3.1.10.19 Pharmaceuticals for treating dementia 
 
Donepezil was not found in the environment (MQL 1.83 ng L-1). Memantine was found in only 
4 samples across the catchment and only at R2, therefore calculated from effluent rather than 
measured in the environment. Concentrations were calculated at 0.04 and 1.6 ng L-1. Donepezil 
shows the higher level of risk as the PNEC is only ~10x higher than the MQL, RQMQL:PNEC of 
0.1,  whereas memantine has a RQMEC:PNEC  of 0.01.  
 
3.1.10.20 Lifestyle Chemicals and creatinine 
 
Both caffeine (n = 53) and nicotine (n = 56) and their metabolites, 1,7-dimetylxanthine (n = 49) 
and cotinine (n = 49) were found throughout the environment, as concentrations ranging from 
132.0 to 791.5 ng L-1, 10.0 to 238.7 ng L-1, 225.9 to 1,534.6 ng L-1, and 16.5 to 67.5 ng L-1 
respectively. Chronic ecotoxicity data was available for caffeine and nicotine, leading to PNEC 
of 3,100 µg L-1 and 2 µg L-1, due to the availability of this data at three trophic levels an AF of 
10 was applied. Combined with the MEC results in RQMEC:PNEC of 0.0002 and 0.04 respectively. 
Similar data was not available for the metabolites, therefore chronic modelled data was replied 
upon for these. Due to this a high AF of 1000 was applied, combined with the high levels of 
the metabolite in environmental surface waters highlights this compound is of particular 
potential risk to the aquatic environment with RQMEC:PNEC ranging from 7.7 to 283 from site R1 
to R8. The sum of toxic units shows the algal trophic layer is most at risk with STU of 0.283. 
More robust ecotoxicity data is required to provide a more accurate ERA. 
 
3.1.10.21 Opioid Analgesics and metabolites 
 
Heroin and its metabolites were not found in the environment, with MQLs of 4.62 ng L-1 and 
0.94 ng L-1. Chronic ecotoxicity data was only available for heroin and for two trophic levels, 
therefore an AF of 100 was applied, this resulted in a PNEC of 63.9 ng L-1. Considering the 





 5 of the other 11 analgesics and metabolites were found in all samples in the environment 
(EDDP, codeine, tramadol, N-desmethyltramadol, and O-desmethyltramadol), dihydrocodeine 
was found in 49 samples, methadone in 42, and normorphine in 7. Dihydromorphine (MQL = 
0.55 ng L-1) and norcodeine (MQL = 9.52 ng L-1) were not found. The PNEC for codeine and 
its metabolites is in the range of 1.1 to 1.8 µg L-1. Tramadol has a higher PNEC with 3.5 µg L-
1, however data could not be obtained on the ecotoxicity of the metabolites. Morphine and its 
metabolites showed similar PNECs ranging from 0.14 to 0.19 µg L-1. Methadone was shown to 
be the most toxic with a PNEC of 36.1 ng L-1, but ecotoxicity data was could not be obtained 
for the metabolite. Overall, morphine poses the highest risk to the environment with RQMEC:PNEC 
of 0.17, then methadone with RQMEC:PNEC of 0.11 and tramadol with RQMEC:PNEC of 0.09. The 
overall RQmixture was 0.436 at the highest concentration of the catchment, for this class of 
compounds. The sum of toxic units show algae is most at risk, though this is still little to no 
risk at these levels. 
 
3.1.10.22 Stimulants and metabolites 
 
6 of the 10 stimulants and metabolites were not found in the environment (amphetamine, MQL 
2.23 ng L-1, methamphetamine, MQL 1.05 ng L-1, anhydroecgonine methylester, MQL 4.67 ng 
L-1, cocaethylene, MQL 0.35 ng L-1, mephedrone, MQL 1.09 ng L-1, MDPV, MQL 0.22 ng L-
1). The 4 found in the environment were MDMA (n = 54), cocaine (n = 56) and their 
metabolites, MDA (n = 28) and benzoylecgonine (n = 51) were found throughout at 0.1 to 31.8 
ng L-1, 0.3 to 13.5 ng L-1, 7.7 to 14.8 ng L-1 and 14.2 to 106.5 ng L-1 respectively. Ecotoxicity 
data could not be obtained for anhydroecgonine methylester, cocaethylene, mephedrone and 
MDPV, therefore the risk for these CECS could not be determined. For amphetamine and 
methamphetamine the PNECs, 348 ng L-1 and 211 ng L-1 respectively, are far higher than the 
MQL, showing potentially unquantifiable levels of these compounds are of negligible risk to 
the aquatic environment. MDMA and its metabolite, MDA, present the highest risk, MDA in 
particular presents a medium risk to the aquatic environment with RQMEC:PNEC > 0.1  of 0.265. 
MDMA, cocaine and benzoylecgonine show low risk to the aquatic environment. Overall, the 
risk of this mixture of compounds at the concentrations found across the catchment show a 
combined risk of 0.299. Furthermore, unlike many classes and compounds these CEC pose the 
greatest risk at the top end of the catchment, where the flows cause less dilution of sources such 






Table 4 Heat map for the chronic environmental risk (RQMEC:PNEC) of each CEC to aquatic organisms 
at each river sampling site (R1 further point upstream, to R8 furthest point downstream). Gradient is 
from low risk (green) to high risk (red). 
Class Analyte R1 R2 R3 R4 R5 R6 R7 R8 
UV Filters 
Benzophenone-1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Benzophenone-2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Benzophenone-3 0.001 0.002 0.001 0.001 0.002 0.002 0.001 0.001 
Benzophenone-4 0.002 0.003 0.003 0.006 0.002 0.004 0.006 0.007 
Parabens 
Methylparaben 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ethylparaben 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Propylparaben 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Butylparaben 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Plasticizer Bisphenol A 0.000 25.739 108.231 136.896 92.177 145.909 178.221 206.857 
Steroid 
estrogens 
E1 0.000 4.772 0.000 0.000 0.000 0.000 0.000 0.000 
E2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 




Sulfasalazine 0.097 0.117 0.189 0.267 0.108 0.157 0.101 0.123 
Clarithromycin 0.152 0.192 0.129 0.276 0.209 0.379 0.334 0.299 
Azithromycin 0.000 0.270 0.058 0.072 0.000 0.000 0.000 0.086 
Trimethoprim 0.000 0.380 0.197 0.321 0.227 0.549 0.468 0.382 
Sulfamethoxazole 0.049 0.057 0.046 0.050 0.048 0.068 0.063 0.064 
Triclosan 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Amoxicillin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Metronidazole 0.000 0.006 0.013 0.011 0.009 0.021 0.016 0.014 
Sulfadiazine 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cefalexin 0.001 0.000 0.000 0.000 0.001 0.001 0.005 0.002 
Ofloxacin 0.204 0.102 0.156 0.123 0.000 0.000 0.173 0.047 
Ciprofloxacin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Tetracycline 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Danofloxacin N/A N/A N/A N/A N/A N/A N/A N/A 
Oxytetracycline 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Chloramphenicol 0.000 0.204 0.000 0.000 0.000 0.000 0.000 0.355 
Penicillin G 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Penicillin V 0.002 0.000 0.002 0.000 0.001 0.000 0.000 0.001 
Erythromycin 0.000 0.183 0.000 2.875 0.476 0.399 0.610 0.750 
Prulifloxacin N/A N/A N/A N/A N/A N/A N/A N/A 
Norfloxacin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Antifungal 
Griseofluvin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ketoconazole 3.515 2.651 2.368 2.287 2.677 3.254 2.976 2.012 
Hypertension 
Valsartan 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Irbesartan N/A N/A N/A N/A N/A N/A N/A N/A 
Lisinopril 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Candesartan Cilexetil N/A N/A N/A N/A N/A N/A N/A N/A 




Class Analyte R1 R2 R3 R4 R5 R6 R7 R8 
Ibuprofen 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Naproxen 0.000 0.000 0.000 0.001 0.000 0.001 0.001 0.001 
Diclofenac 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Acetaminophen 0.004 0.000 0.002 0.009 0.009 0.013 0.013 0.012 
Lipid 
regulator 
Bezafibrate 0.059 0.089 0.107 0.168 0.108 0.170 0.153 0.154 
Atorvastatin 0.000 1.054 2.110 2.929 0.000 2.756 1.664 2.118 
Gemfibrozil 0.000 0.002 0.000 0.000 0.000 0.031 0.000 0.000 
Antihistamine 
Fexofenadine 0.038 0.057 0.046 0.063 0.033 0.062 0.106 0.136 
Cetirizine 0.001 0.001 0.001 0.001 0.000 0.001 0.002 0.002 
GUD/ED Sildenafil 0.003 0.003 0.002 0.011 0.000 0.002 0.003 0.002 
Antidiabetics 
Metformin 0.000 0.004 0.066 0.082 0.054 0.080 0.093 0.090 
Gliclazide 1.073 1.433 1.583 2.321 0.390 0.641 1.436 1.606 
Sitagliptin 0.180 0.275 0.150 0.196 0.092 0.090 0.188 0.164 
Cough 
suppressant 
Pholcodine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Beta-blocker 
Atenolol 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Metoprolol 0.000 0.002 0.000 0.000 0.000 0.000 0.000 0.000 
Propranolol 0.001 0.002 0.001 0.002 0.001 0.002 0.002 0.002 
Bisoprolol 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
H2 receptor 
agonist 
Ranitidine 0.013 0.031 0.016 0.028 0.000 0.024 0.031 0.029 
Cimetidine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
X-ray contrast 
media 
Iopromide N/A N/A N/A N/A N/A N/A N/A N/A 





0.001 0.001 0.001 0.002 0.000 0.001 0.002 0.002 
Norephedrine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Anticancer 
Azathioprine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Methotrexate 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ifosfamide 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Tamoxifen 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Imatinib 0.018 0.001 0.004 0.005 0.004 0.000 0.007 0.005 
Capecitabine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 




Ketamine 0.000 0.013 0.057 0.111 0.071 0.099 0.151 0.158 
Norketamine N/A N/A N/A N/A N/A N/A N/A N/A 
Venlafaxine 0.002 0.003 0.002 0.003 0.001 0.002 0.003 0.003 
Desmethylvenlafaxine 0.049 0.086 0.079 0.109 0.024 0.043 0.065 0.066 
Fluoxetine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Norfluoxetine N/A N/A N/A N/A N/A N/A N/A N/A 
Sertraline 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 
Mirtazapine N/A N/A N/A N/A N/A N/A N/A N/A 
Citalopram 0.000 0.388 0.000 0.000 0.000 0.000 0.000 0.000 
Desmethylcitalopram N/A N/A N/A N/A N/A N/A N/A N/A 




Class Analyte R1 R2 R3 R4 R5 R6 R7 R8 
Duloxetine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Amitriptyline 0.812 0.450 0.814 0.908 0.443 0.620 0.738 0.607 
Nortriptyline 0.000 0.240 0.233 0.525 0.142 0.075 0.539 0.542 
Norsertraline N/A N/A N/A N/A N/A N/A N/A N/A 
Antiepileptic 
Carbamazepine 0.033 0.058 0.049 0.064 0.028 0.037 0.055 0.056 
Carbamazepine 10,11-
epoxide 
N/A N/A N/A N/A N/A N/A N/A N/A 
10,11-Dihydro -10-
hydroxycarbamazepine 




Diltiazem 0.000 0.017 0.000 0.016 0.000 0.025 0.000 0.000 
Verapamil 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Hypnotic 
Temazepam 0.000 0.006 0.000 0.000 0.009 0.014 0.021 0.016 
Oxazepam 0.001 0.004 0.001 0.003 0.001 0.002 0.005 0.004 
Diazepam 0.017 0.029 0.016 0.016 0.016 0.015 0.016 0.016 
Antipsychotic 
Quetiapine 0.000 0.000 0.000 0.000 0.000 0.004 0.000 0.000 
Risperidone 0.020 0.010 0.015 0.012 0.000 0.000 0.013 0.021 
Dementia 
Donepezil 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 




Creatinine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Nicotine 0.035 0.036 0.011 0.018 0.009 0.011 0.023 0.021 
Caffeine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cotinine 0.004 0.000 0.005 0.006 0.005 0.008 0.008 0.008 





Heroin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
6-acetylmorphine N/A N/A N/A N/A N/A N/A N/A N/A 
Morphine 0.000 0.150 0.000 0.000 0.000 0.140 0.170 0.170 
Dihydromorphine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Normorphine 0.000 0.074 0.000 0.000 0.000 0.000 0.000 0.000 
Methadone 0.034 0.069 0.000 0.084 0.000 0.093 0.109 0.114 
EDDP N/A N/A N/A N/A N/A N/A N/A N/A 
Codeine 0.014 0.026 0.035 0.060 0.030 0.063 0.059 0.063 
Norcodeine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Dihydrocodeine 0.000 0.015 0.009 0.020 0.022 0.039 0.018 0.020 
Tramadol 0.040 0.071 0.068 0.093 0.029 0.049 0.066 0.069 
N-desmethyltramadol N/A N/A N/A N/A N/A N/A N/A N/A 




Amphetamine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Methamphetamine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
MDMA 0.014 0.031 0.006 0.019 0.015 0.057 0.071 0.073 
MDA 0.233 0.265 0.184 0.199 0.000 0.000 0.000 0.000 
Cocaine 0.002 0.002 0.004 0.011 0.002 0.012 0.013 0.013 
Benzoylecgonine 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Anhydroecgonine 
methylester 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 




Class Analyte R1 R2 R3 R4 R5 R6 R7 R8 
Mephedrone N/A N/A N/A N/A N/A N/A N/A N/A 




Thiamethoxam 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Imidacloprid 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Clothiniadin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Metazachlor 0.000 0.000 2.102 0.905 0.000 0.000 0.000 0.000 
Terbuthylazine 0.000 0.000 0.000 0.000 0.021 0.000 0.000 0.000 
Methiocarb 0.000 0.000 0.239 0.000 0.000 1.281 0.273 1.092 
Dichlofluanid 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Flufenacet 0.032 0.040 0.032 0.031 0.039 0.039 0.032 0.032 
Oxadiazon 0.722 0.434 0.542 0.636 0.824 0.857 0.935 1.360 
Chlorpyrifos 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 




Tylosin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Sulfapyridine 2.022 3.092 1.430 1.957 0.906 1.093 1.073 1.287 
Sarafloxacin 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Ceftiofur 0.000 0.008 0.031 0.038 0.000 0.000 0.000 0.000 





Table 5 Acute environmental risk (RQmixture) to aquatic organisms, for each class of CEC. Gradient is 
from low risk (green) to high risk (red). 
Class R1 R2 R3 R4 R5 R6 R7 R8 
UV Filter 0.042 0.060 0.042 0.053 0.053 0.070 0.057 0.050 
Parabens 0.001 0.001 0.001 0.002 0.006 0.003 0.001 0.001 
Plasticizer 0.000 0.003 0.011 0.014 0.009 0.015 0.018 0.021 
Steroid estrogens 0.000 0.005 0.000 0.000 0.000 0.000 0.000 0.000 
Antibiotics and antibacterial 1.234 33.294 7.890 11.268 1.797 3.168 2.844 12.868 
Antifungal 0.647 0.488 0.436 0.421 0.492 0.598 0.548 0.370 
Hypertension 0.000 0.000 0.000 0.000 0.000 0.001 0.001 0.001 
NSAIDs 0.706 1.082 1.166 1.710 0.673 1.534 1.248 1.325 
Lipid regulator 0.007 1.074 2.142 2.976 0.014 2.807 1.698 2.155 
Antihistamine 0.005 0.008 0.006 0.008 0.004 0.008 0.014 0.018 
GUD/ED 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.000 
Antidiabetics 0.184 0.261 0.472 0.644 0.234 0.356 0.530 0.549 
Cough suppressant 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Beta-blockers 0.002 0.005 0.003 0.004 0.002 0.003 0.004 0.004 
H2 receptor agonists 0.001 0.002 0.001 0.002 0.000 0.002 0.002 0.002 
X-ray contrast media 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Various 0.158 0.091 0.055 0.099 0.000 0.080 0.084 0.057 
Drug precursor 0.000 0.000 0.000 0.001 0.000 0.000 0.001 0.001 
Anticancer 0.069 0.011 0.020 0.023 0.021 0.006 0.032 0.025 
Anaesthetic and metabolite 0.000 0.002 0.008 0.016 0.010 0.015 0.022 0.023 
Antidepressants 0.235 0.471 0.268 0.379 0.143 0.189 0.279 0.244 
Antiepileptic 0.013 0.023 0.020 0.026 0.011 0.015 0.022 0.022 
Calcium-channel blocker 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.000 
Hypnotic 0.002 0.003 0.002 0.002 0.002 0.002 0.002 0.002 
Antipsychotic 0.003 0.002 0.002 0.002 0.000 0.001 0.002 0.003 
Dementia 0.000 0.002 0.000 0.000 0.000 0.000 0.000 0.000 
Human Indicators 21.732 0.209 54.337 70.143 50.955 53.671 67.229 78.875 
Opioid Analgesics and Metabolites 0.175 0.347 0.306 0.459 0.159 0.328 0.386 0.405 
Stimulants and metabolites 0.048 0.070 0.032 0.049 0.016 0.060 0.075 0.077 
Pesticides, fungicides and herbicides 0.544 0.159 1.146 0.437 0.402 2.855 0.876 3.080 





3.1.11.23  Pesticides, fungicides and herbicides 
 
No CECs from this class was found in all environmental samples. Although many of these 
pesticides were prioritised due to their use in this catchment, data on their exact levels or 
frequency of use that year are unknown. Furthermore, the sampling was carried out during a 
dry period and surface runoff would have at a minimum. Chlorpyrifos, clothianidin, and 
thiamethoxam were not found in the environment (MQLs, of 42.9, 0.19, and 0.42 respectively). 
However, flufenacet was found in 55 samples. Concentrations in the environment between 1.2 
ng L-1 (methiocarb) to 80.8 ng L-1 (imidacloprid). For the compounds that could not be found, 
RQMQL:PNEC, thiamethoxam and clothianidin the potentially unquantifiable concentrations show 
little to no risk to the environment. However, chlorpyrifos, has an exceptionally low PNEC of 
0.05 ng L-1, coupled with the MQL of 42.9 ng L-1, the unquantifiable potential concentrations 
of this compound pose very high risk to the aquatic environment. For the CECs with 
quantifiable levels, 4 showed high risk to the environment, triallate, metazachlor, oxadiazon 
and methiocarb. At R1, R3 and R6, levels of triallate, metazachlor and methiocarb respectively 
were found at each site causing RQMEC:PNEC to reach high risk to the environment. Three were 
found at R8 at levels which individually cause high risk to the environment. Overall, the 
RQmixture at this site was 5.4. STU calculations showed the highest risk was to the daphnid 
trophic level, though with only RQ STU <0.01, showing low overall risk. 
 
3.1.11.24  Veterinary pharmaceuticals 
 
 Of the veterinary pharmaceuticals, 3 were found in the environment. Ceftiofur was only found 
3 times. Sulfapyridine and diazinon were found throughout, in 55 samples across the catchment. 
For these three compounds, concentrations ranged from 6.3 to 31.2 ng L-1, 54.5 to 243.7 ng L-
1 and 5.5 to 46.4 ng L-1 respectively. Sarafloxacin has an MQL of 6.39 ng L-1, considering the 
PNEC the RQMQL:PNEC show no risk to the environment at these levels. No publicly available 
ecotoxicity data could be found for tylosin and therefore the risk is unknown. For the remaining 
compounds ceftiofur shows little to no risk for the aquatic environment (RQMEC:PNEC of 0.04), 
sulfapyridine shows high risk to the environment with RQ of 3.1, however, diazinon showed 
the highest risk to the aquatic environment with RQMEC:PNEC  of 48. Overall, this class shows a 
combined RQmixture of 49.6. The STU shows highest risk to the daphnid trophic layer, with 






Table 6 Chronic environmental risk (RQmixture) to aquatic organisms, for each class of CEC. 
Gradient is from low risk (green) to high risk (red). 
Class R1 R2 R3 R4 R5 R6 R7 R8 
UV Filter 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 
Parabens 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Plasticizer 0.00 25.74 108.23 136.90 92.18 145.91 178.22 206.86 
Steroid estrogens 0.00 4.77 0.00 0.00 0.00 0.00 0.00 0.00 
Antibiotics and antibacterial 0.51 1.51 0.79 3.99 1.08 1.57 1.77 2.12 
Antifungal 3.51 2.65 2.37 2.29 2.68 3.25 2.98 2.01 
Hypertension 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
NSAIDs 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 
Lipid regulator 0.06 1.14 2.22 3.10 0.11 2.96 1.82 2.27 
Antihistamine 0.04 0.06 0.05 0.06 0.03 0.06 0.11 0.14 
GUD/ED 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 
Antidiabetics 1.25 1.71 1.80 2.60 0.54 0.81 1.72 1.86 
Cough suppressant 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Beta-blockers 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
H2 receptor agonists 0.01 0.03 0.02 0.03 0.00 0.02 0.03 0.03 
X-ray contrast media 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Various 1.00 0.58 0.35 0.63 0.00 0.51 0.53 0.36 
Drug precursor 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Anticancer 0.08 0.07 0.05 0.06 0.07 0.06 0.08 0.07 
Anaesthetic and metabolite 0.00 0.01 0.06 0.11 0.07 0.10 0.15 0.16 
Antidepressants 0.86 1.17 1.13 1.55 0.61 0.74 1.34 1.22 
Antiepileptic 0.03 0.06 0.05 0.06 0.03 0.04 0.05 0.06 
Calcium-channel blocker 0.00 0.02 0.00 0.02 0.00 0.02 0.00 0.00 
Hypnotic 0.02 0.04 0.02 0.02 0.03 0.03 0.04 0.04 
Antipsychotic 0.02 0.01 0.01 0.01 0.00 0.00 0.01 0.02 
Dementia 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
Human Indicators 77.25 0.04 195.23 251.92 183.08 192.44 241.07 283.11 
Opioid Analgesics and Metabolites 0.09 0.40 0.11 0.26 0.08 0.38 0.42 0.44 
Stimulants and metabolites 0.25 0.30 0.19 0.23 0.02 0.07 0.08 0.09 
Pesticides, fungicides and herbicides 2.72 0.47 2.91 1.57 0.88 2.18 1.24 5.39 






3.1.11 Overall mixture assessment 
 
Several CECs discussed throughout have shown RQ values greater than 1, therefore it is given 
that throughout the catchment RQmixture values are also greater than 1, with RQmixtures ranging 
from 99 to 517. This shows the mixture is of a considerable risk to the catchment, following 
commonly used mixture assessment guidelines [17, 34]. The acute and chronic RQ values can 
be found in Tables 7 – 10 for the aquatic environments. In particular, the high RQ at site R1 
shows that other sources, such as much smaller WwTWs, septic tanks, surface runoff and other 
discharges, may still have high impact to the environment upstream in the catchment. 
 
However, as stated by Backhaus et al, the use of RQmixture calculated as per Equation 3 does not 
follow the standard rules of concentration addition in mixtures, as these RQs are based on the 
lowest toxicity for each individual CEC across three different trophic levels. For concentration 
addition the risk to each trophic level must be considered separately. This is done using 
Equation 4. The AF used for this mixture was 100, as the data included both modelled and 
literature-based data for three trophic levels. If the risk of the mixture was considered as a 
whole, the daphnid trophic layer is most at risk. In fact, the STU for this trophic level is greater 
than 1 for sites R3 (STU = 2.26) to R8 (STU = 4.25), without application of the assessment 
factor. Application of the AF show RQSTUs greater than 10 from all sites. Furthermore, 
considering the contribution of the individual CECs to the total, BPA was identified as the 
primary source of toxicity at sites R3 to R8 ranging from 78% (R5) to 97% (R8). Diazinon 
contributes to most of the remaining ecotoxicity, ranging between 2.1% (R8) to 80% (R1). The 
high proportion at R1 is due to a lack of BPA upstream of the WwTWs. In a study focused only 
on pesticides by Ccanccapa et al. [104], diazinon has previously been found to be a similar level 
of high risk, where it was one of the most frequently found pesticides in the Ebro river basin, 
with a high chronic risk to aquatic invertebrates RQ of 24.2 in 2010 to 36.4 in 2011. 
Furthermore, in a study by Vallotton et al.[105], which investigated the hazard index and the 
maximum cumulative ratio (MCR), for 3099 mixtures.  The study divided the mixtures into 4 
groups, based on several implications; the mixture presents a risk, the mixture does not present 
a risk, the majority of the risk is based on one or two components, or the contribution of risk is 
more evenly distributed. In 20% of the mixtures where most of the risk is due to one or two 
components, diazinon is in the top 2. Considering these studies, the idea that one or two 
compounds of a mixture show the majority of the toxicological effect as suggested Backhaus 
and Karlsson, is supported [13]. However, this means that studies which do not cover a wide 
range of CECs may be underestimating the risk to the environment. For example, in a previous 




triclosan, TBT and naproxen to be the top contributors to mixture RQs at different locations, 
however diazinon and BPA were not investigated.  
 
This method contains 142 CECs from 32 classes, of the 138 of which were quantifiable in 
surface water, the average mixtures had between 57 (at R1) and 80 (at R2), with a median of 
70 CECs at each site, and across the catchment the majority of the risk was due to diazinon and 
BPA. This is not an exhaustive list of CECs and there are many more which may pose a greater 
risk, as well as other priority substances that have been shown to be present in the environment 
and are not accounted for.  
 
Furthermore, there are other factors to take into account when assessing a mixture with the 
concentration addition model; there is also very likely to  be antagonistic and synergistic effects 
from different CECs. Future work would be required to explore the ecotoxicology of this 
mixture in the lab on three trophic levels, to better understand the full ramifications of this 






Table 7 Acute aquatic RQs for the average mixture of CECs present at each of the sampled sites 
Gradient is from low risk (green) to high risk (red). 
 R1 R2 R3 R4 R5 R6 R7 R8 
RQmixture 32.11 44.88 73.17 93.77 86.69 91.34 82.36 106.03 
RQSTU 24.29 34.98 63.92 83.24 53.55 58.02 71.32 93.38 
 
4  
Table 8 Acute aquatic STU for the average mixture of CECs present at each of the sampled sites  
 R1 R2 R3 R4 R5 R6 R7 R8 
STU Daphnid 0.01 0.01 0.01 0.01 0.03 0.03 0.01 0.01 
STU Fish 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 
STU Algae 0.02 0.03 0.06 0.08 0.05 0.06 0.07 0.09 
         
STU Max 0.02 0.03 0.06 0.08 0.05 0.06 0.07 0.09 
  
Table 9 Chronic aquatic RQs for the average mixture of CECs present at each of the sampled 
sites  
 R1 R2 R3 R4 R5 R6 R7 R8 
RQmixture 99.38 54.92 324.42 415.12 331.06 391.51 442.56 516.50 
RQSTU 11.99 64.91 225.90 284.32 234.17 332.95 368.64 425.21 
 
Table 10 Chronic aquatic STU for the average mixture of CECs present at each of the sampled 
sites 
 R1 R2 R3 R4 R5 R6 R7 R8 
STU Daphnid 0.12 0.65 2.26 2.84 2.34 3.33 3.69 4.25 
STU Fish 0.01 0.10 0.01 0.01 0.00 0.01 0.01 0.01 
STU Algae 0.10 0.03 0.22 0.29 0.21 0.24 0.28 0.32 
         





3.1.12 Spatial trends 
 
With RQmixture and RQSTU ranging from 55 to 516 and 12 to 425 respectively (Table 9), there is 
high risk to the aquatic environment throughout the catchment. Sampling site R8, as the lowest 
point sampled downstream, is most at risk with RQmixture of 517 and RQSTU of 425 for the 
daphnid trophic layer (Table 10). This assessment does not consider the wider implication of 
damage to the daphnid trophic layer and the resultant effect on the ecological balance. Nor does 
it consider bioaccumulation or concentration within organisms, or the potential for these 
organisms to have adapted to this potentially pseudo-persistent mixture. 
 
Although sampling at sites occurred in pairs (e.g. upstream and downstream), the entire 
catchment was not done in a single week. A clear, significant, increasing trend in average 
weekly concentrations can be seen throughout the catchment for certain CECs e.g BPA, 
clarithromycin, trimethoprim, ibuprofen, naproxen, acetaminophen, bezafibrate, metformin, 
caffeine, and oxadiazon (Table 1). 
 
These compounds increase throughout the catchment and unlike many other compounds, do 
not significantly decrease between sites. Furthermore, many of these CECs, pharmaceuticals 
specifically, are those of which have been shown to have high steady usage throughout the 
catchment. The increasing levels from R1 to R8 potentially show a level of persistence and 
transport throughout the catchment, suggesting that the dilution and degradation within the 
environment of these CEC is unable to reduce these levels effectively, leading to increased risk 
to the environment. 
 
Overall, the plasticiser, BPA, lifestyle chemicals and veterinary pharma contribute the most 
risk to the catchment. The increasing levels of BPA can be attributed to its presence in everyday 
objects, such as receipts and plastics. It is leading to a significant increase in environmental risk 
through the catchment and can be attributed to the WwTW discharge, based on comparison of 
upstream and downstream sampling points.  
 
However, there is a huge increase in chronic RQMEC:PNEC, >80, between downstream of WwTW 
A (R2) and upstream of WwTW B (R3), which cannot be attributed to any WwTW in this study 
and requires further investigation. For lifestyle chemicals, most of the risk is due to the caffeine 
metabolite, 1,7-dimethylxanthine, the main source of this can be attributed to WwTW 
discharges and potentially the degradation of caffeine in the environment; addressing the 
increases observed between sites. It also poses a significant risk to R1, with an RQMEC:PNEC of 





For veterinary pharma, the main contributor to the overall toxicity of the class is diazinon, it 
was found at a reasonably consistent chronic level ,RQMEC:PNEC between 7.4 (R3) and 11.0 (R2), 
however there is a significant increase to chronic RQMEC:PNEC of 48.7  at R5, showing there is a 
potential source between WwTW B and C. However, although it was banned in 2009 for use 
as an insecticide in the EU, it may still be used illegally, resulting in its continued presence in 


































total 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 
Ww
TW 
B 0.1 3.3 39.4 0.4 2.4 8.4 0.0 3.3 0.1 7.7 0.0 0.0 0.2 0.2 0.0 1.8 0.0 0.0 0.1 0.0 1.6 0.0 24.4 1.1 0.5 0.0 0.2 0.0 2.4 1.9 0.1 0.0 0.4 0.1 
Ww
TW 
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UV Filter (1) Parabens (2) Plasticizer (3)
Steroids (4) Antibiotic (5) Antifungal (6)
Hypertension (7) NSAIDs (8) Lipid regulator (9)
Anti-hyperlipidemic (10) Anti-hyperintensive (11) Antihistamine (12)
GUD/ED (13) Anti-diabetics (14) Cough suppressant (15)
Beta-blocker (16) H2 receptor agonist (17) X-ray contrast media (18)
Various (19) Drug precursor (20) Anti-cancer (21)
Anaesthetic and metabolite (22) Antidepressants (23) Anti-epileptic (24)
Calcium-channel blocker (25) Hypnotic (26) Anti-psychotic (27)
Dementia (28) Lifestyle Chemicals (29) Analgaesics and Metabolites (30)
Stimulants and metabolites (31) Opiod and metabolite (32) Pesticides, fungicides and herbicides (33)
Veterinary Pharma (34)
Figure 4 Percentage of total concentration in digested solids of the entire catchment as a pie chart of 
classes, with individual pie charts for each site. Note: creatinine is not included. 0.0% shows negligible to no 
contribution to the total. Numbers in brackets indicate numbers assigned for identification in small figures and table 




3.2. Occurrence in digested solids and environmental risk assessment 
3.2.1.  Terrestrial Environmental Concentrations 
 
A route of entry of CECs to the terrestrial environment is via application of digested solids or treated 
wastewater to soils. In the UK, particularly in this catchment, application of digested solids is more 
common. In this study, WwTW B and E received and treated sludges from WwTWs within the 
catchment, and across three consecutive days, the digested solids were found to contain 65 CECs 
out of the 96 quantifiable with this method, across the two sites. Despite the long residence time of 
digested solids there was a high amount of variation for some compounds across the three days 
(Supplementary Information, Tables S6-8). The distribution of classes within this matrix can be 
seen in (Figure 4). The study by Proctor et al, [21] (Chapter 3) identified several classes in the 
digested sludge from this catchment that may be a particular risk to the environment; plasticisers, 
NSAIDs, antidepressants, antibiotics and antifungals, which is due to their high levels in digested 
sludge compared to other chemicals. Other notables CECs in the digested sludge are gemfibrozil, 
propranolol, carbamazepine, methylparaben, chloramphenicol, and nicotine. 
 
Using Equation 2 described in Section 2.8.2, the PECSOIL was calculated for comparison with 
terrestrial ecotoxicity data. This information can be found in Table 11. The majority of compounds 
found were in the ng kg-1 to µg kg-1 range. Total CEC daily average concentrations ranged from 
16.6 µg kg-1 at WwTW B to 64.5 µg kg-1 WwTW E. 
 
The highest predicted concentration of a CEC in amended soils was BPA with 6.1 µg kg-1 from 
digested solids from WwTW B to 58.9 µg kg-1 from digested solids from WwTW E, with several 
other CECs with concentrations around 1 µg kg-1, ketoconazole 0.92 µg kg-1 (WwTW E) to 1.8 µg 
kg-1  (WwTW B), gemfibrozil was only found at WwTW B and ranged from 0.94 µg kg-1 to 1.5 µg 
kg-1, citalopram 1.1 µg kg-1 to 1.3 µg kg-1 (WwTW B), sertraline 0.75 µg kg-1  (WwTW B) to 1.1 µg 







Table 11 PECSOIL (µg kg-1) for digested solids from WwTW B, E and overall, calculated from 
measured digested solids data and Equation 2 
 
  WwTW B WwTW E Overall 
Class of Analyte Analyte Mean Max Min Mean Max Min Mean 
UV Filter Benzophenone-1 N/A N/A N/A N/A N/A N/A N/A 
 Benzophenone-2 0.015 0.024 0.009 0.045 0.047 0.040 0.030 
 Benzophenone-3 N/A N/A N/A N/A N/A N/A N/A 
 Benzophenone-4 N/A N/A N/A 0.012 0.012 0.012 0.012 
Parabens Methylparaben 0.530 0.771 0.360 0.163 0.181 0.138 0.346 
 Ethylparaben N/A N/A N/A N/A N/A N/A N/A 
 Propylparaben N/A N/A N/A N/A N/A N/A N/A 
 Butylparaben N/A N/A N/A N/A N/A N/A N/A 
Plasticizer Bisphenol A 6.42 6.96 6.11 54.4 58.9 45.7 30.4 
Steroid estrogens E1 0.061 0.064 0.058 0.085 0.090 0.078 0.073 
 E2 N/A N/A N/A N/A N/A N/A N/A 
 EE2 N/A N/A N/A N/A N/A N/A N/A 
Antibiotics and 
Antibacterial 
Sulfasalazine N/A N/A N/A N/A N/A N/A N/A 
 Clarithromycin N/A N/A N/A N/A N/A N/A N/A 
 Azithromycin 0.008 0.014 0.005 0.320 0.320 0.320 0.086 
 Trimethoprim 0.016 0.022 0.012 0.012 0.014 0.011 0.014 
 Sulfamethoxazole N/A N/A N/A N/A N/A N/A N/A 
 Triclosan N/A N/A N/A N/A N/A N/A N/A 
 Amoxicillin N/A N/A N/A N/A N/A N/A N/A 
 Metronidazole N/A N/A N/A N/A N/A N/A N/A 
 Sulfadiazine N/A N/A N/A N/A N/A N/A N/A 
 Cefalexin N/A N/A N/A N/A N/A N/A N/A 
 Ofloxacin N/A N/A N/A N/A N/A N/A N/A 
 Ciprofloxacin N/A N/A N/A N/A N/A N/A N/A 
 Tetracycline N/A N/A N/A N/A N/A N/A N/A 
 Danofloxacin N/A N/A N/A 0.443 0.443 0.443 0.443 
 Oxytetracycline N/A N/A N/A N/A N/A N/A N/A 
 Chloramphenicol 0.555 0.575 0.535 0.124 0.124 0.124 0.411 
 Penicillin G N/A N/A N/A N/A N/A N/A N/A 
 Penicillin V N/A N/A N/A N/A N/A N/A N/A 
 Erythromycin N/A N/A N/A N/A N/A N/A N/A 
 Prulifloxacin N/A N/A N/A N/A N/A N/A N/A 
 Norfloxacin N/A N/A N/A N/A N/A N/A N/A 
Antifungal Griseofluvin N/A N/A N/A N/A N/A N/A N/A 
 Ketoconazole 1.37 1.76 1.08 1.03 1.13 0.92 1.20 
Hypertension Valsartan N/A N/A N/A N/A N/A N/A N/A 
 Irbesartan N/A N/A N/A N/A N/A N/A N/A 
 Lisinopril N/A N/A N/A N/A N/A N/A N/A 
 Candesartan Cilexetil N/A N/A N/A N/A N/A N/A N/A 
NSAIDs Ketoprofen 0.341 0.415 0.301 0.248 0.267 0.222 0.294 
 Ibuprofen 0.159 0.165 0.156 0.033 0.039 0.025 0.096 
 Naproxen 0.039 0.045 0.035 0.136 0.142 0.130 0.087 
 Diclofenac N/A N/A N/A 0.079 0.079 0.079 0.079 
 Acetaminophen 0.011 0.012 0.010 0.005 0.005 0.004 0.008 
Lipid regulator Bezafibrate N/A N/A N/A N/A N/A N/A N/A 
 Atorvastatin 1.25 1.46 0.94 N/A N/A N/A 1.25 
 Gemfibrozil N/A N/A N/A N/A N/A N/A N/A 
Antihistamine Fexofenadine N/A N/A N/A N/A N/A N/A N/A 
 Cetirizine N/A N/A N/A N/A N/A N/A N/A 
GUD/ED Sildenafil 0.031 0.032 0.030 0.025 0.026 0.024 0.028 
Diabetes Metformin N/A N/A N/A N/A N/A N/A N/A 
 Gliclazide N/A N/A N/A N/A N/A N/A N/A 
 Sitagliptin 0.041 0.044 0.037 0.020 0.030 0.015 0.030 
Cough suppressant Pholcodine N/A N/A N/A N/A N/A N/A N/A 
Beta-blocker Atenolol N/A N/A N/A 0.036 0.039 0.035 0.036 
 Metoprolol N/A N/A N/A 0.004 0.004 0.004 0.004 
 Propranolol 0.292 0.338 0.263 0.281 0.293 0.265 0.286 
 Bisoprolol N/A N/A N/A N/A N/A N/A N/A 
H2 receptor agonist Ranitidine N/A N/A N/A N/A N/A N/A N/A 
 Cimetidine N/A N/A N/A N/A N/A N/A N/A 
X-ray contrast media Iopromide N/A N/A N/A N/A N/A N/A N/A 
Various Buprenorphine 0.019 0.022 0.017 0.042 0.048 0.034 0.031 
Drug precursor Ephedrine/pseudoephedrine N/A N/A N/A 0.008 0.011 0.007 0.008 
 Norephedrine N/A N/A N/A N/A N/A N/A N/A 
Anti-cancer Azathioprine N/A N/A N/A N/A N/A N/A N/A 




  WwTW B WwTW E Overall 
Class of Analyte Analyte Mean Max Min Mean Max Min Mean 
 Ifosfamide N/A N/A N/A N/A N/A N/A N/A 
 Tamoxifen N/A N/A N/A 0.041 0.041 0.041 0.041 
 Imatinib 0.181 0.260 0.129 0.357 0.503 0.204 0.269 
 Capecitabine N/A N/A N/A N/A N/A N/A N/A 
 Bicalutamide 0.074 0.092 0.059 0.034 0.034 0.034 0.064 
Anaesthetic and 
metabolite 
Ketamine 0.004 0.005 0.004 0.013 0.014 0.013 0.008 
 Norketamine 0.001 0.002 0.001 0.006 0.007 0.004 0.003 
 Venlafaxine 0.186 0.231 0.160 0.094 0.097 0.090 0.140 
 Desmethylvenlafaxine 0.033 0.036 0.030 0.025 0.028 0.022 0.029 
 Fluoxetine 0.285 0.354 0.250 0.418 0.475 0.364 0.352 
 Norfluoxetine 0.134 0.189 0.103 0.191 0.215 0.174 0.162 
 Sertraline 0.831 0.978 0.750 1.07 1.09 1.06 0.952 
 Mirtazapine 0.102 0.117 0.089 0.134 0.139 0.129 0.118 
 Citalopram 1.15 1.31 1.07 1.23 1.27 1.19 1.19 
 Desmethylcitalopram 0.435 0.564 0.358 0.538 0.551 0.525 0.487 
 Paroxetine 0.003 0.009 0.000 0.007 0.008 0.005 0.005 
 Duloxetine 0.026 0.037 0.018 0.030 0.035 0.024 0.028 
 Amitriptyline 0.694 0.779 0.632 0.736 0.764 0.709 0.715 
 Nortriptyline 0.093 0.124 0.075 0.105 0.106 0.103 0.098 
 Norsertraline N/A N/A N/A N/A N/A N/A N/A 








N/A N/A N/A N/A N/A N/A N/A 
Calcium-channel blocker Diltiazem N/A N/A N/A N/A N/A N/A N/A 
 Verapamil 0.075 0.088 0.068 0.051 0.051 0.051 0.069 
Hypnotic Temazepam N/A N/A N/A N/A N/A N/A N/A 
 Oxazepam N/A N/A N/A N/A N/A N/A N/A 
 Diazepam 0.006 0.007 0.006 0.005 0.005 0.005 0.006 
Anti-psychotic Quetiapine 0.026 0.029 0.020 0.040 0.044 0.037 0.033 
 Risperidone N/A N/A N/A N/A N/A N/A N/A 
Dementia Donepezil N/A N/A N/A N/A N/A N/A N/A 
 Memantine 0.012 0.012 0.012 N/A N/A N/A 0.012 
Creatinine Creatinine N/A N/A N/A N/A N/A N/A N/A 
Lifestyle Chemicals Nicotine 0.334 0.418 0.281 0.205 0.224 0.178 0.269 
 Caffeine N/A N/A N/A N/A N/A N/A N/A 
 Cotinine 0.059 0.068 0.053 0.052 0.054 0.049 0.055 
 1,7-dimethylxanthine N/A N/A N/A N/A N/A N/A N/A 
Analgaesics and 
Metabolites 
Morphine 0.093 0.157 0.029 0.607 0.651 0.550 0.401 
 Dihydromorphine N/A N/A N/A 0.090 0.100 0.083 0.090 
 Normorphine N/A N/A N/A 0.040 0.040 0.039 0.040 
 Methadone 0.019 0.023 0.017 0.058 0.058 0.057 0.038 
 EDDP 0.056 0.102 0.031 0.280 0.293 0.266 0.168 
 Codeine 0.066 0.154 0.019 0.052 0.058 0.049 0.059 
 Norcodeine N/A N/A N/A N/A N/A N/A N/A 
 Dihydrocodeine 0.036 0.044 0.032 0.005 0.005 0.005 0.021 
 Tramadol 0.051 0.065 0.041 0.070 0.072 0.068 0.061 
 N-desmethyltramadol 0.025 0.036 0.019 0.032 0.035 0.029 0.028 
 O-desmethyltramadol N/A N/A N/A N/A N/A N/A N/A 
Stimulants and 
metabolites 
Amphetamine N/A N/A N/A 0.026 0.026 0.026 0.026 
 Methamphetamine N/A N/A N/A N/A N/A N/A N/A 
 MDMA 0.009 0.011 0.008 0.037 0.038 0.036 0.023 
 MDA N/A N/A N/A N/A N/A N/A N/A 
 Cocaine N/A N/A N/A 0.006 0.006 0.006 0.006 
 Benzoylecgonine N/A N/A N/A 0.005 0.006 0.004 0.005 
 Anhydroecgoninemethylester N/A N/A N/A N/A N/A N/A N/A 
 Cocaethylene N/A N/A N/A N/A N/A N/A N/A 
 Mephedrone N/A N/A N/A N/A N/A N/A N/A 
 MDPV N/A N/A N/A N/A N/A N/A N/A 
Opiod and metabolite Heroin N/A N/A N/A N/A N/A N/A N/A 
 6-acetylmorphine N/A N/A N/A N/A N/A N/A N/A 
Pesticides, fungicides 
and herbicides 
Thiamethoxam N/A N/A N/A N/A N/A N/A N/A 
 Imidacloprid N/A N/A N/A N/A N/A N/A N/A 
 Clothiniadin N/A N/A N/A N/A N/A N/A N/A 
 Metazachlor N/A N/A N/A N/A N/A N/A N/A 
 Terbuthylazine N/A N/A N/A N/A N/A N/A N/A 
 Methiocarb 0.002 0.003 0.002 N/A N/A N/A 0.002 




  WwTW B WwTW E Overall 
Class of Analyte Analyte Mean Max Min Mean Max Min Mean 
 Flufenacet 0.022 0.023 0.021 0.020 0.020 0.020 0.021 
 Oxadiazon N/A N/A N/A 0.043 0.043 0.043 0.043 
 Chlorpyrifos 0.138 0.138 0.138 N/A N/A N/A 0.138 
 Triallate N/A N/A N/A N/A N/A N/A N/A 
Veterinary 
Pharmaceuticals 
Tylosin N/A N/A N/A N/A N/A N/A N/A 
 Sulfapyridine N/A N/A N/A N/A N/A N/A N/A 
 Sarafloxacin N/A N/A N/A N/A N/A N/A N/A 
 Ceftiofur N/A N/A N/A N/A N/A N/A N/A 






3.2.2.  Terrestrial ecotoxicity 
 
Unlike the aquatic environment, where WwTWs continually discharge CEC containing effluent 
into the environment maintaining pseudo-persistent levels, the application of digested solids is a 
specific event(s) [18, 107]. Therefore, the highest risk to the terrestrial environment is shortly after 
this application. A review by Caracciolo et al shows that microbial communities, if not harmed by 
the application of CECs, can soon (days to weeks) reduce the initial levels for different 
pharmaceuticals [108]. 
 
There is a lack of ecotoxicity information with regards to the CECs in this study, acute ecotoxicity 
data could only be gathered for 21 out of the 65 quantifiable CECs (Table 12). Though there are 
many studies available on the effects of these CECs on a variety of different organisms or plants, 
they are mostly applicable to the aquatic environment, or multifactor tests [109], leading to lack of 
dose-response relationships for a single factor; the concentration of the CEC of interest. Data would 
ideally be required for three trophic levels as with aquatic toxicity. ECOSAR presents ecotoxicity 
data for organisms such as earthworms but no others (except for insects with regards to the 
neonicotinoid pesticides) [60]. Ideally, microorganisms such as bacteria, fungus or protozoa should 
be covered as well as invertebrates, insects and gastropods.  
 
Though there is a focus on earthworm toxicity, the levels in this study suggest once mixed with 
soils the CECs, both individually and as a mixture, show little risk to the earthworms within the 
environment (RQs are predominantly far lower than 1 (Table 13)). However, more data is needed 
regarding the ecotoxicity to other trophic levels of terrestrial relevance. The digested solids 
themselves (Table 13), show high risk of acute toxicity to the earthworms in the environment for 
gemfibrozil in digested solids from WwTW B, with an acute RQMEC:PNEC up to 7.0. Other CECs 
show a similar risk, such as diclofenac in digested solids from both sites shows medium risk with 
RQMEC:PNEC up to 0.34 at WwTW B and high risk in digested solids from WwTW E with an 
RQMEC:PNEC up to 1.1 and ketoconazole shows high risk at both sites with RQMEC:PNEC 1.9 at WwTW 
E. Furthermore, BPA and methylparaben also show high risk at the chronic level with chronic 
RQMEC:PNEC up to 1.3 for digested solids from WwTW B and RQMEC:PNEC of 1.5 for digested solids 
from WwTW E (Table 14). To mitigate the risk of this matrix when applied to soils, it should be 
ensured that they are well mixed to avoid localised pockets of high concentration. Due to the lack 






Table 12 Acute terrestrial ecotoxicity data for soils amended with digested solids with references, 
assessment factor, notes and PNEC 










Ref AF PNEC 
  96h  14d      
  mg kg-1  mg kg-1  mg kg-1   mg kg-1 
UV Filter Benzophenone-1 -  -  -   - 
 Benzophenone-2 -  -  -   - 
 Benzophenone-3 -  -  -   - 
 Benzophenone-4 -  -  -   - 
Parabens Methylparaben -  1989 [60] 56* [110]  56 
 Ethylparaben -  1508 [60] -  1000 1.51 
 Propylparaben -  1136 [60] -  1000 1.14 
 Butylparaben -  850 [60] -  1000 0.850 
Plasticizer Bisphenol A -  -  -  1000 0.000 
Steroid estrogens E1 -  -  -   - 
 E2 -  -  -   - 
 EE2 -  -  -   - 
Antibiotics and 
Antibacterial 
Sulfasalazine -  5951 [60] -  1000 5.95 
 Clarithromycin -  4068 [60] -  1000 4.07 
 Azithromycin -  3881 [60] -  1000 3.88 
 Trimethoprim -  >2000 [111] -  1000 2.00 
 Sulfamethoxazole -  1287 [60] -  1000 1.29 
 Triclosan -  -  -  1000 0.000 
 Amoxicillin -  15509 [60] -  1000 15.5 
 Metronidazole -  -  -   - 
 Sulfadiazine -  1720 [60] -  1000 1.72 
 Cefalexin -  18176 [60] -  1000 18.2 
 Ofloxacin -  -  -   - 
 Ciprofloxacin -  -  -   - 
 Tetracycline -  >2000 [111] -  1000 2.00 
 Danofloxacin -  -  -   - 
 Oxytetracycline -  -  -   - 
 Chloramphenicol -  -  -   - 
 Penicillin G -  10289 [60] -  1000 10.3 
 Penicillin V -  10699 [60] -  1000 10.7 
 Erythromycin -  6709 [60] -  1000 6.71 
 Prulifloxacin -  -  -   - 
 Norfloxacin -  -  -   - 
Antifungal Griseofluvin -  -  -   - 
 Ketoconazole -  629 [60] -  1000 0.629 
Hypertension Valsartan -  6911 [60] -  1000 6.91 
 Irbesartan -  -  -   - 
 Lisinopril -  34784 [60] -  1000 34.8 
 Candesartan Cilexetil -  3482 [60] -  1000 3.48 
NSAIDs Ketoprofen -  64.8 [111] 293.7 [58] 100 0.648 
 Ibuprofen -  3077 [60] -  1000 3.08 
 Naproxen -  90.5 [111] -  1000 0.090 
 Diclofenac -  694 [111] -  1000 0.694 
 Acetaminophen -  4597 [60] -  1000 4.60 
Lipid regulator Bezafibrate -  3275 [60] -  1000 3.28 
 Atorvastatin -  141 [111] -  1000 0.141 
 Gemfibrozil -  -  -   - 
Antihistamine Fexofenadine -  -  -   - 
 Cetirizine -  -  -   - 
GUD/ED Sildenafil -  1161 [60] -  1000 1.16 
Diabetes Metformin -  -  -   - 
 Gliclazide -  -  -   - 
 Sitagliptin -  1483 [60] -  1000 1.48 
Cough suppressant Pholcodine -  -  -   - 
Beta-blocker Atenolol -  1633 [60] -  1000 1.63 
 Metoprolol -  >2000 [111] -  1000 2.00 
 Propranolol -  3299 [111] -  1000 3.30 
 Bisoprolol -  -  -   - 
H2 receptor agonist Ranitidine -  -  -   - 
 Cimetidine -  -  -   - 
X-ray contrast 
media 
Iopromide -  -  -   - 
Various Buprenorphine -  -  -   - 
Drug precursor Ephedrine/pseudoephedrine -  -  -   - 














Ref AF PNEC 
  96h  14d      
  mg kg-1  mg kg-1  mg kg-1   mg kg-1 
Anti-cancer Azathioprine -  -  -   - 
 Methotrexate -  44137 [60] -  1000 44.1 
 Ifosfamide -  7293 [60] -  1000 7.29 
 Tamoxifen -  -  -   - 
 Imatinib -  -  -   - 
 Capecitabine -  -  -   - 
 Bicalutamide -  1123 [60] -  1000 1.12 
Anaesthetic and 
metabolite 
Ketamine -  -  -   - 
 Norketamine -  -  -   - 
 Venlafaxine -  -  -   - 
 Desmethylvenlafaxine -  -  -   - 
 Fluoxetine -  -  -   - 
 Norfluoxetine -  -  -   - 
 Sertraline -  -  -   - 
 Mirtazapine -  -  -   - 
 Citalopram -  -  -   - 
 Desmethylcitalopram -  -  -   - 
 Paroxetine -  -  -   - 
 Duloxetine -  -  -   - 
 Amitriptyline -  -  -   - 
 Nortriptyline -  -  -   - 
 Norsertraline -  -  -   - 








-  -  -   - 
Calcium-channel 
blocker 
Diltiazem -  2996 [60] -  1000 3.00 
 Verapamil -  -  -   - 
Hypnotic Temazepam -  828 [60] -  1000 0.828 
 Oxazepam -  741 [60] -  1000 0.741 
 Diazepam -  641 [60] -  1000 0.641 
Anti-psychotic Quetiapine -  -  -   - 
 Risperidone -  -  -   - 
Dementia Donepezil -  -  -   - 
 Memantine -  -  -   - 
Creatinine Creatinine -  1073 [60]   1000 1.07 
Lifestyle Chemicals Nicotine -  -  -   - 
 Caffeine -  -  -   - 
 Cotinine -  944 [60] -  1000 0.944 
 1,7-dimethylxanthine -  -  -   - 
Analgaesics and 
Metabolites 
Morphine -  -  -   - 
 Dihydromorphine -  -  -   - 
 Normorphine -  -  -   - 
 Methadone -  -  -   - 
 EDDP -  -  -   - 
 Codeine -  -  -   - 
 Norcodeine -  -  -   - 
 Dihydrocodeine -  -  -   - 
 Tramadol -  -  -   - 
 N-desmethyltramadol -  -  -   - 
 O-desmethyltramadol -  -  -   - 
Stimulants and 
metabolites 
Amphetamine -  -  -   - 
 Methamphetamine -  -  -   - 
 MDMA -  -  -   - 
 MDA -  444 [58] 128 [58] 1000 0.128 
 Cocaine -  3487 [60] -  1000 3.49 




-  -  -   - 
 Cocaethylene -  -  -   - 
 Mephedrone -  -  -   - 
 MDPV -  -  -   - 
Opiod and 
metabolite 
Heroin -  5596 [60] -  1000 5.60 














Ref AF PNEC 
  96h  14d      




Thiamethoxam 6.48E-01 [60] >1000 [58] >0.4 [58] 1000 0.0004 
 Imidacloprid 6.47E-01 [60] - [60] -  1000 0.001 
 Clothiniadin 6.02E-01 [60] - [60] -  1000 0.001 
 Metazachlor -  -  -   - 
 Terbuthylazine -  -  -   - 
 Methiocarb -  -  -   - 
 Dichlofluanid -  488 [60] -  1000 0.488 
 Flufenacet -  914 [60] -  1000 0.914 
 Oxadiazon -  -  -   - 
 Chlorpyrifos -  -  -   - 
 Triallate -  257 [60] -  1000 0.257 
Veterinary 
Pharmaceuticals 
Tylosin -  -  -   - 
 Sulfapyridine -  1247 [60] -  1000 1.25 
 Sarafloxacin -  -  -   - 
 Ceftiofur -  17816 [60] -  1000 17.8 
 Diazinon -  -  -   - 





Table 13 Acute terrestrial RQPECsoil:PNEC for amended soils and RQMEC:PNEC for digested solids. Gradient is from low risk (green) to high risk (red). 
  Acute RQPECsoil:PNEC Acute RQMEC:PNEC 
Class Analyte B B Max E E Max 
Average 
Both 




Benzophenone-1 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Benzophenone-2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Benzophenone-3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Benzophenone-4 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Parabens 
Methylparaben 9.46E-06 1.38E-05 2.91E-06 3.23E-06 6.19E-06 6.43E-03 9.37E-03 1.98E-03 2.20E-03 4.21E-03 
Ethylparaben N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Propylparaben N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Butylparaben N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Plasticizer Bisphenol A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Steroid 
estrogens 
E1 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
E2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
EE2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antibiotics and 
Antibacterial 
Sulfasalazine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Clarithromycin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Azithromycin 2.15E-06 3.48E-06 8.25E-05 8.25E-05 2.22E-05 1.46E-03 2.37E-03 5.61E-02 5.61E-02 1.51E-02 
Trimethoprim 8.14E-06 1.09E-05 6.18E-06 6.98E-06 7.16E-06 5.54E-03 7.38E-03 4.20E-03 4.75E-03 4.87E-03 
Sulfamethoxazole N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Triclosan N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Amoxicillin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Metronidazole N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sulfadiazine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cefalexin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ofloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ciprofloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Tetracycline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Danofloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Oxytetracycline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Chloramphenicol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Penicillin G N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Penicillin V N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Erythromycin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Prulifloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norfloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antifungal 
Griseofluvin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ketoconazole 2.17E-03 2.80E-03 1.63E-03 1.79E-03 1.90E-03 1.48E+00 1.91E+00 1.11E+00 1.22E+00 1.29E+00 




  Acute RQPECsoil:PNEC Acute RQMEC:PNEC 
Class Analyte B B Max E E Max 
Average 
Both 
B B Max E E Max 
Average 
Both 
Irbesartan N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Lisinopril N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Candesartan Cilexetil N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
NSAIDs 
Ketoprofen N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ibuprofen 5.26E-04 6.40E-04 3.82E-04 4.12E-04 4.54E-04 3.58E-01 4.35E-01 2.60E-01 2.80E-01 3.09E-01 
Naproxen 5.18E-05 5.36E-05 1.06E-05 1.26E-05 3.12E-05 3.52E-02 3.64E-02 7.22E-03 8.54E-03 2.12E-02 
Diclofenac 4.26E-04 4.95E-04 1.50E-03 1.57E-03 9.64E-04 2.90E-01 3.36E-01 1.02E+00 1.07E+00 6.56E-01 
Acetaminophen N/A N/A 1.13E-04 1.13E-04 1.13E-04 N/A N/A 7.71E-02 7.71E-02 7.71E-02 
Lipid regulator 
Bezafibrate 2.39E-06 2.65E-06 9.88E-07 1.09E-06 1.69E-06 1.63E-03 1.80E-03 6.72E-04 7.42E-04 1.15E-03 
Atorvastatin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Gemfibrozil 8.87E-03 1.03E-02 N/A N/A 8.87E-03 6.03E+00 7.03E+00 N/A N/A 6.03E+00 
Antihistamine 
Fexofenadine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cetirizine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
GUD/ED Sildenafil 2.64E-05 2.78E-05 2.18E-05 2.27E-05 2.41E-05 1.79E-02 1.89E-02 1.48E-02 1.54E-02 1.64E-02 
Antidiabetics 
Metformin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Gliclazide N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sitagliptin 2.74E-05 2.95E-05 1.36E-05 2.04E-05 2.05E-05 1.86E-02 2.00E-02 9.25E-03 1.39E-02 1.39E-02 
Cough 
suppressant 
Pholcodine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Beta-blocker 
Atenolol N/A N/A 2.22E-05 2.39E-05 2.22E-05 N/A N/A 1.51E-02 1.63E-02 1.51E-02 
Metoprolol N/A N/A 1.80E-06 1.80E-06 1.80E-06 N/A N/A 1.23E-03 1.23E-03 1.23E-03 
Propranolol 8.85E-05 1.03E-04 8.52E-05 8.88E-05 8.68E-05 6.02E-02 6.97E-02 5.79E-02 6.04E-02 5.90E-02 
Bisoprolol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
H2 receptor 
agonist 
Ranitidine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cimetidine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
X-ray contrast 
media 
Iopromide N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Various Buprenorphine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Drug precursor 
Ephedrine/pseudoephedrine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norephedrine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Anticancer 
Azathioprine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Methotrexate N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ifosfamide N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Tamoxifen N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Imatinib N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Capecitabine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Bicalutamide 6.55E-05 8.22E-05 3.07E-05 3.07E-05 5.68E-05 4.46E-02 5.59E-02 2.09E-02 2.09E-02 3.86E-02 




  Acute RQPECsoil:PNEC Acute RQMEC:PNEC 
Class Analyte B B Max E E Max 
Average 
Both 





Norketamine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antidepressants 
Venlafaxine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Desmethylvenlafaxine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Fluoxetine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norfluoxetine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sertraline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Mirtazapine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Citalopram N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Desmethylcitalopram N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Paroxetine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Duloxetine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Amitriptyline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Nortriptyline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norsertraline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antiepileptic 
Carbamazepine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Carbamazepine 10,11-
epoxide 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
10,11-Dihydro -10-
hydroxycarbamazepine 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Calcium-
channel blocker 
Diltiazem N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Verapamil N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Hypnotic 
Temazepam N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Oxazepam N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Diazepam 9.73E-06 1.02E-05 8.22E-06 8.50E-06 8.98E-06 6.62E-03 6.95E-03 5.59E-03 5.78E-03 6.10E-03 
Antipsychotic 
Quetiapine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Risperidone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Dementia 
Donepezil N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




Creatinine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Nicotine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Caffeine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cotinine 6.25E-05 7.20E-05 5.49E-05 5.74E-05 5.87E-05 4.25E-02 4.90E-02 3.74E-02 3.90E-02 3.99E-02 




Heroin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
6-acetylmorphine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Morphine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




  Acute RQPECsoil:PNEC Acute RQMEC:PNEC 
Class Analyte B B Max E E Max 
Average 
Both 
B B Max E E Max 
Average 
Both 
Normorphine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Methadone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
EDDP N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Codeine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norcodeine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Dihydrocodeine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Tramadol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
N-desmethyltramadol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
O-desmethyltramadol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Stimulants and 
metabolites 
Amphetamine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Methamphetamine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
MDMA N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
MDA N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cocaine N/A N/A 1.76E-06 1.85E-06 1.76E-06 N/A N/A 1.19E-03 1.26E-03 1.19E-03 
Benzoylecgonine N/A N/A 1.16E-08 1.40E-08 1.16E-08 N/A N/A 7.91E-06 9.51E-06 7.91E-06 
Anhydroecgonine 
methylester 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cocaethylene N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Mephedrone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




Thiamethoxam N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Imidacloprid N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Clothiniadin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Metazachlor N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Terbuthylazine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Methiocarb N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Dichlofluanid N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Flufenacet 2.38E-05 2.48E-05 2.21E-05 2.21E-05 2.34E-05 1.62E-02 1.69E-02 1.50E-02 1.50E-02 1.59E-02 
Oxadiazon N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Chlorpyrifos N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Triallate N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Veterinary 
Pharmaceuticals 
Tylosin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sulfapyridine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sarafloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ceftiofur N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Diazinon N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 






Table 14 Chronic terrestrial RQPECsoil:PNEC for amended soils and RQMEC:PNEC for digested solids. Gradient is from low risk (green) to high risk (red). 
  Chronic RQPECsoil:PNEC Chronic RQMEC:PNEC 
Class Analyte B B Max E E Max 
Average 
Both 




Benzophenone-1 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Benzophenone-2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Benzophenone-3 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Benzophenone-4 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Parabens 
Methylparaben 1.56E-03 2.27E-03 4.80E-04 5.32E-04 1.02E-03 1.06E+00 1.54E+00 3.26E-01 3.62E-01 6.93E-01 
Ethylparaben N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Propylparaben N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Butylparaben N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Plasticizer Bisphenol A 1.74E-03 1.88E-03 1.47E-02 1.59E-02 8.23E-03 1.18E+00 1.28E+00 1.00E+01 10.83 5.59E+00 
Steroid 
estrogens 
E1 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
E2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
EE2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antibiotics and 
Antibacterial 
Sulfasalazine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Clarithromycin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Azithromycin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Trimethoprim N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sulfamethoxazole N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Triclosan N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Amoxicillin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Metronidazole N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sulfadiazine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cefalexin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ofloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ciprofloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Tetracycline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Danofloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Oxytetracycline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Chloramphenicol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Penicillin G N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Penicillin V N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Erythromycin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Prulifloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norfloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




  Chronic RQPECsoil:PNEC Chronic RQMEC:PNEC 
Class Analyte B B Max E E Max 
Average 
Both 
B B Max E E Max 
Average 
Both 
Ketoconazole N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Hypertension 
Valsartan N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Irbesartan N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Lisinopril N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Candesartan Cilexetil N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
NSAIDs 
Ketoprofen N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ibuprofen 5.14E-04 6.26E-04 3.74E-04 4.03E-04 4.44E-04 3.50E-01 4.26E-01 2.54E-01 2.74E-01 3.02E-01 
Naproxen N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Diclofenac N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Acetaminophen N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Lipid regulator 
Bezafibrate N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Atorvastatin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Gemfibrozil N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antihistamine 
Fexofenadine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cetirizine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
GUD/ED Sildenafil N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antidiabetics 
Metformin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Gliclazide N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sitagliptin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cough 
suppressant 
Pholcodine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Beta-blocker 
Atenolol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Metoprolol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Propranolol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Bisoprolol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
H2 receptor 
agonist 
Ranitidine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cimetidine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
X-ray contrast 
media 
Iopromide N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Various Buprenorphine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Drug precursor 
Ephedrine/pseudoephedrine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norephedrine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Anticancer 
Azathioprine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Methotrexate N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ifosfamide N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Tamoxifen N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Imatinib N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




  Chronic RQPECsoil:PNEC Chronic RQMEC:PNEC 
Class Analyte B B Max E E Max 
Average 
Both 
B B Max E E Max 
Average 
Both 
Bicalutamide N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Anaesthetic and 
metabolite 
Ketamine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norketamine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antidepressants 
Venlafaxine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Desmethylvenlafaxine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Fluoxetine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norfluoxetine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sertraline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Mirtazapine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Citalopram N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Desmethylcitalopram N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Paroxetine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Duloxetine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Amitriptyline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Nortriptyline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norsertraline N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antiepileptic 
Carbamazepine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Carbamazepine 10,11-
epoxide 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
10,11-Dihydro -10-
hydroxycarbamazepine 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Calcium-
channel blocker 
Diltiazem N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Verapamil N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Hypnotic 
Temazepam N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Oxazepam N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Diazepam N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Antipsychotic 
Quetiapine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Risperidone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Dementia 
Donepezil N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




Creatinine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Nicotine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Caffeine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cotinine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




Heroin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
6-acetylmorphine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




  Chronic RQPECsoil:PNEC Chronic RQMEC:PNEC 
Class Analyte B B Max E E Max 
Average 
Both 
B B Max E E Max 
Average 
Both 
Dihydromorphine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Normorphine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Methadone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
EDDP N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Codeine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Norcodeine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Dihydrocodeine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Tramadol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
N-desmethyltramadol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
O-desmethyltramadol N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Stimulants and 
metabolites 
Amphetamine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Methamphetamine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
MDMA N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
MDA N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cocaine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Benzoylecgonine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Anhydroecgonine 
methylester 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cocaethylene N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Mephedrone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




Thiamethoxam N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Imidacloprid N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Clothiniadin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Metazachlor N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Terbuthylazine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Methiocarb N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Dichlofluanid N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Flufenacet N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Oxadiazon N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Chlorpyrifos N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Triallate N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Veterinary 
Pharmaceuticals 
Tylosin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sulfapyridine N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sarafloxacin N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ceftiofur N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 





3.3. Anticipated and accidental exposure 
 
Overall the MECs in the low ng L-1 to µg L-1 range (or ng kg-1 to µg kg-1 range), from the discharge 
of treated wastewater from WwTWs or application of digested sludge to soil, are anticipated levels 
of exposure. 
 
In the aquatic environment, these levels are pseudo-persistent due to their continuous release. 
However, they may contain higher levels such as in the case of direct disposal of CECs to 
wastewater, which could be considered as accidental exposure. Several instances of direct or 
incidental disposal have been found within this catchment, such as the cases of fluoxetine, 
carbamazepine and ketoconazole as discussed by Proctor et al., and Petrie et al., [21, 112]. In these 
cases, higher levels are likely to pose much higher levels of risk to the environment, particularly 
where the majority of the pharmaceutical is usually metabolised and excreted in small amounts e.g. 
fluoxetine, where only 2.5 to 11% is excreted unchanged.  Furthermore, the partitioning of the solid 
may also be affected, as in the case of carbamazepine [21], where direct disposal may have led to 
an unusually high relative load in one phase compared to the other. 
 
Further consideration should be given towards the chirality of compounds, as the EF of directly 
disposed CECs may also be different and lead to increased environmental risk. For instance, 
fluoxetine is prescribed as a racemate, however, in humans the R-enantiomer is metabolised faster 
leading to an enrichment of the S-enantiomer in wastewater [113], therefore direct disposal would 
lead to higher levels of R enantiomer in the environment. Andrés-Costa et al., [114] carried out 
activated sludge simulating microcosms, which showed preferential microbial metabolism of S-
enantiomer. In consideration of direct disposal this may lead to enrichment of R-enantiomer during 
activated sludge treatment at the WwTWs. In the same study this enantiomer was shown to be far 
more toxic (x27) than its antipode, to the protozoa, Tetrahymena thermophila, which is a 
microorganism found in activated sludge treatment and soil. Therefore, direct disposal of this CEC 
may result in an increase in the most toxic fluoxetine enantiomer in activated sludge, then digested 
sludge and then the environment, which is particularly hazardous to lower trophic levels. As 
discussed previously, inhibition of microbial communities can further affect the degradation of 
pharmaceuticals and may reduce treatment efficiency within the WwTW and microbial degradation 
with the environment. 
 
CECs which are not removed efficiently though WwTW, or preferentially partition to solids, may 
pose far higher harm to the aquatic and terrestrial environments respectively, as the levels of direct 
disposal will not be mitigated by the treatment process. Furthermore, the low continual release of 




may degrade these contaminants more readily [115], reducing the persistence of CECs and their 
environmental impact. However sudden increases in CECs, especially pesticides and antibiotics, 
may alter the microbial communities significantly, reduce microbial degradation and increase the 




The results calculated show the risk to the environment of the measured concentrations. There is a lack 
of ecotoxicity data for the majority of CECs in the aquatic and terrestrial environment, so risk is 
calculated, rather than true hazard, which is based on modelled data and assessment factors to fill the 
gaps in the data. Although the situation is improving for the aquatic environment, as availability of 
chronic ecotoxicity data has improved compared to 5 years ago [13]. Overall, this accurate measurement 
of exposure to organisms in the aquatic environment gives more confidence in the environmental risk 
assessment than previous PEC calculations.  
 
Spatial and temporal variation of environmental exposure and risk is of critical importance. An 
environmental risk assessment (ERA) based on few samples or anomalous concentrations, poses the 
risk of a snapshot in time or in extreme circumstances and subsequently would not provide a 
representative ERA for the catchment [1]. However, understanding how much CECs concentrations 
fluctuates and what causes this, may be an important consideration for particularly sensitive organisms. 
In the case of pesticides or antibiotics, fluctuations may inhibit microbial communities and reduce 
biodegradation of CECs in the environment. Furthermore, this has shown that certain locations 
subjected to large community discharge will be associated with higher risk. 
 
High acute risk was determined for 5 out of 138 CECs, and high chronic risk was determined for 10 out 
of 138 CECs. The mixture assessment for classes showed 6 classes had high acute risk, and 10 had high 
chronic risk. The overall mixture had total concentrations ranging from 2,604 ng L-1 to 13,817 ng L-1 in 
the river. Organisms in the daphnid trophic levels have been identified as the most sensitive organisms 
to this mixture, though the risk (RQSTU) is low. However, the list of investigated CECs is not exhaustive, 
there are likely to be many more CECs and priority substances present in this environment, that are not 
accounted for in this study, and contributing to the overall ecotoxicological effects. Furthermore, there 
are other factors to take into account when considering the mixture as a whole, as concentration addition 
is a simple model. There may also be antagonistic and synergistic effects from different CECs. Further 
work is required on exploring the ecotoxicology of this mixture in the lab on three trophic levels to 
better understand its full environmental ramifications. 
 





1) Aquatic ERAs still require more chronic data covering three trophic levels for individual 
compounds. 
 
2) Aquatic ERA requires environmental matrices to be analysed for as wide a range of CECs as 
possible, to ensure as many of the trace chemicals are covered in the subsequent analysis. It has 
been shown that a few minor compounds may dominate the overall toxicity of the mixture, this 
has been shown in this study across the catchment with BPA and diazinon [13]. Yet the ‘critical’ 
CECs may differ between studies, therefore necessitating a broad investigation to minimise the 
chance of overlooking the ‘critical’ CECs.  
 
3) With regards to the terrestrial ERA, there is still a significant lack of data for this. With the 
PECSoil, in this study, in the ug kg-1 range, showing minimal risk overall but the data is so limited 
it is hard to be certain.  
 
 
4) RQmixture could not be determined with regards to the mixture and the terrestrial environment 
assessment, due to the lack of data, so could be reinvestigated when sufficient data becomes 
available. 
 
5) The presence of many CECs in digested sludge with log Kow lower than 3, suggesting these will 
have the highest mobility within the environment and may pose further risk to groundwater or 
surface water with leaching and runoff. 
 
 
6) Very little information is present regarding the metabolites of these compounds. Furthermore, 
the significant increase in metabolite concentration in both WwTWs and the environment, show 
that EMA guidelines for metabolites may underestimate the risk these compounds pose to the 
environment, since metabolites that are excreted at <10% of the human body are deemed to 
pose no significant risk to the environment and are not investigated further [18]. The large 
increase in the concentration of these metabolites during wastewater treatment and potential 
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Development of novel approaches and further ecotoxicological considerations 
 
1. Introduction  
 
The work in previous chapters has identified the ubiquitous presence of CECs in the environment 
(Chapter 3). Following this, the potential risk of the mixtures present has been calculated for this 
catchment based on currently available ecotoxicity data (Chapter 4). Although this was possible for the 
aquatic environment, there was limited data available for the terrestrial environment which highlights a 
need for further, more readily available ecotoxicity data and suitable tests. Furthermore, there was a 
significant lack of chronic ecotoxicity data for most of the CECs analysed in both the aquatic and 
terrestrial matrices.  
 
One aspect that is yet to be considered by this work is the stereochemistry of CECs in the environment 
and how this may affect their fate and their ecotoxicity. The stereochemistry of a pharmaceutical is 
known to be an important consideration for their medicinal effects (Evans and Kasprzyk-Hordern, 2014; 
Petrie et al., 2014), however this is still understudied for non-target organisms in the environment 
(Camacho-muñoz et al., 2019; Petrie et al., 2014; Ribeiro et al., 2012). Only a fraction of CECs that 
have been found in the environment by achiral methods have also undergone enantiomeric 
quantification. However, the studies that have been carried out have shown stereoselective partitioning 
between solid and aqueous phases (Sanganyado et al., 2017, 2016), stereoselective uptake in plants  
(Gao et al., 2016; Petrie et al., 2018; Sanganyado et al., 2017; Wang et al., 2013), enantioselective 
degradation (Fono and Sedlak, 2005; Sanganyado et al., 2017) and ecotoxicity to non-target organisms 
(Andrés et al., 2009; Petrie et al., 2014; Sanganyado et al., 2017; Stanley et al., 2007). This is further 
evidence that more stereochemical data is required for a wider range of compounds to begin to fully 
understand the impact of CECs and their enantiomers in the environment. 
 
This chapter explores the currently unpublished work investigating the variation in stereochemistry for 
a select few CECs in the catchment-based study (Chapters 3 and 4). The work goes on to discuss the 
use of standardised toxicity testing to explore the toxicity of ephedrine, followed by fluoxetine, and 
further consideration of the importance of investigating metabolites and mixtures. Following this, 
development began on a new ecotoxicity test to improve upon the standardised test, with the aim of 
increasing the range of application. Both the standardised test and the new test will use the protozoa 
Tetrahymena thermophila, but the new test will aim to reduce the overall volume of the toxicant 




as well as activated sludge. Furthermore, they have a very short lifespan; in 24 hours they go through 
5-6 generations. Their small size and sensitivity to CECs make them ideally suited as an organism for 
ecotoxicity testing (Gerhardt et al., 2010; Gilron and Gransden, 1999). Therefore, studying the response 
of this organism to toxicant will provide crucial chronic ecotoxicity that is relevant for both the aquatic 
and terrestrial compartments. 
 
2. Materials and methods 
2.1. Materials and equipment 
 Chemicals 
 
Chemicals used in this work include reference chemical potassium dichromate (K2Cr2O7), sodium 
bicarbonate (NaHCO3), calcium sulphate (CaSO4.2H2O), magnesium sulphate (MgSO4.7H2O), and 
potassium chloride (KCl), which were purchased at the highest purity bioreagent grade available from 
Sigma Aldrich (Gillingham, UK). 1R,2S-(-)-ephedrine ((-)-Eph), 1S,2R-(+)-ephedrine ((+)-Eph), 
1S,2S-(+)-pseudoephedrine, ((-)-Pse), 1R,2R-(-)-pseudoephedrine ((+)-Pse), were of ≥98% purity and 
were purchased from Sigma Aldrich. Rac-Fluoxetine, rac-norfluoxetine and internal standard IS FL-d5 
were purchased from LGC standards with >97% purity. Enantiomerically pure standards of fluoxetine 
and norfluoxetine were synthesised at the University of Bath, from purchased chiral starting materials 
R- and S- 3-chloro-1-phenyl-1-propanol, each with 99% enantiomeric excess. The synthesis is 
described in the following paper ‘Enantioselective transformation of fluoxetine in water and its 
ecological relevance.’(Andrés-Costa et al., 2017). R-(-)-methamphetamine, S-(+)-methamphetamine, 
R-(-)-amphetamine, S-(+)-amphetamine, were purchased from Cerilliant, Sigma Aldrich at 1.0 mg mL-
1 solutions in methanol. High purity deionised water was obtained from a MilliQ system (18.2 MΩ). 
 
 Standard toxicity test equipment 
 
The standard toxicity test, Chronic Protoxkit F, was purchased from MicroBioTests (University of 
Ghent, Belgium). This is supplied with enough consumables, stock culture of Tetrahymena 
thermophila, food substrate and reconstitution medium for 6 tests. The change in optical density (OD) 
was detected using the Jenway Spectrophotometer 6305 with a 440 nm wavelength filter.  
 
Further tests were carried out with independently sourced consumables, which were matched as closely 
as possible to those supplied with the test kit. Semi-macro (1.6 mL), macro (4.0 mL) polystyrene 
cuvettes with 10 mm light path, cuvette caps and screw cap Pyrex autoclavable culture tubes were 
purchased from Fisher Scientific. Terumo 1.0 mL insulin syringes with needle (27 g x 0.5”) were 
purchased from Medisave (Weymouth, UK). T. thermophila, food substrate and reconstitution medium 





 Development of nanocosm test 
 
24-well plates and 48-well plates were obtained from Greiner Bio One (Stonehouse, UK). The final 
well plates used were 48-well plates, from Thermo Fisher Scientific (Manchester, UK). Optical 
adhesive film plate cover was purchased from Applied Biosystems by Life Technologies, Thermo 
Fisher Scientific. Changes in OD were measured with the SpectraMax M3-R from Molecular Devices 
(Berkshire, UK) and purchased via VWR (Leicestershire, UK). SoftMax Pro software was used to 
program the plate reader and visualise the data. A TurboVap evaporator (Caliper, UK, 40˚C, N2, 5 – 15 
psi), was used to evaporate off methanol from the purchased 1.0 mg mL-1 solutions of enantiomerically 
pure amphetamine and methamphetamine standards. 
 
 Analysis of enantiomeric fraction (EF) of CECs in environmental matrices 
 
The reference standards: R/S (±)-propranolol, R/S (±)-mirtazapine, R/S (±)-atenolol, R/S (±)-
metoprolol, R/S (±)-fluoxetine, R/S (±)-citalopram, R/S (±)-venlafaxine, and 1R,2R/1S,2S (±)-tramadol 
were purchased from Sigma Aldrich and R/S (±)-desmethylcitalopram was purchased from Toronto 
Research Chemicals (TRC, Toronto, Canada). Internal standards R/S (±)-atenolol-d7, R/S (±)-
mirtazapine-d3, R/S (±)-fluoxetine-d5, R/S (±)-citalopram-d6 was purchased from Sigma Aldrich and 
R/S (±)-propranolol-d7, R/S (±)-metoprolol-d7, were purchased from TRC. All solvents were HPLC 
grade and purchased from Sigma Aldrich. Formic acid and ammonium acetate were HPLC grade and 
obtained from Sigma Aldrich. 
 
Consumables include: Whatman GF/F glass fibre filters with 0.7 µm pore size were purchased from 
Sigma Aldrich, Oasis MCX (mixed cation exchange, 60 mg) solid-phase extraction (SPE) cartridges, 
0.2 µm PTFE filters (Whatman, Puradisc, 13 mm) and polypropylene liquid-chromatography (LC) vials 
were obtained from Waters (UK). All glassware used in sample preparation and analysis was 
deactivated with dimethyldichlorosilane (5% DMDCS in toluene, Sigma Aldrich).  
 
Equipment used in the preparation and analysis of samples includes: ScanVac CoolSafe freeze dryer, 
(Lynge, Denmark), 800 W MARS 6 microwave and perfluoroalkoxy (PFA) microwave-assisted 
extraction (MAE) tubes (CEM, UK), Waters ACQUITY UPLCTM system (Waters, UK) with CBV 
column (chirobiotic V, 250 x 2.1 mm, I.D. 5 µm (Sigma Aldrich, UK, column packed with and antibiotic 
Vancomycin), guard column, 20 x 2.0 mm, I.D. 5 µm. Analysis was with Xevo TQD (Triple 




Waters ACQUITY system and the Xevo TQD. Data processing was carried out with TargetLynx 
software (Waters UK). 
 
2.2. Methods 
 Preparation of synthetic freshwater 
 
Synthetic freshwater was required for the standard microbiotest protocol (MicroBioTests, n.d.). This 
was prepared from purchased biological grade reagents. 96.0 mg of NaHCO3, 120.0 mg CaSO4.2H2O, 
123.0 mg MgSO4.7H2O and 4.0 mg KCl were added to 1.0 L of high purity deionised water. This was 
sonicated for approximately 60 seconds to dissolve the powder. The solution was thoroughly mixed, 
and the pH was checked to be ~ 7.6. It was then stored in a sterile, airtight bottle in the dark at 4˚C, and 
has a shelf life of up to one month. 
 
 Standard microbiotest protocol  
 
Each test cell contains protozoa, food, and a certain concentration of toxic substance in synthetic 
freshwater. The protozoa, food and overall volume remain consistent in all cells. The only variable is 
the concentration of the toxicant. At the start of the test (T0) the OD is measured with the 
spectrophotometer. Over the next 24 hours, as the population of protozoa grows, the food will 
decrease. The food causes increased levels of turbidity within the test cell. Therefore after 24 hours if 
the population is uninhibited or unaffected in its growth by the toxicant, the measurements of the OD 
should decrease. The chosen concentrations of the test should cover a range which inhibits the 
decrease in food by 80-100% of the control to 0-20% of the control, to allow a suitable range for the 
effect concentrations to be statistically calculated. 
 
The standard microbiotest protocol (MicroBioTests, n.d.) was adhered to, although minor 
improvements to the protocol were made, which are highlighted and described where they occurred. 
The protocol consists of 5 steps and is as follows: 
 
1) Preparation of toxicant dilution series 
 
There are two types of dilution series; range finding test and definitive test. The range finding 
test is for finding the appropriate range for the final definitive test. 
 
i. Range finding test 
Prepare a stock solution of the toxicant that should theoretically show 100% inhibition (C1). 




vial. This is carried out by transferring 1.0 mL of C1 and 9.0 mL of synthetic freshwater to a 
test tube labelled C2. Mix thoroughly. Then transfer 1.0 mL of C2 and 9.0 of synthetic 
freshwater to a test tube labelled C3 and mixed this thoroughly. This process continue until 
there are five concentrations. 
 
ii. Definitive test 
From the results of the range finding test, 80-100% inhibition of population growth and 
0-20% inhibition growth should be determined. If not, then the test should be repeated 
for a more appropriate range until these concentrations are found. The definitive test is 
prepared from the lowest concentration which causes 80 – 100% inhibition (this will be 
C1 in the definitive test) and the highest concentration which causes less than 20% 
inhibition (this will C5). The remaining concentrations (C2-C4) are prepared to cover 
the range between these two concentrations. If the range is one order of magnitude, the 
concentrations should be; C2 = 0.56 x C1, C3 = 0.32 x C1, C4 = 0.18 x C1, and C5 = 
0.10 x C1. If the range is two orders of magnitude; C2 = 0.32 x C1, C3 = 0.1 x C1, C4 
= 0.03 x C1 and C5 = 0.01 x C1. Use synthetic freshwater to dilute. 
 
2) Preparation of ciliate inoculum 
 
Carefully shake the stock T. thermophila culture vial to mix, then using a sterile syringe, extract 
500 µL from the vial and transfer to semi-macro cuvette. Add 1.0 mL of deionised water. Cap 
the cuvette and shake gently to mix. Using the spectrophotometer at 440 nm wavelength, 
measure the OD of the vial. Calculate the amount of deionised water required to reach a 
theoretical OD value of 0.040, using equation 1 and 2. 
 
𝐹 = 𝑂𝐷𝑣𝑎𝑙𝑢𝑒 ÷ 0.040         (1) 
𝑉 = 0.5 × (𝐹 − 1)         (2) 
 
Where F equals the dilution factor, ODvalue is the initial OD measurement, and V is the dilution 
volume required to reach the theoretical OD measurement of 0.040. Transfer 500 µL of the 
inoculum in the semi-macro cuvette to the ciliate inoculum tube and add the dilution volume 
determined from equation 2. Cap the tube and mix thoroughly. This is important to regulate the 
ciliate population, as this will result in approximately 100 protozoan per mL in each of the final 





3) Preparation of the food substrate 
 
Transfer one vial of reconstitution medium to the food substrate vial, close the vial and 
mix thoroughly. 
 
4) Inoculation of the test cells 
 
Label 12 macro cuvettes with C0 to C5 (each in duplicate). Add 2.0 mL of synthetic 
freshwater to the cuvettes labelled C0. For the remaining cuvettes, add 2.0 mL of each 
of the five concentrations to the corresponding labelled vials. Add 40 µL of food 
substrate and 40 µL of the prepared ciliate inoculum to each vial. Cap each cuvette. 
 
5) OD measurements and incubation of test cells 
 
Calibrate the spectrophotometer with 2.0 mL of distilled water in a macro cuvette. Then take 
each capped test cuvette, carefully invert several times to mix and measure the OD. Place the 
cuvettes in an incubator at 30˚C for 24 hours. Gently invert the cuvette to mix and repeat the 
OD measurement in the calibrated spectrophotometer. The OD measurement should decrease 
with population growth, as the OD measurement correlates with the quantity of food remaining 
in the cuvette. The more the population that grows in 24 hours, the more the food is eaten and 
therefore the lower the OD measurement. The test can be considered valid when the OD of the 
controls are reduced to 40% of the original OD measurement. If this does occur, place the 
cuvettes back in the incubator for another 2 hours before testing the OD again and repeat up to 
3 times (until 30 hours) if necessary. If the tests do not pass the validation criteria by this point, 
they can be considered to have failed. 
 
6) Data processing 
 
The standard tox kit is supplied with software to calculate the % inhibition using 
equation 3 and the 24 h EC50 (also EC10, EC20, EC70 and EC90). 
 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛(𝐶1−𝐶5) =  (
∆𝑂𝐷(𝐶1−𝐶5)
∆𝑂𝐷𝐶0





 Analysis of EFs in environmental matrices 
 
Suspended particulate matter (SPM) was filtered (using GF/F glass fibre filter paper with 0.7 µm pore 
size) from influent wastewaters and collected on seven consecutive days at each WwTW, as described 
in the catchment study by Proctor et al., (Proctor et al., 2020). Digested sludge was also collected on 
three consecutive days at the WwTWs with sludge treatment (WwTW B and E). The collected solids 
were frozen at -20 ˚C, freeze-dried, homogenised, weighed to 0.25 g (a note was taken of the mass to 5 
decimal places), spiked with 50 µL of 1.0 mg mL-1 internal standard mix and extracted by MAE 
following the protocol described by Evans et al., (Evans et al., 2015). 
 
Enantiomer separation and analysis was carried out with Waters ACQUITY UPLCTM system with CBV 
(Chirobiotic V) column coupled with Xevo TQD (Triple Quadrupole) mass spectrometer. The mobile 
phase used was 4 mM ammonium acetate in 100% methanol with 0.005% formic acid with a flow rate 
of 0.1 mL min-1 under isocratic conditions. The column temperature was 25 ˚C and injection volume 
was 20 µL. Nitrogen, supplied by a high purity nitrogen generator, was used as the nebulising and 
desolvation gas. Argon was used as the collision gas. Other mass spectrometer parameters include 
capillary voltage at 3.49 kV, source temperature at 150 ˚C, and desolvation gas flow was at 300 L h-1. 
Data analysis was carried out using TargetLynx. The enantiomeric fraction (EF) was calculated using 
equation 4, where E1 is the concentration of (+)-enantiomer or the enantiomer with the lowest retention 
time and E2 is the concentration of (-)-enantiomer or the enantiomer with the highest retention time.  
 
𝐸𝐹 =  
𝐸1
𝐸1+𝐸2
           (4) 
 
The EFs were calculated for atenolol, metoprolol, propranolol, venlafaxine, desmethylvanlafaxine, 
fluoxetine, mirtazapine, citalopram, desmethylcitalopram, amphetamine, methamphetamine, MDMA, 
MDA, and mephedrone. 
 
3. Results and Discussion 
3.1. Stereochemistry of CECs and environmental risk assessment 
 
Since chiral analysis is completed with a different method than CEC quantification, the method has 
different minimum quantification limits (MQLs). Therefore, there are some instances where despite  
CECs being quantifiable in the same sample with the achiral method, the chiral methods could not 
quantify the compound and an EF could not be calculated. Despite many CECs being chiral and known 




stereoselective ecotoxicity, there is a lack of information on their enantiomeric composition in 
wastewaters and the environment.  
 
  Stereochemical variation within influent solid and liquid phases 
 
In the liquid phase (LP) of influent wastewater, the mean EF of studied CECs ranged from 0.21 for 
mirtazapine at WwTW D to 0.69 for fluoxetine at WwTW E (Table 1). These are within the range of 
previously reported EFs for chiral pharmaceuticals and illicit drugs in influent LP (Camacho-muñoz et 
al., 2019; Kasprzyk-Hordern and Baker, 2012; López-Serna et al., 2013; MacLeod et al., 2007; 
Sanganyado et al., 2016).  There is limited data available in the literature on the enantiomeric 




Table 1 Enantiomeric fractions of influent and effluent matrices throughout the catchment. 
  Influent Effluent 






















Atenolol 0.50 ± 0.01 0.50 ± 0.00 0.50 ± 0.00 0.50 ± 0.00 0.49 ± 0.00 0.58 ± 0.01 0.47 ± 0.00 0.49 ± 0.01 0.49 ± 0.02 0.55 ± 0.00 
Metoprolol 0.46 ± 0.02 0.48 ± 0.05 0.45 ± 0.04 0.47 ± 0.02 0.42 ± 0.04 0.45 ± 0.01 0.42 ± 0.04 0.44 ± 0.03 0.38 ± 0.01 0.42 ± 0.02 
Propranolol 0.44 ± 0.01 0.41 ± 0.01 0.42 ± 0.01 0.41 ± 0.02 0.40 ± 0.01 0.38 ± 0.01 0.36 ± 0.00 0.37 ± 0.01 0.39 ± 0.03 0.37 ± 0.01 
Venlafaxine 0.39 ± 0.04 0.39 ± 0.04 0.44 ± 0.04 0.37 ± 0.04 0.33 ± 0.03 0.46 ± 0.07 0.45 ± 0.01 0.35 ± 0.06 0.44 ± 0.01 0.39 ± 0.01 
Desmethylvenlafaxine 0.51 ± 0.03 0.50 ± 0.03 0.53 ± 0.02 0.49 ± 0.08 0.45 ± 0.02 0.49 ± 0.01 0.48 ± 0.01 0.49 ± 0.03 0.49 ± 0.01 0.46 ± 0.01 
Fluoxetine 0.68 ± 0.02 0.68 ± 0.02 0.68 ± 0.02 0.67 ± 0.02 0.69 ± 0.02 0.65 ± 0.03 0.66 ± 0.01 0.68 ± 0.03 0.65 ± 0.02 0.63 ± 0.01 
Mirtazapine 0.24 ± 0.03 0.27 ± 0.04 0.31 ± 0.02 0.21 ± 0.03 0.24 ± 0.05 0.29 ± 0.01 0.28 ± 0.02 0.27 ± 0.04 0.27 ± 0.01 0.27 ± 0.02 
Citalopram 0.36 ± 0.02 0.37 ± 0.00 0.35 ± 0.01 0.36 ± 0.02 0.35 ± 0.01 0.31 ± 0.00 0.34 ± 0.01 0.36 ± 0.01 0.34 ± 0.02 0.32 ± 0.01 
Desmethylcitalopram 0.43 ± 0.01 0.45 ± 0.01 0.43 ± 0.02 0.42 ± 0.01 0.42 ± 0.01 0.43 ± 0.02 0.42 ± 0.01 0.43 ± 0.01 0.41 ± 0.01 0.43 ± 0.01 
Amphetamine 0.42 ± 0.02 0.42 ± 0.01 0.44 ± 0.01 0.40 ± 0.02 0.44 ± 0.02 <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A 
Methamphetamine <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A 
MDMA 0.33 ± 0.04 0.34 ± 0.05 0.33 ± 0.05 0.32 ± 0.07 0.36 ± 0.05 0.17 ± 0.04 0.24 ± 0.05 0.28 ± 0.04 0.29 ± 0.03 0.19 ± 0.03 
MDA <MQL ± 0.14 <MQL ± 0.25 0.53 ± 0.51 0.52 ± N/A 0.56 ± N/A <MQL ± 0.02 <MQL ± 0.06 0.40 ± 0.08 0.20 ± N/A 0.53 ± N/A 




(Castrignanò et al., 2016), reported EFs of mephedrone in influent LP ranging from 0.53 to 0.59.  A 
later studied verified that the enrichment of mephedrone, in influent LP, with R-(+)-mephedrone, from 
the racemate form in which it is distributed, was due to human metabolism (Castrignanò et al., 2017). 
 
In SPM, only pharmaceuticals and not the illicit drugs underwent chiral analysis. Overall, most 
pharmaceuticals saw no difference in EF between SPM and influent LP (Table 1 and 2). However, 
metoprolol showed a significant difference at WwTW C and WwTW D with 0.21 and 0.28 in SPM 
respectively, 0.45 and 0.47 in influent LP. Citalopram and its metabolite, desmethylcitalopram also 
showed a significant difference in EF between the two phases and this was more consistent across all 
WwTW, ranging from 0.60-0.62 in SPM across all sites and 0.35-0.37 in influent LP for citalopram and 
0.57 to 0.59 in SPM to 0.42 to 0.45 in influent LP for desmethylcitalopram. This may be indicative of 
stereoselective partitioning for these compounds (Sanganyado et al., 2017). 
 
Tramadol was not analysed with chiral methods in influent LP, but in SPM shows the widest range of 
EF from an average of 0.73 at WwTW A to an average of 0.20 at WwTW C. WwTW C and E (0.34) 
show the lowest EF, which may be linked to the presence of hospitals, however more investigation is 
needed for both phases. 
 
With regards to temporal trends, there was little variance of EF for most CECs entering the WwTWs in 
either influent LP or SPM. However, mirtazapine, in SPM, showed a significant increase of EF at 
WwTW A, 0.61 on Friday compared to 0.30 – 0.43 for the rest of the week. This was not observed in 
influent. At the other WwTWs, the EF is relatively consistent between 0.26 and 0.30. 
 
 Stereochemical variation within wastewater treatment works – aqueous removal 
 
MDMA showed a greater change in EF, at WwTWs with activated sludge treatment, a 49% and 47% 
decrease in EF at WwTW A and E. The WwTWs with trickling filters also showed a decrease in EF, 
which ranged from 28%, 17% and 9% at WwTW B, C and D respectively (Table 1). Overall MDMA 
showed an increase in EFs over the weekend (0.26, 0.35 and 0.28 at WwTW E, D and B, respectively) 
and lower over the week (0.14, 0.23 and 0.21 at WwTW E, D and B, respectively), but this was not 
seen at WwTW A or C. MDMA’s metabolite, MDA, was largely undetected in effluent across the 
catchment. When it was detected, it showed the EF was highly variable. 
Atenolol also showed variation in EF between WwTWs using activated sludge treatment or trickling 
filters. At WwTWs A and E the EF increased by 16% and 12% respectively, whereas WwTWs B, C 
and D decreased slightly, by 2-5%. The other beta-blockers showed an overall decrease of EF at all 




Table 2 Enantiomeric fractions of solid environmental matrices throughout the catchment. 
 
 Digested Solids Suspended particulate matter 
 WwTW B  WwTW E  WwTW A WwTW B WwTW C WwTW D WwTW E 
Compound EF  SD EF  SD EF  SD EF  SD EF  SD EF  SD EF  SD 
Propranolol 0.45 ± 0.01 0.45 ± 0.02 0.44 ± 0.03 0.43 ± 0.01 0.45 ± 0.02 0.44 ± 0.02 0.43 ± 0.02 
Mirtazapine 0.32 ± 0.01 0.33 ± 0.01 0.38 ± 0.11 0.28 ± 0.05 0.26 ± 0.02 0.27 ± 0.01 0.30 ± 0.02 
Atenolol 0.47 ± 0.06 - ± - - ± - - ± - - ± - - ± - - ± - 
Metoprolol 0.41 ± 0.01 0.36 ± 0.06 0.50 ± 0.02 0.48 ± 0.05 0.21 ± 0.07 0.28 ± 0.03 0.37 ± 0.07 
Fluoxetine 0.67 ± 0.01 0.66 ± 0.02 0.67 ± 0.02 0.67 ± 0.02 0.68 ± 0.02 0.68 ± 0.02 0.67 ± 0.02 
Desmethylcitalopram 0.53 ± 0.01 0.56 ± 0.01 0.59 ± 0.02 0.59 ± 0.01 0.57 ± 0.01 0.59 ± 0.01 0.58 ± 0.01 
Citalopram 0.61 ± 0.00 0.61 ± 0.02 0.62 ± 0.01 0.61 ± 0.01 0.60 ± 0.01 0.62 ± 0.01 0.62 ± 0.01 
Venlafaxine 0.47 ± 0.02 0.51 ± 0.01 0.49 ± 0.02 0.41 ± 0.03 0.34 ± 0.03 0.44 ± 0.02 0.39 ± 0.05 





metoprolol, and 5-12% decrease for propranolol. The differences in EF between influent LP and effluent 
show stereoselective processes also occurred during wastewater treatment.  The results for atenolol 
contradict what was previously found by Ribeiro et al. (Ribeiro et al., 2013), who found atenolol showed 
no enantioselectivity in activated sludge inoculum treatment. This is likely due to different 
microorganisms in the different activated sludge systems. 
 
Temporal trends showed little variation of EFs in effluent across the week for the pharmaceuticals, with 
coefficients of variance less than 10%, apart from WwTW C (20%) and WwTW E (15%) for 
venlafaxine, and WwTW C for mirtazapine (13%). At WwTW C, the EF of venlafaxine was steady 
from Wednesday to Saturday with EFs in the range of 0.39 - 0.40. However, between Sunday and 
Tuesday, the EF drops to 0.28. Whereas at WwTW E, the EF shows an increasing trend across the week 
from 0.33 on Wednesday to 0.45 on the following Tuesday.  
 
 Stereochemical variation between effluent and river water 
 
Venlafaxine showed a lower EF in effluent compared to river water upstream or downstream at WwTW 
C (0.35 to 0.48 and 0.50 respectively). However, desmethylvenlafaxine does not show significant 
differences between the three sampling points at WwTW C, or at any WwTW or river sampling site. 
Atenolol showed a significant increase between EF of upstream samples and downstream samples at 
WwTW A, from 0.47 to 0.57. This is likely due to the effluent discharge at this point, which had an EF 
of 0.58. 
 
All other CECs analysed showed no significant difference between any samples, between effluent and 
river water upstream and downstream of the discharge point in which they were detected. This is similar 
to what was found in the same catchment by Camacho-Muñoz et al., (Camacho-Muñoz et al., 2019). 
 
 Stereochemical variation through a water course 
 
Kasprzyk-Hordern et al. (Kasprzyk-Hordern and Baker, 2012), have previously shown that EFs of 
various CECs can change, not only within WwTWs, but also throughout a watercourse. Changes in EF 
in the aquatic environment were seen for MDMA, ephedrine/pseudoephedrine (diastereomeric fraction, 
DF), but venlafaxine and atenolol didn’t show a significant change. For ephedrine, this shows an 
enrichment of (1R,2S)-ephedrine upstream and an enrichment of the least toxic (1S,2S)-
pseudoephedrine downstream. 
 
However, in this study few spatial trends were seen. Most CECs were consistent throughout the 
catchment when they were above the MQL (Table 3). MDMA was the only illicit drug that was detected 




Table 3 Enantiomeric fractions of river water matrices throughout the catchment. 
 


















Atenolol 0.47 ± 0.01 0.57 ± 0.01 0.48 ± 0.01 0.47 ± 0.02 0.46 ± 0.01 0.47 ± 0.01 0.50 ± 0.04 0.48 ± 0.01 
Metoprolol <MQL ± N/A 0.46 ± 0.02 <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A 
Propranolol 0.39 ± 0.01 0.39 ± 0.02 0.38 ± 0.01 0.37 ± 0.01 0.39 ± 0.01 0.39 ± 0.01 0.39 ± 0.01 0.40 ± 0.01 
Venlafaxine 0.50 ± 0.02 0.48 ± 0.02 0.48 ± 0.01 0.48 ± 0.01 0.48 ± 0.03 0.50 ± 0.05 0.48 ± 0.01 0.50 ± 0.03 
Desmethylvenlafaxine 0.49 ± 0.01 0.50 ± 0.01 0.44 ± 0.01 0.47 ± 0.01 0.50 ± 0.02 0.48 ± 0.01 0.48 ± 0.01 0.48 ± 0.01 
Fluoxetine <MQL ± N/A 0.64 ± 0.02 <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A 0.64 ± 0.12 0.68 ± 0.03 
Mirtazapine <MQL ± N/A 0.30 ± 0.01 0.28 ± 0.02 0.27 ± 0.02 <MQL ± N/A 0.27 ± 0.02 0.29 ± 0.02 0.27 ± 0.04 
Citalopram 0.31 ± 0.01 0.31 ± 0.01 <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A 
Desmethylcitalopram 0.40 ± 0.02 0.42 ± 0.02 0.40 ± 0.01 0.41 ± 0.01 0.40 ± 0.05 0.42 ± 0.02 0.42 ± 0.02 0.42 ± 0.02 
Amphetamine <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A 
Methamphetamine <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A 
MDMA 0.30 ± 0.04 0.17 ± 0.03 0.19 ± 0.05 0.22 ± 0.04 0.28 ± 0.04 0.25 ± 0.04 0.25 ± 0.05 0.25 ± 0.05 
MDA <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A <MQL ± N/A 




At R2 the EF was 0.17, which was likely due to the discharge from the WwTWs which also had an EF 
of 0.17. From this point on however, the EF slowly rose throughout the catchment to 0.28 at R5 and 
then remained at 0.25 at the remaining sampling points. 
Atenolol also showed an EF change related to discharge between river sampling points R1 (EF = 0.47) 
and R2 (0.57), again this is likely due to the discharge of WwTW A, which had a very similar EF (0.58). 
 
Overall, the similarities of EF between the effluent sampling point and downstream sampling point may 
indicate the proximity of R2 is too close to WwTW A, as previously discussed in chapters 3 and 4. The 
results for venlafaxine contrasts to what was previously observed by Li et al. (Li et al., 2013), would 
found venlafaxine consistently decreased via stereoselective microbial degradation. 
 
 Digested solids 
 
Enantioselective analysis of sludge extracts revealed chiral CECs were not present in the racemic form.  
Average EFs ranged from 0.16 for tramadol to 0.67 for fluoxetine (Table 2) and are similar to the limited 
work done on this area previously (Evans et al., 2015). For most CECs, no significant differences in EF 
were observed between sludge produced by WwTWs B and E.  Overall, Figure 1, shows similar EFs 
present in digested sludge as in SPM, with the exception of tramadol, which shows high variance in 
SPM as well.  
 
Beta-blockers have previously shown stereoselective biodegradation during wastewater treatment 
(Camacho-Muñoz et al., 2016; Fono and Sedlak, 2005; López-Serna et al., 2013; MacLeod et al., 2007; 
Vazquez-Roig et al., 2014), whereas this comparison between EFs in SPM and digested solids suggests 




Figure 1 Average EF of seven consecutive days for SPM and three consecutive days for digested solids 
























 Preliminary conclusions 
 
This work so far has indicated that sorption to SPM maybe stereoselective, for metoprolol, citalopram 
and desmethylcitalopram. Whilst this observation requires further confirmation, it may be of critical 
importance if this trend can also be seen in the aquatic and benthic environment. 
 
Removal from the liquid phase was also stereoselective for many compounds, with significant 
changes in EF between the two matrices. Differences possibly resulting from the two treatment types 
could also be seen for atenolol and MDMA. 
 
In this catchment, the patterns of EF between effluent discharge, river upstream and downstream are 
very consistent, and indicate that the stereochemistry within the environment is highly influenced by 
the effluent. Furthermore, there is comparatively little stereochemical variation in river water for 
CECs throughout this catchment compared to previous studies, which indicates a lack of 
stereoselective microbial degradation. This was also seen for most CECs in the study by Camacho-
Muñoz et al., (Camacho-Muñoz et al., 2019), however that work was further supported by lab-based 
river water microcosms. This practice should be a further consideration for this work. 
 
Regarding the changes of EF in solids, further work is still required as they, prior to treatment, are a 
mixture of solids from the WwTW and tankered sludge from other WwTWs. Therefore, the 
contribution of SPM from each source to this mixture is unknown and further investigation would be 
required to fully understand the process. 
 
Overall, few of these chiral CECs are racemic (50:50 ratio) in the environment (Table 1). This is of 
critical importance, as shown by the two papers following this work (Andrés-Costa et al., 2017; Rice 
et al., 2018), as different enantiomers can have different levels of effect and one may be far more 
toxic than another. Currently this is not taken into account in ERAs unless the pharmaceutical is sold 
as a pure enantiomer or human metabolism produces >10% of the other enantiomer. Therefore, 
changes within this ratio from wastewater treatment processes and within the environment are not 
considered. The ERAs of chiral CECs need to be treated as a mixture of enantiomers, or different 
compounds, to provide a more accurate risk assessment. Furthermore, as evidenced by the papers by 
Andrés-Costa et al. (Andrés-Costa et al., 2017),or Sanchez et al. (Sánchez et al., 2004) these 
enantiomers or their metabolites may have a synergistic or antagonistic effect on each other. This is 






3.2. Application of the T. thermophila standard test protocol and further consideration towards 
future ecotoxicity tests and ERA 
 
 Application of the T. thermophila standard test protocol  
 
The standard test protocol was used, as part of a battery of toxicity tests of various trophic levels, to 
explore the environmental significance of the varying stereochemistry found within wastewater 
treatment works and the environment, of ephedrine and fluoxetine. The context of this collaborative 
work and the results can be found in the following two published pieces (Andrés-Costa et al., 2017; 
Rice et al., 2018). The main conclusions for the studies are as follows: 
 
3.2.1.1. Organism sensitivity towards differences in stereochemistry  
 
Both studies (Andrés-Costa et al., 2017; Rice et al., 2018) show the importance of understanding 
enantioselective transformation within the WwTWs and the environment, and how this may differ from 
the human metabolism. This consideration is a key factor that is not taken into account with current 
guidelines for the ERA for new medicinal products (Camacho-Muñoz et al., 2016; European Medicines 
Agency, 2018). Furthermore, these pieces show the importance of considering the effects across 
different trophic levels. Not only to illustrate which trophic level is most at risk in the environment but 
to understand how some organisms may be more affected by differences in stereochemistry than others. 
For example, fluoxetine is far more toxic to the fish P. promelas than D. magna or T. thermophila 
(Andrés-Costa et al., 2017; Stanley et al., 2007). For the endpoint with the lower LOEC for this 
organism, (S)-fluoxetine is 3.4 times more effective than the (R)-enantiomer. Whereas, D. magna, a 
model organism and frequently used in ecotoxicity tests, shows a negligible difference between the two 
enantiomers. However, for T. thermophila the difference is clear, showing the (R)-enantiomer is 27 
times more toxic than the (S)-enantiomer. Furthermore, this sensitivity to stereochemistry has been 
shown to vary between the diastereomers of ephedrine and fluoxetine for the lower trophic levels, as 
despite showing negligible difference between the enantiomers of fluoxetine, D. magna shows greater 
relative difference in toxicity between the two enantiomers of pseudoephedrine. T. thermophila on the 
other hand, shows a small difference in toxicity between the (1S,2R) and (1R,2S)-enantiomers of 
ephedrine (42.6 mg L-1 compared to 36.0 mg L-1). Yet the enantiomers, (1S,2S)- and (1R,2R) of 
pseudoephedrine, differ by almost 22 times. 
 
Some of this difference may be due to the ability of these organisms to adapt to what is entering the 
environment consistently at a low level. For example, of the four diastereomers of ephedrine, the two 




frequently used in medicine, are the most abundant in the environment (Kasprzyk-Hordern and Baker, 
2012) and are also the least toxic enantiomers for D. magna, and (1S,2S)-pseudoephedrine is the least 
toxic enantiomer to all three trophic levels (Rice et al., 2018). 
 
3.2.1.2. Stereochemistry of ephedrine highlights the potential issue of seasonal potency  
The ephedrine paper, (Rice et al., 2018), also highlights the potential issues with variation in seasonal 
potency of an environmental mixture with regards to the diastereomers of ephedrine, with the 
cumulative loads of these compounds reaching 180 g d-1 in winter (February) compared to <80 g d-1 in 
summer (August) (Kasprzyk-Hordern and Baker, 2012). At first glance, the winter loads might be 
considered a greater environmental risk than those seen in summer, however, the winter loads were 
enriched with the least toxic diastereomers (1S,2S)-pseudoephedrine and the summer ones were 




The standard test protocol was applied to an equal mixture of the diastereomers of ephedrine (Rice et 
al., 2018) and the equal mixture of the enantiomers of fluoxetine and the enantiomers of its metabolite 
norfluoxetine (unpublished, see Figure 2). For ephedrine, the mixture shows that concentration addition 
is a good approximation for the mixture of the diastereomers. The mixture of fluoxetine and 
norfluoxetine suggest a more synergistic effect, as the EC50 of 0.84 mg L-1 of the mixture is far lower 










3.3. Development of new nanotest method 
 
  Nanotest development 
 
The main limitation of the practicality of the standard toxicity test was the quantity of toxicant required. 
For example: 
 
- For a range finding test, 10 mL is required of highest concentration to both test this 
concentration and prepare the other concentrations in the dilution series e.g. 100 mg L-
1 would require 1 mg of toxicant. 
 
- For the definitive test, 15.6 mL, or 20 mL for accurate preparation using a volumetric 
flask, is required for the highest concentration and preparation of the remaining 
concentrations e.g. 100 mg L-1 would require 2 mg of toxicant.  
 
 
Therefore, to carry out 1 range finding test and duplicate the definitive test to ensure reproducibility, a 
minimum of 5 mg is required for each toxicant. Whilst this may appear to be a relatively small quantity, 
many toxicants are very expensive, not available in powder form or in quantities larger than 1 mg e.g. 
illicit drugs, enantiomers, and metabolites. Therefore, the initial aim of the nanotest development was 
to reduce the quantity of toxicant required, ultimately to increase the range of toxicants that can be 
tested. 
 
24, 48 and 96-well plates were considered. The maximum working volume for the well plates were 
generally 1.0 mL, 0.5 mL, and 0.20 mL respectively. This would result in a population of (based on 
using the same proportion of protozoa inoculate to total volume as used in the standard test (40 µL 
ciliate inoculum in 2.0 mL test solution, resulting in ~100 protozoa per 1.0 mL)) of  approximately 100, 
50 and 20 protozoa in the final test cell. A population of only 20 protozoa was deemed far too small for 
a population-based inhibition test on a microorganism. Therefore, both 24-well and 48-well plates were 
considered further. 
 
The following plate plans (Figures 3-5) were devised where C0 is the control and C1-C5 are the 







C0 C0 C0 C0 C0 C0 
C0 C1 C2 C3 C4 C5 
C0 C1’ C2’ C3’ C4’ C5’ 
C0 C0 C0 C0 C0 C0 
 
Figure 3 24-well plate plan, where C0 is the control and C1 – C5 are the concentrations as planned in 
the standard toxicity test. C1’ – C5’ are the replicates 
 
C0 C0 C0 C0 C0 C0 C0 C0 
C0 aC1 aC2 aC3 aC4 aC5 aC6 C0 
C0 aC1’ aC2’ aC3’ aC4’ aC5’ aC6’ C0 
C0 bC1 bC2 bC3 bC4 bC5 bC6 C0 
C0 bC1’ bC2’ bC3’ bC4’ bC5’ bC6’ C0 
C0 C0 C0 C0 C0 C0 C0 C0 
 
Figure 4 48-well plate plan, where C0 is the control, aC1 – aC6 are a range of 6 concentrations for 
toxicant ‘a’, bC1 – bC6 are a range of 6 concentrations for toxicant ‘b’, aC1’ – aC6’ and bC1’ – bC6’ 
are the replicates 
 
The wells around the plate perimeter are most at risk from temperature fluctuations, so these wells were 
made controls, as the relatively large number of them will enable any outliers to be removed and provide 
a relevant average control response. From these two plans, the 48-well plate shows clear advantages of 
lower volumes, more controls, a larger range of concentrations and the space to test more than one 
toxicant at a time. Therefore the 48-well plate plan was progressed. 
 
For coloured toxicants, such as the references chemical K2Cr2O7, a further test plate was devised (see 
Figure 5), based on the original standard protocol. This was to accommodate how the colour of the 






C0 C0 C0 C0 C0 C0 C0 C0 
C0 C0 C1 C2 C3 C4 C5 C0 
C0 C0 C1’ C2’ C3’ C4’ C5’ C0 
C0 C0 C0 C0 C0 C0 C0 C0 
C0 C0 C1x C2x C3x C4x C5x C0 
C0 C0 C0 C0 C0 C0 C0 C0 
 
Figure 5 48-well plate plan for reference test with K2Cr2O7, or coloured toxicant, where C0 is the 
control, C1 – C5 are a range of 5 concentrations for the reference standard, C1’ – C5’ are the replicates 
and C1x - C5x are wells filled only with the reference standard solution at the respective concentrations 
i.e. no food or protozoa. 
 
Overall, the application of this test highlighted several issues: shaking, test length and condensation. 
Automatic shaking was enabled to ensure a homogenous mixture prior to OD measurement however, 
this resulted in a shift of the plate and subsequent inaccuracy of measurements. Therefore, the shaking 
function was disabled. 
 
Initially, it took far longer than the original 24 hours for the protozoa to clear 60% of the food in the 
well. This was thought to be due to one of two factors; temperature or population. The protozoa are 
sensitive to small changes in temperature. Therefore, increasing the temperature to 32 ˚C reduced the 
test time by several hours. Variations in population were also tested; increasing the population by a 
factor of 2 and 3 showed increasing stability in the first 16 hours of the test and a greater difference 
between the maximum OD and minimum OD of the test. These changes ensured the controls began 
passing the validation criteria of a 60% reduction in OD within 24 hours.  
 
Condensation on the test plate lid became a considerable problem, leading to drastic changes in OD 
throughout the test. Conducting the test without a lid caused high levels of evaporation of the test 
medium and resulted in an inaccurate test of toxicity. Therefore, optical adhesive films were used 
instead of lids. Despite that this film also built up a layer of condensation, small holes could be carefully 
pricked though the optical film over each well, to prevent condensation and limit evaporation. 1, 5 and 
9 holes were tested as shown in Figure 6. Overall, 9 holes were found to be the most effective at 







Figure 6 The distribution of holes over a well, ‘x’ in the test wells, 1, 5 and 9 holes respectively. 
 
 Optimised nanotest protocol 
 
The final well test plate plan included positive control, using a concentration of 100 mg L-1 of K2Cr2O7, 
and four negative controls, duplicates of food and synthetic freshwater (no protozoa) to show no 
variation over 24 hours without protozoa, and duplicates of protozoa only and synthetic freshwater (no 
food) to show lack of response without food. These plans can be seen in Figure 7. Furthermore, a 
seventh concentration was added. 
 
With this optimised nanotest, the primary aim of reducing the mass of toxicant required has been 
achieved. 
- For a range finding test, 1.5 mL is required of highest concentration to test this 
concentration and prepare the other concentrations in the dilution series e.g. 100 mg L-
1 would require 0.15 mg of toxicant. 
 
- For the definitive test, less than 5 mL is required for the highest concentration and 
preparation of seven concentrations e.g. 100 mg L-1 would require 0.5 mg of toxicant.  
 
The results of this nanotest were reproducible. However, the 24h EC50 (17.0 mg L-1) showed a reduction 
in the toxicity of the reference material compared with the reference values from the batch specification 
sheet (8.2 mg L-1 with an acceptable range of 5.3 – 10.5 mg L-1). This is likely due to the change in ratio 
of population:food:test medium.  
 
Future work to validate the test should explore the different ratio of population:food:test medium, to 
further understand the subsequent effects. Furthermore, the number of protozoa present in each well is 
currently determined theoretically. Tests should be carried out to determine how many protozoa are in 




















 1 2 3 4 5 6 7 8 
A C0 C0 C0 C0 C0 C0 C0 C0 
B C0 C1 C2 C3 C4 C5 C6 C7 
C C0 C11 C21 C31 C41 C51 C61 C71 
D C0 C0 C0 C0 C0 C0 C0 C0 
E C0 C1x C2x C3x C4x C5x C6x C7x 












 1 2 3 4 5 6 7 8 
A C0 C0 C0 C0 C0 C0 C0 C0 
B C0 C1 C2 C3 C4 C5 C6 C7 
C C0 C11 C21 C31 C41 C51 C61 C71 
D C0 C1 C2 C3 C4 C5 C6 C7 
E C0 C11 C21 C31 C41 C51 C61 C71 












Figure 7 Final 48 well plate plans, top shows reference/coloured toxicant test plate and the bottom 
shows a two toxicant test plate. 
 
The optimised nanotest protocol is as follows: 
 
1) Preparation of toxicant dilution series 
 
i. Range finding test 
Prepare a stock solution of the toxicant that should theoretically show 100% inhibition (C1). 
From this prepare a 1:10 dilution series spanning 7 orders of magnitude, with 1.5 mL in each 
eppendorf. This is carried out by transferring 0.15 mL of C1 and 1.35 mL of synthetic 
freshwater to a test tube labelled C2. Mix thoroughly. Then transfer 0.15 mL of C2 and 1.35 
mL of synthetic freshwater to a test tube labelled C3 and mixed this thoroughly. Continue this 
process until there are 7 concentrations. 
 




From the results of the range finding test, 80-100% inhibition of population growth and 
0-20% inhibition growth should be determined. If not, then the test should be repeated 
for a more appropriate range until these concentrations are found. The definitive test is 
prepared from the lowest concentration which causes 80 – 100% inhibition (this will be 
C1 in the definitive test) and the highest concentration which causes less than 20% 
inhibition (this will be C7). The remaining concentrations (C2-C6) are prepared to 
cover the range between these two concentrations. The range of concentrations should 
be; C2 = 0.56 x C1, C3 = 0.32 x C1, C4 = 0.18 x C1, C5 = 0.10 x C1, C6 = 0.03 x C1 
and C7 = 0.01 x C1. Use synthetic freshwater to dilute. 
 
2) Preparation of ciliate inoculum 
 
Carefully shake the stock T. thermophila culture vial to mix, then using a sterile syringe, 
extract 500 µL from the vial and transfer to semi-macro cuvette. Add 1.0 mL of 
deionised water. Cap the cuvette and shake gently to mix. Using the spectrophotometer 
at 440 nm wavelength, measure the OD of the vial. Calculate the amount of deionised 
water required to reach a theoretical OD value of 0.040, using equation 1 and 2. Transfer 
500 µL of the inoculum in the semi-macro cuvette to the ciliate inoculum tube and add 
the dilution volume determined from equation 2. Cap the tube and mix thoroughly. This 
is important to regulate the ciliate population, as this will result in approximately 100 
protozoan per mL in each of the final test cells (MicroBioTests, n.d.). 
 
3) Preparation of the food substrate 
 
Transfer one vial of reconstitution medium to the food substrate vial, close the vial and 
mix thoroughly. 
 
4) Inoculation of the test cells 
 
Following the relevant plate plan, add 0.5 mL of synthetic freshwater to the wells 
labelled C0. To the remaining wells, add 0.5 mL of each of the 7 concentrations to the 
corresponding wells. To each well, add 10 µL of food substrate and 20 µL of the 




3 times, the inoculated test solution into the pipette and release back into the cell to mix 
and to ensure no protozoa remain in the tip. Make sure to use a new tip for each well. 
 
5) Seal plate 
 
Cover plate with optical adhesive film. Carefully pierce 9 holes in the film above each well as 
illustrated in Figure 6, being careful not to touch the test medium within each well.  
 
6) OD measurements and incubation of test plate 
 
Place the plate into pre-heated plate reader at 32˚C. Close plate drawer. Set plate reader to take 
an OD measurement at 440 nm wavelength, every 5 minutes for 28 hours, with no shaking. 
 
7) Data processing 
 
Export raw data to Excel. Calculate change in optical density between T0h and T24h. 
Input this into the standard tox kit software to calculate the 24 h EC50 (also EC10, EC20, 
EC70 and EC90). 
 
This test protocol not only uses less toxicant but also allows more than one toxicant to be easily prepared 
and tested in parallel, reducing overall experiment time. Furthermore, the range of kinetic data may be 
of use. Previous tests only had two OD measurements, once at the beginning and once at the end. With 
this method, trends across 24 hours can be seen. 
 
4. Preliminary conclusions and future work 
 
During ecotoxicity testing using a standard protocol, a variety of test organisms indicated some are 
more sensitive to varying stereochemistry. T. thermophila has been shown to be particularly sensitive 
to this (Andrés-Costa et al., 2017; Rice et al., 2018). Furthermore, this unusual test organism can be 
found in both the aquatic and terrestrial environment, as well as within WwTW processes.  
 
Standard toxicity tests are inefficient in their use of toxicants, this can be minimised for some test 
organisms, i.e. microorganisms. This work shows the development of a new nanotest using the ciliate 
protozoa T. thermophila, adapted from the standard Protoxkit toxicity test produced by MicroBioTests. 




toolbox. It not only uses less toxicant, but also enables testing of multiple toxicants on one plate. Firstly, 
this is particularly beneficial when studying different enantiomers, as pure enantiomers are often far 
more expensive than their racemic mixture of the compound. Therefore, the ability of using smaller 
quantities in the tests is financially and logistically beneficial. Secondly, the ability to test multiple 
toxicants on one plate will allow both enantiomers to be tested at the same time, reducing any potential 
unintended variation from carrying out the tests at different times. Furthermore, the SpectraMax M3-R 
plate reader enabled continuous kinetic data acquisition, therefore not only allowing determination of 
population growth by measuring the reduction of the OD, but also allowing assessment of the curve 
characteristics as an additional quality control measure.   
 
Overall this work shows significant differences in the ecotoxicity of stereoisomers of CECs, particularly 
pharmaceuticals. However, this is overlooked in current ERA guidelines. Inaccuracies in ERAs for 
chiral CECs is therefore highly likely, as MECs determined via achiral analysis provide no information 
on the EF and therefore the actual potency of the mixture cannot be determined. More investigation and 
further development of efficient toxicity tests would be highly beneficial to building up a 
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Enantioselective transformation 
of fluoxetine in water and its 
ecotoxicological relevance
María Jesús Andrés-Costa1,2, Kathryn Proctor2, Marco T. Sabatini2, Anthony P. Gee2, Simon E. 
Lewis2, Yolanda Pico1 & Barbara Kasprzyk-Hordern2
European legislation focusing on water quality is expected to broaden to encompass several 
pharmaceuticals as priority hazardous substances. This manuscript aims to challenge current regulatory 
approaches that do not recognize stereochemistry of chiral pharmaceuticals by testing the hypothesis 
that environmental transformation and effects of chiral pharmaceuticals are stereoselective. Our 
experiments revealed that, while degradation of chiral fluoxetine (FL) in river water occurs via non-
enantioselective photochemical and mildly-enantioselective microbial processes favoring the (R)-
enantiomer, a pronounced enantioselectivity favoring (S)-FL (leading to the formation of (S)-NFL 
(norfluoxetine)) is observed during activated sludge treatment. Toxicity tests proved strong enantiomer-
specific toxicity in the case of Tetrahymena thermophila, protozoa that are utilized during activated 
sludge treatment ((R)-FL is 30× more toxic than (S)-FL; (S)-NFL is 10× more toxic than (S)-FL). This is 
of paramount importance as preferential degradation of (S)-FL in activated sludge microcosms leads 
to the enrichment of FL with 30× more toxic (R)-FL and formation of 10× more toxic (S)-NFL. It is 
commonly assumed that a decreased concentration of FL leads to decreased biological impact. Our 
study proves that despite the overall decrease in FL concentration, accumulation of toxic (R)-FL and 
formation of toxic (S)-NFL leads to much higher than presumed toxicological effects.
Pharmaceuticals are a group of pollutants with growing evidence regarding their environmental impacts. 
European legislation focusing on water quality is expected to broaden to encompass several pharmaceuticals as 
priority hazardous substances. This manuscript challenges current regulatory approaches that do not recognize 
stereochemistry of chiral pharmaceuticals. Fluoxetine (FL, known as Prozac) is used here as an example.
FL is a diphenhydramine derivative and selective serotonin reuptake inhibitor (SSRI). It is used to treat a 
variety of mental health problems such as depression, panic, anxiety, or obsessive-compulsive symptoms. There 
was a 165% increase in the prescribing of antidepressant drugs in England between 1998 and 2012 (an average of 
7.2% per year)1. Indeed, FL is the fourth most prescribed antidepressant in England, and accounts for 11.3% of 
all antidepressant drug use2.
FL is extensively metabolized to norfluoxetine (NFL) and several other metabolites such as FL glucuronide, 
NFL glucuronide, para-trifluoromethylphenol and hippuric acid. The principal metabolite, NFL, is formed by 
N-demethylation of FL. The potency and selectivity of NFL’s SSRI activity is similar to that of the parent drug. The 
elimination of FL accounts for 80% excreted in the urine (as 11.6% FL, 7.4% FL glucuronide, 6.8% NFL, 8.2% NFL 
glucuronide, >20% hippuric acid, 46% other) and approximately 15% excreted in the feces3.
Recent research studies have shown that most pharmaceuticals, including FL and NFL, enter the aquatic envi-
ronment via (un)treated communal wastewater. Both FL and NFL have been detected in wastewater and receiving 
waters at levels ranging from ng L−1 to μg L−1 4–14. Furthermore, they were found in the tissue of fish collected near 
municipal wastewater discharges. Both FL and NFL remain biochemically active in the environment and can have 
marked effects on the morphology, physiology, and behavior of different species6,10,15–18.
Despite some limited research on fate and effects of FL, there has been very little attention paid to the stereo-
chemistry of FL and its possible environmental impacts. FL has one chiral carbon in its structure and as a result 
it exists in two enantiomeric forms as (S)-FL and (R)-FL. Similarly, NFL exists in two enantiomeric forms as 
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(S)-NFL and (R)-NFL. Enantiomers of the same drug have identical physicochemical properties but may differ in 
their biological properties. Thus, chiral drugs can undergo stereoselective mechanisms controlling their fate such 
as distribution, metabolism and excretion, as these processes (due to stereoselective interactions of enantiomers 
with biological systems) usually favor one enantiomer over the other. This leads to process-dependent changes 
in the enantiomeric composition of chiral compounds9. Metabolism of FL was found to be enantioselective in 
humans, with the (R)-enantiomer being metabolized faster than (S)-enantiomer19. Additionally, due to different 
pharmacological activity, enantiomers of chiral drugs can differ in their biological actions, potency and toxicity20. 
Enantiomers of FL have similar potency as inhibitors of the serotonin reuptake pump in humans whereas enanti-
omers of NFL act differently, with (S)-NFL showing higher inhibition capacity21.
Ecotoxicity of FL (and other pharmaceuticals) is currently assessed for the racemate, as FL is marketed as a 
racemic mixture of two enantiomers. Environmental risk assessment (ERA) approaches need to be re-evaluated 
as they are based on a simplistic assumption that FL present in the environment is racemic9. Indeed, limited 
research indicates that FL and NFL are present in the aqueous environment as non-racemic mixtures, i.e. 
enriched with one enantiomer5,22–26. Furthermore, FL was found to undergo enantioselective transformation 
during wastewater treatment5,27. In a recent study, Barclay et al. (2011) found a slight enrichment of FL and 
NFL with (S)-enantiomer in both raw and treated wastewater22. In contrast, MacLeod et al. (2007) reported that 
in their monitoring study FL was enriched with (R)-enantiomer in wastewater indicating faster degradation of 
(S)-enantiomer during wastewater treatment5,23. Ribeiro et al.28 did not observe enantioselectivity in fluoxetine’s 
biodegradation in activated sludge. However, the same group observed enantioselective degradation favouring 
(R)-FL by Labrys portucalensis strain F1129.
FL is often used as a model compound for assessing SSRI impact on aquatic organisms such as zebraf-
ish, Japanese medaka, goldfish, gulf toadfish, rainbow trout, fathead minnows and polychaete worms 
(Capitella teleta)30–36. FL was reported as toxic at low concentrations to several aquatic species30,37–39 but 
enantiomer-dependent toxicity was not considered. In fact, FL was proposed as one of 10 pharmaceuticals poten-
tially dangerous for the environment5. Enantioselective toxicity of FL was demonstrated for Primephales prome-
las and Tetrahymena thermophila, where (S)-FL was found to be more toxic than its respective enantiomer34,38. 
On the other hand (R)-FL was considered more harmful to Pseudokirchneriella subcapitata38. To the authors’ 
knowledge, there are no published reports on NFL toxicity to aquatic organisms at enantiomeric level. NFL was 
reported to be more active in humans than the parent compound40. Fuller et al.21 determined that enantiomers of 
NFL have markedly different potencies as inhibitors of the uptake of serotonin with (S)-NFL being more potent 
than the (R)-enantiomer in rats. It is therefore expected that NFL’s ecotoxicity to aquatic organisms might also be 
enantiomer-dependent.
The above discussion clearly indicates that current ERA approaches that do not recognize stereochemistry of 
chiral pharmaceuticals are inaccurate and could lead to incorrect conclusions being drawn regarding the ecotox-
icological effects of chiral drugs. The limited work in the area of stereochemistry-induced fate and effects of FL 
(and pharmaceuticals in general) is mainly due to lack of enantioselective analytical methods as well as availabil-
ity of (affordable) enantiomerically pure analytical standards. Such analytical methods and affordable enantiom-
erically pure standards are essential to gather accurate data needed for comprehensive ERA of these compounds.
The overarching aim of this study was to verify, for the first time, enantiomer-dependent fate and ecotoxico-
logical effects of FL and its main metabolite NFL in the aquatic environment. To achieve the aim, the key compo-
nents of this study were:
 i) To synthesize single enantiomers of FL and NFL.
 ii) To develop an analytical method for the detection and quantification of enantiomers of FL and NFL utiliz-
ing chiral liquid chromatography coupled with tandem mass spectrometry.
 iii) To undertake, for the first time, mechanistic study of the degradation of FL and NFL formation in con-
trolled river water and activated sludge simulating microcosm experiments.
 iv) To verify, for the first time, enantiomer-specific toxicity of FL and NFL in aquatic species.
Results
Synthesis of enantiomerically pure FL and NFL enantiomers. Lack of commercially available and 
affordable enantiomerically pure standards is the key factor hindering progress in the understanding of bio-phys-
icochemical processes governing the fate and effects of chiral pharmaceuticals and the resulting environmen-
tal risks. To overcome this limitation and to enable toxicity studies on single-enantiomer drugs, we propose a 
conceptually straightforward approach. For any given drug of interest, our approach relies on taking a known 
chemical synthesis of the racemic form (for example, from the patent literature), and carrying out the same pro-
cedure, yet employing a single enantiomer of starting material. This removes the need to develop new synthetic 
procedures and allows for the rapid and cost-effective production of single enantiomer drug substance on a scale 
sufficient to enable toxicity studies. Careful choice must be given to the selection of the most appropriate literature 
synthesis, since the concept is not universally applicable – in some instances, a synthetic procedure might induce 
unwanted racemisation of one of the synthetic intermediates en route to the final drug substance. Nevertheless, in 
the case of FL and NFL, we have established a synthetic protocol that allows access to single enantiomers of NFL 
and FL, in just 3 or 4 synthetic steps, respectively. The single enantiomer starting material required (1) is com-
mercially available in both the (R) and (S) forms (99% e.e.), and the cost is not prohibitive. Our protocol draws on 
multiple literature sources, as shown in Fig. 1. Thus, from single enantiomer starting material 1, as per one of the 
original patents on fluoxetine41, reaction with potassium phthalimide affords single enantiomer 2, which in turn 
undergoes hydrazinolysis to give single enantiomer 3. Primary amine 3 can then be employed in a SNAr reaction 
to give single enantiomer NFL. Various synthetic procedures are reported for the conversion of NFL into FL; we 
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opted to employ carbamate formation followed by hydride reduction to convert a proportion of our synthesized 
NFL into FL42. By the above means we were able rapidly to access the required quantities of single enantiomer 
material to carry out the studies detailed below.
Enantioseparation of FL and NFL enantiomers with chiral LC-MS/MS. Unavailability of analytical 
methods allowing for enantiomeric separations of trace concentrations of chiral drugs in complex environmen-
tal matrices is a limiting factor hindering progress in fundamental understanding of their fate and effects. We 
therefore developed a robust, sensitive and selective method utilizing chiral liquid chromatography coupled with 
tandem mass spectrometry for enantiomeric separation of FL and NFL. We used Astec Chirobiotic V (CBV) col-
umn with mobile phase (pH 6.5, 0.06 mL min−1, 25 °C) composed of 70% of ethanol (EtOH), 30% of ultra-pure 
water (HQ water), 4 mM of ammonium acetate (AAC) and 0.005% of formic acid (FA) under isocratic conditions 
to achieve baseline separation of enantiomeric pairs (Fig. 2, Rs (resolution of enantiomers) = 1.41 and 1.00 for 
FL and NFL‚ respectively). All conditions tested and results can be found in Table S1 in the supplementary infor-
mation section. The method showed good linearity (R2 > 0.99) for all four enantiomers within the studied range 
(0.5–100 µg L−1). Method detection and quantification limits (MDLs and MQLs) for river water matrices ranged 
from 1.2 to 1.3 ng L−1 and from 4.6 to 5.1 ng L−1, respectively. In the case of activated sludge matrices, MDLs 
ranged from 0.4 to 0.8 ng L−1 and MQLs ranged from 1.7 to 3.1 ng L−1 (Table S2). The accuracy and precision 
were within ±20% (Table S3). Very good recoveries accounting for >67% were observed in the case of all four 
enantiomers in all studied matrices. Matrix effect (ME) accounted for <15.6%.
Figure 1. Synthesis of single enantiomers of NFL and FL. Reagents and conditions: (a) 1.2 equiv. potassium 
phthalimide, DMF, 90 °C, 2 h, 88%. (b) 3 equiv. NH2NH2.H2O, ethanol (EtOH), reflux, 2 h, 85%. (c) 1.5 equiv. 
sodium hydride, 1 equiv. p-fluorobenzotrifluoride, DMSO, 1 h, 90 °C, 71%. (d) 1.1 equiv. methyl chloroformate, 
5 equiv potassium carbonate, CH2Cl2/H2O 1:2, 20 min, room temp., then 2 equiv. lithium aluminium hydride, 
THF, 2 h, reflux, 80%.
Figure 2. Chromatographic separation of enantiomers of FL and NFL.
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Synthesized enantiomerically pure FL and developed chiral LC-MS/MS method were used to verify transfor-
mation of FL in river and activated sludge simulating microcosms and their ecoxoticological impacts.
Transformation of FL and NFL in river and activated sludge simulating microcosms. River water 
microcosms. The river simulating microcosms revealed that degradation of FL takes place via both microbial 
and photochemical processes (Fig. 3 and Table S4). Photolysis is considered to be the most important phenome-
non contributing to the degradation of FL, as 74.5% (S)-FL and 79.2% (R)-FL of FL were removed in light abiotic 
conditions (LAR). This process, as expected, was found not to be enantioselective. Microbial processes resulted 
in mild enantioselectivity towards (R)-enantiomer and led to the removal of 60.4% of (S)-FL and 67.9% of (R)-FL 
at dark biotic conditions (DBR). As expected, the light biotic reactor (LBR) utilizing both photochemical and 
microbial processes led to the highest removal of FL: 98.4% of (S)-FL and 96.7% of (R)-FL. Dark abiotic condi-
tions (DAR) did not lead to any significant removal of FL. Traces of NFL were observed in both abiotic and biotic 
conditions (Figure S1). This indicates that degradation of FL leading to NFL formation takes place as a result of 
both photochemical and microbial processes.
Activated sludge microcosm. Transformation of FL in activated sludge simulating microcosms was studied at two 
concentration levels: 10 and 100 µg L−1 of racemic FL (Fig. 4 and Table S5). In both cases a significant decrease in 
the concentration of (S)-FL and (R)-FL was observed. In the microcosm spiked with 10 µg L−1 rapid removal of 
FL occurred during the first 30 minutes (50% degradation). This process was not stereoselective (enantiomeric 
fraction (EF) 0.5) and did not lead to expected formation of NFL. It is therefore postulated that this high rapid 
removal of FL from the aqueous phase during the first 30 min of the experiment is due to its sorption to sus-
pended particulate matter. Further removal of FL in 10 µg L−1 reactor was much slower and led to its stereoselec-
tive transformation favoring (S)-FL (EF < 0.3) and leading to the formation of NFL enriched with (S)-enantiomer 
(EF > 0.7). As the activated sludge simulating microcosms were undertaken in the dark, it is postulated that 
observed stereoselective transformation of FL and stereoselective formation of NFL is due to the prevalence of 
stereoselective microbial metabolic processes in studied bioreactors. Molar percentage yield of NFL formation 
denoted: 10.7% and 6.2% for (S)-FL and (R)-FL‚ respectively.
Similar observations were recorded in the microcosm spiked with 100 µg L−1 of FL. However, the effect of 
sorption was not observed. This is probably due to much higher initial FL load in 100 µg L−1 bioreactor not allow-
ing for the change to be recorded. Stereoselective microbial processes resulted in 60% transformation of FL with 
Figure 3. Degradation of FL in river water simulating microcosms under dark abiotic (DAR), dark biotic 
(DBR), light abiotic (LAR) and light biotic (LBR) conditions (concentrations are represented by bars, 
enantiomeric fractions are represented by symbols).
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twice as high preference towards (S)-FL (EF < 0.3, 80% removal of (S)-FL and only 38% removal of (R)-FL) and 
formation of NFL enriched with (S)-enantiomer (EF > 0.7). Molar percentage yield of NFL formation denoted: 
11.7% and 7.4% for (S)-FL and (R)-FL. This is in agreement with results obtained for 10 µg L−1 bioreactor. 
Interestingly in both bioreactors, long lag phases (3 h and 2 h in the case of 10 µg L−1 and 100 µg L−1 FL bioreactor‚ 
respectively) were observed.
Kinetic studies (Table 1) confirmed low biodegradation of FL and the more recalcitrant nature of (R)-FL. kbiol 
and t1/2biol of (S)-FL transformation were 0.04 LgSS−1h−1 and 19 h respectively in both 10 and 100 µg L−1 bioreac-
tors. kbiol and t1/2biol of (R)-FL transformation were much lower and denoted 0.01 LgSS−1h−1 and 68 h respectively 
in 100 µg L−1 bioreactors. Due to the lack of degradation of (R)-FL in 10 µg L−1 bioreactor, no kinetic studies could 
be undertaken.
Figure 4. Degradation of FL and formation of NFL in activated sludge simulating microcosms under dark 
biotic (DBR) conditions (concentrations are represented by bars, enantiomeric fractions are represented by 
symbols).
R2 SS [g L−1] k1 [h−1] t1/2 [h] kbiol [LgSS−1h−1] t1/2biol [h]
10 µg L−1
(S)-FL y = −0.0715x - 0.0584 0.8696 2.0 0.07 9.69 0.04 18.9
(R)-FL No degradation   n/a  n/a  n/a  n/a  n/a  n/a
100 µg L−1
(S)-FL y = −0.0721x - 0.0667 0.8216 2.0 0.07 9.61 0.04 19.4
(R)-FL y = −0.0206x - 0.0274 0.8202 2.0 0.02 33.6 0.01 68.0
Table 1. Degradation pseudo-first order rate constants (k1 and kbiol) in single-compound activated sludge 
simulating microcosm. n/a - not calculated due to no degradation of (R)-(−)-enantiomer.
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The results above indicate that longer sludge retention times might be needed during wastewater treatment 
in order to facilitate degradation of FL. However, it should be noted that these processes are likely to be stereose-
lective and could potentially lead to enrichment of FL with the more potent enantiomer, as well as formation of 
biologically active metabolites; this is despite the nominal decrease in concentration levels of FL.
Ecotoxicity of FL and NFL. Enantiomer-dependent toxicity of FL and NFL was evaluated for two aquatic 
organisms: Daphnia magna and Tetrahymena thermophila. EC5048h for FL enantiomers towards D. magna was 
3.6 mg L−1 and 4.1 mg L−1 for (S)-FL and (R)-FL respectively (Table 2). EC5048h for NFL towards D. magna 
denoted 2.8 mg L−1 and 2.9 mg L−1 for (S)-NFL and (R)-NFL (raw data are shown in Table S6). The results indicate 
a noticeable difference between the toxicity of FL and NFL, NFL being more toxic than FL, but no significant 
enantioselectivity was observed for studied enantiomeric pairs. In contrast, EC5024h for FL enantiomers towards 
T. thermophila was strongly enantiomer dependent and denoted 35.3 mg L−1 and 1.3 mg L−1 for (S)-FL and 
(R)-FL‚ respectively. These results contradict those published by De Andrés et al.38 as within that study it was 
observed that the (S)-enantiomer was more toxic with an EC5024h of  3.2 mg L−1 compared to the (R)-enantiomer 
with an EC5024h  30.5 mg L−1. To confirm the validity of measurement undertaken in this work, the stock solutions 
and the test cells were analyzed with the chiral-LC-MS/MS method. The results showed that the changes in the 
concentrations of the toxicants were minimal during the test, however they support the use of the correct enanti-
omer in this test. This was further confirmed by the use of enantiomerically pure analytical standards to confirm 
the retention time of each enantiomer (Figure S2).
Similarly to FL, EC5024h for NFL enantiomers towards T. thermophila was strongly enantiomer dependent. 
The EC5024h for NFL denoted 3.8 mg L−1 and 5.8 mg L−1 for (S)-NFL and (R)-NFL‚ respectively. Unlike FL, the 
(S)-NFL is more toxic than (R)-NFL. This is of paramount importance as preferential degradation of less toxic 
(S)-FL in activated sludge microcosms leads to the formation (and accumulation) of more toxic (S)-NFL. This is 
also an important consideration as T. thermophila is part of the microbial community of activated sludge (EC5024h 
data for T. thermophila is shown in Fig. 5 and Tables S7–S14).
Discussion
This report is, to the authors’ knowledge, the first to study transformation of FL in environment simulating micro-
cosms combined with ecotoxicological effects. The research reported in this manuscript tested and validated the 
hypothesis that degradation of FL, and formation of its main metabolite NFL, are enantioselective and biological 
in nature, and that their toxicity is enantiomer-dependent.




(S)- (R)- (S)- (R)-
P. promelas
LOEC7d
-survival 0.10 0.17 n/a n/a 34
-growth 0.05 0.17 n/a n/a
-feeding 0.05 0.17 n/a n/a
LC5048h -survival 0.22 0.21 n/a n/a 34
D. magna
LOEC21d
-immobilization 0.44 0.43 n/a n/a 34
-reproduction 0.44 0.43 n/a n/a
-grazing 0.20 none n/a n/a
LC5048h -immobilization 6.9 8.1 n/a n/a 38
EC5048h -immobilization 3.6 4.1 2.8 2.9 (this study)
T. thermophila
EC5024h -growth 3.2 30.5 n/a n/a 38
EC5024h -growth 35.2 1.3 3.8 5.8 (this study)
Table 2. Ecotoxicity of FL and its metabolite NFL (n/a – not analysed).
Figure 5. EC5024h for the T. thermophila test. See Tables S7–14 for CV% of individual tests.
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The river simulating microcosms revealed that degradation of FL takes place via both microbial and pho-
tochemical processes. Non-stereoselective photolysis was observed to be the most important phenomenon 
contributing to the degradation of FL. Microbial processes resulted in only mild enantioselectivity towards the 
(R)-enantiomer. However, a pronounced stereoselectivity was observed during activated sludge simulating micro-
cosms. Microbial metabolic processes of FL during activated treatment process favored the (S)-enantiomer, which 
led to the enrichment of FL with the (R)-enantiomer. This is in contrast to metabolic processes in humans, which 
favor the (R)-enantiomer and lead to enrichment of FL in urine with the (S)-enantiomer19. The outcomes of 
human metabolism studies as well as full scale and microcosm wastewater treatment measurements indicate that 
enantiomeric signature of FL can change subject to composition and structure of microbial communities present 
in wastewater. Indeed in our full scale untreated wastewater study, FL was enriched with the (S)-enantiomer 
(EF 0.7)43. This confirms, yet again, complexity of environmental processes and reinforces the need for further 
comprehensive studies focusing on transformation of chiral pollutants in the environment.
Toxicity tests showed that while there is no significant enantioselectivity in the toxic response from D. magna 
to both FL and NFL, a strong enantiomer-dependent toxicity is observed in the case of T. thermophila ((R)-FL 
30× higher than (S)-FL and (S)-NFL 10× higher than (S)-FL).
The above results indicate that traditional toxicological studies that do not recognize the importance of ste-
reochemistry might not reveal the true toxicological impact resulting from stereochemistry of chiral drugs. Our 
research indicates that (S)-FL is preferentially degraded in activated sludge microcosms. This is expected, as 
(S)-FL is the least toxic to protozoa (organisms that are known to be key contributors to activated sludge treat-
ment process) out of all four FL/NFL enantiomers studied. Unfortunately, this also indicates that FL, due to pref-
erential metabolic degradation of (S)-FL, gets enriched with more toxic (R)-FL and leads to the formation of more 
toxic (S)-NFL. This accumulation of toxic (R)-FL and (S)-NFL will have detrimental effects on the performance 
of activated sludge treatment processes.
This study revealed that there are several, unaccounted for, underlying issues in both exposure and hazard 
assessment within ERA of chiral pharmaceuticals. One can assume that, if the stereochemistry of FL is not con-
sidered, decreased concentration of FL as a result of activated sludge treatment leads to decreased biological 
impact. Such an approach (as currently applied in ERA) can lead to false conclusions impacting environmental 
health. Our study proves that despite the overall decrease in FL concentration, accumulation of toxic (R)-FL and 
formation of toxic (S)-NFL in activated sludge will likely lead to higher toxicological effects, as observed in the 
case of protozoa. The European Medicines Agency guideline on the ERA of Medicinal Products for Human Use44 
and the EU Directive for ERA for Veterinary Medicinal Products45 recommend the estimation of exposure and 
the prediction of risk calculation for the whole parent compounds only i.e. as a racemate or a mixture of stereoi-
somers if distributed as such. Therefore, current ERA leads to under or overestimation of toxicity of chiral phar-
maceuticals and to incorrect ERA as chiral pharmaceuticals are present in the environment in their non-racemic 
forms and they show enantiomer-specific biological effects. We therefore recommend the adoption of a new 
strategy within ERA acknowledging stereochemistry of studied targets.
Methods
Chemicals and materials. HPLC-grade methanol (MeOH), EtOH, AAC, (99%), FA (98%) were purchased 
from Sigma Aldrich (Cambridge, UK). HQ water was supplied by a Milli-Q system (PURELAB, Elga, UK).
The reference standards, rac-FL and rac-NFL and the internal standard (IS) FL-d5 were purchased from LGC 
Standards (Teddington, UK). All standards and ISs were of the highest purity available (>97%). Structures, 
molecular formulae and molecular weights of target enantiomers are summarized in Table S15.
Stock solutions of the individual compounds were purchased in MeOH at a concentration of 1 mg mL−1 or 
0.1 mg mL−1 and stored in the dark at −16 °C. Working solutions were prepared by diluting stock solutions in 
mobile phase or MeOH on a daily basis and stored at 4 °C.
All glassware was deactivated with dimethyldichlorosilane (5% DMDCS in toluene, Sigma-Aldrich) to 
minimize sample loss through adsorption of basic analytes onto –OH sites present on the glass surface46. Oasis 
HLB (60 mg, 3 mL, Waters, UK) were used for solid phase extraction (SPE). HQ water, river water (collected in 
South-West England) and activated sludge (collected from a local wastewater treatment plant) were used for 
method development and validation.
Synthesis of FL and NFL enantiomers. This procedure employs 3-chloro-1-phenyl-1-propanol as start-
ing material and source of chirality. This was purchased from Sigma-Aldrich chemical company: (R)-enantiomer 
product #338419; (S)-enantiomer product #324612. Both were certified as having 99% enantiomeric excess. 
Experimental procedures are described for the (R)-enantiomer; identical procedures were carried out with the 
(S)-enantiomer of starting material to synthesize (S)-NFL and (S)-FL.
Step 1: (R)-3-phthalimido-1-phenylpropanol (2). At room temperature, to a stirring suspension of potassium 
phthalimide (3.93 g, 21.25 mmol) in dry dimethylformamide (DMF) (115 mL) was added (R)-3-chloro-1-phenyl-
1-propanol 1 (3.00 g, 17.65 mmol) in dry DMF (5 mL). The reaction mixture was heated to 90 °C and left to stir for 
2 hours, until completion was observed by thin layer chromatography (TLC.) To the cooled reaction mixture was 
added H2O (300 mL), and extracted with diethyl ether (2 × 300 mL). The combined organic extracts were washed 
with a saturated solution of LiCl (300 mL), brine (300 mL), dried over MgSO4 and filtered. The filtrate was concen-
trated in vacuo to give (R)-3-phthalimido-1-phenylpropanol 2 as a white powder (4.30 g, 88%); mp 78–79 °C; Rf 
0.36 (3:1 Petrol/ethyl acetate). δH (250 MHz, CDCl3) 7.86–7.83 (2 H, m, ArH), 7.74–7.71 (2 H, m, ArH), 7.36–7.21 
(5 H, m, ArH), 4.69 (1 H, t, J 6.5 Hz, CHOH), 3.91 (2 H, t, J 6.5 Hz, CH2N), 2.13–2.05 (2 H, m, CH2CHOH); δC 
(300 MHz, CDCl3) 168.8, 143.5, 134.0, 131.9, 128.4, 127.4, 125.6, 123.3, 71.2, 37.6, 34.8 (Figure S3).
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Step 2: (R)-3-amino-1-phenyl-1-propanol (3). At room temperature, to a stirred solution of (R)-3-phthalimido-
1-phenylpropanol 2 (4.10 g, 14.5 mmol) in EtOH (90 mL) was added hydrazine hydrate (2.09 mL, 43.5 mmol). 
The reaction mixture was stirred for 1 hour and then heated to reflux for 2 hours. The reaction mixture became 
thick and cloudy upon heating, and when cooled, precipitate was filtered off. Recovered filtrate was concen-
trated under reduced pressure, diluted with dichloromethane (DCM) (10 mL) and filtered, washed with DCM 
(2 × 5 mL). The recovered filtrate was concentrated in vacuo to give the title compound (R)-3-amino-1-phenyl-
1-propanol 3 as a brown oil (1.85 g, 85%); Rf 0.09 (100:10:1 DCM/MeOH/ Et3N). δH (300 MHz, dimethylsulfoxide 
(DMSO-d6)) 7.34–7.27 (4 H, m, ArH), 7.24–7.17 (1 H, m, ArH), 4.66 (1 H, dd, J 7.0, 6.0 Hz Hz CHOH), 2.71–2.60 
(2 H, m, CH2N), 1.69–1.62 (2 H, m, CH2CHOH); δC (75 MHz, DMSO-d6) 146.6, 128.0, 126.6, 125.7, 71.3, 42.2, 
38.9 (Figure S4).
Step 3: (R)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine•HCl [(R)-NFL hydrochloride salt]. At 
0 °C, to a stirred suspension of sodium hydride (60% in oil, 0.73 g, 18.34 mmol) in DMSO (3.0 mL) was added 
(R)-3-amino-1-phenyl-1-propanol 3 (1.85 g, 12.23 mmol) in DMSO (1.0 mL). The reaction mixture was stirred 
at 55 °C for 30 min and 4-fluorobenzotrifluoride (3.01 g, 18.34 mmol) in 1.85 mL DMSO was added dropwise. 
The resulting mixture was heated for 1 hour at 90 °C, until completion was observed by TLC. The mixture was 
cooled to 0 °C, and diluted with aqueous 1 N NaOH (20 mL). Toluene was used to extract the product (3 × 20 mL), 
and combined organic extracts were dried over MgSO4 and filtered. The crude product was purified by column 
chromatography (100:0:1 to 100:6:1 DCM/MeOH/Et3N) to give (R)-3-phenyl-3-[4-(trifluoromethyl)phenox-
y]-1-propanamine [(R)-NFL] as a brown oil (2.10 g, 58%). Product (1.0 g, 3.39 mmol) was dissolved in 4 M HCl in 
dioxane (10.0 mL, 40 mmol), and left to stir for 2 hours. Reaction mixture was concentrated in vacuo, and recrys-
tallized (50 mL of 3:2 diethyl ether/hexane) to give (R)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine 
hydrochloride [(R)-NFL•HCl] as a white solid (0.80 g, 71%); mp 128–129 °C; Rf 0.04; δH (250 MHz, CDCl3) 8.45 
(3 H, br s, NH3) 7.39 (2 H, d, J 8.5 Hz, ArH), 7.27–7.32 (5 H, m, ArH), 6.91 (2 H, d, J 8.5 Hz, ArH), 5.42 (1 H, dd, 
J 7.5, 4.5 Hz, CHO), 3.18 (2 H, app t, J 5.5 Hz, CH2CH2NH), 2.47–2.27 (2 H, m, CH2N); δC (300 MHz, CDCl3): 
159.5, 139.0, 129.1, 128.4, 126.7 (q, 3JCF 3.8 Hz), 125.7, 124.2 (q, 1JCF 270 Hz), 123.3 (q, 2JCF 32.6 Hz), 115.9, 77.4, 
36.9, 36.0; νmax (film) 3385 (N-H), 2891 (C-H), 2015, 1613 cm−1; [α]D + 14.0° (c 1, CHCl3); for (S)-enantiomer: 
[α]D –15.0° (c 1, CHCl3) (Figure S5).
Step 4: (R)-N-Methyl-3-(4-trifluoromethylphenoxy)-3-phenylpropylamine [(R)-FL]. At room temperature, to a 
stirred solution of 3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine (R)-NFL (1.0 g, 3.38 mmol) and 
methyl chloroformate (0.29 mL, 3.72 mmol) in DCM (15.0 mL) was added aqueous K2CO3 (2.33 g, 16.89 mmol 
in 30 mL H2O). The reaction mixture was vigorously stirred for 20 minutes, until completion was observed 
by TLC, dyed with ninhydrin. The organic phase was separated and the aqueous phase extracted with DCM 
(2 × 30 mL). The combined organic extracts were dried over MgSO4 and filtered. The filtrate was concentrated 
in vacuo to yield intermediate carbamate as a pale yellow oil. At 0 °C, to a stirring suspension of LiAlH4 (0.25 g, 
6.59 mmol) in dry tetrahydrofuran (THF) (15.0 mL) was added dropwise a solution of the intermediate car-
bamate in dry THF (5.0 mL). The reaction mixture was gradually heated to reflux for 2 hours. To the cooled 
mixture were cautiously added 0.25 mL of water, followed by 0.25 mL of 2 N NaOH, and 0.75 mL of water, in 
that order. The solution was dried over MgSO4 and filtered. The filtrate was concentrated over reduced pressure, 
and the crude product was purified by column chromatography (100:0:1 to 100:1:1 EtOAc/MeOH/Et3N) to give 
(R)-N-Methyl-3-(4-trifluoromethylphenoxy)-3-phenylpropylamine [(R)-FL] as a pale yellow oil (0.84 g, 80%); Rf 
0.09 (100:1:1 EtOAc/MeOH/Et3N); δH (300 MHz, CDCl3) 7.43 (2 H, d, J 8.5 Hz, ArH), 7.34–7.23 (5 H, m, ArH), 
6.90 (2 H, d, J 8.5 Hz, ArH), 5.31 (1 H, dd, J 8.0, 4.5 Hz, CHO), 2.82–2.66 (2 H, m, CH2CH2NH), 2.44 (3 H, s, 
CH3), 2.27–2.16 (1 H, m, CHHN), 2.08–1.97 (1 H, m, CHHN), 1.69 (1 H, br. s, NH); δC (300 MHz, CDCl3) 160.5, 
141.0, 128.8, 127.8, 126.7 (q, 3JCF 3.8 Hz), 125.7, 115.7, 78.5, 48.2, 38.6, 36.4 (signals for -CF3 and C-CF3 were not 
observed); νmax (film) 3033 (ArC-H), 2937 (ArC-H), 2846 (C-H), 2796, 1614 cm−1; [α]D + 3.0° (c 1, CHCl3); for 
(S)-enantiomer: [α]D – 3.0° (c 1, CHCl3) (Figure S6).
Microcosm bioreactors. River water simulating microcosms. River water microcosm experiments were 
conducted in light (L) and dark (D) conditions, and biotic (B) or abiotic (A) conditions with or without sodium 
azide (an inhibitor of microbial processes) respectively as shown in Fig. 6. Four microcosm bioreactors were 
investigated in duplicate thus eight autoclaved conical flasks were used as bioreactors in microcosm experiments. 
Each bioreactor was filled with 2 L of river water collected from a local river and spiked with racemic standard of 
S/R (±) FL to obtain a final concentration of 1 µg L−1. Abiotic bioreactors were spiked with sodium azide at a con-
centration of 1 g L−1 to inhibit biotic processes. Two replicates of biotic and abiotic bioreactors were exposed to 
light and another two replicates of each bioreactor were kept in the dark. Light conditions were simulated with an 
Osram 400 W HQI BT daylight lamp during 8 h each day. Average photon flux measured at the level of the bottle 
base was 395 µmol m−2 s−1. Dark conditions were simulated covering up the flask with foil. Magnetic stirrers were 
used to ensure good mixing. The experiment was carried out during 16 days. Samples (50 mL each) were collected 
every day, with the exception of weekends. IS was added to each sample (to obtain a final concentration of 100 ng 
mL−1). Samples were then frozen to prevent compound degradation until their analysis.
Dissolved oxygen (DO), pH and temperature (T) were analyzed during sampling period and total suspended 
solids (TSS), NO2−, NH4, and chemical oxygen demand (COD) were analyzed at the beginning of the experimen-
tal period (Table S16).
Activated sludge simulating microcosms. Activated sludge microcosm experiments were conducted in the dark 
and aerobic conditions. Three microcosm bioreactors were investigated in duplicate. They were filled with 2 L of 
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fresh activated sludge collected from a local wastewater treatment plant. One bioreactor remained un-spiked and 
the other two bioreactors were spiked with a racemic standard of S/R (±) FL to obtain concentrations of either 
10 or 100 µg L−1. Dark conditions were simulated by covering up the flask with foil. Aerobic conditions were 
obtained using air from BOC air cylinder and a thorough mixing was maintained using magnetic stirrers. The 
experiment was 24 hours long. Samples (100 mL each) were taken at the following time intervals: 0, 0.5, 1, 1.5, 2, 
3, 5, 8, 12 and 24 h. After sample collection, IS was added to each sample to obtain a final concentration of 100 
ng mL−1. Collected samples were subsequently frozen until their analysis to prevent degradation of compounds.
DO, pH, T and TOC, were analyzed throughout the experimental period and TSS, NO3−, NO2−, NH4 and 
COD were analyzed at the beginning of the experiment at t = 0 min (Table S17).
Kinetics – activated sludge simulating microcosms. The compounds studied are characterized as having low vol-
atility and therefore volatilization was not considered as a potential removal pathway in studied microcosms. 
Photodegradation was also not considered (not relevant) under tested activated sludge conditions. Therefore 
the two important degradation mechanisms to consider were biodegradation and sorption to sludge. FL was 
reported to have high sorption affinity towards particulate matter47. However, in this study, sorption equilibrium 
was assumed and therefore sorption could be considered negligible. This is because sorption is assumed to be fast 
when compared to biological degradation48. Section “Activated sludge microcosm” confirms this hypothesis as FL 
in activated sludge microcosms remained constant in FL 100 µg L−1 microcosm during the first 2 h of the exper-
iment. In the case of FL 10 µg L−1, a significant drop of FL concentration took place during the first 0.5 h (likely 
due to sorption) and then remained stable during the first 3 h of the experiment, showing a significant lag phase.
Several reports utilized pseudo-first-order kinetics for degradation of micropollutants in activated sludge 
reactors48–50. Indeed when applying pseudo-first order kinetics (OECD 303) in this work, ln(Ce/Ci) plotted as a 
function of time yielded a straight line (R2 > 0.9). Pseudo-first order biodegradation rate k1 [L g−1h−1] (normal-
ised for concentration of suspended solids) was therefore calculated using the following formula (equation (1)):







where: t = aeration time (24 h), Ce = concentration at time point t (µg L−1), Ci = initial concentration (µg L−1), 
SS = concentration of activated sludge solids (g L−1).
Analysis. Solid phase extraction. Samples (50 mL of river water and 100 mL of activated sludge) were fil-
tered using Whatman GF/F 0.7 µm glass fiber filter and passed through Oasis HLB cartridges (60 mg, 3 mL) 
pre-conditioned with 2 mL of MeOH and equilibrated with 2 mL of HQ water at a rate of 8 mL min−1. Samples 
were passed through the HLB cartridge at a rate of 8 mL min−1 and then dried under the vacuum for 30 min to 
dry out residual water. Analytes were eluted with 4 mL of MeOH at a rate of <1 mL min−1. Extracts were then 
evaporated to dryness with TurboVap evaporator (Caliper, UK, 40 °C, N2, <5 psi) and reconstituted in 0.5 mL of 
mobile phase. All samples were filtered through 0.2 µm PTFE filters (Whatman, Puradisc, 13 mm) and transferred 
to popylpropylene 0.3 mL capacity vials (Waters, UK).
SPE recoveries of FL and NFL in HQ water, river water and activated sludge were calculated as the ratio of the 
analyte peak area in the sample extract spiked with analytes before extraction (the peak area of analyte un-spiked 
sample extract was subtracted) to the analyte peak area in the non-extracted standard solution.
ME was calculated for each chiral drug as a percentage decrease or increase in signal intensity in a sample 





Figure 6. Scheme of river and activated sludge simulating microcosms.
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where Δmatrix is the standard calibration graph slope in different matrix (river water or active sludge) and ΔHQ 
water is the standard calibration graph slope in HQ water.
Chiral-LC-MS/MS method. Chromatographic analysis was performed using an Acquity UPLC system (Waters, 
Manchester, UK) consisting of Acquity UPLC binary solvent manager and Acquity UPLC sample manager. To 
achieve suitable separation of FL and NFL and their two stereoisomers, two chiral columns, namely Chiralpak 
CBH (10 cm × 2.0 mm, 5 μm particle size) and Astec CBV (25 cm × 2.1 mm, 5 μm particle size) were screened.
Several mobile phases were tested in order to obtain chiral separation of FL and NFL using LC and to main-
tain satisfactory electrospray ionization (ESI) performance in the positive ionization mode. MeOH, EtOH and 
HQ water were used at different concentrations as the mobile phase solvents. Among the mobile phase additives, 
different concentrations of AAC (1, 4 and 10 mM), MeOH (85, 80 and 70%) and EtOH (70 and 80%) were tested 
to maximize the Rs of FL and NFL.
The composition of the mobile phase was optimized to enhance the chromatographic efficiency and resolution 












where trE1 and trE2 are the retention times of the first and the second eluted enantiomers, respectively, and WE1 
and WE2 are the widths of these responses at the base peak.
The best enantiomeric separation of the studied drugs was achieved with a mobile phase (pH 6.5) composed 
of 70% of EtOH, 30% HQ water, 4 mM of AAC and 0.005% of FA using an Astec CBV column. The separation of 
enantiomers of chiral pharmaceuticals was undertaken under isocratic conditions, with an injection volume of 
20 µL. The column was kept at 25 °C and the temperature in the sample manager was kept at 4 °C. The flow rate 
was 0.06 mL min−1, which gave an initial pressure of ~850 psi.
Identification and quantification of FL and NFL was undertaken with an Acquity Xevo TQD (Waters, 
Manchester, UK), a triple quadrupole MS equipped with an ESI source. The analyses were performed in pos-
itive mode with a capillary voltage of 3 kV, a source temperature of 150 °C and a desolvation temperature of 
250 °C. A cone gas flow of 50 L h−1 and desolvation gas flow of 450 L h−1 were used. Nitrogen, used as a nebulising 
and desolvation gas, was provided by a high purity nitrogen generator (Peak Scientific Instruments Ltd., UK). 
Argon (99.99%) was used as a collision gas. The mass spectrometer was operated in multiple reaction monitor-
ing (MRM) mode, measuring the fragmentation of the protonated pseudo-molecular ions of each compound. 
A dwell time of 20 ms per ion pair was optimized to maintain high sensitivity of the analysis. MassLynx v4.1 
(Waters, UK) software was used to collect and analyze the obtained data.
Quantifier and qualifier transitions were optimized for each compound based on the most intense signal. 
Specific parameters such as collision energy (CE) and cone voltage (CV) were optimized for FL, NFL and FL-d5 
separately in a continuous flow mode through direct injection of standard solution at a concentration of 50 µg L−1 
into the stream of the mobile phase. FL presents a precursor ion [M + H]+ m/z of 310.3 and a product ion of m/z 
44.2 (quantifier transition) with a CV of 34 and CE of 10 and m/z 148.2 (qualifier transition) with a CV of 25 
and CE of 8. NFL presents a precursor ion [M + H]+ m/z 298.4 and a corresponding product ions at m/z 134.1 
(quantifier transition) with a CV of 17 and CE of 7 and m/z 30 (qualifier transition) with a CV of 17 and CE of 7. 
FL-d5 presents a precursor ion [M − H]+ m/z 315.2 and a corresponding product ions at m/z 136.2 (quantifier 
transition) with a CV of 26 and CE of 71 and m/z 20.
Method validation parameters. A 10-point multi-component IS calibration curve was applied for quan-
tification of FL and NFL enantiomers. All instrumental and method validation parameters such as linearity and 
range, accuracy, precision, detection and quantification limits and calibration curve were determined for HQ 
water, river water and activated sludge spiked with known concentrations of chiral compounds.
Linearity and range of the analytical procedure were undertaken by serial dilution of stock solution 
(10 µg mL−1). Accuracy of the method was evaluated at three concentration levels (5, 25 and 250 µg L−1) as a 
percentage deviation from known added quantity of each enantiomer in the sample. Intra-day and inter-day 
precision was expressed by the relative standard deviation (RSD) of 3 replicate measurements at three different 
concentration levels (5, 25 and 250 µg L−1) on the same and three different days.
HQ water standard solutions were used for instrumental detection limit (IDL) and instrumental quantifica-
tion limit (IQL). The IQL was estimated for the concentration of a compound that gave a signal-to-noise ratio of 
10:1. The IDL corresponded to the concentration that gave a signal-to-noise of 3:1.



















where IDLS/N is the instrumental detection limit (µg L−1), IQLS/N is the instrumental quantification limit (µg 
L−1), Rec is the absolute recovery of the analyte (%) at 25 µg L−1, and CF is the concentration factor, which in this 
method denotes 200 for active sludge and 100 for river water.
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( ) ( ) (6)
Where (S) and (R) are concentrations of the (S)- and (R)- enantiomers, respectively.
Toxicity tests. Daphnia magna acute 48 h immobilization assay. The D. magna bioassay was carried out 
using DaphtoxkitTM (Crustacean Toxicity Screening Test for Freshwater; Microbiotests, Nazareth, Belgium) fol-
lowing the standard operational procedure in accordance to the ISO standard 6341:2012 and the OECD 202 
guideline. Less than 24 h old daphnids were exposed to a series of concentrations of each enantiomer of FL and 
NFL. Six concentration levels (5 concentrations plus control, four replicate beakers for each concentrations, five 
individual for each beaker) were tested. The concentrations were from 0.5 to 50 mg L−1 for FL and NFL enantiom-
ers based on preliminary range finding tests. Each experiment was repeated in triplicate. After 48 h incubation, 
daphnids were observed and the mobile daphnids in each container were reported. The EC50 were calculated 
using 48 h results.
Tetrahymena thermophila chronic 24 h population growth assay. T. thermophila bioassay was carried out using 
Protoxkit F (Microbiotests, Ghent University, Belgium). The tests were performed in accordance with the proto-
cols provided by the manufacturer. Protoxkit F is a 24 h chronic population growth assay.
The tests were carried out in disposable spectrophotometric cells of 1 cm path-length, to enable the measure-
ment of the optical density (OD) at 440 nm. These measurements were taken at T0h and T24h, as well as two hour 
increments after initial 24 h incubation to monitor the change in turbidity of the sample. The reconstituted food 
substrate supplied with each test provides an initial high turbidity at T0h, which, in the control cells, drastically 
decreases over the next 24 h due to the uninhibited growth of the ciliate population. This change in OD over the 
time period is used to quantify the degree of inhibition and subsequent calculation of the EC50. Each concentra-
tion was repeated in duplicate.
The initial protozoa inoculum was prepared by measuring an aliquot of the live suspension using photometry 
absorbance at 440 nm and diluted to achieve a theoretical OD value of 0.040. Each test cell is inoculated with 
40 µL of this suspension, lending to an approximate population density of 100 protozoa per milliliter.
An initial study was carried out to find the approximate range of uninhibited growth and 100% inhibition for 
each enantiomer/compound across 7 orders of magnitude. The definitive toxicity test was carried out from the 
lowest concentration with a percentage population growth inhibition of 80–100% to the highest concentration 
with an inhibition between 0–20%. To ensure the test was valid the control must reach 60% OD decrease after 
24 h. In some tests this may take 2–4 h longer than 24 h, this is batch dependent and indicates a slightly slower 
growth of the ciliates, however this is still considered valid. In this case all the tests carried out were with the same 
batch which took 28 h to fulfill the validation criteria. The EC50 values were calculated using 28 h results.
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A B S T R A C T
Analysis of drugs and pharmaceuticals in the environment is typically performed with non-chiral chromato-
graphic techniques. The environmental risks posed by chiral compounds analysed in this way must therefore be
assumed to be independent of chirality, meaning that each enantiomer is equally potent in toxicity and long-
lived in stability. This manuscript examines the degradation of each of the four isomers of ephedrine in river
simulating microcosms and links this to toxicity data obtained by exposing three different organisms (D. magna,
P. subcapitata and T. thermophila) to each of the isomers individually. Microcosms showed that significant de-
gradation only occurred in biotic conditions and that only two isomers (1R,2S-(-)-ephedrine, 1S,2S-(+)-pseu-
doephedrine) degraded significantly over a period of fourteen days. This is concerning because at least one of the
non-degraded isomers (1S,2R-(+)-ephedrine) has been observed in wastewater effluent, which discharges di-
rectly into rivers, meaning these isomers could be persistent in the environment. We also observed formation of
1S,2R-(+)-ephedrine in single isomer 1R,2S-(-)-ephedrine river simulating microcosms. Human liver microsome
assays and mass spectrometry based data mining revealed that 1S,2R-(+)-ephedrine is not human derived but it
could be formed as a results of microbial metabolic processes. Across all three organisms tested the persistent
isomers (1S,2R-(+)-ephedrine and 1R,2R-(-)-pseudoephedrine) were more toxic than those that undergo de-
gradation; meaning that if these isomers are entering or formed in the environment they might represent a
potentially hazardous contaminant.
1. Introduction
Ephedrine has two chiral centres and can therefore exist in the form
of four stereoisomers:
1R,2S-(-)-ephedrine, 1S,2R-(+)-ephedrine, 1S,2S-(+)-pseudoephe-
drine and 1R,2R-(-)-pseudoephedrine (Table 1). However, only two
stereoisomers: 1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine are
believed to exist in natural sources such as ephedra. 1R,2S-(-)-ephedrine
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finds wide applications as a bronchodilator to treat bronchospasm as-
sociated with asthma, bronchitis and emphysema. It is also abused for
its stimulant properties. 1S,2S-(+)-pseudoephedrine is used as a de-
congestant [1].
Ephedrine has been detected previously in environmental matrices
[2,3] but with the usage of non-enantioselective methodology, which
did not allow for stereoisomeric profiling of ephedrine. As a result this
did not allow for an accurate assessment of the possible effects ephe-
drine might have on the environment. Stereoisomeric profiling is of
vital importance as different stereoisomers of ephedrine differ sig-
nificantly in potency, 1R,2S-(-)-ephedrine has much higher stimulant
properties than 1S,2S-(+)-pseudoephedrine, and possibly also in toxi-
city to certain organisms.
In our previous study [1], a verification of the enantiomer-specific
fate of ephedrine isomers was undertaken in a full scale WWTP and in
receiving waters. Of the two enantiomers of (± )-ephedrine only the
natural 1R,2S-(-)-ephedrine enantiomer was frequently detected.
However, ‘non-natural’ 1S,2R-(+)-ephedrine was detected at low levels
in only certain WWTPs throughout the sampling campaign, mainly in
treated wastewater, which might suggest stereoselective processes oc-
curring during treatment (e.g. chiral inversion although there is cur-
rently no experimental evidence to support this claim) leading to en-
richment of ephedrine with 1S,2R-(+)-enantiomer. It is worth noting
that the most prevalent formation of 1S,2R-(+)-ephedrine occurred
during spring/summer time due to potentially higher activity of mi-
croorganisms. The possibility of chiral inversion occurring during
treatment is of critical importance in understanding the fate of ephe-
drines in the environment and has to be studied further.
The verification of cumulative concentrations of ephedrines in raw
wastewater indicated that higher levels of these compounds were ob-
served during winter time (reaching 180 g/day in February in all stu-
died WWTPs) than during summer time (< 80 g/day in August) [1,4].
Interestingly, the analysis of diastereomeric fractions (DFs) of natural
1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine in raw wastewater
revealed that over the winter months ephedrines were enriched with
1S,2S-(+)-pseudoephedrine. This is possibly due to higher usage of
over-the-counter medications (containing 1S,2S-(+)-pseudoephedrine)
for the treatment of mild symptoms of cold. During the spring and
summer months a reverse situation was observed as ephedrine was
found to be enriched with a much more potent stimulant, 1R,2S-
(-)-ephedrine. This is a very important finding indicating that non-en-
antioselective measurement of ephedrines cannot be a reliable indicator
of actual potency of ephedrines in the environment. Higher cumulative
concentrations of ephedrines, which are enriched with less potent
1S,2S-(+)-pseudoephedrine (as was observed during winter time in this
study) might be of lower environmental significance than lower con-
centrations of ephedrines enriched with much more potent 1R,2S-
(-)-ephedrine (in summer in this study). Furthermore, wastewater
treatment resulted in almost all cases in further enrichment of ephe-
drines in the aqueous phase with more potent 1R,2S-(-)-ephedrine, with
an average increase in DFs from 0.25 in raw wastewater to 0.35 in
treated wastewater. Interestingly, the monitoring of receiving waters
revealed that ephedrine was enriched with 1R,2S-(-)-ephedrine at the
beginning of the course of the river and its DFs decreased over the
course of the river indicating an increase of 1S,2S-(+)-pseudoephedrine
(e.g. during the August sampling campaign DF of ephedrine denoted
0.93 ± 0.03 at the beginning of the river course and decreased to
0.33 ± 0.03 over 50 km downstream); a reverse situation to the one
observed during wastewater treatment. This might indicate that dif-
ferent microbial communities are responsible for transformation of
ephedrines during wastewater treatment and in the environment.
The absence of 1S,2R-(+)-ephedrine in influent wastewater sug-
gests that it is not formed by metabolism of ephedrine in humans.
However previous research into human metabolism of ephedrine was
not carried out in a stereoselective manner and is mostly limited to
1R,2S-(-)-ephedrine, rather than the more prescribed and en-
vironmentally abundant 1S,2S-(+)-pseudoephedrine. Metabolic data
indicates that 1R,2S-(-)-ephedrine is excreted primarily unchanged,
with norephedrine and other metabolites forming in smaller quantities
[5,6]. Whilst literature data was not available for the metabolism of
other ephedrine isomers in humans, metabolism of 1S,2R-(+)-ephe-
drine in rabbits and rabbit liver microsomes was observed to be slower
than metabolism of 1R,2S-(-)-ephedrine [7]. Whilst this shows that a
metabolic preference for the naturally occurring isomer, which may be
important for the formation of synthetic isomers in the environment,
rabbit metabolism of ephedrine is different from human metabolism
with only a small percentage of (± )-ephedrine excreted [7,8] or iso-
lated from rabbit liver microsomes [7].
Our previous research raises several questions undermining validity
of widely accepted environmental risk assessment procedures for
pharmacologically active compounds. This includes lack of apprecia-
tion of the phenomenon of chirality in environmental risk assessment
(ERA) for human and veterinary medicines [9,10]. This paper attempts
to answer the most urgent questions regarding the significance of ste-
reochemistry of pharmaceuticals (using stereoisomers of ephedrine as a
model example) in the context of their environmental fate and effects.
To the authors’ knowledge this is the first report tackling stereoselective
transformation of ephedrines in river simulating microcosms and as-
sociated enantiomer-specific ecotoxicity.
2. Experimental
2.1. Chemicals and materials
Reference standards: 1R,2S-(-)-ephedrine [(-)-Eph], 1S,2R-
(+)-ephedrine [(+)-Eph], 1S,2S-(+)-pseudoephedrine [(+)-Pse],
1R,2R-(-)-pseudoephedrine [(-)-Pse], 1R,2S-(-)-norephedrine
[(-)-NorEph] and 1S,2R-(+)-norephedrine [(+)-NorEph] were of
≥98% purity and were purchased from Sigma-Aldrich (Gillingham,
UK). Surrogate/internal standards (SS/IS): 1S,2R-(+)-ephedrine-d3
(CAS No. 285979-73-9) and R/S-(± )-methamphetamine-d5 (CAS No.
60124-88-1, were purchased from Sigma Aldrich (Gillingham, UK) and
Toronto Research Chemicals (Canada) respectively (Table 1). All sur-
rogate/internal standards were added to the samples before extraction
and were also used for the quantification of the analytes.
Table 1
Studied chemicals and their properties.
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2.2. Sample preparation and analysis
Chiral drugs were extracted from surface water (50mL) using Solid-
Phase Extraction (SPE) and Oasis HLB cartridges (Waters, UK). All
samples were spiked with 50 ng of each surrogate/internal standard
and filtered with GF/F filters. Analytes were then eluted with 4mL of
MeOH and the extracts evaporated to dryness under nitrogen with a
TurboVap evaporator (Caliper, UK, 40 °C, N2, 5–15 psi) and recon-
stituted in 0.5 mL of mobile phase.
Waters ACQUITY UPLC™ system (Waters, Manchester, UK) equipped
with Chiral-CBH column, 100×2mm, 5 μm (Chromtech, Congleton,
UK) and Chiral-CBH 10×2.0mm guard column (Chromtech,
Congleton, UK) were used for the analysis of enantiomers of ephedrines.
The separation of ephedrines was undertaken using two different
methods depending on the experiment. Samples from river simulating
microcosm experiments were analysed using the method described by
Evans et al. [11]. The elution order of the four ephedrine isomers was:
1S,2R-(+)-ephedrine, 1R,2R-(-)-pseudoephedrine, 1R,2S-(-)-ephedrine,
1S,2S-(+)-pseudoephedrine. Samples from human liver microsome
experiments were analysed using the method described by Castrignanò
et al. [12]. The elution order of the four ephedrine isomers was the
same as in the previous method, but with co-elution of 1R,2S-
(-)-ephedrine and 1R,2R-(-)-pseudoephedrine. This co-elution was not
considered a hindrance for the analysis undertaken in the human liver
microsome experiments. An injection volume of 20 μL was used in both
experiments. Method validation parameters for both methods are
summarised in Tables S1–4.
A XevoTQD (triple quadrupole) mass spectrometer (Waters,
Manchester, UK) equipped with an electrospray ionisation source (ESI)
was used for the quantification of ephedrines in both methods. The
analyses were performed in ESI positive mode using multiple-reaction
monitoring (MRM). Nitrogen was used as the nebulising gas at a flow
rate of 500 L/Hr, supplied by a high-purity nitrogen generator (Waters,
Manchester, UK). Argon (99.998%) was used as the collision gas and
supplied by BOC cylinder. MassLynx 4.1 (Waters, UK) and TargetLynx
(Waters, UK) software was used to collect and analyse the obtained
data.
The relative concentration of enantiomers of chiral drugs was ex-












( ) ( ) (1)
Where C-(+)-enantiomer and C-(-)-enantiomer are concentrations for
the (+) and (-) enantiomers of (± )-ephedrine or (± )-pseudoephe-
drine. EF equals 1 or 0 in the case of single enantiomer form and 0.5 in
the case of racemate.
A range of common inorganic ions (NO2−, NO3− and NH4+) and
chemical oxygen demand (COD) were quantified to assess environ-
mental conditions at the time of sampling and for experimental mon-
itoring. Commercially available testing kits (purchased from Merck)
were used and concentrations determined photochemically utilising a
Merck Spectroquant® Pharo 300 spectrophotometer. Collected surface
water was tested before spiking with ephedrine and again after a two
week testing period.
2.3. River simulating microcosm experiments
2.3.1. Mixed river simulating microcosms
Mixed compound microcosm experiments were conducted to in-
vestigate the fate of ephedrines at an enantiomeric level due to biode-
gradation, photodegradation and other abiotic processes including
sorption. River water for the microcosm bioreactor experiments was
collected from a large river in the South-West of the UK in November.
Degradation experiments were conducted with and without light, to
study photochemical and physical processes, e.g. hydrolysis and sorp-
tion, and with or without sodium azide, as an inhibitor to biotic pro-
cesses (see Fig. S1). Eight conical flasks, made of borosilicate 3.3 glass
with no visible light absorption and UV light cut-off at< 275 nm, were
used as bioreactors in all microcosm experiments and were autoclaved
prior to use. All were subsequently spiked with 1 μg/L each of 1S,2R-
(+)-ephedrine, 1R,2S-(-)-ephedrine, 1S,2S-(+)-pseudoephedrine,
1R,2R-(-)-pseudoephedrine, 1R,2S-(-)-norephedrine and 1S,2R-
(+)-norephedrine. Norephedrine was tested alongside ephedrines as it
is the primary metabolite of ephedrine [5]. Microcosms were then filled
with 2 L of unfiltered river water and four were spiked with sodium
azide to a concentration of 1 g/L to inhibit biotic processes (Abiotic
Reactors). Four bioreactors remained un-spiked in order to allow biotic
processes to occur (Biotic Reactors). Two biotic and two abiotic reactors
were then wrapped in aluminium foil (Dark Reactors) and the re-
maining two biotic and two abiotic reactors left uncovered (Light Re-
actors). To limit outside contamination of the microcosms, all eight
were plugged at the top with cotton wool, as this still allowed for the
flow of air into the microcosm. Finally, each reactor had a magnetic
stirrer bar added and were placed onto unheated magnetic stirring pads
at the lowest speed that allowed a vortex to form.
Daylight conditions were simulated using an Osram400W power-
star® HGI®-BT daylight lamp, which was switched on for eight hours
each day to mimic average sunlight conditions in the UK. The bulb
provides 23.64 μmol S−1 m−2 per microamp of illumination at the 2 L
mark of a 2 L conical flask, with the probe facing perpendicular to light
source. The bulb provides 158.34 μmol S−1 m−2 per microamp of illu-
mination at the bottom of a dry 2 L conical flask, with the probe directly
facing the light source. All light intensity measurements were made
using a LI-250A light meter with a quantum sensor. In order to decrease
the effect of heat generated by the lamp all the microcosms, including
those in the dark, were cooled using fans to ensure a roughly equal
temperature inside each microcosm.
Samples were taken at regular intervals (once per day) over a fif-
teen-day sampling period and analysed as detailed by Evans et al. [11].
Other parameters analysed during the sampling period included dis-
solved oxygen (DO), pH, temperature, COD, ammonium, nitrate and
nitrite (Fig. S2).
2.3.2. Single-isomer ephedrine river simulating microcosms
Single-isomer ephedrine microcosms were carried out as an exten-
sion of the river water simulating microcosms described in 2.3.1, to
examine the effects of chirality on ephedrine degradation. The micro-
cosms were set up as described previously using river water collected
from a large river in the South West of the UK in February and spiked
with 1 μg/L of either 1R,2S-(-)-ephedrine or 1S,2S-(+)-pseudoephe-
drine, the naturally occurring isomers. Eight microcosms were prepared
in total (see Fig. S3): four containing 1R,2S-(-)-ephedrine and four
containing 1S,2S-(+)-pseudoephedrine. For each set of four single-
isomer ephedrine microcosms, two were wrapped in foil (Dark
Reactors) and the others left exposed to eight hours a day of simulated
daylight (Light Reactors) from an Osram400W powerstar® HGI®-BT
daylight lamp as described previously.
Samples were taken at regular intervals (once per day) over a fif-
teen-day sampling period and analysed as detailed by Evans et al. [11].
Other parameters analysed during the sampling period included dis-
solved oxygen (DO), pH, temperature, COD, ammonium, nitrate and
nitrite (Fig. S4).
2.4. Human liver microsome metabolism
Human liver microsomes (HLMs) were set-up in accordance to the
method described by Lopardo et al. [13] and were performed in du-
plicate for both 1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine,
with each isomer examined in isolation. Metabolism studies were car-
ried out to investigate if human metabolism of either ephedrine isomer
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lead to the formation of any other isomer. Currently available data on
(± )-ephedrine metabolism in humans suggests that if metabolised
ephedrine will primarily undergo hydroxylation or demethylation
[5,6]. The microsomes were incubated for a total of six hours as this
matched the expected in vitro half-life of 1R,2S-(-)-ephedrine [5]. To
determine absolute ephedrine and norephedrine isomer concentrations
the samples were analysed as described by Castrignanò et al. [12].
2.5. Retrospective analysis with UHPLC-QTOF – screening for precursors of
1S,2R-(+)-ephedrine
River water samples collected during seven consecutive days in
South-West England were analysed in accordance to the method de-
scribed by Lopardo et al. [13]. Briefly, river water samples were filtered
using GF/F glass microfibre filter 0.75 μm (Fisher Scientific, UK) fol-
lowed by a solid phase extraction (SPE) using HLB Oasis® cartridges
Water, UK) and concentrated 400-fold. Extracts were then dried under
nitrogen using a TurboVap evaporator (Caliper, UK, 40 ◦C). Dry extract
was then reconstituted in 250 μL 80:20 H2O:MeOH, transferred to
polypropylene vials.
A Dionex Ultimate 3000 HPLC (Thermo Fisher UK Ltd.) coupled
with a Bruker Maxis HD Q-TOF (Bruker) equipped with an ESI was
utilized for the analysis of extracts. ESI positive and negative mode
acquisition was performed in broadband CID acquisition mode.
HyStar™ Bruker was used to coordinate the LC–MS system.
Chromatographic separation and MS source conditions are described by
Lopardo et al. [13].
After analysis, data extracted from the Bruker system were pro-
cessed with MetID software (Advanced Chemistry Development, Inc.,
ACD/Labs, UK) in order to predict metabolite structures.
2.6. Toxicity testing
2.6.1. Daphnia magna toxicity tests
The experiment was performed using Daphtoxkit F Magna
(Laboratory for Biological Research in Aquatic Pollution, Ghent
University, Belgium) in accordance with test procedures described by
national and international organizations (OECD test no. 202 [14]).
24 h–48 h EC50 (or LC50) bioassays were performed in multiwell
test plates starting from neonates, uniform in size and in age, hatched
from ephippia. In order to provide the neonates hatched from the
ephippia with food prior to the test, a 2 h “pre-feeding” was applied
with a suspension of Spirulina micro-algae. Each ephedrine isomer was
tested individually at the following concentrations 7.8, 15.6, 31.3, 62.4,
125, 250, 500, 1000mg/L. These were prepared by serial dilution of an
initial 1 g/L ephedrines solution with standard fresh water [14]. For a
statistically acceptable evaluation of the effects each test concentration,
as well as the control, were assayed in four replicates of five neonates.
Daphnia magna neonates were incubated at 20–22 °C for 48 h and the
number of dead or immobilised organisms was counted after 24 and
48 h. The EC50/LC50 is the concentration where 50% of the D. magna
are dead or immobilised, determined by if they can swim freely after
gently agitating the solution.
2.6.2. Pseudokirchneriella subcapitata toxicity tests
The experiment was performed using Algaltoxkit F (Laboratory for
Biological Research in Aquatic Pollution, Ghent University, Belgium) in
accordance with test procedures prescribed by national and interna-
tional organizations (e.g. ‘Algal growth inhibition test’ (OECD
Guideline 201 [15]) and the ISO "Water Quality - Freshwater Algal
Growth Inhibition Tests with Unicellular Green Algae" (ISO Standard
8692). A 72 h algal growth inhibition test was performed with Pseu-
dokirchneriella subcapitata de-immobilized from algal beads. The test is
based on the measurement of the optical density of algal cell suspen-
sions (at 670 nm) in spectrophotometric cells of 10 cm path-length.
Optical densities were then converted into algal numbers with the aid of
the regression formula. The algae density was measured by photometry
absorbance at 670 nm and it was diluted with culturing medium to
achieve a density of 1.106. Each ephedrine isomer was individually
diluted to a concentration of 500mg L−1, 300mg L−1, 160mg L−1,
50mg L−1, 5 mg L−1 and 0mg L−1 with culturing medium. Algae were
added to these dilutions to achieve a density of 1.104mL−1. 25mL of
this solution was placed in 10 cm spectrophotometer cells, in triplicate.
The absorbance was measured every 24 h after agitation to re-suspend
the algae. They were stored at 20 °C under cool white fluorescent lamps
in a random order. The data was statistically analyzed using the Al-
galtox kit F Data treatment ErC50 spreadsheet.
2.6.3. Tetrahymena thermophila toxicity tests
The 24 h protozoan growth inhibition bioassay was performed using
Protoxkit F (Laboratory for Biological Research in Aquatic Pollution,
Ghent University, Belgium). Tetrahymena thermophila were chosen for
toxicity testing due to their sensitivity to a variety of emerging organic
contaminants at environmentally relevant concentrations, as well as
their position within the ecosystem and the potential for further
bioaccumulation [16].
The test was carried out in disposable spectrophotometric cells of
1 cm path-length to measure changes in optical density (OD) at 440 nm.
Each test cell contains T. thermophila ciliate inoculum (40 μL), food
substrate (40 μL) and known concentration of the isomer or isomers
being tested in synthetic freshwater (pH 7.75 ± 0.19, 2mL). The OD
measurements were taken at T0 h and at T24 h. At T0 h the turbidity of
the test cell will be high due to the food substrate. Over 24 h the tur-
bidity will drastically decrease as the uninhibited growth of the ciliates
will consume the food substrate. The degree of inhibition can be cal-
culated from the difference in OD between the control cells and the test
cells after 24 h.
A preliminary investigation was carried out for 1R,2S-(-)-ephedrine
and 1S,2S-(+)-pseudoephedrine to ascertain the approximate range
between 100% inhibition and uninhibited growth across 4 orders of
magnitude. Based on these results (see Supplementary Tables 14 and
17), further definitive tests were carried out for each isomer between
the lowest concentrations with a population growth inhibition of
80–100% and the highest concentration with an inhibition between
0–20%. To ensure the tests were valid each concentration was ex-
amined in duplicate and the control had to reach 60% OD decrease after
24 h. Some tests required an extra 2–4 h to reach the validation criteria,
which was batch dependent and indicated a slightly slower growth of
the ciliates. The EC50 values for this study were calculated using 28 h
results.
3. Results and discussion
3.1. Stereoselective degradation of a mixture of ephedrine stereoisomers in
river simulating microcosms
Degradation of a mixture of all four ephedrine stereoisomers and
norephedrine enantiomers was studied in well-defined laboratory river
water microcosm experiments. The following parameters were in-
vestigated: microbial degradation, photochemical reactions as well as
other physicochemical processes such as sorption.
As can be observed from Fig. 1 during a 14-day period (± )-ephe-
drine degradation only occurs in biotic microcosms, which indicates
that microbial metabolic processes are the main degradation pathway
for this compound in the environment (under studied experimental
conditions). It is worth noting that the rate of biodegradation is higher
in dark biotic microcosms than in those exposed to light. This shows
that ephedrine is photostable under the experimental conditions. Fur-
thermore, biotic degradation of ephedrine shows high stereoselectivity
favouring degradation of natural 1R,2S-(-)-ephedrine and leading to
enrichment of (± )-ephedrine with synthetic 1S,2R-(+)-enantiomer.
This process is much more pronounced in dark biotic microcosms.
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Pseudoephedrine was found to degrade in a similar manner to
ephedrine (Fig. 2). It shows high photostability in both biotic and
abiotic microcosms and no changes in enantiomeric composition were
observed in both light and dark abiotic microcosms, whilst microbial
metabolic processes are effective in the degradation of pseudoephe-
drine. These processes show high stereoselectivity with preferential
degradation of 1S,2S-(+)-pseudoephedrine and subsequent enrichment
of pseudoephedrine with synthetic 1R,2R-(-)-enantiomer. Similarly to
ephedrine, degradation of pseudoephedrine is faster and shows higher
stereoselectivity in the absence of external light. The increased rate of
1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine degradation in the
biotic dark microcosms compared to biotic light might be due to the
growth of algae in the presence of light and needs to be investigated
further.
Similar to ephedrine and pseudoephedrine, degradation of nor-
ephedrine was observed in the biotic microcosms only indicating an
importance of microbial metabolic processes (Fig. 3). (± )-Norephe-
drine was examined in this experiment due to its potential importance
as a breakdown product of (± )-ephedrine in animals and man [5–8],













































































































































































Fig. 1. Mixed-compound river simulating micro-
cosms – (± )-ephedrine degradation under dark
abiotic (DAR), dark biotic (DBR), light abiotic (LAR)
and light biotic (LBR) conditions (concentrations are
represented by bars, enantiomeric fractions are re-


























































































































































Fig. 2. Mixed-compound river simulating micro-
cosms – pseudoephedrine degradation under dark
abiotic (DAR), dark biotic (DBR), light abiotic (LAR)
and light biotic (LBR) conditions (concentrations are
represented by bars, enantiomeric fractions are re-
presented by symbols). See Tables S10–S13 for raw
data.
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observed in either of the biotic microcosms. Daily pH, temperature and
dissolved oxygen (DO) measurements on each microcosms showed little
variation between replicate samples (Fig. S2), as well as limited inter-
microcosm variation.
3.2. Single 1R,2S-(-)-ephedrine or 1S,2S-(+)-pseudoephedrine river
simulating microcosms
In the light of the observed extensive biodegradation of naturally
occurring 1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine, single
isomer 1R,2S-(-)-ephedrine or 1S,2S-(+)-pseudoephedrine river simu-
lating microcosms were undertaken to verify if chiral inversion leading
to the formation of non-natural 1S,2R-(+)-ephedrine or 1R,2R-
(-)-pseudoephedrine can occur in the aqueous environment (Fig. S3).
Formation of 1S,2R-(+)-ephedrine was observed in a single-isomer
biotic-light 1R,2S-(-)-ephedrine microcosm (Fig. S5). It is important to
note that the river water used in the microcosm experiments did not
contain any ephedrine isomers prior to the start of the experiment. The
observed peak passed method identification criteria, including reten-
tion time and MRM transition ratios, and is possibly formed as a result
of chiral inversion, albeit after long residence time of 14 days and de-
spite limited degradation of 1R,2S-(-)-ephedrine (Fig. S6). This is a very
important result, as it matches the observation of Kasprzyk-Hordern
and Baker [1] showing formation of 1S,2R-(+)-ephedrine after biolo-
gical wastewater treatment. The limited degradation of 1R,2S-
(-)-ephedrine in this experiment (explained by matrix collection during
heavy rainfall and low biomass content) has hindered the observation
of metabolite formation within early stages of the experiment.
3.3. Human liver microsome assays to verify human metabolism of 1R,2S-
(-)-ephedrine and 1S,2S-(+)-pseudoephedrine
Human liver microsomes assays were utilized to verify if human
metabolism can contribute to environmental occurrences of 1S,2R-
(+)-ephedrine via stereoselective metabolic processes of ephedrine
isomers including chiral inversion. Across the six hours of incubation a
sample was taken and quenched at 1, 3 and 6 h after addition of HLMs.
At each of these time points there was no significant change in the
concentration of 1R,2S-(-)-ephedrine relative to the control samples
(Table S5), this is in line with literature data showing that 1R,2S-
(-)-ephedrine is generally excreted unchanged in humans [5,6]. This is
further supported by the absence of (± )-norephedrine or any other
ephedrine isomer, which were expected to be the main metabolites
[5,6] if 1R,2S-(-)-ephedrine was metabolised. The concentration of
1S,2S-(+)-pseudoephedrine however did decrease relative to the con-
trol sample, but no (± )-norephedrine or any other ephedrine isomers
were observed. The HLM experiments for both compounds therefore
support the available literature data that ephedrines are mainly ex-
creted un-metabolised and without chiral conversion. This also elim-
inates human metabolism of ephedrines as a source for the previous
detection of 1S,2R-(+)-ephedrine in wastewater [1].
3.4. Retrospective analysis for 1S,2R-(+)-ephedrine precursors in river
water
It is important to mention that there could be other sources of
1S,2R-(+)-ephedrine formation in water such as the reduction of R-
(+)-methcathinone during human metabolism [17]. (± )-Methcathi-
none has been occasionally detected in wastewater influent [18,19] but
not in other environmental samples, and never with a focus on chirality.
However as no ephedrine isomers were present in the river water used
for microcosm experiments, and as relatively low percentages of
methcathinone are excreted un-metabolised [17], it is postulated that
1S,2R-(+)-ephedrine was formed as a result of microbial transforma-
tion of 1R,2S-(-)-ephedrine. Further work is needed to confirm this
hypothesis, however retrospective analysis of river water collected in a
week long sampling campaign in England, using the procedure detailed
in [13], showed no evidence of methcathinone.
3.5. Ecotoxicity of ephedrine stereoisomers to Daphnia magna,
Pseudokirchneriella subcapitata and Tetrahymena thermophila
Ecotoxicity tests and obtained EC50 data for the non-natural iso-
mers 1R,2R-(-)-pseudoephedrine and 1S,2R-(+)-ephedrine revealed
that these isomers are more toxic to D. magna than their naturally oc-




































































































































































Fig. 3. Mixed-compound river simulating micro-
cosms – norephedrine degradation under dark abiotic
(DAR), dark biotic (DBR), light abiotic (LAR) and
light biotic (LBR) conditions (concentrations are re-
presented by bars, enantiomeric fractions are re-
presented by symbols). See Tables S10–S13 for raw
data.
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follows: 107 and 171mg/L in the case of 1R,2R-(-)-pseudoephedrine
and 1S,2R-(+)-ephedrine respectively. EC5048h for the natural isomers
1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine, being widely
used as prescription and over-the-counter medications, were much
higher: 253 and 274 g/L respectively.
Similarly, non-natural 1R,2R-(-)-pseudoephedrine was found to be
the most toxic isomer (< 100mg/L) for P. subcapitata after 72 h ex-
posure time. Interestingly, 1S,2R-(+)-ephedrine was found to be less
toxic than its natural isomer. 1R,2S-(-)-ephedrine and was found to be
the least toxic isomer.
The results show T. thermophila are far more sensitive to the pre-
sence of the ephedrine isomers than the other organisms explored in
this study. As with the other organisms 1R,2R-(-)-pseudoephedrine is by
far the most toxic and its enantiomer 1S,2S-(+)-pseudoephedrine the
least: 4.6 and 99.3 mg/L, respectively. The ephedrine enantiomers
1S,2R-(+)-ephedrine and 1R,2S-(-)-ephedrine are much more similar in
toxicity: 42.6 and 36.0 mg/L, respectively. As with P. subcapitata 1R,2S-
(-)-ephedrine was more toxic than 1S,2R-(+)-ephedrine, although with
less disparity.
The T. thermophila EC5024h results for the ephedrine mixtures ‘nat-
ural’ (containing 1S,2S-(+)-pseudoephedrine and 1R,2S-(-)-ephedrine,
DF=0.5) and ‘all’ (which contains all the isomers, all EF and DF=0.5)
are 61.8 and 52.4mg/L respectively. These two mixtures are less toxic
than all of the individual isomers apart from 1S,2S-(+)-pseudoephe-
drine, which is present in both mixtures, so it does not appear that there
are any synergistic effects. All T. thermophila EC5024h results are clas-
sified as harmful (< 100mg/L), however 1R,2R-(-)-pseudoephedrine is
toxic (1–10mg/L) according to the classification made by OECD and
Commission of the European Communities [20–23]. For more detailed
results please see Supplementary Tables 14–21.
4. Conclusions
This manuscript examined the degradation of each of the four iso-
mers of ephedrine in river simulating microcosms and verified toxicity
of each isomer to aquatic test organisms (D. magna, P. subcapitata and T.
thermophila). Microcosms showed that significant degradation only
occurred in biotic conditions and that only two isomers (1R,2S-
(-)-ephedrine, 1S,2S-(+)-pseudoephedrine) degraded significantly over
a period of fourteen days. Across all three organisms tested the per-
sistent isomers (1S,2R-(+)-ephedrine and 1R,2R-(-)-pseudoephedrine)
were more toxic than those that undergo degradation.
The high toxicity of 1S,2R-(+)-ephedrine is of significant environ-
mental importance. Kasprzyk-Hordern and Baker [1] have detected
1S,2R-(+)-ephedrine in wastewater effluent, assumed to be formed
during wastewater treatment, which is eventually discharged into the
environment. HLM assays support previous literature evidence that
human metabolism of ephedrines does not proceed with any conversion
of chirality, so that 1S,2R-(+)-ephedrine formation is occurring after
excretion or during wastewater treatment. Multi-compound microcosm
experiments show that, if present, 1S,2R-(+)-ephedrine is persistent
within the environment, allowing it to become more widely spread. The
detection of 1S,2R-(+)-ephedrine in single isomer microcosms con-
taining only
1R,2S-(-)-ephedrine suggests that chiral inversion from biological
processes is possible, further increasing the risk of pseudo-persistent
environmental exposure to 1S,2R-(+)-ephedrine and that chiral in-
version could occur during biological treatment of wastewater con-
taining 1R,2S-(-)-ephedrine.
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1.1 Development and validation of a multi-residue method for exposure-driven catchment-
based study 
 
This thesis initially identified the current limitations of existing exposure driven studies, such as lack 
of harmonised methods, lack of monitoring solid phases and limited range of investigated CECs. These 
limitations reduce the ability to compare between studies, and the environmental burden is often 
underestimated. Therefore, a list of 56 CECs covering 20 classes, was prioritised by reviewing existing 
regulation, literature, physicochemical parameters, persistence, metabolism and excretion. These were 
combined with 90 additional CECs covering 26 classes from another method (Petrie et al., 2016), and 
validated for quantitative analysis in 5 matrices, 3 liquid and 2 solid, across a catchment. The resultant 
validated method included a range of 142 analytes covering 34 classes. This is one of the largest multi-
residue methods published, which can quantify CECs in both liquid and solids matrices relevant to 
WwTW processes and environmental exposure to concentrations below current PNECs (Proctor et al., 
2019). 
 
1.2 Application of method to multiple matrices to evaluate the impact of WwTWs on 
receiving waters and micropollutant fluxes 
 
This method was applied in a catchment-based study in 2015 to quantify CECs across a catchment in 
the South-West of the UK, at 5 WwTWs covering >75% of the ~1.5 million population. Each WwTW 
had samples collected from influent, effluent, upstream and downstream for 7 consecutive days. SPM 
was filtered from each influent sample for solids preparation and analysis, and digested solids were 
collected from sites with sludge treatment facilities. This comprehensive high-resolution work found 
112 out of 138 CECs in liquid influent, 76 out of  98 in SPM, 106 out of 137 in effluent, 50 out of 138 
upstream of the first WwTW studied, 84 out of 138 downstream and 65 out of 96 in digested solids 
(Proctor et al., 2020).  
Analysis of influent and SPM allowed the partitioning of solids to be quantified prior to coagulant 
addition and primary treatment. This is key for wastewater-based epidemiology (WBE) approaches and 
an accurate understanding of temporal and spatial trends in the usage and disposal of these CECs. 
Several spatial and temporal trends were identified between urban and rural areas, and between the 





Population, urbanisation and industry are key to the CEC levels found in influent. SPM was found to 
be the primary matrix for several classes and certain compounds. This finding shows that only analysing 
the liquid phase of influent in previous studies will have led to an underestimation of those CECs. 
WwTWs showed effective removal from the liquid phase for many classes, however many of these 
classes are of particularly high usage and enter the WwTW at a very high level, therefore despite high 
removal they are still present in effluent and discharge to the environment at a significant level. 
 
Many CECs are found throughout the aquatic environment, largely introduced from the effluent of 
WwTWs at a continuous, low, anticipated level. Some are present due to unexpected or accidental 
events, such as direct disposal, which may cause short bursts of high concentrations, often leading to 
higher solid partitioning of the CEC within influent. Whilst the acquisition of downstream/upstream 
samples in the aquatic environment were subject to timing limitations, of the samples taken, some CECs 
showed no degradation between sites. Measurements taken down the river showed an increasing trend 
in overall CEC load and concentration. This is concerning, as it indicates the environment is 
overburdened and cannot degrade the CECs at the same rate they are entering, leading to pseudo-
persistent CECs being transported throughout the aquatic environment that may reach more sensitive 
areas of the catchment. Based on these findings, a catchment-based approach to risk assessment should 
be an important consideration for the environmental impact of new chemicals and medicinal products 
in future.  
 
The aquatic organisms are not the only organisms at risk; this work showed potential exposure to 
terrestrial organisms from digested solids, if applied to the terrestrial environment. A wide range of 
CECs have been found in digested sludge, including many which were previously not considered or 
expected to be present in solids. This is likely due to very high concentrations entering the WwTW, 
leading to detectable concentrations in the solid phase despite poor partitioning. This may be followed 
by a lack of removal in solid treatment processes. If then applied to soil, this may result in the presence 
of weakly bound CECs entering the environment, where they have the mobility to be transported to 
groundwater, surface waters or crops. 
 
1.3 Assessment of environmental risk of CECs from a catchment perspective 
 
This work also considered the potential effects of these levels of exposure. Using acute and chronic 
aquatic ecotoxicity data from literature and quantitative structure activity relationships (QSAR) 
modelled data to devise appropriate PNECs for all CECs, it was found several classes posed an acute 
risk to the environment (based on RQMEC:PNEC >1, antibiotics (RQMEC:PNEC up to 33.29), NSAIDs 
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(RQMEC:PNEC up to 1.71), lipid regulators (RQMEC:PNEC up to 2.98), lifestyle chemicals (RQMEC:PNEC up to 
78.88), and veterinary pharma (RQMEC:PNEC up to 31.68). Overall, lifestyle chemicals showed the highest 
acute risk to the environment. The chronic PNECs indicated other classes may also be of risk, including; 
plasticiser (RQMEC:PNEC up to 206.86), antifungals (RQMEC:PNEC up to 3.51), antidiabetics (RQMEC:PNEC 
up to 2.60), antidepressants (RQMEC:PNEC up to 1.55), and pesticides (RQMEC:PNEC up to 5.39). As well as 
these chronic assessments, several classes were identified to be of acute risk, such as lifestyle chemicals, 
which also showed a chronic RQMEC:PNEC of 283.11. Overall this assessment showed that lifestyle 
chemicals and the plasticiser, bisphenol A, pose the most long-term risk to the environment. 
 
The overall mixture at each river sampling site was also assessed, showing an overall chronic 
RQMEC:PNEC of up to 516.5 and an acute RQMEC:PNEC of up to 105. This shows that these mixtures are 
likely to pose a risk to the environment throughout the catchment. However, this is for a mixture of 
dissimilarly acting chemicals and in such cases, RQSTU has been suggested as a more appropriate 
criterion, as it assesses the risk of the mixture to each trophic level individually before calculating the 
RQSTU for the trophic level most at risk. The acute RQSTU shows the algal trophic level was most at risk, 
with an RQSTU up to 93.4 and the most significant contributor was veterinary pharma, specifically 
diazinon. The chronic RQSTU showed the daphnid trophic level was most at risk, with RQSTU up to 425.2, 
the most significant contributor was the plasticiser, bisphenol A. This shows a handful of CECs may 
pose the greatest environmental risk, as previously discussed by Backhaus and Karlsson, as well as 
others, therefore it is very important to ensure a wide range of CECs are investigated (Backhaus and 
Karlsson, 2014; Gustavsson et al., 2017; Verro et al., 2009). If key CECs are not included in the 
investigation, it may lead to an underestimation of environmental risk in the subsequent assessment. 
 
Unsurprisingly, spatial ecotoxicity trends showed an increasing environmental risk downstream. The 
chronic RQSTU and RQMEC:PNEC increased downstream across the catchment by 35 times and 5.2 times 
respectively. The acute RQSTU and RQMEC:PNEC increased by 3.8 and 3.3 times respectively. Furthermore, 
there was a high risk to the environment before the most upstream sampling point, suggesting that other 
smaller WwTWs still pose a significant risk to the environment, as well as other more diffuse sources. 
 
The analysis of the risk to the terrestrial environment was more difficult due to the lack of available 
ecotoxicity data in literature and modelled QSAR data. The environmental risk was considered for both 
predicted environmental levels in soil after application of digested solids and for undiluted digested 
solids, to estimate localised risk posed by inadequate mixing. Most available data focussed only on 
earthworms. Therefore, assessments for both the whole mixture and individual classes could not be 




The same ecotoxicity data was applied to both amended soils and undiluted digested solids. For 
amended soils, the acute ecotoxicity data showed there was minimal risk to terrestrial organisms, as the 
most toxic CEC was gemfibrozil, with a negligible RQPECsoil:PNEC of 0.01. The chronic ecotoxicity, for 
the three CECs for which it could be found; ibuprofen, methylparaben and bisphenol A, showed no 
environmental risk. For undiluted digested solids however, the acute ecotoxicity data showed high risk 
to the environment for individual CECs. The highest RQMEC:PNEC was from gemfibrozil was 7.03. 
Ketoconazole and diclofenac also posed a significant acute risk at the levels detected, with RQMEC:PNEC 
up to 1.91 and 1.07 respectively. The chronic test data for ibuprofen, methylparaben and bisphenol A, 
showed medium to high risk to the terrestrial environment with RQMEC:PNEC of up to 0.43, 1.54 and 10.8 
respectively. Even with this limited ecotoxicological dataset, undiluted, this matrix shows high risk to 
the environment. 
 
Overall, the utilised quantitative method provided MQLs lower than the PNEC for most compounds in 
the aquatic environment, showing this method is suitable for the environmental risk assessment (ERA) 
for this mixture of CECs. However, conclusions could not be drawn for the suitability of the method 
for assessing environment risk of CECs to the terrestrial environment, due to lack of sufficient 
ecotoxicological data.  
 
1.4 Development of novel approaches and further ecotoxicological considerations 
 
Several aspects were not considered during this ERA, including metabolites, transformation products 
and the effect of stereochemistry. Though several metabolites were included in this study, there was 
limited ecotoxicity data available for the ERA. Guidelines on the ERA of medicinal products suggest 
ERA should only be carried out on metabolites which are excreted > 10% of the administered dose. 
Therefore, metabolites such as norfluoxetine would not be considered for ERA. However, based on the 
findings of this work, such as the toxicity the enantiomers of fluoxetine compared to its metabolite 
norfluoxetine, it is advised that at least a preliminary assessment for all metabolites is undertaken. This 
is because it has been shown that the metabolite can be significantly more toxic than the parent or may 
have the potential for synergistic effects to compound toxicity; if the metabolite is ignored just because 
it is excreted at a low rate, the subsequent ERA may underestimate the overall environmental risk. 
Furthermore, this work provided evidence that these metabolites are also produced during wastewater 
treatment. 
 
Most of the available literature on environmental monitoring of CECs focuses on the achiral analysis. 
This work briefly explores the stereochemistry for a few chiral CECs in this method. It finds that 
enantiomeric fractions (EFs) vary between different matrices and are not present as a racemic mixture. 
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This can have important ramifications on the ecotoxicity and existing ERAs, which are currently based 
on the initial formulation produced, or in the case of pharmaceuticals, based on the predominant 
metabolised form. Therefore, the EFs present in the environment may cause different biological effects. 
This is an under investigated aspect of ecotoxicological work. The effect of stereochemistry on 
ecotoxicity was explored in depth for ephedrine and fluoxetine and showed that the ecotoxicological 
impact for different stereoisomers can be drastically different, such as for one fluoxetine enantiomer, 
which is 35 more toxic for T. thermophila than the other enantiomer. Furthermore, different organisms 
may have a different toxic response to a range of EFs, therefore a wide range of test organisms need to 
be investigated. Overall, more ecotoxicity data on chiral compounds would increase the accuracy of 
ERAs but the study of which is currently limited by the availability of enantiomers in a suitable and 
affordable form. 
 
This work also explored the development of a ‘nanotest’ for the T. thermophila which allowed a far 
lower level of toxicant to be tested at relevant concentrations, allowing a full dose-response curve to be 
developed for this organism, which can be found in a range of environment matrices. 
 
Overall, the CEC loads seen in the aquatic environment and digested solids are likely to increase if 
nothing is done to mitigate CEC usage and/or release, making this an issue of critical importance. With 
the increasing and aging population in the UK, and continued urbanisation, catchments like the one 
studied in this work are at high risk of increasing levels of exposure to CECs in the environment. CECs 
with low removal levels by WwTW processes, or CECs which are poorly metabolised, are a particular 
risk of increasing presence in environmental matrices. Furthermore, consideration of a single compound 
as a mixture of its metabolites, transformation products or even as a different ratio of its enantiomers 
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1.1 Future developments in multi-residue methods for exposure-driven approaches 
 
Though the multi-residue method developed and validated in this work covers one of the widest range 
of CECs using a single preparation method, it still only covers a fraction of the potential CECs in the 
environment. Review of recent literature shows work is being carried out in developing screening 
methods using high-resolution mass spectrometry to scan far a larger range of CECs against libraries 
(Pesticides HRMS ref) and up until recently, sensitivity, was a major limitation of this methods, with 
their inability to detect the lower PNEC ranges in the environment. However, with recent advances in 
high-resolution mass spectrometry soon this may not be a problem.  
 
A key aspect of further work is the inclusion of metabolites and transformation products in future 
sampling campaigns and ecotoxicity work, currently available data on both aspects is very limited and 
therefore the true environmental risk of these compounds is unknown. Though it is often assumed to be 
negligible, there is not enough data for this assertion to be valid. However, further work considering 
non-targeted analysis with high-resolution mass spectrometry will be critical in the identification of 
metabolites and transformations products from WwTW and determining their impact.  
 
1.2 Further considerations for future catchment studies 
 
This was a comprehensive catchment-based study and essential data was gathered on a number of 
critical points discussed herein. However, these studies are limited by currently available sampling and 
sensing technology. With better tools this may allow spatial and temporal variation in concentration of 
CECs to be tracked with more reliability and provide a more realistic assessment for chronic levels. 
 
The catchment study has shown the potential for several compounds to absorb to sediments, particularly 
antidepressants and diclofenac. Both these compounds should be investigated further, as well as others 
which have shown an affinity for partitioning to the solid phase. As there are many benthic organisms 
at risk from these concentrations within the sediment, it should also be assessed for environmental 
impact. Furthermore, the spatial trend of increasing CEC concentration downriver is likely to be 




The estuarine environment is potentially at high risk due to the increasing CEC levels downstream 
towards the estuary, but also from close proximity to the output of the largest WwTW in the catchment, 
which receives influent from the greatest population equivalent. Though the mass balance showed this 
WwTW had the best removal per person overall, due to the quantity received, it also had the largest 
output. The potentially high levels of CECs leaving the catchment and entering this area suggest future 
work should strongly consider including estuary sampling in future catchment monitoring. Previous 
studies in Sweden have shown that CECs are present at detectable levels within the marine environment 
(B. M. Gustavsson et al., 2017) and this is compounded by their potential to bioaccumulate within 
marine organism (Mezzelani et al., 2018), which shows that if the estuary is becoming contaminated, it 
is an important issue. 
 
1.3 Future perspectives on environmental risk assessment of CECs  
 
Overall, with regards to environmental risk assessment, there is a need for more publicly available 
ecotoxicity data with more detailed accounts of research methods, to encourage harmonisation of future 
methods, and to produce more consistent PNECs and ERAs. Moreover, the collection of data within 
databases such as ECOTOX and TOXNET, as well as the availability of modelled data from sources 
such as ECOSAR, can provide a further level of consistency across environmental risk assessments in 
literature. 
 
Chronic ecotoxicological data is seen as far more applicable to the environment as there is a constant 
anticipated release into surface water or long-term presence within the terrestrial environment and yet 
this data is still far less available than acute data. Furthermore, the lower effect concentration levels, 
such as NOEC and LOEC are not always statistically defined, as they are just based on the lowest 
concentration tested and therefore the environmental risk assessment using this may be misleading.  
The presence of CECs in digested solids and the lack of relevant ecotoxicity data, indicates a key area 
of further work, for both individual CECs and mixtures. Furthermore, the removal of CECs from solids 
during treatment to digested solids is unknown, which warrants further investigation. This is particularly 
important due to the potential hazard of these CECs in the environment after application of digested 
solids to soils. 
 
The risk assessment of mixtures carried out in this study, as well as other studies, has shown that a few 
constituent compounds may account for most of the toxic effect (Backhaus and Karlsson, 2014; M. 
Gustavsson et al., 2017; Verro et al., 2009). However, different studies have shown these key CECs to 
differ; this may be due to a limited selection of investigated CECs in each study, further emphasising 




1.4 Future development and ecotoxicological considerations 
 
Bioaccumulation, bioconcentration and other sublethal effects were not considered in this work. 
However, this is still critical information for assessing the wider impact of the CECs in the environment. 
Sublethal effects and behavioural studies show responses at levels several magnitudes lower than the 
standard ecotoxicity endpoints. However, these methods still require further work to improve 
reproducibility and understanding of the potential ecological implications, as well as optimisation and 
harmonisation of methods before they can be used more widely (Kohler et al., 2018). 
 
Seasonal trends should be a further consideration for future catchment-based sampling campaigns, 
particularly in consideration of the impact that seasonal variations of the CEC content of mixtures may 
have on the lifecycle of flora and fauna throughout the year. As previous studies have shown, there can 
be seasonal trends in CEC removal, pharmaceutical usage and environmental concentrations (Burns et 
al., 2018; Golovko et al., 2014; Ma et al., 2017; Papageorgiou et al., 2016; Tsui et al., 2014). 
 
Overall, approaches which combine the use of exposure and effects-based methods are needed. High 
resolution methods which can simultaneously analyse the chemical exposure and biological effect 
would be ideal and are in fact applied in the field of environmental metabolomics. This approach uses 
methods to analyse the exogenous and endogenous metabolites that an organism(s) produces in 
response to a stressor. This stressor may be physical, such as temperature or lack of food, or it may be 
chemical e.g. exposure to a CEC. Depending on the stressor, changes will occur in the organism’s 
metabolome. The potential for this approach is high, but an understanding of which stressors causes 
what effects is still required for the biological interpretation of the data collected (Lankadurai et al., 
2013; Miller et al., 2018). 
 
Understanding the levels of exposure and their effect is of high importance. However, research has 
shown that there is currently a high level of risk to the environment and with increasing population and 
levels of urbanisation, this is only going to get worse. Therefore, further work should also be undertaken 
to take mitigative steps. 
 
Firstly, better optimisation of current removal processes could be achieved, as many of the processes 
are not designed for the removal of CECs. The evidence shows that current technology could be 
improved or expanded e.g. improving CEC sorption to solids, increasing retention time and introduction 
of tertiary treatments such as membrane bioreactors (MBRs) (Grandclément et al., 2017) and reed beds 




Secondly, pre-treatment of highly potent CEC sources e.g. hospitals and trade-effluents, may reduce 
the burden on WwTWs. This is currently implemented for common aspects such as sanitary 
determinands and pH but is yet to be widely implemented with regards to CECs. 
 
Thirdly, source control should be considered. This includes spreading public awareness including the 
overall picture of CECs in the environment, correct disposal practices of CECS, and reducing 
unnecessary usage e.g. minimising unnecessary pharmaceutical use. Other than public awareness it 
could include banning particularly toxic and persistent CECs, such as pesticides, and development of 
‘greener’ alternatives to CECs which are designed to degrade and be less persist and toxic (Taylor and 
Senac, 2014). Further changes may also be made to the guidelines for regulation of CECs, their 
registration into the open market and continued use. Currently these guidelines do not consider mixtures 
of similarly acting compounds, stereochemistry of CECs and their enantioselective transformation. 
Consideration for impact of CECs on the terrestrial environment is low and could be improved further, 
though recent changes to the ‘Guidelines for ERA of medicinal products’ now considers soils to be 
potentially at risk from pharmaceuticals with Koc <10,000 L kg-1 in sludge and considers a range of Koc 
for sludge which trigger further ERA and PEC of surface water (European Medicines Agency (EMEA), 
2006; European Medicines Agency, 2018; Whomsley et al., 2019). This is likely to improve the 
assessment of the terrestrial environment for compounds like ibuprofen. 
 
Finally, efforts towards bioremediation should be made. Current research shows many CECs and 
priority substances are highly persistent in the environment. For example, legacy pesticides, which have 
been banned in the EU for many years, are still appearing in storm water in catchments with large areas 
of agriculture, due to their persistence within agricultural soils. Furthermore, their preferences to 
partition to solids rather than liquids may pose a particular environmental risk to benthic organisms 
once they enter surface waters (Rasmussen et al., 2015).  For these highly persistent compounds, 
bioremediation efforts could help accelerate removal and degradation of them, mitigating the chance 
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